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Abstract 
This Thesis aimed (1) to produce and validate a novel polyclonal antibody against the 
'neonatal' splice variant of Navl.5 (nNavl.5), the predominant voltage-gated Na"*" 
channel (VGSC) isoform expressed in metastatic human breast cancer (BCa) cells and 
(2) to elucidate mechanisms regulating the VGSC/nNavl.5 expression and their 
influence on in vitro metastatic cell behaviour (MCB). 
The first set of studies involved purification and validation of the antibody 
("NESO-pAb"). Western blots and immunocytochemistry on a range of mouse and 
rat tissues, as well as transfectant EBNA cells showed that the antibody was indeed 
specific for nNavl.5. NESO-pAb application showed that nNavl.5 was responsible 
for the VGSC-induced enhancement of MCBs. 
Expression and localisation of nNavl.5 in weakly (MCF-7) and strongly 
(MDA-MB-231) metastatic human BCa cell lines were studied. Compared with 
MCF-7, MDA-MB-231 cells had much higher nNavl.5 mRNA and protein and 
expressed a considerably higher level of nNavl.5 protein in plasma membrane (PM). 
Both cell lines exhibited significant levels of intracellular nNavl.5 protein. 
nNavl.5 regulation by positive feedback, with protein kinase A as a key 
signalling intermediate, was shown. Trafficking of VGSCa protein to PM increased 
in vitro invasiveness. The PM (but not total) VGSCa protein expression decreased 
when cells were pre-treated with the VGSC blocker tetrodotoxin (TTX) and this 
eliminated the VGSC-dependent component of the cells' MCBs. 
Expression of VGSC (3-subunits and their involvement in MCBs were studied. 
MCF-7 cells expressed higher levels of VGSCpi, -(32 and -|34 subunits compared to 
MDA-MB-231 cells, with VGSCpl being dominant. TTX decreased specifically 
VGSCp2 mRNA expression. RNAi targeting VGSCpi in MCF-7 cells reduced 
expression of VGSCpi but nNavl.5 a-subunit mRNA and protein levels were 
increased. The VGSCpi-RNAi treatment decreased MCF-7 cells' adhesion but 
increased Transwell migration. 
The Thesis is concluded with a General Discussion chapter integrating the 
findings and highlighting their clinical potential. 
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PART A: GENERAL ASPECTS OF CANCER AND METASTASIS 
This chapter is a review of the research hterature on voltage-gated sodium channels 
(VGSCs), in relation to breast cancer and metastatic disease. 
1.1 Cancer basics 
Over 90 % of tumours are derived from epithelial tissues and are referred to as 
"carcinomas" (Majno and Joris, 1996; Ahson and Sarraf, 1997). Whilst cancer may 
be caused by gene mutations, there are two important differences between cancer and 
other genetic diseases: (a) Cancer is caused mainly by mutations in somatic cells, 
whilst in other genetic diseases, mutations occur only in the germ line 
(Blagosklonny, 2005); and (b) cancer does not always result from a single mutation 
(Lodish et al., 1999; Garcia-Garcia et al., 2005). 
Although cancer can not often be ascribed to only a single event or cause, 
factors such as the following are significant: genetic make-up (Taioli, 2005), diet 
(Kamat and Lamm, 2000; Go et al., 2001; Go et al., 2003; Key et al., 2004; Zhou et 
al., 2004), environment (Doll and Peto, 1981; Alison and Sarraf, 1997; Dogliotti et 
al., 1998), immune deficiency (Alison and Sarraf, 1997), age and viruses (Fine and 
Haseltine, 1993; Gallo, 1995; Villa, 1997). In general, cancer cells need to (1) be 
self-sufficient in growth signals, (2) be insensitive to growth inhibitory signals, (3) 
be immortal to apoptosis, (4) be able to proliferate continually, (5) be able to sustain 
angiogenesis, and (6) be able to invade neighbouring tissues and eventually be able 
to migrate to other organs (Hanahan and Weinberg, 2000; Blagosklonny, 2003; 
Gibbs, 2003). 
In order for a cell to become cancerous, there have to be a number of genetic 
mutations. DNA micro array studies have revealed that many genes are over- or 
under-expressed in malignant tissues (van't Veer et al., 2002b; Garcia-Garcia et al., 
2005). Cancer incidence increases with age, and this has classically been thought to 
be a reflection of the time required to accumulate a critical number of genetic 
mutations necessary for cancer to occur (Alison and Sarraf, 1997; Hanahan and 
Weinberg, 2000). 
Although it is generally agreed that cancer is 'ultimately a disease of DNA' 
and a list of cancer-related mutations have been identified, the real question is what 
comes first - mutations or aneuploidy (large-scale chromosomal abnormalities) 
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(Gibbs, 2003). There are at least three competing answers, as follows (Gibbs, 2003): 
(1) The standard dogma, which states that multiple gene mutations can eliminate 
tumour suppressor proteins and activate oncoproteins. (2) The modified dogma 
supports the idea that random mutations will affect just one gene in any cell over a 
hfetime and another factor (e.g. a carcinogen, reactive oxidant, malfunction in the 
DNA repair machinery) might dramatically accelerate the mutation rate. (3) The 
early instability theory, according to which chromosomal instability can occur early 
on and a benign growth might develop and later be converted to an invasive cancer 
and metastasis. In this theory, even if one 'key' gene (whose function is important 
for correct cell reproduction) is malfunctioning, either by mutation or epigenetically, 
can 'muddle' some of the chromosomes into aneuploid state. Eventually, this might 
have as an effect, for example, the suppression of a tumour suppressor gene. 
None of the above four theories alone can fully explain cancer. Cancer has 
many layers of complexity and there may be more than one theory closer to the truth 
or a combination of theories depending on the type of cancer. However, all theories 
should incorporate the role of epigenetic phenomena in order to make a more 
accurate prediction about the kinds of therapy that will be succesfull. 
There are two major categories of genes that are involved in human cancers, 
oncogenes and tumour suppressor genes. More than 100 oncogenes and 15 tumour 
suppressor genes have been linked to cancer (Gibbs, 2003; Bild et al., 2006). 
1.1.1 Oncogenes 
Proto-oncogenes originate as normal cellular genes encoding proteins responsible for 
basic cell proliferation and differentiation (Alison and Sarraf, 1997). When mutated, 
proto-oncogenes form oncogenes, which in turn, regulate growth and tumour 
suppressor genes; the latter are negative regulators of growth and apoptotic genes 
involved in programmed cell death (Hanahan and Weinberg, 2000; Leonard, 2000). 
Activation of a proto-oncogene into an oncogene (e.g. ras, raf, myc, fos, src, fms, sis, 
bcl-2, PI3K and erbB) can occur by point mutation, gene amplification and gene 
translocation (Lodish et al., 1999; Giehl, 2005; Samuels et al., 2005; Bild et al., 
2006; Samuels and Ericson, 2006). The first human oncogene was isolated from a 
human bladder carcinoma and found to encode a signal transduction protein, the 
active form of Ras (Fieg, 1993). In fact, the most frequently mutated oncogene 
detected in a variety of human cancers is ras (Giehl, 2005). 
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In order for a cancer cell to acquire autonomy in growth signalling, avoid 
differentiation and sustain angiogenesis, it needs dominance of oncogenes. In the 
case of growth signalling autonomy, proteins derived from oncogenes are found 
structurally altered in cancer cells and enable continuous production of mitogenic 
signals (Medema and Bos, 1993; Hanahan and Weinberg, 2000; Giehl, 2005). 
Oncogenes such as Myc and Ras can upregulate endothelial cell migration and 
proliferation and alter apoptosis (Giehl, 2005; Ren et al., 2005). PTEN has been 
demonstrated to dephosphorylate focal adhesion kinase (FAK) as well as 
phosphatidylinositol (3,4,5) triphosphate (PIP3), and inhibit cell migration, spreading 
and focal adhesion formation (Tamura et al., 1999a; Tamura et al., 1999b). 
1.1.2 Tumour suppressor genes 
Tumour suppressor genes (e.g. p53, RB, BRCAl, BRCA2, WT-1, APC and DCC) 
encode proteins that slow down or inhibit the cell cycle at a specific stage, i.e. these 
are checkpoint control proteins that arrest the cell cycle, e.g. if DNA is damaged 
(Mendelsohn et al., 1995). Tumour suppressor proteins promote apoptosis and DNA 
repair enzymes. Studies of inherited mutations causing retinoblastoma led to the 
identification of the first tumour-suppressor gene, RB (Lee et al., 1987). In normal 
cells, retinoblastoma protein (pRb) blocks cell proliferation (Weinberg, 1995; 
Hanahan and Weinberg, 2000; Blagosklonny, 2003). However, in cancer, mutations 
to pRb allow uncontrolled cell proliferation (Hanahan and Weinberg, 2000). Some 
tumour suppressor genes (e.g p53) induce apoptosis in response to DNA damage. 
When apoptosis is necessary under normal conditions, p53 will upregulate 
expression of proapoptotic Box, which in turn stimulates mitochondria to release 
cytochrome C, a potent catalyst of apoptosis (Green and Reed, 1998). However, 
when mutated, cancer cells acquire resistance to apoptosis, a common hallmark of 
most types of cancer (Hanahan and Weinberg, 2000). 
Recently, REl-silencing transcription factor (REST)/neuron-restrictive 
silencing factor (NRSF), a transcriptional repressor of neuronal gene expression, has 
also been recognized as a tumour suppressor gene (Westbrook et al., 2005). REST 
has been recognized as a frequent target of deletion as well as for frameshift 
mutation in colorectal cancer cells (Westbrook et al., 2005). Interestingly, REST can 
also control expression of membrane ion channels such as voltage gated Na"^  
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channels (VGSCs) (Marban et al., 1998; Nadeau and Lester, 2002) which have 
recently been linked to metastatic disease (Diss et al., 2005; Eraser et al., 2005). 
1.2 Metastasis 
Metastasis, which is the major cause of death for cancer parients, is the formation of 
secondary tumours by cells escaping from a primary tumour, circulating around the 
body (in lymph or blood) and getting lodged at tissue-specific or non-specific sites at 
a distance (Harlozinska, 2005). Metastasis involves intimate interactions between 
cancer cells and their environment initially via cytoplasmic extensions, such as 
pseudopodia and microvilli (Kawaguchi, 2005). On the whole, there are two different 
mechanisms; (1) Active-translocation of cancer cells mainly as a result of their own 
movement; and (2) passive-translocation of cancer cells by the host cells, e.g. 
myofibroblasts, fibroblasts, endothelial cells, mesothelial cells and heamatopoietic 
cells (Kawaguchi, 2005). 
In general, metastasis results from the survival and proliferation of 
specialised sub-populations of cells within the parent tumour (Fidler and Poste, 1982; 
Webb, 2003). Millions of tumour cells may be shed into the vasculature daily but 
only a few reach a target organ and even fewer can grow into full-blown secondary 
tumours (Couzin, 2003; Hunter, 2004). 
Until recently, it was generally accepted that metastasis is the result of a 
primary tumour that starts off benign and later acquires multiple mutations that 
ultimately give the ability to some cells to metastasize (Webb, 2003; Ramaswamy, 
2006). However, recent microarray studies suggested that acquisition of the 
metastatic phenotype may not always occur late in tumourgenesis, depending on the 
tumour, but some primary tumours can actually be preprogrammed to metastasize, 
while other will grow only as local tumours (Bernards and Weinberg, 2002; Webb, 
2003; Hede, 2004; Ramaswamy, 2006). Thus, a number of genetic events may occur 
in the primary tumour, that enable a small subpopulation of cells to progress in the 
metastatic cascade and finally colonise a secondary site (Hunter, 2004). 
According to the classic model of metastasis, the primary tumour is 
biologically heterogeneous and only some cells gain metastatic ability late in 
tumorigenesis (Fidler, 2003; Wittekind and Neid, 2005). Furthermore, 
subpopulations of cells may have a tissue-specific expression profile, predetermining 
the site of metastasis (Kang et al., 2003). The "seed and soil" hypothesis is based 
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upon three principles (Fidler, 2003): (1) Primary and secondary tumours consist of 
both tumour cells and host cells (epithelial cells, fibroblasts, endothelial cells and 
infiltrating leukocytes), i.e. neoplasms are heterogeneous and hold both 
genotypically and phenotypically diverse subpopulations. (2) Only cells ("seeds") 
that can succeed in invasion, embolisms, survival in circulation and extravasation 
might progress to metastasis. (3) Metastasis can only develop in specific organs, i.e. 
the microenvironment ("soil") is biologically unique. 
The reasons why migrating cells may choose to colonize in particular organs 
(e.g. lungs, liver, and bone) or at specific sites within this organ are not yet clear. 
Such specificity may be due to (1) branching out within the organ, the blood vessels 
becoming narrow and thus trapping the circulating tumour cells (Weiss et al , 1986 
as reviewed by Steeg, 2005); (2) existence of particular proteins that line the 
capillaries of the target tissues (Pasqualini and Ruoslahti, 1996); and (3) cancer cells' 
ability to change the local environment and being attracted to form metastases 
(Kaplan et al., 2005). 
Although the process of metastasis is complex and dynamic, it can be 
considered as a series of discrete basic cellular steps, as follows (Fidler and Poste, 
1982; Zetter, 1998; Leonard, 2000; Fidler, 2003; Wittekind and Neid, 2005; Steeg, 
2006) (Figure 1.1): 
1. Local proliferation and breaking of links with adjacent cells, resulting in 
detachment firom surroundings. 
2. Migration and invasion through local tissue. Extensive vascularization must 
occur if the primary tumour is bigger than ~1 mm in diameter (Fidler, 2003) 
(Figure l.lb,c). 
3. Intravasation: Cancer cells attach to the stromal face of blood or lymph vessel 
basement membrane, digest the membrane by releasing proteases and enter the 
circulation (Figure l . ld) (Zetter, 1998). 
4. Bloodstream or lymphatic transport and tolerance of mechanical stress (Figure 
l . ld) (Wittekind and Neid, 2005). 
5. Attachment to blood/ lymphatic vessel wall near the secondary site (Figure Lie) 
(Wittekind and Neid, 2005). 
6. Extravasation: Invasion through the vessel wall and exit (Figure l . l f ) (Zetter, 
1998). This occurs in three main steps: (i) attachment to the endothelial lining 
(adhesion); (ii) retraction of the endothelial cells followed by cancer cell 
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Figure 1,1 Steps in the metastatic cascade. 
The main steps are as follows: (a) proliferation within primary tumour; (b) digestion 
by cancer cells from the primary tumour of the local epithelial basement membrane; 
(c) angiogenesis in the expanding primary tumour; (d) invasion- the newly formed 
blood vessels provide a route of entry into the bloodstream; (e) attachment around 
the secondary site; (f): extravasation through the vessel wall; (g) migration to 
secondary tumour site, usually proximal to arterioles where their growth is enhanced; 
(h) micrometastasis, which can stay stable for a period of time and thus angiogenesis 
is suppressed; (i) rapid uncontrolled cell proliferation of cancer cells from the 
secondary tumour and initiation of angiogenesis. Modified from Alberts et al. (1994) 
and Zetter (1998). 
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attachment to the basement membrane (invasion) and (iii) migration into 
surrounding stroma. 
7. Migration to sites close to arterioles where cancer cell growth is enhanced 
(Figure l . lg) (Zetter, 1998). 
8. Proliferation in recipient tissue bed. Such micrometastases can remain 'dormant' 
during which period angiogenesis is suppressed (Figure l . lh) (Zetter, 1998; 
Fidler, 2003). 
9. Angiogenesis is initiated in the secondary tumour in order to create new blood 
supply, thus allowing further growth (Figure l . l i ) (Zetter, 1998; Carmeliet and 
Jain, 2000). 
1.2.1 Cell-cell and cell-matrix interactions during invasion 
Cell contact and adhesion are considered to be fundamental to metastasis. Invasion 
occurs initially by breaking the links with adjacent epithelial cells, migration through 
the extracellular matrix (ECM) and invasion of blood vessels (King, 2000; Steeg, 
2006). Matrix metalloproteinases (MMPs), urokinase plasminogen activator/receptor, 
integrins, cathepsins, cadherins, CD44 and many more specific cell-surface-
associated molecules can modulate cell-ECM and cell-cell interactions and are also 
involved in cancer cell invasiveness (Stetler-Stevenson et al., 1993; Wittekind and 
Neid, 2005). Tumour cells communicate with surrounding cells such as stromal cells 
(e.g. macrophages, fibroblasts, endothelial cells, inflammatory cells) as well as 
within themselves via (i) soluble factors (e.g. growth factors and cytokines) that act 
as paracrine or autocrine signals and (ii) cell surface proteins (e.g. cadherins, 
integrins). Tumour cells releasing chemotactic factors can attract inflammatory cells, 
thus raising the level of cytokines and growth factors produced by the latter (Zigrino 
et al., 2005). These soluble factors act on stromal cells to induce release of proteases 
for degradation of ECM (Zigrino et al., 2005). 
1.2.1.1 Proteolytic enzymes 
There are a number of proteolytic enzymes involved in basement membrane 
degradation and many of these are also of prognostic value (Imren et al., 1996). 
Examples of proteases involved in ECM degradation are urokinase plasminogen 
activator (uPA), cathepsin B (CB), cathepsin D (CD), plasminogen and 
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metalloproteases (MMPs) (Chin et al., 2005; Zigrino et al., 2005). Engagement of 
cells with ECM proteins is important for a variety of metastatic cellular processes 
such as adhesion, proliferation, differentiation, migration and apoptosis (Lee and 
Juliano, 2004). Secretion of proteolytic enzymes and proteolysis of ECM are 
recurring events in metastasis. 
There are 6 categories of human MMPs (Kerkela and Saarialho-Kere, 2003; 
Vihinen et al., 2005): (1) collagenases, (2) gelatinases, (3) stromelysins/stromelysin-
like MMPs, (4) matrilysins, (5) membrane type MMPs, and (6) other MMPs. MMPs 
are degradative enzymes expressed at moderate levels in normal tissues; their 
production/activation is greatly increased during tissue remodelling (Kerkela and 
Saarialho-Kere, 2003). MMPs play an important role in cancer progression by and 
breaking down of local tissue and basement membranes and enhancing tumour-
induced angiogenesis, thus allowing tumour invasion and metastasis (McCawley and 
Matrisian, 2000; Foda and Zucker, 2001; Kerkela and Saarialho-Kere, 2003; 
Mannello et al., 2005; Sato et al., 2005; Fingleton, 2006; Gorogh et al., 2006). 
MMPs can cleave the majority of ECM components, cell-surface and perinuclear 
molecules, thus assisting cell migration, cell-cell and cell-matrix interactions 
(Mannello et al., 2005). Additional roles of MMPs in cancer are as follows 
(Folgueras et al., 2004): 
(1) Formation of a complex microenviroment that promotes malignant 
transformation at early stages of cancer. This might include activation of 
growth factors, suppression of tumour cell apoptosis and release of 
angiogenic factors (Hojilla et al., 2003). 
(2) Regulation of tumour growth by releasing cell proliferation factors, e.g. 
insulin-like growth factors (Manes et al., 1997). 
(3) Suppression of tumour cell apoptosis (Boulay et al., 2001). 
(4) Association with various 'escape mechanisms' that cancer cells develop to 
avoid host immune response (Coussens et al., 2002). For example, MMP-9 
can suppress proliferation of T-lymphocytes (Sheu et al., 2001), and MMP-11 
can decrease the sensitivity of tumour cells to natural killer cells (Kataoka et 
al., 1999). Furthermore, MMPs have the ability to modulate anti-tumour 
immune reactions by cleaving some chemokines or regulating their 
mobilization (Li et al., 2002). 
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(5) Regulation of tumour angiogenesis. Pro-angiogenic factors such as vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) or 
transforming growth factor |3 (TGF-p) are activated by MMPs (Belotti et al., 
2003). However, some MMPs, such as MMP-9, have opposite effects, i.e 
they can suppress angiogenesis, by generating active forms of endogenous 
angiogenic inhibitors (Ferreras et al., 2000; Hamano et al., 2003). 
So far, clinical application of MMP inhibitors have not been promising (Coussens et 
al., 2002; Folgueras et al., 2004; Mannello et al., 2005; Acuff et al., 2006). Acuff et 
al. (2006) demonstrated the importance of MMP-9 in metastasis but this was only for 
a short time after the arrival of tumour cells at their target organ (lung). This would 
imply that for a successful outcome, it might be best to treat patients with MMP 
blockers at an early stage of cancer (Folgueras et al., 2004). 
1.2.1.2 Cell adhesion 
Altered adhesion of tumour cells to substrate has also been linked to metastatic 
potential. Loss of cell adhesion allows cancer cells to escape from the primary 
tumour, degrade ECM, and acquire a more motile and invasive phenotype (Okegawa 
et al., 2004; Steeg, 2006). Most extracellular adhesion properties are lost in 
metastatic cells, apart from the minimal essential elements, e.g. laminin receptor and 
late antigen-3 (Kawaguchi, 2005). 
Cadherins are a family of Ca^'^-dependent glycoproteins functioning as 
adhesion molecules mediating interactions between adjacent cells. Cadherins have a 
large extracellular domain, a transmembrane segment and a short cytoplasmic 
domain that associates with the actin cytoskeleton through catenins, specialized 
linker molecules (Humphries and Newham, 1998). Inactivation of E-cadherin by 
either genetic or epigenetic mechanisms plays a significant role cancer, including 
breast cancer (Frixen et al., 1991; Hazan et al., 2000; Hajra et al., 2002; Hirohashi 
and Kanai, 2003). 
CD44 is a transmembrane glycoprotein that binds to several components of 
ECM; the principal ligands are hyaluronic acid and chondroitin sulphate, but 
collagen, fibronectin, laminin and chondroitin sulfate also bind (Annabi et al., 2004; 
Eccles, 2004). As well as mediating cell migration, CD44 can potentiate proliferation 
and angiogenesis by regulating Rho/GTPases and growth factors such as fibroblast 
growth factor-2 (FGF-2) and VEGF (Eccles, 2004). CD44 can initiate a cascade of 
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events during cancer progression that require regulation of cell adhesion (Marhaba 
and Zoller, 2004). In addition, CD44 can stimulate growth and rescue cells from 
apoptosis (Marhaba et al., 2005). Stimulation of CD44 can induce upregulation of 
cell adhesion molecules (CAMs), such as integrins (van der Voort et al., 2000). 
Furthermore, CD44 is involved in ECM degradation during angiogenesis and tumour 
progression by its capacity to facilitate localization of MMPs (e.g. MMP-9) at the 
cell surface (Yu and Stamenkovic, 1999). 
1.2.1.3 Integrins 
Integrins (a family of ECM receptors) are widely involved in cancer progression 
(Juliano and Vamer, 1993; Seftor et al., 1999; Steeg, 2006). These are heterodimeric 
transmembrane receptors consisting of a and a p subunits, providing an essential link 
between actin cytoskeleton and ECM during cell migration (Humphries and 
Newham, 1998; Seftor et al., 1999; Brakebusch and Fassler, 2005; Kopfstein and 
Christofori, 2006). The main stages of cancer cell progression where integrins are 
involved are as follows (Danen, 2005): (1) Penetration of basement membranes; (2) 
invasion of stromal tissue; (3) entry into the circulation; (4) extravasation and (5) 
formation of secondary tumours. Integrins mediate interactions between cancer cells 
and a number of ECM components, such as laminins, collagens and fibronectin 
(Zigrino et al., 2005). Some intergins bind to other cells' receptors, such as 
disintegrin and metalloprotease or immunoglobulin-type receptors, such as 
intracellular adhesion molecules (ICAMs) and vascular cell adhesion molecules 
(VCAMs) that are expressed on leukocytes and endothelial cells (Danen, 2005). 
Since integrins do not have an actin binding domain or enzymatic activity, associated 
molecules (e.g. a-actinin, talin filamin, MAPK, PI3K, PKC, FAK, caveolin-1, and 
integrin linked kinase) are necessary to mediate the interaction with actin 
cytoskeleton (Zhu et al., 1996; Tamura et al., 1999c; McCawley and Matrisian, 2000; 
Ballestrem et al., 2001; Brakebusch and Fassler, 2005). Integrin-mediated cell 
adhesion can trigger a number of signalling cascades, including the Rho family of 
small GTPases that control the actin cytoskeleton (Danen, 2005; Titus et al., 2005). 
Furthermore, integrins facilitate membrane extrusions that are essential for cell 
spreading on ECM, where integrins and associated proteins are organised into cell-
matrix adhesions in large multi-protein aggregates (Danen, 2005). 
38 
1.2.2 Angiogenesis 
In order for cancer to progress and metastasise, formation of new blood vessels is 
necessary as a route of exit from the primary tumour into the circulation as well as to 
provide oxygen and nutrients (Figure 1.1c and i) (Zetter, 1998). In fact, without new 
blood vessel supply tumours can not grow more than ~1 mm (Hart, 1999; Dvorak, 
2005). Transfection of an oncogene (i.e. ras) into a tumour cell increases angiogenic 
activity by increasing VEGF expression and decreasing expression of antiangiogenic 
protein, e.g. thrombosponin-l (Folkman, 2006). Thus, blocking the angiogenic 
component of oncogene expression can produce a small, non-angiogenic tumour that 
is not lethal, despite the high proliferation rate of cancer cells (Folkman, 2006). 
Angiogenesis is initiated by tumour-derived growth factors, which stimulate local 
endothelial proliferation (Zetter, 1998). Therefore, increased secretion from cancer 
cells of mitogenic growth factors such as PDGF (platelet derived growth factor), 
FGF and VEGF, can initiate angiogenesis (Zetter, 1998; Carmeliet and Jain, 2000). 
Angiogenesis is "o f f when the effect of pro-angiogenic molecules is balanced by 
anti-angiogenic molecules, and it is "on" when this balance gets interrupted in favor 
of angiogenesis. This pro- and anti-angiogenic molecules can originate from both 
cancer and 'host' cells (e.g. endothelial cells, stromal cells, blood and ECM) 
(Carmeliet and Jain, 2000; Hanahan and Weinberg, 2000; Coomber et al., 2003; 
Sottile, 2004). Integrins and adhesion molecules mediating cell-ECM and cell-cell 
association also play an important role in angiogenesis (Hanahan and Weinberg, 
2000). Signals, like VEGF, MMPs and NO (nitric oxide), that are involved in 
angiogenesis, can induce (1) metaboUc stress (e.g low oxygen), (2) mechanical stress 
(e.g. proliferating tumour cells generating pressure), (3) immune/inflammatory 
response and (4) genetic mutations (e.g. activation of oncogenes and/or loss of 
function of tumour-suppressor genes that control production of angiogenesis 
regulators) (Carmeliet and Jain, 2000). The initiating signals for angiogenesis, 
including VEGF and FGF, bind to transmembrane tyrosine kinase receptors of 
endothelial cells (Hanahan and Weinberg, 2000). There are three main cellular stages 
in the formation of tumour vessels (Figure 1.2): (1) Sprouting, the host vascular 
network expands by growth of endothelial sprouts and forming "bridges"; (2) 
intussusception, tumour vessels remodel and expand by the insertion of tissue colums 
into the lumen of pre-existing vessels; and (3) angioplasts (endothelial cell 
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precursors), from bone marrow or peripherial blood, travel into tumour and develop 
tumour vessels (Carmeliet and Jain, 2000). 
VEGF is a very specific growth factor for epithelial cells that often is secreted 
by tumour cells in response to hypoxia in order to 'attract' new blood supply. 
Therefore, it is a major target for angiogenic cancer treatment (Fryer and Field, 
2005). Clinical studies, showed a clear association between formation of primary 
tumour blood micro vessels and metastasis in breast cancer patients (Benoy et al., 
2005; Fukata et al., 2005; Kopfstein and Christofori, 2006). hiterestingly, some anti-
tumour drugs that are already in use (e.g. taxol, tamoxifen, adriamycin) also have 
some antiangiogenic activity (Belotti et al., 1996; Gagliardi et al., 1996; Zetter, 1998; 
Schneider and Miller, 2005). Generally, angiogenesis inhibitors can be separated into 
the following main modes of action: (1) Antagonists of angiogenesis stimulators (e.g. 
VEGF) and their receptors (e.g. VEGFRl) and (2) inhibition of endothelial cell 
proliferation, survival, as well as inhibition of ECM degradation by inhibiting MMPs 
(Cox et al., 2005; Schneider and Miller, 2005). Inhibition of angiogenesis by using 
anti-VEGF monoclonal antibodies (e.g. bevacizumab) is a new strategy in cancer 
therapy (Klagsbrun, 1999; Sledge and Miller, 2003; Willett et al., 2004; Harlozinska, 
2005). Other anti-VEGF strategies include small molecule inhibitors of VEGF 
receptor tyrosine kinase activity (Fryer and Field, 2005). 
1.3 Breast cancer 
Breast cancer (BCa) affects about one in nine Western women in their lifetimes and 
is only second to lung cancer as a cause of death from cancer (Mendelshon et al., 
1995; Hagmaim, 1999; Parkin et al., 1999; Schwirzke et al., 1999; Edwards et al., 
2005). As for most cancer types, BCa incidence rises with age and has all the 
hallmarks of a multistep genetic disease. About 15 % of BCa patients have an 
aggressive form which can lead to metastatic disease within ~3 years of primary 
diagnosis (Weigelt et al., 2005). BCa metastases can occur to bone and lung (~80 %) 
and brain (~30 %) (Kang et al., 2003; Kirsch and Loeffler, 2005; Kozlow and Guise, 
2005; Weigelt et al., 2005). The risk of metastasis increases with lymph-node 
invasion, size of primary tumour and histopathological differentiation (grade), which 
are established prognostic markers (Weigelt et al., 2005). Other prognostic markers 
for metastatic BCa are angioinvasion, low steroid-receptor expression, ERBB2 
(epidermal growth factor receptor 2) gene amplification and protein expression. 
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Figure 1. 2 Cellular mechanisms of angiogenesis. 
Tumour vessels grow by a variety of mechanisms. 
(A) Incorporation of bone marrow-derived endothelial precursors (angioblasts) into 
tumours which contribute to the endothelial lining of tumour vessels. 
(B) Tumour vessels remodel and expand by incorporating interstitial tissue coloums 
into the lumen of pre-existing vessels (intussusception). 
(C) The vascular network expands by budding of endothelial sprouts or formation of 
bridges (angiogenesis), during which vessels initially dilate and become leaky in 
response to VEGF (vascular endothelial growth factor). 
(D) Lymphatic vessels around tumours drain the interstitial fluid and provide a 
gateway for metastasizing tumour cells. Modified from Carmeliet and Jain (2000). 
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Other marker is high protein levels of uPA (urokinase-type plasminogen activator), 
PAIl (plasminogen activator inhibitor 1) (Weigelt et al., 2005). The 'poor-prognosis' 
signature also includes genes involved in cell cycle, invasion, metastasis, 
angiogenesis and genes expressed by the stromal cells that surround epithelial cells 
in BCa tumours (e.g. MMPl and MMP9) (Sledge and Miller, 2003; Veronesi et al., 
2005; Weigelt et al., 2005). 
Mutations in two particular genes, BRCAl and BRCA2, are thought to be 
mainly responsible for inherited BCa which account for ~ 10 % of all BCa cases 
(Miki et al., 1994; Wooster et al., 1995; Rahman and Stratton, 1998; Hagmann, 1999; 
Ingvarsson, 2004; Fan et al., 2006). There is also evidence connecting BRCAl 
defects to loss of p53, which itself is mutated in about 50 % of BCa cases (Hagmann, 
1999). Several oncogenes are also amplified in BCa, including MYC, CCNDl, 
HER2, EMSY and STK15, althought the frequency of the amplifications is only 15-25 
% (Ingvarsson, 2004). 
1.3.1 Diagnosis 
The most commonly used methods of diagnosing BCa are ultrasonography, 
mammography, MRI (magnetic resonance imaging), PET (positron emission 
tomography), surgical biopsy and physical examination (Veronesi et al., 2005). 
Physical examination is still very important since about 11 % of BCa are not detected 
by mammography (Benson et al., 2004). Nevertheless, mammography is an 
important diagnostic method for detecting small lesions in patients whose breast 
tissue is not dense, but there are still limitations in identifying some lobular invasive 
carcinomas, inflammatory carcinomas and small peripheral carcinomas (Gordon and 
Goldenberg, 1995). On the other hand, ultrasonography is more effective in women 
with dense breast tissue and can differentiate solid lesions fi'om cystic (Crystal et al., 
2003; Veronesi et al., 2005). MRI is very sensitive and is used for high-risk BRCA-
positive BCa patients although the percentage of false-positive remains quite high 
(Heywang-Kobrunner et al., 2001; Szabo et al., 2003; Veronesi et al., 2005). Last but 
not least, PET is good for detecting metastatic foci in many distant organs but often 
fails to detect axillae with small and few nodal metastases (Wahl et al., 2004). 
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1.3.2 Treatment 
Early detection of primary tumour and disseminated cancer cells can help to predict 
and choose the appropriate therapy. Most therapies aim to prevent metastasis or 
metastatic relapse. However, characterization of the primary tumour is not enough as 
a therapeutic target and detection of disseminated tumour cells is also important 
(Pantel and Brakenhoff, 2004). New therapies that work on proliferating, invading 
and dormant tumour cells (e.g. immunotherapy) are in the pipeline and look 
promising (Pantel and Brakenhoff, 2004). Breast cancer is commonly treated by a 
combination of surgery, radiation therapy, chemotherapy and hormone therapy. 
When chemotheraphy fails to reduce the size of the primary tumour and the 
carcinoma is invasive or inflammatory, removal of the mammary gland by surgery is 
necessary (Veronesi et al., 2005). hi most cases of patients with early-stage BCa, 
breast-conserving surgery followed by a few weeks of radiotherapy are effective 
(Veronesi et al., 2005). 
Classically, the two widely used predictive factors for BCa therapy are 
estrogen receptor (ER) and progesterone receptor (PR) expression. Both are ligand-
activated transcription factors from the same family of nuclear receptors and are used 
to determine whether patients would respond to hormone therapy (Duffy, 2005). 
Elevated blood levels of endogenous estrogen, as well as exposure to exogenous 
estrogen plus progestin (a synthetic steroid hormone that has the effect of 
progesterone), resulting from hormone replacement therapy or use of oral 
contraceptives, could increase BCa risk (Yager and Davidson, 2006). Estrogen-
dependent BCa can be treated with estrogen antagonists that inhibit ER action and 
reduce BCa mortality (Ali and Coombes, 2002). For example, aromatase inhibitors 
can help block the growth of estrogen-sensitive tumours, by suppressing estrogen 
synthesis and thus lowering the amount of estrogen in the body (Buzdar et al., 2006). 
Tamoxifen is a very widely used anti-estrogen drug against metastatic BCa and led to 
about 30 % disease regression (Ali and Coombes, 2002; Jordan, 2006). Another anti-
estrogen drug is raloxifen (Glaeser et al., 2006). Some BCa patients develop 
resistance to endocrine therapy, although in most cases ER remains in resistant 
tumours and its activity continue to regulate tumour growth. The majority of 
advanced BCa patients who relapsed on tamoxifen were able to respond to another 
ER antagonist called faslodex (Howell et al., 1996; Ali and Coombes, 2002). 
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Recently, HER-2 has been used as a marker for selecting patients with 
advanced BCa for treatment with the antibody trastuzumab (Herceptin) (lannello and 
Ahmad, 2005; Rampaul et al., 2005; Chom, 2006; Houssami et al., 2006). HER-2 
protein is a member of receptor tyrosine kinases, and trastuzumab binds to this 
protein and inhibits the growth of BCa cells over-expressing HER-2 (Carter et al., 
1992). In addition, down-regulation of HER-2 inhibited cell cycle progression, 
inhibited angiogenesis and induced an immune response (Albanell and Baselga, 
2001; Duffy, 2005). Interestingly, there is evidence for cross-talk between ER and 
HER-2 signalling pathways (Kurokawa and Arteaga, 2003). HER-2 positive BCa's 
are less sensitive to ER modulation, especially with tamoxifen (Dowsett et al., 2001; 
Sledge and Miller, 2003). Also, epidermal growth factor receptor (EGFR) specific 
inhibitors (e.g. receptor blocking antibodies) have successfully been used in clinical 
trials (Schmidt and Lichtner, 2002; Bozec et al., 2006; Scartozzi et al., 2006). ER and 
EGFR expressions have an inverse relationship (Klijn et al., 1992; Lichtner, 2003). 
When EGFR expression is high, response to tamoxifen has a low response rate, 
compared to tumours with low or no EGFR expression (Nicholson et al., 1994; 
Lichtner, 2003). Other BCa treatments strategies include inhibitors of cdks (cyclin-
dependent kinases) such as flavopiridol (Sledge and Miller, 2003). Anti-estrogen 
therapies can also decrease cdk (e.g. cdk2 and cdk4) expression (Skildum et al., 
2002; Sledge and Miller, 2003). 
PART B: VOLTAGE GATED Na^ CHANNEL 
Voltage-gated Na"^  channels (VGSCs) are integral membrane proteins, crucial to 
action potential generation and propagation in 'excitable' cells. VGSCs can initiate 
action potentials by opening in response to membrane depolarisation (Rohl et al., 
1999). The three main functional characteristics of VGSC are voltage-dependant 
activation, rapid inactivation and selective ion (Na"^ ) permeation (Catterall, 2000). 
The first VGSC protein purified from mammalian brain revealed a 260 kDa 
a-subunit, a 36 kDa VGSCpi subunit and a 33 kDa VGSCP2 subunit (Beneski and 
Catterall, 1980; Hartshome and Catterall, 1981; Hartshome et al., 1982). VGSCs 
consist of two generic subunits, a single heavily glycosylated a-subunit, and a 
variable number of auxiliary VGSCP-subunits (Figure 1.3) (Catterall, 1992; Goldin, 
2001). Four VGSCP (32-42 kDa) subunits have been identified, VGSCpl (SCNIB), 
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VGSCpiA (a splice variant of SCNIB gene) (Qin et al., 2003), VGSCP2 (SCN2B) 
(Catterall, 1992), VGSCp3 (SCN3B) (Morgan et al., 2000) and VGSCp4 (SCN4B) 
(Yu et al., 2003). 
1.4 Molecular architecture 
1.4.1 VGSCa 
A family of ten VGSC a-subunits has been revealed (Catterall, 1995, 2001). 
Expression of only the a-subunit is sufficient for functional channel formation 
(Marban et al., 1998). The amino acid sequences of various VGSC a-subunits 
(VGSCas) were determined by cloning and sequence analysis of the cDNAs derived 
from rat brain, human heart and rat skeletal muscle (Sato and Matsumoto, 1995). 
Topologically, VGSCa consists of four homologous domains (D1-D4), each of 
which contains six membrane-spanning segments, SI- S6 (Figure 1.3). The 
homologous domains are repeated in tandem with 23 cormecting linkers between 
neighbouring membrane-spanning segments (Sato and Matsumoto, 1995; Marban et 
al., 1998). Each segment has a different function. The fourth segment (S4) in each 
domain is positively charged (containing a positively charged amino acid residue, 
such as arginine or lysine at every third position) and this acts as the voltage sensor 
(Yang et al., 1996). During activation, 84 coils across the membrane along a spiral 
path, moving its positive gating charges across the membrane's electric field (Yang et 
al., 1996; Catterall, 2001). The sixth segment (86) forms the wider inner lining of the 
pore. The P loops (881/882 segments) form the narrower, ion selective outer lining 
of the pore. The VGSCa protein is bell-shaped and has about 47 % of its mass on the 
intracellular side of the membrane and 24 % on the extracellular side (Catterall, 
2001; Sato et al., 2001). Thus, most of the intracellular mass is contributed by the 
large N- and C-termini and the large intracellular loops connecting domains, Dl, D2 
and D3 (Catterall, 2001). 
1.4.2 VGSCp 
VGSCP subunits are transmembrane glycoproteins with one segment. VGSCpi and 
VG8CP3 have higher homology between them (~ 55 %) and are both associated 
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Figure 1.3 Functional architecture of VGSC protein. 
(A) Molecular 'map' of a typical VGSC a-subunit and association with p-subunits 
(P1 and (32). The a-subunit is composed of four homologous domains (D1-D4), each 
of which has six transmembrane segments (S1-S6). Regions of the protein, which are 
involved in voltage sensing (S4), formation of the ionic pore (SS1-SS2), modulation 
by phosphorylation (P) and inactivation (D3-D4) are highlighted. Locations of 
binding sites of various drugs are indicated as follows: aScTx: a scorpion toxin, 
delays inactivation; pScTx: [3 scorpion toxin, enhances inactivation; TTX: 
Tetrodotoxin, inhibits ion conductance; BTX: Batrachotoxin, causes persistent 
activation. Modified from (Clare et al., 2000). Glycosylation sites are also indicated 
(B) Subunit composition of the sodium channel showing (31 and (32 subunits. Not all 
VGSCs include either or both (3 subunits, but the a-subunit is fundamental for the 
function of the VGSC. Modified from Marban et al. (1998). 
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noncovalently with the a-subunit (Isom et al., 1992; Morgan et al., 2000). Similarly 
the VGSCp2 and VGSCP4 also have sequence similarities (~ 35 %) and they are 
disulfide-linked with a-subunit (Isom et al., 1995; Yu et al., 2003). VGSCP-subunits 
have a large extracellular N-terminal domain with four potential glycosylation sites 
(Isom et al., 1992), and a smaller intracellular C-terminal domain (Figure 1.4) 
(Hanlon and Wallace, 2002). The extracellular N-terminal domain, which includes an 
immunoglobulin-like loop (Isom et al., 1995), is important for interactions with the 
a-subunit as well as CAMs (Isom, 2001). In the case of VGSCP2 subunit the N-
terminal domain includes V-like immunoglobulin fold that has -45 % homology 
with the CAM contactin (Isom et al., 1995). The intracellular domain is known to 
interact with ankyrin and receptor tyrosine phosphatase p (RPTPP) (Isom, 2001) and 
may also be involved in VGSCa- subunit regulation (An et al., 1998). 
1.4.3 Activation of VGSCs 
Activation of VGSCs can be separated into two different stages: (1) stimulus 
detection ("voltage-sensirig") and (2) channel/pore opening ("gating"). The role of 
the S4 helix in voltage-dependent activation was establish by introducing point 
mutations, such as substitution of positively charged arginine or lysine residues by 
either neutral or negatively charged residues, into the S4 regions of D1 and D2 
(Stuhmer et al., 1989; Kallen et al., 1993; Catterall, 2000). S4 detects the electric 
force created by membrane depolarisation and undergoes a conformational change, 
leading to the opening of the pore and passive influx of Na^ (Figure 1.5A and B) 
(Catterall, 2000). 
In the 'shding helix' model (Figure 1.6Aii), partial translocation of the 
voltage-sensing S4 of each domain can account for the voltage-depending gating 
(Catterall, 1986, 1992). Upon depolarisation, the S4 moves outward and rotates to 
place the positively charged residues in more outward positions. Positively charged 
residues are 'neutralized' by interacting with the surrounding negatively charged 
residues, mainly S2 and S3 segments (Catterall, 1992). 
1.4.4 In activation of VGSC 
The VGSC inactivation gate was the first functional component to be identified 
experimentally (Ptacek et al., 1991). A few to several hundred msecs after opening, 
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Figure 1.4 Basic structure and membrane topology of VGSC p-subunit. 
VGSC P-subunits have a large extracellular N-terminal Ig domain and a smaller 
intracellular C-terminal. Extracellular domain is critical for a-P subunit interactions 
and cell adhesion. The intracellular domain is involved in ankyrin recruitment and 
interaction with RPTPp. Furthermore, interaction with of the intracellular loop with 
the a-subunit has been reported previously. White circles indicate individual amino 
acids. Splicing site of p i /p iA indicated with a blue circle. Putative sites of N-linked 
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Figure 1. 5 Schematic representation of a VGSC undergoing gating transitions. 
The VGSCa protein contains four voltage-sensing a-helices (one in each domain), 
which have positively charged side chains every third residue. 
(A) The attraction of these charges for the negative interior of resting cells helps to 
ensure that the channel is closed. The channels inactivating peptide is free to the 
cytosol. 
(B) When the membrane is depolarized, the gating helix moves towards the outer 
plasma membrane surface. The channel opens within milliseconds and allows influx 
ofNa+. 
(C) Following opening, the gating helices return to the resting position and the 
channel-inactivating segment moves into the open channel and thus prevent any 
further ion movement. When the membrane potential is reversed the channel 
inactivating segment and the voltage sensing helix move back. 
Finally, the channel returns to the resting state whereupon it can open again by 
membrane depolarisation. Modified from Lodish et al. (1999). 
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D3/D4 intracellular linker 
Figure 1.6 Mechanisms of activation and inactivation ofVGSC. 
(A) VGSC activation occurs by outward movement of the vohage sensor S4 
segment, (i) Amino acids in the S4 segment of D4 are illustrated in single letter code. 
Positively charged argenine residues in every third position are indicated in yellow, 
(ii) The "sliding helix" or "helical screw"model of gating. The rigid cylinder is the 
voltage sensor S4 segment in a single domain. The S4 segment moves through 
narrow channels in each domain of the VGSCa protein. Positively charged residues 
(yellow circles) are neutralized by interacting with negatively charged residues from 
the surrounding regions of the protein (mainly the S2 and S3 segments). Upon 
depolarisation, the S4 moves outward and rotates to place the positively charged 
residues in more outward positions but they are still neutralized by the interaction 
with negative residues in the transmembrane part of the VGSCa protein. 
(B) Mechanism of VGSC inactivation. The D3/D4 intracellular linker forms the lid 
and this mechanism is called the "hinged-lid". The Phenylalanine-1489 residue (F) 
occluding the intracellular mouth of the VGSCa pore during the inactivation process. 
Modified from Catterall (2000). 
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the VGSC closes by the process of "inactivation" (Figure 1.5C). The closure is very 
fast on repolarisation or slow on prolonged depolarisation (Ulbricht, 2005). The 
inactivation "gate" was predicted to be on the inside of the membrane (Armstrong 
and Bezanilla, 1973; Armstrong et al., 1973). Thus, fast inactivation is mediated by 
an intracellular gate which binds to the intracellular mouth of the pore and was 
modelled as "ball-and chain" or "hinged lid" mechanism (Figure 1.513) (Armstrong, 
1981; Rohl et al., 1999; Catterall, 2000; Goldin, 2003). Fast activation occurs in a 
portion of the cytoplasmic linker connecting D3 and D4, with the crucial region 
centering on a group of four amino acids (isoleucine, phenylalanine, methionine and 
threonine), which close the pore by binding to a nearby region, the docking site 
(Goldin, 2003). The docking site consists of multiple regions such as the cytoplasmic 
linkers connecting S4 and S5 in D3 and D4 and the cytoplasmic end of S6 in D4 
(Goldin, 2003). Mutagenesis experiments on D3/D4 revealed that the hydrophobic 
triad of isoleucine phenylalanine and methionine (IFM) is important for the fast 
inactivation (West et al., 1992; McPhee et al., 1995) 
The slow inactivation is a different process that is not so well understood but 
it does not involve the D3-D4 linker (Goldin, 2003). After prolonged depolarisation, 
recovery from inactivation may happen very slowly, over minutes (Ulbricht, 2005). 
Many studies suggested that the pore is the site of conformational change during the 
slow inactivation process (Liu et al., 1996; Ong et al., 2000; Struyk and Cannon, 
2002). The slow inactivation may also involve other regions of the VGSC, such as 
D4:S4 (Mitrovic et al., 2000), D2:S5-S6 (Mitrovic et al., 2000; Vilin et al., 2001; 
Vilin and Ruben, 2001) and D2:S6 (O'Reilly et al., 2001; Goldin, 2003). 
1.4.5 Ionic permeation and selectivity of VGSCs 
In general, VGSCs are very efficient in ion conductance (Catterall and Epstein, 
1992). The identification of segments that line the transmembrane pore and define 
the ion selectivity of the channels is fundamental, because a number of toxins, drugs 
and inorganic cations can act as blockers of VGSCs (Catterall, 1995). Four residues 
in the S5/S6 linkers have been found, which are responsible for the VGSC's strong 
selectivity for Na"^ . These are aspartate-384, glutaminate-943, lysine-1422 and 
alanine-1714 (DEKA) and together they form the inner ring of the selectivity filter 
(Figure 1.7) (Noda et al., 1989). Even small changes in the amino acid residues in the 
SS1/SS2 region can affect the ion conductance and selectivity (Catterall, 1995). For 
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Figure 1.7 The VGSCa ionic selectivity filter. 
(A) Schematic representation of transmembrane VGSCa folding. The voltage 
sensing S4 segment is shown in yellow and the pore-lining P segments are shown in 
green. The VGSCa protein wrap around a central pore. The pore-lining (P-segments) 
is responsible for ion selectivity. 
(B) Aligned primary amino acid sequences in single letter code of the P-segment in 
VGSCa. Residues shown in upper case are highly conserved among VGSCas. Red 
boxes outline the putative selectivity filters. Green circles are residues most 
important for ion selectivity in VGSCa. Modified from Marban et al. (1998). 
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example, changing DEKA motif to EEEE changed Navl.2 channel selectivity from 
Na^to Ca^^ (Heinemann et al., 1992b). 
1.5 VGSCa gene family 
A systematic nomenclature has been proposed for VGSCas (Figure 1.8) (Goldin et 
al., 2000). There are ten different VGSC isoforms Navl. l- 1.9 and Nax (Kallen et al., 
1993; Plummer and Meisler, 1999; Goldin et al., 2000; Goldin, 2001). The genes for 
Navl.l, Navl.2, Navl.3, Navl.7 and Nax are located on chromosome 2, in both 
mouse and human, and phylogenetically are more closely related (Goldin, 2001). The 
genes for Navl.5, Navl.8 and Navl.9 are located on chromosome 9 in mouse, but on 
chromosome 3 in human (Table 1.1). The genes for Navl.4 and Navl.6 are on two 
different chromosomes, 2 and 9 in mouse, and 2 and 3 in human. 
Different VGSCa isoforms are expressed differentially in various tissues 
(Table 1.1). Navl . l ; Navl.2; Navl.3 and Navl.6 are expressed strongly in the 
central nervous system (CNS) (Lu et al., 1992; Kallen et al., 1993; Fozzard and 
Hanck, 1996; Felts et al., 1997; Goldin et al., 2000; Planells-Cases et al., 2000; 
Goldin, 2001). The VGSCa isoforms that are expressed at high levels in muscle are 
Navl.4 (adult skeletal muscle) and Navl.5 (embryonic and denervated skeletal 
muscle and heart muscle) (Cooperman et al., 1987; Kraner et al., 1989; Kallen et al., 
1990; Gellens et al., 1992; Goldin, 2001). The isoforms that are abundant in 
peripheral nervous system (PNS) are Navl.7, Navl.8 and Navl.9 (Toledo-Aral et al., 
1997; Smith and Goldin, 1998; Goldin, 2001). Nax is expressed (but not functional) 
in tissues such as heart, uterus, muscle, astrocytes and the dorsal root ganglion 
(DRG) (Black et al., 1999; Goldin, 2001). 
1.5.1 Sensitivity to tetrodotoxin 
Voltage-gated sodium channels have also been classified according to their 
sensitivity to a number of toxins (Kallen et al., 1993; Diss et al., 2004a). The toxin 
that has been used most extensively is tetrodotoxin (TTX), naturally found in the 
internal organs of puffer fish, which acquire it by consuming marine bacteria. TTX 
binds to VGSCas on the connecting segments between S5 and S6 in each domain. 
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Figure 1.8 Phylogenetic tree of VGSCa subunits. 
Rat VGSCa protein sequences were aligned using ClustalW and the tree was 
constructed using PAUP. The tree was rooted by including the invertebrate VGSC 
sequences during the generation of the tree (sequences not shown in the figure). The 
human chromosomes on which the human ortholog of each rat gene is, indicated on 
the far right. VGSCs that are TTX-sensitive (TTX-S) and TTX-resistant (TTX-R) are 
also shown. Adapted from Goldin et al. (2000) and Yu and Catterall (2003). 
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Table 1.1 Classification of VGSC a-subunits. 
The mammahan VGSCa subunit gene family. TTX sensitivity, chromosomal 
location, primary tissue expression, splice variant ans genebank number are 
indicated. Key: ^ The letter in parenthesis indicates the species of origin for the 
sequence, as follows: h = human, r =rat, rb = rabbit, m = mouse, gp = guinea pig, d = 
dog. This gene was originally assigned symbols SCN6A and SCN7A, which were 
found in human and mouse, respectively. The two most likely represent the same 
gene and SCN6A may be deleted. CNS: central nervous system, PNS: peripheral 
nervous system, DRG: dorsal root ganglion. TTX: tetrodotoxin. S: sensitive. R: 
resistant. Sk.: Skeletal. Modified from Goldin et al. (2000). 
VGSCa Gene TTX Chromosomal Primary Splice Genebank 
sensitivity location tissues Variant Number^ 
Mouse Human 
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resistant (TTX-R) VGSCs require 1-10 |iM TTX (Waxman, 2000; Goldin, 2001). 
TTX-S VGSCas are Navl.l , Navl.2, Navl.3, Navl.4, Navl.6 and Navl.7. TTX-R 
VGSCa are Navl.5, Navl.8 and Navl.9 (Table 1.1) (Goldin et al., 2000). From 
analysis of deduced VGSCa sequences, sensitivity to TTX was found to be 
determined mainly by one residue (denoted X) in the conserved SS2 pore region of 
D1:S5/S6 (TMQDXWE). TTX-S VGSCa's have an aromatic (either tyrosine or 
phenylalanine) residue at this position, whilst TTX-R VGSCas have a polar residue, 
either a cysteine or a serine (Heinemann et al., 1992a; Mendelshon et al., 1995). A 
number of other residues in the outer mouth of the channel contribute to the binding 
of TTX and saxitoxin (STX), suggesting that the toxin has a large footprint on the 
external surface of VGSCa protein (Marban et al., 1998). 
1.5.2 Splicing of VGSCa genes 
VGSCas have 24 to 28 exons within 32.5 to 90 kb of genomic DNA. hi both 
invertebrates and vertebrates, multiple alternative spliced exons have been described 
(McClatchey et al., 1992; Plummer et al., 1997; Souslova et al., 1997; Dib-Hajj et al., 
1999; Kasai et al., 2001) (Figure 1.9). To date, five major sites for alternative 
splicing has been identified: (1) Domain 1: Segment 3 (D1:S3) adult and neonatal 
isoforms, (2) Domain 3: segment 3 (D3:S3) isoforms (3), Domain 4: segment 3 
(D4:S3) isoforms, (4) hiterdomain 1-2 (ID 1-2) isoforms, and (5) Interdomain 2-3 
(ID2-3) isoforms. These alternative splicings enable inclusion, exclusion or 
substitution of amino acids in key modulatory regions, resulting in spliced VGSCa 
proteins with major alterations to the conserved transmembrane structure (Diss et 
al., 2004a). 
A potentially important site of alternative splicing is S3 in Dl , D3 and D4 
(Figure 1.10). A developmentally controlled alternative splicing in mammalian 
D1:S3 gives rise to two alternative transcripts usually with only 1-2 amino acid 
difference (Figure 1.11). Such splicing was first described in Navl.2 and Navl.3 
(Sarao et al., 1991; Gustafson et al., 1993) and later in Navl.8 (Plummer et al., 1997) 
and Navl.9 (Belcher et al., 1995) in rat brain. The neonatal transcripts were found at 
birth and were gradually replaced by the adult transcripts as development proceeded 
over days. 
Evidence of D1:S3 alternative splicing also exists in three other VGSCas: 




— Exon boundary position 
Figure 1.9 Conserved exon positions in VGSCas. 
Basic molecular structure of VGSCa showing conserved exon boundary positions 
(thick black bars) present in all VGSCa isoforms. The VGSCas have 24 to 28 exons 
within 32.5 to 90 kb genomic DNA. Modified from Diss et al. (2004). 
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Figure 1.10 Alternative splicing of VGSCa. 
Five major sites for alternative splicing has been identified in Domain 1: Segment 3 
(D1:S3) adult and neonatal isoforms, Domain 3: segment 3 (D3:S3) isoforms, 
Domain 4: segment 3 (D4:S3) isoforms, Interdomain 1-2 (ID 1-2) isoforms, and 
Interdomain 2-3 (ID2-3) isoforms.Thick black bars indicate exon boundaries where 
alternative splicing can occur. Conserved exon boundaries which have not been 
found to be positions of alternative splicing are indicated as thin black lines. (A) 
Common areas of the VGSCa protein (dark dashed) which can be alternatively 
spliced at the indicated exon boundaries (thick black bars) to yield diverse VGSCa 
isoforms from a single VGSCa gene. Less common splicing areas are indicated as 
light grey. (B) A simpler schematic diagram of VGSCa alternative splicing. 
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Figure 1.11 Amino acid sequences of D1:S3 splice variants. 
Comparison of amino acids sequence between "adult" (5A) and "neonatal" (5N) 
exons in Navl.5, Navl.2, Navl.3, Navl.6, and Navl.7. A developmentally 
controlled alternative splicing in mammalian D1:S3 gives rise to two alternative 
transcripts (adult and neonatal) usually with only 1-2 amino acid difference. Such 
splicing was first described in Navl.2 and Navl.3 (Sarao et al., 1991; Gustafson et 
al., 1993) and later in Navl.8 (Plummer et al., 1997) and Navl.9 (Belcher et al., 
1995). Evidence of D1:S3 alternative splicing also exists in three other VGSCas: 
Navl.l (GenBank [NM_006820]), Navl.6 (Plummer et al., 1997) and Navl.7 
(Belcher et al., 1995; Klugbauer et al., 1995; Toledo-Aral et al., 1995b). Only the 
'neonatal' Navl.5 D1:S3 exon differs from the adult exon at 31 of its 92 nucleotides 
resulting in seven amino acids substitutions. Modified from Diss (2001). 
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(Belcher et al., 1995; Klugbauer et al., 1995; Toledo-Aral et al., 1995b). However, 
the developmental regulation of these VGSCa subtypes has not been investigated. In 
all cases, there was a substitution of a negatively charged asparate residue at the 
extracellular end of D1:S3, at exon residue seven in the adult form, to a non-charged 
amino acid in the case of the neonatal splice variant: Serine in Navl.3 and asparagine 
inNavl. l , Navl.2, Navl.6, Navl.7, Navl.8 andNavl.9. Such an alternative splicing 
of D1:S3 neonatal and adult exons has also found in human Navl.5 from BCa cell 
lines (Diss, 2001) (Figure 1.12). Interestingly, the same splicing event in D1:S3 
(exon 6) and a second splicing variant in the intracellular loop between D2 and D3, 
lacking exon 18 in Navl.5 have recently been described in human neuroblastoma 
cells (Ou et al., 2005). 
The existence of neonatal Navl.5 (nNavl.5) has been confirmed by 
sequencing the Navl.5 gene on human chromosome 3 and mouse chromosome 9 and 
also from RT-PCRs performed on human BCa cell lines (Diss, 2001). The 'neonatal' 
Navl.5 D1 :S3 exon differs from the adult exon at 31 of its 92 nucleotides resulting in 
seven amino acids substitutions (Figure 1.12). These substitutions are conserved 
across human, mouse and rat Navl.5 genes. This novel isoform would code for a 
protein with a positively charged lysine residue replacing the conserved aspartate 
residue at the extreme extracellular end of D1:S3 (Diss, 2001). 
The effect(s) that this substitution would have on channel frinction has not 
been fully elucidated, but its conservation across different VGSCa genes and species 
would suggest that it is likely to be significant. In the only study performed to date, it 
was found that the voltage-dependence of activation and the steady-state inactivation 
of the 'neonatal' form of Navl.2 were slightly hyperpolarized (Vi/2's shifted by 6-7 
mV), compared to the 'adult' isoform (Auld et al., 1990). The physiological 
implication is that neurones expressing neonatal Navl.2 would have a greater 
probability of firing (Gustafson et al., 1993). For the first time, a recent study 
determined electrophysiological differences between 'neonatal' and 'adult' Navl.5 
D1:S3 splicing variants (Mattis et al., 2006). The main differences were that the 
nNavl.5 exhibited slower kinetics of activation and inactivation and had longer 
recovery from inactivation, compared with aNavl.5 (Mattis et al., 2006). 
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* * + * * * * * * * * * * * * * 
Exon6A ATACACAACTGAATTTGTGGACCTGGGCAATGTCTCAGCCTTACGCACCT 50 
Exon6N GTATGTATCAGAAAATATAAAACTAGGCAATTTGTCGGCTCTTCGAACTT 50 
+ + * * * * + * + * + 
Exoii6A TCCGAGTCCTTCCGGCCCTGAAAACTATATCAGTCATTTCAG 
Exon 6N TCAGAGTCCTGAGAGCTCTAAAAACTATTTCAGTTATCCCAG 
92 
92 
Figure 1.12 Alternative splicing of D1:S3 Navl.5. 
(A) Comparison of alternative D1:S3 Navl.5 adult and neonatal exons deduced 
amino acid sequences. Alternative splicing at Dl:S3/4 (star) is where the neonatal 
Navl.5 splicing occurs (in red). 
(B) A schematic representation of Navl.5 D1:S3 splicing. Differentially shaded 
regions representing different exons. N and A denote neonatal and adult alternative 
spliced exons, respectively. D1 and S3 denote domain 1 and segment 3 of Navl.5 
VGSCa, respectively. cDNA sequence of the D1:S3 Navl.5 neonatal exon compared 
to that of the adult exon is also shown. Asterisks indicate the location of the 31 
nucleotide differences. Modified from Diss et al. (2004). 
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A transient change in VGSCa sphcing (upregulation of 'neonatal' Navl.2 
and Navl.3 and concomitant down-regulation of their 'adult' isoforms) in the dentate 
gyrus and hippocampus CAl were found during kainic acid induced seizures and 
could facilitate neuronal firing and epileptic discharges in these areas of the brain 
(Bartolomei et al., 1997). 
Alternative splicing of Navl.6 in D3:S3 has been reported in pufferfish, 
mouse and human at exon 18. This splicing was developmentally regulated as well as 
tissue specific (Schaller et al., 1995; Plummer et al., 1997; Oh and Waxman, 1998). 
The splicing resulted in translocation of either a full-length (adult) or a highly 
truncated (neonatal) two-domain VGSCa. However, in transfection studies on cell 
lines the neonatal isoform was not functional (Plummer et al., 1997). Alternative 
splicing by exon-skipping events in D3 was also reported in Navl.l and Navl.6 in 
both human and rat (Oh and Waxman, 1998; Diss, 2001; Diss et al., 2004a). Two 
alternative splice variants of Navl.9 were identified in human brain. The location of 
the splicing was in D4:S3 (Jeong et al., 2000). In addition, a 19-nucleotide insert at 
D4:S3, resulting in an alternative splice variant was identified in human Navl.5 
(Gellens et al., 1992). 
Splicing at interdomain 1-2 (ID 1-2) may have a significant effect on VGSCa 
function, since it is a region with potential phosphorylation sides by PKA and PKC 
(Diss et al., 2004a). This kind of splicing has been reported for Navl.l (resulting in 
two isoforms), Navl.3 (resulting in four isoforms), Navl.6 (resulting in two 
isoforms) and Navl.7 (resulting in two isoforms) (Schaller et al., 1992; Klugbauer et 
al., 1995; Sangameswaran et al., 1997; Toledo-Aral et al., 1997; Dietrich et al., 1998; 
Plummer et al., 1998; Diss et al., 2004a). Alternative splicing of Navl.5 in 
interdomain 2-3 (ID2-3), result of the skipping of a short exon, produced a smaller 
(by 53 amino acids) alternative spliced isoform in rat brain, mouse heart and 
embryonic hippocampal precursor cell line (HiB5) (Gersdorff Korsgaard et al., 2001; 
Zimmer et al., 2002c). 
A number of other alternative splicing has been reported. In DRG neurons, a 
splice variant of Navl.8 contained an exact repeat of exons 12 and 14, encoding part 
of ID 1-2 and D2:Sl-3 has been described (Akopian et al., 1997). Another alternative 
transcript of Navl.9 has been identified in DRG and predicted to produce a truncated 
protein because of a frame-shift introduced by a new sequence on exon 23C (E23c) 
(Dib-Hajj et al., 2002a; Dib-Hajj et al., 2002b; Diss et al., 2004a). 
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1.6 VGSCps 
1.6.1 Interactions between VGSCps and VGSCa 
VGSCPs can interact with a number of different VGSCa isoforms (Table 1.2) and 
can directly modify VGSC electrophysiological properties. The exact site where 
VGSCa and VGSCP interact is not yet folly determined. Although most studies have 
been done on VGSCpi, the homology between the different VGSCP subunits would 
suggest that there would be similarities in the structural motifs responsible for a-p 
subunit interactions. VGSCa binding site for VGSCpi has been proposed to be 
modulated by both D1 and D4 S5/S6 loops of VGSCa (Makita et al., 1996). 
Furthermore, binding of VGSCpi to extracellular loops D4:S3/S4 and D4;S5/S6 of 
VGSCa is important for modulating channels kinetics (Qu et al., 1999). However, 
the extracellular domain of VGSCpi is critical for VGSCa gating and modulation of 
voltage dependence in Navl.4, Navl.2, Navl.2 and Navl.3 (Makita et al., 1996; 
McCormick et al., 1998; McCormick et al., 1999; Isom, 2001). Site-directed 
mutagenesis in the extracellular Ig loop of VGSCpi, suggested that it is a key area 
for interaction with Navl.2 in Xenopus oocytes (McCormick et al., 1998). 
Interestingly, a mutation in the transmembrane region of VGSCpi suggested that this 
region might also play a role in interacting with VGSCa. However, the extracellular 
region, close the membrane, or the N-linked glycosylation sites were not involved in 
interaction between the two subunits (McCormick et al., 1998). It has also been 
suggested that interaction of Navl.5 and VGSCpi might occur intracellularly (An et 
aL, 1998). 
1.6.2 Functional aspects of VGSCps 
VGSCp subunits are multifunctional molecules. Apart from their role in modulating 
channel gating (Isom, 2001; Hanlon and Wallace, 2002), they can also regulate the 
level of VGSCa expression in plasma membrane (PM) (Kazarinova-Noyes et al., 
2001; Chen et al., 2002) and fonction as CAMs (Isom and Catterall, 1996; Isom, 
2002). The latter could involve interaction with: (1) ECM proteins, thus influencing 
cell migration (Undrovinas et al., 1995; Faissner, 1997; Srinivasan et al., 1998; Xiao 
et al., 1999), (2) cytoskeleton (Peles et al., 1995; Malhotra et al., 2000; Ratcliffe et 
al., 2000) and (3) other CAMs (Isom, 2001; McEwen and Isom, 2004). 
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Table 1.2 Reported interactions of VGSCps with VGSCas. 
'yes' indicates demonstrated interactions, 'No' indicates there was found no 
interaction, and (-) means there are no evidence or reports on the particular 
investigation. Modified from Diss (2001). 
VGSCa 
isoforms 
pi P2 P3 P4 References 
Navl. l Yes Yes - - (Smith and Goldin, 1998) 
Navl.2 Yes Yes Yes Yes (Isom et al., 1992) 
(Patton et al., 1994) 
(Morgan et al., 2000) 
(Isom et al., 1995b) 
(Isom et al., 1995a) 
(Yu et al.. 2003) 
(Malhotra et al., 2001) 
(Stevens et al., 2001) 
Navl.3 Yes - Yes - (Patton et al., 1994) 
(Shah et al., 2000) 
Navl.4 Yes - Yes Yes (Patton et al., 1994) 
(Yu et al., 2003) 
(Ferrera and Moran, 2006) 
(Stevens et al., 2001) 
(Schreibmayer et al., 1994) 
Navl.5 Yes Yes Yes No (Xiao et al., 2000) 
(Qu et al., 1995) 
(Yu et al., 2003) 
(Yu et al., 2005) 
(Kupershmidt et al., 1998) 
Navl.6 Yes - - - (Smith and Goldin, 1998) 
(Dietrich et al., 1998) 
Navl.7 No No - - (Klugbauer et al., 1995) 
(Sangameswaran et al., 1997) 
Navl.8 Yes Yes Yes - (Shah et al., 2000) 
(Rabert et al., 1998) 
(Vijayaragavan et al., 2004b) 
Navl.9 
- - - -
-
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Both VGSCpi and VGSCp2 are CAMs of the immunoglobuUn superfamily 
and can interact with ankyrin in areas of cell-cell contact (Malhotra et al., 2000), as 
well as with the ECM components, tenascin-C and tenascin-R (Srinivasan et al., 
1998; Xiao et al., 1999). Literactions of VGSCpi, but not VGSCP2, with CAM 
contactin and neurofascin-186 has been reported to result in increased VGSC density 
at cell surface (Kazarinova-Noyes et al., 2001; Ratchffe et al., 2001; McEwen et al., 
2004). In heart, tyrosine phosphorylated VGSCpi has been demonstrated to interact 
with Nav 1.5, N-cadherin and connexin-43 (Malhotra et al., 2004). 
Both VGSCpi and VGSCP2 can associate with Navl.5 in heart (Malhotra et 
al., 2001) but the nature of this interaction is not yet clear. In human heart, Navl.5/ 
VGSCpi (but not VGSCp2) complex exists already in endoplasmic reticulum (ER) 
and possibly assists trafficking of VGSCa protein to PM (Zimmer et al., 2002a). The 
interaction of Navl.5 with VGSCP2 occurs in PM, after the proteins have passed 
Golgi (Zimmer et al., 2002a), and it has been suggested that the VGSCP2 can then 
modulate channel conductance (Cruz et al., 1999). Association of nonphosphorylated 
VGSCpi with TTX-sensitive VGSCs and ankyrinB in cardiac myocytes can mediate 
coupling of electrical excitation to contraction (Malhotra et al., 2004). Furthermore, 
expression of VGSCpi can modulate Navl.4 current by increasing the density of 
surface negative charges and thus altering channel gating (Ferrera and Moran, 2006). 
The VGSCp2 subunit has been shown to play a crucial role in regulating VGSC 
density in neurons and hence in the control of excitability (Isom et al., 1995; Chen et 
al., 2002). In addition, VGSCP2 has been shown to regulate translocation and 
immobilization of VGSC in PM and thus contribute to neuropathic pain signalling 
(Pertin et al., 2005). 
Yu et al. (2005) reported that transport of VGSCa to the PM did not depend 
on VGSCpS, but functional association between the two subunits could occur either 
in PM or ER. Similar to VGSCpi (McCormick et al., 1998), VGSCpS was shown to 
be essential for VGSC activity (Yu et al., 2005). 
In rat brain Navl.2 and skeletal muscle Navl.4, VGSCP4 caused negative 
shifts in activation voltage, but Navl.5 was not affected (Yu et al., 2003). As regards 
VGSCp4, it has been predicted that, like the other VGSCP-subunits, this also has an 
extracellular Ig-like fold that could associate with ECM and CAMs (Yu et al., 2003). 
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1.6.3 Splicing of VGSCp genes 
Four different VGSCps derived from different genes have been identified, VGSCpi 
(SCNlB) (Isom et al., 1992; Qin et al., 2003), VGSCp2 (SCN2B) (Catterall, 1992), 
VGSCP3 (SCN3B) (Morgan et al., 2000) and VGSCp4 (SCN4B) (Yu et al., 2003). 
Only VGSCpi has been shown to be alternative spliced (Figure 1.13) (Dib-Hajj and 
Waxman, 1995; Kazen-Gillespie et al., 2000). This alternative splicing is the result 
of the retention of a conserved, 86 nt in rat and 90 nt in human, intron in the 3' 
untranslated sequence (Dib-Hajj and Waxman, 1995). VGSCpiA is about 3000 nt 
longer than VGSCpi, which is about 1400 nt. VGSCpi A splice form is composed of 
the 5' portion of VGSCpi, which includes exonsl,2 and 3, but its 3' end results from 
the partial retention of 3500 nt intron 3 of VGSCpi gene (Kazen-Gillespie et al., 
2000). Thus, VGSCpiA has an 66 amino acid extension in the extracellular part of 
pi, a 19 amino acid transmembrane segment and a short 39 amino acid intracellular 
carboxyl terminus, compared with the 11-, 22- and 36 amino acids in the case of 
VGSCpi, respectively (Kazen-Gillespie et al., 2000). The VGSCpiA protein is 
expressed in heart, skeletal muscle and adrenal gland, but not in adult brain or spinal 
cord; although VGSCpiA mRNA was expressed in neonatal brain, its expression 
became undetectable with the onset of VGSCpi expression (Kazen-Gillespie et al., 
2000). The same studies showed that VGSCpiA can increase the proportion of cells 
expressing functional VGSCs as well as VGSC current density. 
1.7 Transcriptional regulation of VGSC expression 
A variety of stimuli such as injury (Waxman et al., 1994) and growth factors, e.g. 
nerve growth factor (NGF) can cause induction of functional VGSCs in PC12 cells 
(Rudy et al., 1987; Toledo-Aral et al., 1995a). Also, electrical activity (e.g. seizures) 
can alter VGSC gene expression (Marban et al., 1998). These effects may change 
according to host condition, stage of development and cell type (Zur et al., 1995). 
One transcription factor has been identified to inhibit the expression of at 
least one specific VGSCa (Chong et al., 1995; Toledo-Aral et al., 1997). REST is a 
transcription silencer with C2H2 zinc finger motifs that binds to a specific repressor 
element 1 (RE-1) in the promoter of the Navl.2. REST is present in most 
tissues/cells, apart from neurons, and its absence permits expression of the Navl.2 






Figure 1.13 VGSCpiA and VGSCpi splice variants. 
VGSCpiA is predicted to encode a membrane protein very similar to VGSCpi. The 
disulfate-linked immunoglobulin fold is common in both isoforms. The arrow 
indicates where the alternative splicing occurs. VGSCpiA has 66 amino acid near 
the membrane region, 19-amino acid transmembrane segment and 3 9-amino acid 
intracellular domain, compared to the 11-, 22- and 36 amino acids in the case of 
VGSCpi, respectively. R: residues. Modified from Kazen-Gillespie et al. (2000). 
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have shown that over-expression of REST in cultured neurones would result in 
reduction of VGSC currents, similar to long-term TTX application (Nadeau and 
Lester, 2002). The suppression was reversed by high levels of intracellular cyclic 
adenosine monophosphate (cAMP) suggesting that REST might be useful as a 
genetic 'silencer' (Nadeau and Lester, 2002). hi addition, REST has being shown to 
repress voltage gated potassium channel (VGPC) expression in vascular smooth 
muscle cells (Cheong et al., 2005). Decrease in REST enabled expression of Kca3.1 
(KCNN4) which facilitates proliferation (Cheong et al., 2005). Interestingly, REST 
has also been implicated as a human tumour suppressor that might present a novel 
approach to identify candidate genes that suppress cancer development (Westbrook 
et al., 2005). 
1.8 Post-transcriptional modulation of VGSCs 
Phosphorylation, glycosylation, intracellular trafficking, localization, association with 
cytoskeletal proteins and G-proteins are all mechanisms of post-translational 
modification. For example, [By subunits of G-proteins can cause persistent Na"^  currents 
(Ma et al., 1997; Lu et al., 1999; Motlagh et al., 2002). hiteractions with the 
cytoskeleton can occur via either a- or p-subunits and can be direct (via PDZ domains) 
or indirect via cytoskeleton (Isom, 2000). It is possible that VGSCps may also act 
through the cytoskeleton in order to modulate VGSCas (Isom, 2000). Post-
transcriptional down-regulation of VGSC a- and P-subunit mRNA levels as well as cell 
surface functional VGSC expression have been shown to occur via elevation of 
intracellular Ca^^ (Shiraishi et al., 2001). It has also been shown that pi was required to 
modulate and enhance cell surface expression of Navl.2 (McEwen et al., 2004). 
1.8.1 Phosphorylation 
The 'neuronal' isoforms of VGSC (i.e. Navl.l , Navl.2, Navl.3, Navl.7), which 
have a large D1-D2 intracellular linker, contain five consensus sites for cyclic AMP-
dependent protein kinase (PKA) phosphorylation (Figure 1.14A) (Marban et al. 
1998). The 'cardiac' channel Navl.5 has eight distinct PKA phosphorylation sites in 
the D1-D2 linker (Murphy et al. 1996). Although the skeletal muscle isoform 
(Navl.4) is a good substrate for phosphorylation, its function has not been found to 
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Figure 1.14 Phosphorylation characteristics of VGSCa. 
(A) PKA phosphorylation sites of the a-subunit in the long Dl-2 linker (red circles) 
and PKC phosphorylation sites in the D3-4 linker (green square). 
(B) VGSCs are also associated with and regulated by receptor protein tyrosine 
phosphatase (RPTP) p. The CAH (carbonic anhydrase-homology) domain and not 
the FN (fibronectin type II) domain of RPTPP binds to the extracellular region of 
VGSC and VGSC might act as an extracellular ligand for the receptor portion of 
RPTP(3. (i) In developing neurons, the a-subunit may be dephosphorylated by 
RPTPp associates with the channel complex and might be dephosphorylated through 
growth factor receptor signalling, (ii) In the adult, the non-catalytic splice variant, 
phosphacan, associate with the VGSC complex and may displace RPTPp. RTK: 
receptor tyrosin kinase. Modified from Salter & Wang (2000). 
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functional regulation of Navl.8 were found to be located in intracellular Dl-2 loop 
(Fitzgerald et al., 1999). 
Phosphorylation by PKA can have different effects on different VGSC 
isoforms. For example, PKA phosphorylation reduced current amplitude of Navl.l 
but whole-cell conductance increased in Navl.5 (Murphy et al., 1993; Cantrell et al., 
1997). After treatment of bovine adrenal chromaffin cells with membrane permeant 
dibutyryl-cAMP (dbcAMP) or an activator of adenylate cyclase (AC), forskolin, an 
increase in the number of PM VGSCs was detected by radio-labelled STX binding; 
the effect was reversed by the addition of either a PKA inhibitor (H-89) or an 
inhibitor of protein synthesis (cyclohexamide) (Yuhi et al., 1996). Activation of 
PKA has been reported to result (1) in a dose-dependent potentiation of Navl.8 and 
(2) a reduction of Navl.7 currents, with no change in voltage dependency of 
activation or inactivation (Vijayaragavan et al., 2004). The PKA-mediated increase 
in Navl.8 current amplitude was prevented after inhibition of PKA, suggesting that 
intracellular trafficking could contribute to the changes in Navl.8 current amplitude 
(Vijayaragavan et al., 2004). In general, increase in VGSC current after PKA 
activation was followed by (1) a hyperpolarizing shift in the voltage-dependence of 
activation and (2) an increase in the rates of activation, deactivation and inactivation 
(England et al., 1996; Gold et al., 1996; Gold et al., 1998; Chahine et al., 2005). 
Protein kinase C (PKC) altered the functioning of all mammalian VGSC 
isoforms studies and a possible mechanism of action is described in Figure 1.15B 
(Murray et al., 1997; Chahine et al., 2005). PKC would phosphorylate VGSCa at a 
highly conserved serine residue in the D3-D4 linker (Marban et al., 1998). Activation 
of conventional PKC (PKC-a) reduced the VGSC expressed in PM by accelerating 
intemalisation of VGSC protein (Kobayashi et al., 2002). Activation of Ca^ "^ -
dependent PKC-s increased degradation of VGSCa mRNA (Kobayashi et al., 2002). 
Thus, isoform-specific PKC can down-regulate PM expression of VGSCa by 
shortening its half-life without changing its gene transcription (Yanagita et al., 2000). 
A further study demonstrated a dose-dependent decrease in both Navl.7 and Navl.8 
currents after activation of PKC (Vijayaragavan et al., 2004). On the other hand, 
PKC caused a reduction in Navl.2 currents when phosphorylated in the serine 
residues in cytoplasmic linker between D3-D4 and D1-D2 (Cantrell and Catterall, 


















Figure 1.15 Regulation of VGSC by PKA and PKC. 
(A) Regulation of VGSC by protein kinase A (PKA). Activation of the Gq-coupled 
receptor (GPCR) leads to stimulation of adenylyl cyclase (AC) and activation of 
PKA. Activated PKA phosphorylates VGSC protein and promotes its trafficking to 
plasma membrane. 
(B) Regulation of VGSC by protein kinase C (PKC). Activation of a G-coupled 
receptor leads to activation of phospholipase C (PLC) and production of inositol 
(l,4,5)-trisphosphate (IP3) and diaglycerol (DAG). Ins[l,4,5]P3 releases intracellular 
Ca"^ ^ and, together with DAG, activate PKC. Association of activated PKC with the 
receptor for activated C kinase (RACK) generates a physiological response that 
results in the phosphorylation of VGSC. 
PIP2: Phosphatidylinositol(4,5)-bisphosphate. Modified from Chahine et al. (2005). 
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across VGSCas, similar mechanisms might be involved in other VGSCas (Chahine 
et al., 2005). 
Interestingly, it has been suggested that PKA and PKC effects on VGSCs 
may be interactive (Chahine et al., 2005). A key site of Navl.2 phosphorylation by 
PKC is that of serine residue at position 1506 (SI506) on D3-D4 linker (West et al., 
1991). Phosphorylation of SI506 by PKC assisted phosphorylation of the D1-D2 
loop by PKA (Murphy et al., 1993; Cantrell et al., 2002). In addition, PKC-
dependent phosphorylation of S576 in D1-D2 hnker was required for enhancement 
of PKA modulation of Navl.2 (Cantrell et al., 2002). A recent study demonstrated 
enhancement of Navl.2 slow inactivation due to neuromodulation by PKA and PKC 
(Chen et al., 2006). 
Following serum deprivation, treatment of cultured bovine adrenal 
chromaffin cells, which express Navl.7, with PD98059 or U0126 (MEK inhibitors) 
increased VGSC expression in PM was seen (Yanagita et al., 2003). Either treatment 
inhibited constitutive phosphorylation of extracellular signal- regulated kinase (ERK) 
1 and ERK2 (Yanagita et al., 2003). It was suggested that constitutively 
phosphorylated/activated ERK would destabilize VGSC mRNA via a translational 
event, and this negatively regulated steady-state level of VGSCa mRNA and PM 
expression of functional VGSCs (Yanagita et al., 2003). 
VGSC regulation by tyrosine phosphorylation has been well documented 
(Davis et al., 2001). In rat pheochromocytoma (PC 12) cells, activation of receptor 
tyrosine kinases (RTKs) by application of epidermal growth factor (EGF) and 
platelet-derived growth factor (PDGF) rapidly inhibited whole-cell currents of 
Navl.7 channel (Hilbom et al., 1998). VGSCs are also associated with and regulated 
by receptor protein tyrosine phosphatase (RPTP) P (Figure 1.14B) (Salter and Wang, 
2000). VGSCs in brain neurons interacted with RPTP(3 both extracellularly and 
intracellularly and regulated VGSC modulation by tyrosine phosphorylation 
(Ratcliffe et al., 2000). Interestingly, tyrosine dephosphorylation slowed VGSC 
inactivation and increased whole cell VGSC current (Ratcliffe et al., 2000). The 
CAH (carbonic anhydrase-homology) domain and not the FN (fibronectin type II) 
domain of RPTP(3 binds to the extracellular region of VGSC and VGSC might act as 
an extracellular ligand for the receptor portion of RPTPp. Intracellularly, the first 
PTP (phosphotyrosine phosphatase) domain was found to bind to both a and pi 
subunit (Salter and Wang, 2000). It is possible that the intracellular binding to 
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VGSCa acts as a substrate trapping and the pi-subunit may serve to bring the 
phosphatase domain near phosphorylation sites on the intracellular domain of the 
VGSC (Salter and Wang, 2000). 
1.8.2 Glycosylation 
All VGSCas have a number of potential extracellular glycosylation sites situated in 
the putative pore lining regions of D1 and D3 (Figure 1.3) and are heavily 
glycosylated, with up to 40 % of the mass being carbohydrate (Marban et al., 1998; 
Bennett, 2002). In neurons and Schwann cells, glycosylation is very important for the 
maintenance of PM expression of VGSCs. Indeed, in neuroblastoma cells, inhibition 
of glycosylation by tunicamycin decreased the number of STX binding sites (Marban 
et al., 1998). 
Glycosylation can affect electrophysiological properties of VGSCas. The 
gating of two human VGSCa (Navl.4 and Navl.5) had different dependencies on 
sialic acid (Bennett, 2002; Stocker and Bennett, 2006). Under conditions of reduced 
sialylation, Navl.4 showed a depolarizing shift in activation voltage, whilst Navl.5 
showed no change. Further studies indicated that sialylation of Navl.4, but not 
Navl.5, resulted in a negative surface potential (Bennett, 2002). When the Dl: S5-S6 
of Navl.4 was replaced by the equivalent Navl.5 loop, changing sialylation had no 
significant effect, hi contrast, when Navl.4 D1:S5-S6 was added to Navl.5, 
activation voltage was depolarised under conditions of reduced sialylation. These 
findings indicated that the functionally relevant sialic acid residues were localized to 
the D1:S5-S6 loop in Navl.4 (Bennett, 2002). 
Many pathological conditions, such as neuropathic pain and cardiac arythmia, 
have been linked with deficient glycosylation of VGSCa (Ufret-Vincenty et al., 
2001; Zhang et al., 2003). Interestingly, 15-day embryonic VGSCa displayed a lower 
apparent molecular weight and a lower sialylation level than postnatal VGSCa, 
suggesting that VGSCa glycosylation might be developmentally regulated (Castillo 
et al., 2003), as in the case of rat Navl.9 (Tyrrell et al., 2001). 
1.8.3 Protein trafficking 
In general, newly synthesized proteins, carbohydrates and lipids traffic to PM 
through the secterory membrane system (Figure 1.16). Organelles such as ER, Golgi 
73 
and PM and tubulovesicular transport intermediates are all parts of this system, 
facilitating transport to PM (Lippincott-Schwartz et al., 2000). Proteins, including 
VSGCs, synthesized in ER are transported to Golgi for ftirther maturation, through 
pre-Golgi intermediates (transport vehicles for protein delivery). Then post-Golgi 
carriers, transport the mature protein to its final destination, PM (Lippincott-
Schwartz et al., 2000). 
L8.3.1 Signal peptides 
Different types of signal peptides are fundamental for directing proteins within cells 
(Figure 1.16B and C) (Alberts et al., 1994). For example, proteins that travel to ER 
usually have a signal peptide at their amino terminus and most of these proteins pass 
to Golgi. Proteins with a specific sequence in their C-terminus are retained in ER. 
Other signal peptides exist for proteins to be retained in Golgi or to be allowed to 
reach PM. 
Signal peptides have also been identified for ion channels, including VGSCs (Figure 
1.17). hi a splice variant of voltage- and -activated channel (SVl), a 
hydrophobic ER retention/retrieval motif (CVLF) was identified that inhibited PM 
expression (Zarei et al., 2004). Another ER retention/retrieval motif that restricts PM 
expression was identified in ATP-sensitive channels (Zerangue et al., 1999). hi 
NMDA (N-methyl-D-aspartate) receptors, an ER retention/retrieval motif was 
identified in C-terminal, that regulated PM expression in neurons (Scott et al., 2001). 
Interestingly, phosphorylation by PKC suppressed ER retention (Scott et al., 2001). 
Another type of signal peptide was found in the N-terimal of the inward rectifier 
channel Kir2.1 (Stockklausner and Klocker, 2003). This peptide was necessary for 
protein export fi-om Golgi, and in the absence of this sequence, accumulation of the 
protein in Golgi and reduction of PM expression were observed (Stockklausner and 
Klocker, 2003). hi intermediate-conductance Ca^^-activated K"^  channel h lKl , 
another motif in the N-terminal was essential for channel assembly and trafficking to 
PM (Jones et al., 2004). In Navl.5, it has been demonstrated that both 
phosphorylation of Navl.5 and the presence of a putative ER retention signal were 
required for PKA-mediated increase in functional Navl.5 expression (Zhou et al., 
2002). ER may also have particular chaperones that bind to the ER retention signals 
of proteins (Kim and Arvan, 1998). If another protein is bound to the ER retention 
motif, then the retention effect is abolished and hence the protein is then permitted to 
travel to its final destination usually to PM, through Golgi (Herfst et al., 2004). In the 
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Figure 1.16 Protein trafficking to the PM, 
(A) Protein trafficking to PM through secretory pathway. A protein destined to be 
secreted or to be localised to PM leave the endoplasmic reticulum (ER) through 
tubular-vesicular structures (pre-Golgi) toward the (-) end of microtubules. They 
merge with Golgi membranes which in many mammalian cells are located near the 
microtubule organizing centre (MTOC). From the Golgi, the protein is packed into 
post-Golgi transport intermediates (Post-Golgi), which translocate towards the plus-
end (+) directed along microtubules to the PM. Modified from Lippincott-Schwartz 
et al. (2000). 
(B) A simple schematic representation of protein trafficking. Newly synthesed 
proteins traffic fi^om ER to Golgi or are retained in ER. In Golgi, they can either be 
retained or continue their journey to secretory vesicles (or lysosomes, which contain 
digestive enzymes, if they are not properly made) and may finally reach PM. 
Different types of signal peptides are responsible for the protein destination in the 
cell. For example, proteins that travel to ER, usually have a signal peptide at their 
amino terminus, and most of these proteins will pass to Golgi. However, proteins 
with a specific sequence to their C-terminus are retained to ER. Modified from 
Alberts et al. (1994). 
(C) There are two kinds of sorting signals on proteins: (i) signal peptides and (ii) 
signal patch. The signal peptide is a continuous stretch of 15-60 amino acids and is 
often removed from the final protein by a specialised signal peptidase once the 
sorting process has been completed. In the signal patch, the amino acid residues that 
comprise it, can be distant from each other in a linear amino acid sequence but they 
formed close together when the protein is folded in a specific way. Usually, this 
sequences stay in the finished form of the protein. 
Modified from Alberts et al. (1994). 
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Figure 1.17 Regulation of Navl.5 trafficking and expression. 
(A) Schematic representation of regulatory motifs, putative locations of binding sites 
for protein-protein interactions, and phosphorylation sites by PKA on Navl.5 
protein. 
(B) Trafficking of Navl.5 from ER to the plasma membrane. Major regulatory 
events are also indicated in this schematic representation. Navl. l , Navl.3 and 
Navl.6 are also isoform found in the heart, but they only account for less than 5 % 
of the total VGSC. Briefly, regulation of VGSC protein depends on a number of 
processes such as VGSC gene transcription, RNA processing, protein synthesis, 
post-transcriptional modifications, transport to the PM through ER and Golgi, 
anchoring to cytoskeletcal elements and regulation of endocytosis and controlled 
protein degradation. 
Abreviations: (3x: VGSCp-subunit; Cv: caveolae; IcD: intercalated disk; Ls: 
lysosome; N-glyc: N-glycosylation; Phos: phosphorylation; RER: rough 
endoplasmic reticulum; TE: tubular element; TT: transverse tubule; TV: transport 
vesicle. Modified from Herfst et al. (2004). 
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case of the ER retention signal of Navl.5, PKA mediated an increase in functional 
expression of Navl.5 in PM, but the effect was eliminated when the ER retention 
motif was altered (Zhou et al., 2002). This result indicated that PKA activity would 
mask the ER retention motif (Herfst et al., 2004). 
1.8.3.2 Protein kinases A and C 
Recent studies on subcellular localisation of Navl.5 in cardiac myocytes and 
HEK293 cells showed that some Navl.5 a-subunits were localised to ER (Zimmer et 
al., 2002b). When VGSCa, -pi and -P2 subunits were transfected in EBNA293 
cells, Navl.5 a-subunit co-localised only with VGSCpi and not VGSCp2 in ER 
(Zimmer et al., 2002a). Although the mechanism involved in trafficking it is not yet 
known, there is evidence from Xenopus oocyte expression studies that activation of 
PKA modulate the trafficking of both Navl.5 and Navl.8 firom ER to PM (Zhou et 
al., 2000; Vijayaragavan et al., 2004). 
hnmunoprecipitation and immunofluorescence microscopy demonstrated that 
caveolae might also be involved in Navl.5 regulation by a mechanism involving G-
protein activity, independent of cAMP (Yarbrough et al., 2002). 
Differences in trafficking of VGSCs protein to PM would indicate that there 
is a link between activation of PKA and potentiation of currents in some VGSCas 
(e.g. Navl.5 and Navl.8) but not in others (e.g. Navl.2 and Navl.7) (Figure 1.15A) 
(Chahine et al., 2005). cAMP can also stimulate transcription of VGSC genes. An 
increase in functional Navl.4 expression was found to be cAMP/PKA dependent 
(Yuhi et al., 1996). 
Increased levels of cAMP/PKA were important for the transport of 
synaptotagmin (Syt) protein to PM (Fukuda and Yamamoto, 2004). Interestingly, 
activation of PKC down-regulated functional Navl.2, Navl.4, Navl.5, Navl.7 and 
Navl.8 expression (Schreibmayer et al., 1991; Bendahhou et al., 1995; Murray et al., 
1997; Tateyama et al., 2003; Vijayaragavan et al., 2004; Wada et al., 2004). PKC-a 
isoform promoted internalization of Navl.7 via an endocytotic mechanism, whilst 
PKC-8 destabilised Navl.7 mRNA but did not change Navl.7 gene transcription. On 
the other hand, PKA up-regulated Navl.7 by modulating its intemalisation and/or 
extemalisation fi-om Golgi (Wada et al., 2004). Thus, 
phosphorylation/dephosphorylation can up- or down-regulate functional VGSCa 
expression by affecting mRNA stability and intracellular trafficking of VGSCa 
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protein (Wada et al., 2004). Furthermore, in DRG neurons activation of PKC 
increased Navl.8 and Navl.9 current amplitudes (Gold et al., 1998; Baker, 2005). 
In A6 epithelial cells, density of apical membrane epithelial Na^ channels 
(ENaCs) was regulated by a cAMP/PKA mechanism via increased exocytosis and 
transport to PM (Butterworth et al., 2001). Another study also suggested that ENaC 
recycling can result from cAMP stimulation (Butterworth et al., 2005). Similarly, in 
distal lung epithelial cells (H441), cAMP/PKA stimulated an increase in ENaC 
current by trafficking to the apical membrane (Thomas et al., 2004). However, long-
term effects required synthesis of de novo ENaC mRNA and protein. Long-term 
effects involved activation of PKA, phosphatidyl inositol 3-kinase (PIS-kinase) and 
p28 MAP kinase (Thomas et al., 2004). Interestingly, in cerebellar granule cells, an 
increase of Na^ influx elevated cAMP levels (Cooper et al., 1998). Another study 
suggested that Na, K-ATPase protein might traffic to PM after a rise in intracellular 
Na"^  concentration through cAMP-independent PKA activation (Vinciguerra et al., 
2003). It would seem possible, therefore, that VGSC control is under auto-control via 
intracellular Na'^  and PKA-dependent phosphorylation/dephosphorylation. 
1.8.3.3 Interaction with other proteins 
Six main types of intracellular protein have been reported to interact with and 
contribute to regulation of VGSCa: (1) ankyrin, (2) FGF homologous factor IB 
(FHFIB), (3) calmodulin, (4) Nedd4-like ubiquitin-protein ligases, (5) syntrophin 
proteins and (6) annexin II (Abriel and Kass, 2005; Chahine et al., 2005). The C-
terminus (C-T) has been recognized as an importent region of VGSCa for protein-
protein interactions (Abriel and Kass, 2005) and intramolecular effects also involving 
the cytoplasmic D3-4 linker (Figure 1.18A red arrow) (Motoike et al., 2004). The 
VGSC C-T is well structured and has six a helices (Abriel and Kass, 2005). The 
following protein interaction sites have been found: (1) a calmodulin binding IQ 
motif (Tan et al., 2002; Kim et al., 2004), (2) a PY motif (Abriel et al., 2000; Fotia et 
al., 2004; van Bemmelen et al., 2004) and (3) a PDZ binding motif (Gee et al., 1998). 
Intracellular trafficking of VGSC to and from PM, modulation of VGSC 
function via phosphorylation and control of Na'^-dependent endocytosis might also 
be controlled by association with the synaptic vesicle protein, synaptotagmin (as 
reviewed by Diss et al., 2004). Although Navl.4 does not have the domain necessary 




C O O H C O O H 
BSEE8HSK. 
SQESSIBDt 'COOH 
C-terminus pf Nav l .5 and interacting proteins ] 
Structured region 
PY motif PDZ binding motif 
s i v l - C O O H 
1773-1832 segment IQ motif 
Figure 1.18 Association of Navl.5 with interacting proteins. 
(A) VGSCa interaction with the two VGSCp-subunits (red) and other interacting 
proteins. Six proteins (Annexin II, ankyrin, Nedd4-like, syntrophin, calmodulin, 
FHFIB) that have been reported to interact with VGSCas are shown with their 
approximate binding sites. Except Anexin II, all interacting proteins have been 
reported to associate with a number of VGSCas including Navl.5. Annexin II has 
been reported to interact with Navl.8. D1-D4 indicate the four domains of the 
channel; the voltage-sensor S4 is coloured green. The IFM (isoleucine-
phenylalanine-methionine) motif (intracellular loop D3-4, in red) is important for fast 
inactivation. The red arrow indicates the intramolecular interaction between D3-4 
linker and the C-terminus (C-T). Phosphorylation sited by PKA and PKC are shown 
as blue circles. 
(B) The C-T of Navl.5 and interacting proteins. The structured region has six grey 
boxes indicating the a helices that Navl.5 C-T has been proposed to be composed of 
and the IQ motif. Four sites have been reported to be responsible for protein-protein 
interactions. Different proteins bind to specific motifs as shown on the figure. 
Modified from Abrial & Kass (2005) and Chahine et al. (2005). 
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with this protein through a binding region in D1-D2 cytoplasmic loop (Sampo et al., 
2000). 
Syntrophins are members of a family of intracellular adapter proteins which 
mediate interactions so as to adapt different proteins (e.g. protein kinases or ion 
channels) to the muscle protein dystrophin (Abriel and Kass, 2005). Syntrophins 
have PDZ domains and can interact with proteins that have PDZ-binding domains in 
their C-Ts (Abriel and Kass, 2005). Both Navl.4 and Navl.5 have been reported to 
interact with syntrophin through PDZ domains (Gee et al., 1998). Interaction of 
syntrophin and Navl.5 in HEK-293 cells shifted channel activation and reduced 
currents and this depended on interactions between Navl.5 C-T and syntrophin PDZ 
domain (Ou et al., 2003; Chahine et al., 2005). Navl.5 can also interact with actin 
cytoskeleton via syntrophin (Ou et al., 2003). In a recent review, Abriel et al. (2005) 
speculated that the association of VGSCa with syntrophin might be important for 
targeting or stabilization of Navl.5 to PM. 
Thus, the VGSCa C-T is a very important regulatory region. For example, 
Navl.8 C-T regulates functional channel density in PM as well as channel gating 
(Choi et al., 2004). C-T interacts with a number of cytoskeletal and adaptor proteins, 
including (i) contactin, which can associate with Navl.9, Navl.3 and Navl.2, (ii) a-
tubulin, (iii) p-actin and (iv) moesin; Navl.8 being able to interact will all four 
(Kazarinova-Noyes et al., 2001; Liu et al., 2001b; Malik-Hall et al., 2003; Shah et 
al., 2004; Chahine et al., 2005). Interaction of Navl.2 with contactin (a CAM) 
increased PM expression of functional chaimels (Kazarinova-Noyes et al., 2001). 
Such an association may also control clustering of VGSCas at nodes of Ranvier in 
DRG neurons (Peles and Salzer, 2000; Rios et al., 2000; Kazarinova-Noyes et al., 
2001; Chahine et al., 2005). 
Ankyrin proteins (i.e. Ankyrin-G and -B) are adapter proteins that link 
membrane proteins to cytoskeleton (Abriel and Kass, 2005). Interaction of VGSCa 
with ankyrin-G has been well documented (Michel et al., 1999; Lustig et al., 2001; 
Mohler et al., 2004a). Mutation studies determined that ankyrin-G facilitates normal 
trafficking of Navl.5 (Mohler et al., 2004a). Interaction of Navl.5 with ankyrin-B 
has also been documented but the role of this interaction is still not fully understood 
(Mohler et al., 2004b). It has also been suggested that ankyrin-G could anchor 
VGSCas to PM (Garrido et al., 2003). 
81 
FHFIB, a member of the FGF family, is expressed in cardiac tissue 
intracellularly (Liu et al., 2001a). FHFIB has been reported to associate with Navl.9 
and Navl.5 but not with Navl.7 and Navl.8 (Liu et al., 2001a; Liu et al., 2003). As 
regards Navl.5, FHFIB interacts with the proximal part of C-T and this modulates 
the channels functional properties (Liu et al., 2003; Abriel and Kass, 2005). Liu et al. 
(2003) also suggested that FHFIB might help to adapt protein kinases to VGSCa. 
Interaction of calmodulin (CaM) with the IQ motif of Navl.5, and other 
channels, has been studied (Tan et al., 2002; Herzog et al., 2003; Mori et al., 2003; 
Kim et al., 2004; Young and Caldwell, 2005). Navl.4 and Navl.6 currents were 
reduced when the interaction with CaM was disturbed (Mori et al., 2003). Another 
study indicated that the C-T domain in Navl.4 and Navl.5 was responsible for CaM 
effects on chaimel inactivation (Young and Caldwell, 2005), enhancing the entry of 
Navl.5 into slow inactivation state (Tan et al., 2002). 
Annexin II is a cytoskeletal (F-actin) binding protein that associates with PM 
in a Ca^^-dependent manner (Gerke and Moss, 2002). Annexin binds to the N-
terimin of the VGSCa protein (Figure 1.18) (Chahine et al., 2005). Association of 
annexin II light chain with Navl.8 facilitated functional expression of Navl.8 and 
promoted its translocation to PM (Okuse et al., 2002). 
1.8.3.4 Protein recycling and degradation 
Ubiquitin is a protein that plays a key role in trafficking, internalization, lysosomal or 
proteasomal degradation of membrane proteins, including VGSCa (Figure 1.19) 
(Abriel et al., 2000; Hicke and Dunn, 2003; Abriel and Kass, 2005). Any change in 
the balance between synthesis and degradation of VGSC protein can control the 
expression levels of functional VGSCs in PM (Herfst et al., 2004). Ubiquitin-
dependent internalization and degradation of VGSCs also controls PM expression of 
Navl.5 (Abriel et al., 2000; Herfst et al., 2004). Ubiquitin is carried by three sets of 
enzymes (El, E2 and E3). The E3 enzymes (e.g. Nedd4/Nedd4-like E3 enzymes) are 
ubiquitin-protein ligases that interact directly with target proteins, including Navl.5. 
In these enzymes, ubiquitin is carried by a cystine residue found in the catalytic 
domain homologous to EG-AP protein C-terminal (HECT). The interaction takes 
place between one of the protein-protein interaction WW domains (Staub and Rotin, 
1996) and the PY motif of Navl.5 (Rotin et al., 2000). The PY motifs have been 
found in the C-Ts of all VGSCas except Navl.4 and Navl.9 
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Figure 1.19 Regulation of Navl.5 by ubiquitination. 
Ubiquitin is carried by three enzymes: El, E2 and E3. The E3 enzymes (e.g. 
Nedd4/Nedd4-like E3 enzymes) are ubiquitin-protein Ugases and interact directly 
with target proteins. In these enzymes, ubiquitin is carried by a cystine residue found 
in the catalytic homologous to EG-AP protein C-terminal (HECT; light green box) 
domain. The interaction takes place between one of the protein-protein interaction 
WW domains (darker green) and the FY motif of Navl.5 (blue circle). 
Nedd4/Nedd4-like E3 enzymes ubiquitinate Navl.5 which then gets recognized by 
the "internalization machinery". When internalized, the Navl.5 might be recycled 
back to the plasma membrane or degraded. Modified from Abriel & Kass (2005). 
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(Abriel et al., 2000; Fotia et al., 2004). Nedd4/Nedd4-like E3 enzymes ubiquitinate 
Navl.5 which then gets recognized by the "internalization machinery" (Abriel and 
Kass, 2005). When internalized, Navl.5 might be recycled back to PM, or degraded 
(Abriel and Kass, 2005). Interaction of Navl.5 with ubiquitin protein Hgase Nedd4 
reduced the expression of Navl.5 on PM possibly by ubiquitination of the protein 
and subsequent endocytosis (Abriel et al., 2000; van Bemmelen et al., 2004). Nedd4-
2 also increased the internalization rate of Navl.5 in HEL293 cells (Rougier et al., 
2005). 
1.8.3.5 VGSCp-subunits 
VGSCa association with VGSCP-subunit(s) may also play a role in protein 
trafficking by mediating interaction of VGSCas with modulatory molecules such as 
RPTPP (Ratcliffe et al., 2000). Interaction of VGSCa with P-subunits is important 
for stabilisation and concentration of functional VGSCs in PM (Kazen-Gillespie et 
al., 2000; Vijayaragavan et al., 2001; Chahine et al., 2005). hiterestingly, when 
VGSCpi was co-expressed with Navl.5 in HEK-293 cells, the protein complex was 
retained in ER (Zimmer et al., 2002a). Furthermore, in Xenopus oocytes, co-
expression of either VGSCpi or VGSCPS with Navl.5 caused an increase in current 
amplitude possibly because VGSCpi/p3 facilited VGSC export from ER to PM 
(Fahmi et al., 2001). Another study revealed that co-expression of VGSCP2 with 
VGSCa in Xenopus oocytes (i) increased functional expression, (ii) modulated gating 
and (iii) caused up to a 4-fold increase in membrane capacitance, consistent with 
increased fusion of intracellular vesicles, possibly containing newly synthesized 
VGSC, with PM (Isom et al., 1995). Another recent study, has shown that the 
intracellular domain of VGSCp3 was necessary for its delevery to PM (Yu et al., 
2005). However, a deletion of the intracellular domain of VGSCp3 showed that it 
could navigate the secretory pathway independently of the VGSCa (Yu et al., 2005). 
1.8.3.6 Endosomal pathway 
An endosomal pathway may also be involved in VGSC protein trafficking. 
Endocytosis of PM proteins including neurotransmitter receptors is well documented 
(Figure 1.20) (Buckley et al., 2000). Proteins that traffic through the secretory and 
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Figure 1.20 Models for regulation of protein trafficking by the endosomal 
pathway. 
(A) Clathrin mediated endocytosis (CME) of plasma membrane (PM) proteins. CME 
of transferring receptor (TR), a PM protein, happens at a rapid rate due to 
interactions between a motif in the cytoplasmic domains of the internalized proteins 
and AP-2, which is a clathrin adaptor protein. Following internalization into clathrin-
coated vesicles, the TR is transported to the early endosome. Some proteins (i.e. TR) 
are trafficked in lysosomes for degradation or leave the early endosome with a short 
halftime, and accumulate in the endosomal recycling compartment (ERC). A longer 
time is required for exit from ERC. (tl; half life =12 min; t2: half life = 4 min) 
(B) Regulation of neurotransmitter receptors by endocytosis. PM receptors exist in 
two states, (1) free receptor and (2) immobilized receptor concenfrated at synaptic 
sites. Downregulation of free receptor can be accomplished by stimuli that lead to 
enhanced endocytosis (CME). Different stimuli determine whether the receptor can 
be rapidly recycled to the cell surface through the ERC (green diamond) or degraded 
in the lysosome (red diamond). Modified from Buckley et al. (2000). 
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by vesicle 'coat' proteins. Association with clathrin adaptor AP-2 mediates rapid 
endocytosis from PM (Buckley et al., 2000). PM proteins that do not have the 
specific signals for such interactions undergo endocytosis at a lower rate (Buckley et 
al., 2000). A number of other motifs have been identified that mediate interactions 
between the cytoplasmic domain of internalized proteins and AP-2 (Marsh and 
McMahon, 1999). Clathrin mediated endocytosis (CME) of transferring receptor 
(TR), a PM protein, happens at a fast rate due to interactions between a motif in the 
cytoplasmic domains of the internalized proteins and AP-2, which is a clathrin 
adaptor protein (Figure 1.20A). Following internalization into clathrin-coated 
vesicles, TR is transported to the early endosome. Some proteins (i.e. TR) are 
trafficked to lysosomes for degradation or left in the early endosome and accumulate 
in the endosomal recycling compartment (ERC). A longer time is required for exit 
from ERC (Buckley et al., 2000). Regulation of PM neurotransmitter receptors can 
occur by CME (Figure 1.20B). Downregulation of 'free' PM receptor can be 
accomplished by stimuli that lead to enhanced CME. Different stimuh determine 
whether the receptor can be rapidly recycled to the cell surface through ERC or 
degraded in the lysosome (Buckley et al., 2000). 
PKA also has a regulatory role in trafficking of vesicles from Golgi to PM 
(Muniz et al., 1996; Muniz et al., 1997). Interestingly, synaptotagmin, a synaptic 
vesicle protein implicated in vesicular fusion, was found to interact with VGSCs in 
neurons (Sampo et al., 2000). These observation would suggest (1) that the VGSC-
synaptotagmin complex is involved in VGSC exocytosis or/and (2) that 
synaptotagamin might be involved in regulated endocytosis of VGSC (Sampo et al., 
2000), since synaptotagmin interacts with clathrin adaptor AP-2 (Zhang et al., 1994; 
Li et al., 1995). 
PART C: ION CHANNELS AND CANCER 
1.9 Ion channel expression in cancer 
There is increasing evidence that the role of ion channels in cancer is important 
(Figure 1.21) (Schonherr, 2005). Many types of ion channels have been found to be 
expressed in various cell lines derived from different cancers, including cancers of 
prostate, lung, melanoma, breast, bladder, liver, brain, colon and cervix (Fraser et al., 
2002b) (Table 1.3). Thus, the establishment of ion channel profiles in tumour 
biopsies may have novel prognostic and/or therapeutic values. 
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Figure 1.21 Ion channels expression in common cancers. 
Horizontal bars on the left indicate incidence rates (%) of common cancers in 
Germany. On the right, up-regulation of ion channels with potential relevance to 
cancer. The data of Navl.5 has been taken from Fraser et al. (2005). (X) denotes that 
VGSC was found to be expressed in SCLC (Blandino et al., 1995; Onganer and 
Djamgoz, 2005) and melanoma (Allen et al., 1997) but the specific isoform was not 
identified. Modified from Schonherr (2005). 
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Table 1.3 Summary of voltage-gated ion channels expressed in cancer lines and 
their effect on cellular proliferation. 
Abbreviations: H: human; M: mouse; R: rat; VGPC: voltage-gated channel; 
VGSC: Voltage-gated Na"^  channel; KATP: ATP-sensitive K"^  channel; Kjr: inward-
rectifier K"^  channel; Kc :^ Ca^ "^  - dependent K"^  channel; VSCCL: Volume-sensitive 
c r channel; VGCC: Voltage-gated CI" channel; SOC: Store-operated Ca^ "^  channel. 
Modified from Fraser et al. (2002). 
Cancer & Ion channel Effect of block Proposed mechanisms 
cell line examined on proliferation of involvement 
Prostate 
MAT-LyLu (R) VGPC Minimal effect Not known 
AT-2 (R) VGPC Reduction Not known 
MAT-LyLu (R) VGSC No effect Not involved 
LNCaP (H) VGPC Reduction Not known 
Breast 
MDA-MB-231 (H) VGSC None -
MCF-7 (H) Kca Not tested Not known 
MCF-7 (H) Katp Reduction Membrane potential 
MCF-7 (H) K JR Reduction Not known 
EFM-19 (H) K J R Reduction Not known 
Melanoma 
SK MEL 28 (H) K JR Reduction Control of [Ca^ "^ ]; 
Kca No effect Not involved 
IGRl (H) VGPC Reduction Control of [Ca^ "^ ]i ? 
Cervix 
HeLa (H) Kca Not tested Cell volume 
HeLa(H) K J R Reduction Not known 
SiHa (H) VGCC Reduction Volume-regulation 
Colon 
HRT-18(H) SOC Reduction Control of [Ca^ "^ ]i ? 
Gastric 
SC-Ml (H) Kca Not tested Membrane potential ? 
KATO-III (H) Kc. Not tested Not involved 
Brain 
NG 108-15 (M) VGPC Reduction Not resting potential 
VGPC Reduction Cell volume 
v s c c Reduction Cell volume 
C6(R) VGPC & VGCC Reduction Cell volume 
Not resting potential 
SH-SY5Y (H) KjR Not tested Not known 
STTG-1 (H) VGCC Reduction/increase Cytockeleton ? 
U87&A172(H) VGPC Reduction Not known 
Bladder 
HTB-9 (H) Katp Reduction Protein synthesis 




Not Ca^ ^ influx Nb2(R) VGPC Reduction 
Liver 
HepG2 (H) Katp Reduction Decrease DNA synthesis 
HuH-7 (H) Katp Reduction Decrease DNA synthesis 
HFL (H) Katp Reduction Decrease DNA synthesis 
89 
1.9.1 channels 
Calcium is an important regulator of cell cycle and proliferation (Kunzelmann, 
2005). Calcium is involved in the control of growth in BCa cell Unes, through its 
interaction with calmodulin. There is not much evidence for VGCC expression in 
carcinoma cell lines, although voltage-independent Ca^ "^  permeation mechanisms 
have been found (Sergeev and Rhoten, 1998; Gutierrez et al., 1999; Ferret et al , 
1999; Skryma et al., 2000; Ding et al., 2006b). hi the case of BCa MCF-7 cells, 
Eraser et al. (2005) found no depolarization-activated inward current, although Strobl 
et al. (1995) had reported both voltage-dependent and voltage-independent plasma 
membrane Ca^^ channels. As regards MDA-MB-231 cells, the inward currents are 
abolished completely in Na'^-free medium and no VGCC activity was apparent 
(Fraser et al., 2005). Studies on BCa cell lines, such as MDA-MB-231 and MCF-7, 
proved that a Ca^^-activated CI" channel may act as a tumour suppressor (Gruber and 
Pauli, 1999). Patch clamp has not detected any type of voltage-gated channel 
(VGCC) in the human prostate cancer (PCa) LNCaP cell line (Skryma et al., 1997). 
Similarly, in rat PCa Mat-LyLu (strongly metastatic) and AT-2 (weakly metastatic) 
cell lines, patch clamp recordings did not detect any VGCCs (Ding et al., 2006b). 
Interestingly, AT-2 cells had higher resting intracellular than Mat-LyLu, 
suggesting that only the weakly metastatic cells expressed a tonic, voltage-
independent Ca^ "^  influx mechanism (Ding et al., 2006b). A Ca^-permeable non-
selective cation channel in LNCaP cells was activated by two different inducers of 
apoptosis, ionomycin and serum removal (Gutierrez et al., 1999). In LNCaP cells, 
also, alphal-adreno-receptors (alphal-ARs) and muscarinic ml-acetylcholine 
receptors (ml-AChRs) were found to be functionally coupled to Ca^^-permeable, 
diacylglycerol (DAG) -gated cationic channels (Sydorenko et al., 2003). Molecular 
analysis by RT-PCR showed that DAG-gated members of the transient receptor 
potential (TRP) charmel family, including TRPCl and TRPC3, were present in 
LNCaP cells (Sydorenko et al., 2003). 
1.9.2 channels 
Voltage-gated K"^  channels (VGPCs) are involved in a variety of cellular functions 
such as (1) solute and water transport, (2) cell volume regulation, (3) cell adhesion, 
(4) lymphocyte activation and (5) apoptosis, many of which would be involved in 
90 
metastasis (reviews: Eraser et al., 2002; Pardo et al., 2005). It is widely accepted that 
VGPCs are implicated in cell proliferation, since VGPC blockers have been shown to 
inhibit cell proliferation (Conti, 2004; Pardo, 2004; Kunzelmann, 2005; Pardo et al., 
2005). Since growth and proliferation are usually associated with cell volume, this 
might be a function that VGPCs subserve (Pardo et al., 2005). 
Electrophysiological recordings from human BCa cell lines revealed that 
normal epithelial MCF-lOA cells and weakly metastatic MCF-7 cells expressed a 
large outward currents (possibly generated by VGPCs), while this was much smaller 
in strongly metastatic MDA-MB-231 cells (Fraser et al., 2005). There is evidence 
that the membrane potential of human BCa MCF-7 cells in early G1 phase is 
depolarized, and hyperpolarization of the membrane potential occurs during the 
progression from G1 to S phase (Strobl et al., 1995). The mechanism that is likely to 
be responsible for this hyperpolarization is opening of channels (Strobl et al., 
1995; Wonderlin et al., 1995). In MCF-7 cells, activation of ATP-sensitive 
channels were required for this hyperpolarizing transition (Strobl et al., 1995; Wang 
et al., 1998a; Ouadid-Ahidouch et al., 2000). Also, Galagher et al. (1996) described 
that in T47D BCa cells, a CI" current and a delayed rectifier VGPC were present. 
Electrophysiological, immunocytochemical and RT-PCR studies identified Kvl.l but 
not Kvl.2 or Kvl.3 in MCF-7 human breast cancer cells (Ouadid-Ahidouch et al., 
2000). In addition, the VGPCs in MCF-7 cells was reduced by a-dentrotoxin (a-
DTX) and this also suppressed cell proliferation (Ouadid-Ahidouch et al., 2000). 
Expression of non-Kvl VGPC, possibly an intermediate-conductance Ca^^-activated 
K"^  channel (FIBC) and a TWIK-related acid sensitive charmel (a two-pore domain 
family of K"^  channel; TASK 3) have also been reported by electrophysiology in rat 
PCa cells (Mat-LyLu and AT2.1) and in in vivo human BCa samples, respectively 
(Rane, 2000; Mu et al., 2003). 
Electrophysiological recordings have shown that LNCaP cells have a Ca^-
dependent, voltage-sensitive K"^  charmel (Skryma et al., 1997). Proliferation of 
LNCaP cells was reduced significantly by VGPC inhibitors, such as 
tetraethylammonium (TEA) (Skryma et al., 1997). Experiments on the rat Dunning 
model of PCa showed that the weakly metastatic AT-2 cells expressed a much higher 
density of VGPCs than the corresponding isogenic strongly metastatic Mat-Lylu 
cells (Grimes et al., 1995; Fraser et al., 2003a). However, pharmacological analysis 
showed that VGPC activity was involved in controlling proliferation of the weakly 
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metastatic AT-2 cells only (Eraser et al., 2000). Weakly metastatic LNCaP human 
PCa cell lines also showed a higher VGPC current density compared to the strongly 
metastatic PC-3 human PCa cells (Laniado et al., 2001). Electrophysiological, 
pharmacological and molecular experiments on rat PCa (MAT-LyLu and AT-2) cell 
lines showed that both expressed Kvl.3, Kvl.4 and Kvl.6 a-subunits, Kvl.3 being 
predominant; the electrophysiological characteristics suggested that the VGPC in the 
strongly metastatic cells would be less active (Eraser et al., 2003b). 
Interestingly, the VGPC expression pattern in relation to metastatic potential 
was reflected in vivo. Immunohistochemisty showed that Kvl.3 immunoreactivity 
was strong in normal human prostate and tended to be reduced in PCa specimens 
(Abdul and Hoosein, 2002a). 
1.9.3 Voltage-gated Na^ channels 
Genetic (sequence) or epigenetic (expression level) changes in specific VGSC 
isoforms can result in abnormal electrophysiological signalling and therefore, cause 
disease. For example mutations in Navl.5 can cause syncope, seizures, even sudden 
death as a result of a lethal cardiac arrhythmias associated with long QT syndrome 
(Wang et al., 1995), cardiac conduction disease and Brugada syndrome (Wu et al., 
2002). 
There is increasing evidence that VGSC are also involved in metastatic 
human BCa and PCa. The following sections will discuss current evidence of the 
involvement of VGSCs in regulation of metastatic behavior and their expression both 
in vitro and in vivo. 
1.9.3.1 Electrophysiology 
Electrophysiological studies showed that functional expression of a VGSC can 
distinguish strongly (PC-3 and MAT-LyLu) and weakly (LNCaP and AT-2) 
metastatic human and rat PCa cells (Table 1.4) (Grimes et al., 1995; Laniado et al., 
1997). Similarly, whole-cell patch-clamp recordings showed that VGSCs are 
functionally expressed only in the strongly metastatic human BCa cell line, MDA-
MB-231 (Eraser et al., 2002, 2005; Roger et al., 2004). hi contrast, there was no 
depolarisation-activated Na^ current in the weakly metastatic MCF-7 cells or the 
'normal' human breast epithelial cell line MCE-1 OA. The VGSCs were mainly TTX-
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Table 1.4 VGSCa expression in cancer cell lines. 
VGSCa expression in different human and rat cancer cell lines and the method of 
identification are indicated. Key; RT-PCR; reverse transcriptase polymerase chain 
reaction; WB; Western blot; ICC: immunocytochemistry; SCLC; small cell lung 
carcinoma. (*) indicates predominant isoform expressed. (**) A TTX-S VGSC was 
recorded but its identity was not determined. 
Cell lines Cancer VGSCa Method of References 
(species) Isoform identification 
MDA-MB-231 BCa (human) Navl.5* RT-PCR, Eraser et al. 
MCF-7 Navl.7 Electrophysiology, (2005) 
Navl.6 WB, ICC 
PC-3M, PCa (human) Navl.7' RT-PCR, Diss et al. 
PC-3, Nay 1.2 electrophysiology, (2001X 
LNCaP Navl.3 WB Laniado et 
Navl.6 aL(I997) 
Mat-LyLu, PCa (rat) Navl .7 ' RT-PCR, Diss et al. 
AT-2 Nav 1.1 electrophysiology (2001X 
Nav 1.2 Grimes & 
Nav 1.4 Djamgoz 
Nav 1.9 (1998) 
Nax 
Jurkat lymphoma Nav 1.5 RT-PCR, Eraser et al. 
(human) electrophysiology. (2004) 
WB 
H69, SCLC Navl.3 Real-time PCR, Onganer 
H209, (human) Navl.5 electrophysiology &Djamgoz 
H510 Navl.6 (2005X 
Nav 1.9 Onganer et 
ah(2005) 
NB-1 neuroblastoma Navl.5 PCR, Ou et al. 
(human) TTX-S** Electrophysiology (2005) 
DNA cloning 
C8161 melanoma unknown electrophysiology Allen et al. 
C8146 (human) (1997) 
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R and only less than 10 % was TTX-S (Fraser et al., 2005). It was shown that resting 
potentials were inversely correlated with metastatic potential: MDA-MB-231 (~ -19 
mv), MDA-MB-468 (~ -31 mv), MCF-7 (~ -40 mv) and MCFIOA (~ -50 mv) (Fraser 
et al., 2005). Interestingly, VGSCs have also been detected in other cancers such as, 
small-cell lung carcinoma (SCLC) (Blandino et al., 1995; Onganer and Djamgoz, 
2005), neuroblastoma (Ou et al., 2005), lymphoma (Jurkat-Rott and Lehmann-Hom, 
2001; Fraser et al., 2004b), melanoma (Allen et al., 1997) and in neoplastic 
mesothelial cells (Fulgenzi et al., 2006). 
1.9.3.2 Molecular biology 
Human PC-3 cells were found by Western blot and flow cytometry to express VGSC 
localized to the cell membrane (Laniado et al., 1997; Smith et al., 1998; Smith and 
Goldin, 1998). Smith et al. (1998b) studied sixteen different PCa cell lines, both 
human and rat, and found that the strongly metastatic cell lines expressed VGSC 
protein in PM but only a low level of VGSC protein was found in the weakly 
metastatic cells, which was undetectable electrophysiologically. RT-PCR, protein 
studies and electrophysiology together revealed that Navl. l , Navl.2, Navl.4, 
Navl.9, Navl.7 and Nax were expressed in rat PCa cells; whilst Navl.7, Navl.2, 
Navl.3 and Navl.6 were expressed in human PCa cells (Table 1.4) (Laniado et al., 
1997; Grimes and Djamgoz, 1998; Diss, 2001). In both strongly metastatic rat (Mat-
LyLu) and human (PC-3M and PC-3) PCa cells the predominant isoform Navl.7 was 
-1000 fold higher expressed at mRNA level compared to weakly metastatic cells 
(Diss et al., 2001). Importantly, DNA sequencing revealed that the Navl.7 was 
present predominantly in its'neonatal' D1:S3 5'-splice (Diss, 2001; Diss et al., 
2004a). Another study demonstrated by molecular biology that both Mat-LyLu and 
AT-2 cell lines express Navl.4 VGSC mRNA. Navl.4 mRNA was also expressed in 
the equivalent human PCa cell lines (PC-3 and LNCaP) (Diss et al., 1998). 
Diss (2001) determined by RT-PCR that Navl.5 VGSCa may be the 
predominant isoform, consistent with the TTX sensitivity. In fact, three VGSCa 
subunit genes were found in both MCF-7 and MDA-MB-231 BCa cell lines: Navl.5, 
Navl.7 and Navl.6 (Table 1.4). Semi-quantitative RT-PCR analyses indicated that 
the relative levels of expression were as follows: Navl.5 (over expressed -1800-
folds) » Navl.7 » Navl.6 (Fraser et al., 2005). Interestingly, the Navl.5 was in it 
'neonatal' D1:S3 5'-splice form (Fraser et al., 2005). The Navl.5 gene structure has 
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been investigated previously by Wang et al (1996). The neonatal Navl.5 (nNavl.5) 
exon differs from the previously published case (Gellens et al., 1992) at 31 of its 92 
nucleotides, resulting in 7 amino acids differences (Figure 1.12) (Eraser et al., 2005). 
A similar D1:S3 5'-splice variant of Navl.5 has recently been described in the 
human neuroblastoma cell line, nBl (Hermonat et al., 2005). Furthermore, 
immunocytochemistry with a novel anti-nNavl.5 antibody (NESO-pAb) showed that 
nNavl.5 was higher expressed in PM of human BCa strongly metastatic MDA-MB-
231 cells than weakly metastatic MCF-7 cells (Chioni et al., 2005; Fraser et al., 
2005). 
1.9.3.3 Role in metastatic cell behaviour 
Studies on VGSC expression in PCa and BCa, showed that VGSC activity can 
enhance a variety of cellular functions in vitro, possibly involved in metastasis, such 
as: 
• changes in morphology and process extension (Fraser et al., 1999); 
• motility (Fraser et al., 2003, 2005); 
• galvanotaxis (Djamgoz et al., 2001; Fraser et al., 2005); 
• invasion (Grimes et al., 1995; Smith et al., 1998; Laniado et al., 1997, 
Fraser et al., 2005; Bennett et al., 2004); 
• proliferation (Abdul and Hoosein, 2002b; Anderson et al., 2003); 
• adhesion (Palmer et al., 2006); 
• gene expression (Mycielska et al., 2005) and 
• secretory membrane activity (Mycielska et al., 2003; Krasowska et 
al., 2004; Fraser et al., 2005). 
Fluorometric in vitro invasion assays on weakly-metastatic LNCaP cell lines 
and two variants of LNCaP cells, that were increasingly tumorigenic, C4 and C4-2 
cell lines showed that C4 and C4-2 cells were more invasive and Western blot 
analyses showed that VGSC expression increased with invasive potential of the cell 
lines (Bennett et al., 2004). The invasiveness could be inhibited by treatment with 
TTX (Bennett et al., 2004). Interestingly, when Navl.4 was over-expressed 
transiently in each cell line, there was an increase in the numbers of invading 
LNCaP, C4 and C4-2 cells. However, the increased invasiveness was also reduced to 
the control levels after treatment with TTX (Bennett et al., 2004). These data 
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suggested that increase VGSC expression alone was "necessary and sufficient" for 
the invasiveness of the PCa cell lines (Bennett et al., 2004). Also TTX treatment 
inhibited invasiveness of both PC-3 (Laniado et al., 1997) and Mat-LyLu cells 
(Grimes and Djamgoz, 1998). In addition, anticonvulsants (phenytoin and 
carbamazepine) which would suppress VGSC activity inhibited the secretion of PSA 
(prostate specific antigen) fi-om LNCaP and PC-3 PCa human cell lines. The growth 
of the two human PCa (LNCaP and PCS) cell lines in Matrigel was inhibited by four 
different anticonvulsants (phenytoin, carbamazepine, valproate and ethosuximide), at 
clinically relevant doses (Abdul and Hoosein, 2001). 
Importantly, Fraser et al (2005) showed that VGSC activity contributes to 
metastatic cell behavior in vitro. TTX treatment inhibited (i) motility, (ii) endocytosis 
and (iii) invasion in MDA-MB-231 cells (Fraser et al., 2005). 
1.9.3.4 VGSC expression in vivo 
In addition, in vivo studies using PCa specimens on a tissue micro array slide were 
examined by immunohistochemistry using an anti-VGSC antibody, revealed that 
VGSC expression was increased in 55 % PCa specimens compared to normal 
prostate tissues (Abdul and Hoosein, 2002b). Furthermore, real-time PCR and 
immunohistochemistry of human PCa biopsies revealed upregulation of Navl.7 in 
metastatic PCa samples (Diss et al., 2005). 
In a double-blind RT-PCR test of VGSCa mRNA expression in human breast 
biopsy tissues, patients that had clear lymph node metastasis (LNM) expressed 
Navl.5 VGSCa mRNA, whilst patients that were free from LNM did not express 
any Navl.5 VGSCa mRNA (Fraser et al., 2005). Importantly, the Navl.5 a-subunit 
was present in the tissues as in BCa cell lines in its novel neonatal splice form 
(Figure 1.12). In addition, immunohistochemistry with the novel nNav 1.5-specific 
polyclonal antibody (NESO-pAb) revealed that nNavl.5 protein was remarkably 
upregulated in human BCa biopsies in comparison with normal human breast tissues 
(Fraser et al., 2005). These results suggested that the nNavl.5 upregulation could 
serve as a novel marker for the metastatic phenotype. 
At present, diagnosis/prognosis of BCa is based upon multiple criteria one of 
which is LNM. However, a significant proportion of women (about 25 %) who are 
LNM-negative go onto developing metastatic disease. Therefore, the development of 
new methods for early diagnosis/prognosis and ultimate cure of metastatic BCa, but 
96 
also other cancers such as PCa, are urgently required. The involvement of VGSCs in 
metastatic cell behaviour and their susceptibility to different drugs and channel 
blockers would suggest that VGSCs, may serve as a potential target for prognosis 
and novel therapeutic approaches. 
1.9.3.5 Regulation of VGSC expression 
The cause(s) and mechanism(s) of VGSC upregulation in metastatic cancer is not 
known yet. However, EGF is shown to increase VGSC current density in Mat-LyLu 
cells and although EGF upregulated cell migration, TTX treatment reduced this 
effect, suggesting that this upregulation was VGSC dependent (Ding et al., 2006a). 
In addition, serum concentration has been proved to be very important factor for 
VGSC activity in Mat-LyLu cells (Ding and Djamgoz, 2004). Increasing serum 
concentration in 24 hours starved Mat-LyLu cells from 1% to 5 % decreased 
functional VGSC and increased TTX sensitivity. Taking into account the previous 
statement that EGF increases VGSC current in Mat-LyLu cells, it may be expected 
that an increase in serum concentration would increase VGSC function rather than 
decrease. However, serum contains many growth factors and hormones that might 
well have different modes of action, including stimulatory or inhibitory effects, on 
VGSC expression/activity. Nevertheless, these results proposed a possible 
involvement of serum components, such as proteins and growth factors, in 
transcriptional and post-translational modifications of VGSC expression and/or 
activity (Ding and Djamgoz, 2004). Last but not least, another recent study showed 
that VGSC activity in Mat-LyLu cells was upregulated via activity-dependent 
positive feedback mechanism involving PKA (Brackenbury and Djamgoz, 2006b). 
VGSC auto-regulation occurred via Na^ influx following PKA activation 
(Brackenbury and Djamgoz, 2006b). 
1.9.4 Effects of estrogenic drugs on ion channels 
A widely used anti-estrogen drug, tamoxifen (section 1.3.1) has been reported to 
have effects on a variety of ion channels. For example, tamoxifen directly activated 
large-conductance Ca^'^-activated (BK) channels, through the pi subunit (Perez, 
2005). In other studies, tamoxifen significantly depressed currents such as the 
Ca^^-independent transient outward K"^  current (Ito), sustained outward delayed 
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rectifier VGPC current (Isus), inward rectifier current (EECl), and a VGSC current 
(iNa) in myocytes (He et al , 2003). Tamoxifen also blocked HERG K"^  channels (the 
human ether-a-go-go related gene, which encodes the rapid component of the cardiac 
delayed rectifier VGPC) in Xenopus laevis oocytes (Thomas et al., 2003). In another 
study, therapeutic concentrations of tamoxifen at increased BK channel activity in 
canine colonic smooth muscle cells (Dick et al., 2001; Dick and Sanders, 2001). 
Tamoxifen binding responsible for activation of BK channels was found to be at an 
extracellular site, either within the extracellular loop of the betal-subunit or on an 
unidentified mediator that has an extracellular binding site (Dick et al., 2002) . In 
further study, tamoxifen had a dual effect activating or inhibiting native arterial KCa 
channels (Perez, 2005). Tamoxifen-induced modulation of BK channel was subunit 
specific (Duncan, 2005). The drug reduced single single-channel conductance 
through interaction with the a-subunit, whilst, if the P-subunit was co-expressed, 
tamoxifen, increased channels opening and shifted the voltage activation range to 
more negative potentials (Duncan, 2005). Tamoxifen, also inhibited VGPC currents 
in smooth muscle cells, in a dose dependent manner (Lee et al., 2005). Both, 
tamoxifen and toremifene, another non-steroidal antioestrogen drug, were able to 
inhibit voltage-gated cationic currents in two types of neuronal cells (primary culture 
of hypothalamic neurons and C1300 neuroblastoma cells). Both drugs were able to 
block VGSCs and inhibit K"^  charmels, in both cells lines (Hardy et al., 1998). 
Another anti-estrogen drug, Faslodex, activated BK channels in smooth 
muscle (Dick, 2002). Furthermore, estradiol-17p reduced K^ current in CHO cells 
transfected with human cardiac KCNQi/KCNEl K^ charmel gene in a dose 
dependent manner (Moller and Netzer, 2006). Estradiol-17p also had a minor effect 
on Navl.5, by reducing current amplitude (Moller and Netzer, 2006). In addition, 
daily estradiol-17p treatment increased expression of pi-subunit of BK channels in 
proximal and distal uterine arterial vascular smooth muscle, without changing a-
subunit of BK channel (Nagar et al., 2005). This might suggest that prolonged 
treatment with estradiol-IVP altered BK function by modifying a:pi stoichiometry 
(Nagar et al., 2005). 
1.10 Aims and scope 
The overall aims of the thesis were (1) to produce and validate a novel polyclonal 
antibody against the 'neonatal' splice variant of Navl.5 (nNavl.5), which is the 
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predominant VGSC isoform expressed in metastatic hnman BCa cells and (2) to 
evaluate mechanisms regulating VGSC expression in human BCa cell lines and their 
effects on in vitro metastatic cell behaviour. A multi-faceted approach was used, 
including pharmacology, real-time PGR, Western blot, immunocytochemistry, 
immunohistochemistry, confocal microscopy, and in vitro migration, invasion, 
proliferation and adhesion assays. The specific aims were as follows: 
1. To purify and validate a novel polyclonal anti-'neonatal Navl.5' (nNavl.5) 
antibody (NESO-pAb) from sera of rabbits immunized with a short peptide, 
the amino acid sequence of which was specific to an extracellular epitope of 
nNavl.5. 
2. To use NESO-pAb to test the hypothesis that nNavl .5 was indeed responsible 
for the VGSC-induced enhancement of metastatic cell behaviour in vitro. 
3. To determine the status and localization of nNavl.5 protein in weakly (MCF-
7) and strongly (MDA-MB-231) metastatic human BCa cell lines. 
4. To investigate VGSCa regulation by PKA as well as by autoregulation. 
5. To examine the expression of VGSC |3-subunits in human BCa cell lines and 
to determine the involvement of the predominant isoform in metastatic cell 
behaviour in vitro. 
99 
Chapter 2: METHODS AND MATERIALS 
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2.1 Breast epithelial cell lines 
Three different human breast epithelial cell lines were used: MCF-lOA, MCF-7 and 
MDA-MB-231. MCF-lOA is a normal epithelial breast cell line, retaining many 
characteristics of normal breast epithelium (Kiosses, 2001). MCF-7 and MDA-MB-231 
were derived from human breast carcinomas. MCF-7 cells are non/weakly metastatic 
and were established originally from the breast pleural effusion adenocarcinoma of a 69-
year old Caucasian female (Soule et al., 1973). MDA-MB-231 cells are moderately 
metastatic and have been established from the breast pleural effusion adenocarcinoma of 
a 51-year old Caucasian female (Cailleau et al., 1974). In female nude mice, MDA-MB-
231 cells metastasize mainly to lung, lymph node and brain (Morini et al., 2000). On the 
other hand, although MCF-7 cells have been considered to be weakly metastatic, when 
injected into nude mice, they could metastasize slowly to lung, lymph nodes and spleen 
(Shafie and Liotta, 1980; Kazan et al., 2000). The MDA-MB-231 and MCF-7 cells were 
a gift from Professor Ian Hart from stocks held at St Thomas' Hospital, London. The 
MCF-lOA cells line was donated by Dr Julian Downward (I.C.R.F). 
Morphologically, MDA-MB-231 cells were more rounded in comparison to 
MCF-7 cells which had a characteristic polygonal shape and were more flat (Figure 
2.1 A and B). MCF-lOA cells shared some morphological similarities with MCF-7 cells, 
both having a polygonal structure but MCF-lOA cells appeared more flat (Figure 2.IB 
and C). 
2.2 Mouse and rat tissues 
Rat (Sprague dawley) and mice {Mus musculus) (neonatal: < 2 days old, and adult ~2-5 
months old) were maintained in the Central Biomedical Services (CBS) of Imperial 
College London, Sir Alexander Building, South Kensington, with free access to food 
and water. They were killed by cervical dislocation, without the use of anaesthetic. This 
procedure was performed by a trained technician under a UK Home Office licence. All 








Figure 2.1 Human breast epithelial cell lines in culture. 
(A) Strongly metastatic breast cancer cell line (MDA-MB-231). (B) Weakly metastatic 
human breast cancer cell line and (C) normal human breast epithelial cell line (MCF-
lOA). X200 magnification. Scale bar 16 |im for all. 
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2.2.1 Heart 
Whole heart tissues from both mouse (adult and neonatal) and rat (adult) were used for 
total protein extraction as a positive control for Navl.5 voltage gated sodium channel 
(VGSC) a-subunit (cardiac type VGSC). Heart muscle expresses mainly Navl.5 
(Gellens et al., 1992) and served as a good positive control for immunoblotting with the 
anti-Navl.5 antibody (Maier et al., 2002). 
2.2.2 Brain 
Whole brain tissues from both mouse (neonatal and adult) and rat (adult) were used for 
total protein extraction as a positive control for the pan-VGSCa and anti-Navl.7 
antibodies. It was previously shown that brain expresses Navl.7 (Toledo-Aral et al., 
1997). In addition, limbic regions and pyriform cortex express Navl.5 (Hartmann et al., 
1999) and Navl.l is present at lower levels (Beckh, 1990). Mammalian, brain is also 
known to express Navl.2 and Navl.3 isoforms (Goldin et al., 2000). Thus, brain 
promised to be a good positive control for pan-VGSCa and anti-Navl .7 antibodies. 
2.2.3 Skeletal muscle 
Skeletal muscle from the leg of an adult rat was also used as a control. It is known that 
Navl.5 is expressed at significant levels in skeletal muscle of neonatal rat or denervated 
muscle of adult rat (Rogart et al., 1989; Trimmer et al., 1989). On the other hand, 
Navl.5 was not expressed in innervated adult rat skeletal muscle (Kallen et al., 1990; 
Gellens et al., 1992; Akopian et al., 1996). Thus, total protein extraction from innervated 
adult skeletal muscle was used in this study as a negative confrol to test for the 
specificity of the anti- NESO-pAb antibody for neonatal Navl.5 (nNavl.5). 
2.2.4 Other tissues 
Liver and spleen from adult rat were also used as negative controls to test for the 
specificity of NESO-pAb, since these tissues have been tested by Northern blot and 
found to express Navl.6, Navl.3, Navl.4 but not Navl.5 VGSC a-subunit mRNA 
(Rogart et al., 1989; Kallen et al., 1990; Gellens et al., 1992; Akopian et al., 1996; 
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Raymond et al., 2004). Kidney was used mainly as a negative control since it is known 
not to express Navl.5 (Wu et al., 2002). Kidney was also found to express Navl.3, 
Navl.4 andNavl.9 mRNAs (Raymond et al., 2004). 
Other tissues, such as bladder, testis and lung, have also been tested for VGSCa 
protein expression. Lung from monkey was found to express Navl.3, Navl.4, Navl.7 
and Navl.9 mRNA (Raymond et al., 2004). Furthermore, bladder from monkey was 
found to express Navl.l, Navl.3, Navl.4, Navl.6, Navl.9 mRNAs (Raymond et al., 
2004). Finally, testis from monkey also expressed Navl.3, Navl.4, Navl.6, Navl.7, 
Navl .9 mRNA (Raymond et al., 2004). 
2.3 Human embryonic kidney (EBNA-293) and MCF-7 cell line 
transfections 
EBNA-293 and MCF-7 cells were fransfected with 'neonatal' Navl.5 (nNavl.5) cDNA 
using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. In 
the present study, nNavl.5 contained the D1:S3 5'-splice variant in exon 6 area (Figure 
1.13) and the rest of the gene was considered the same as in Navl.5. The procedure was 
performed by Mr Filippo Pani and Dr SP Fraser, as follows (Chioni et al., 2005): 
2.3.1 Site-directed mutagenesis to generate an expression vector for 'neonatal' 
Navl.5 
An expression vector yielding nNavl.5 gene was generated from pcDNA3.1/hHl by 
substituting ten key nucleotides of the 'adult' Navl.5 sequence in two steps (seven 
substitutions in step 1, three in step 2) using the QuikChange® XL Site-Directed 
Mutagenesis Kit (QCXLM, Stratagene) with a modified protocol (Wang and Malcolm, 
1999X 
Step 1: Two single-primer PGR reactions were performed in a final volume of 50 
fil on 10 ng of the pcDNA3.1/hHl cDNA template using the following PGR primers in 
the QCXLM PGR buffer/dNTP mix: 
Forwardl - 5' GTG TGA TTA TGA TGG CAT AGG CAT GTG AAA ATG TAA 
ACC TGG GCA ATG TGT GAG GGT TAG GCA CCT TCC G 3' and 
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Reversel - 5' CGG AAG GTG CGT AAG GCT GAG AGA TTG CCC AGG TTT 
ACA TTT TCA GAT GCG TAT GCC ATG ATA ATC ACA C 3' 
Reactions were performed as follows: 
(1) Initial denaturation at 95 °C for 5 min; 
(2) addition of 2.5 U of Pfu Turbo DNA polymerase; 
(3) 18 cycles of denaturation at 95 °C for 1 min, annealing at 60 °C for 50 sec, and 
elongation at 68 °C for 28 min (2.5 minute/kb of plasmid length); and 
(4) final elongation at 68 °C for 7 min. 
Of each of these PCR reactions, 25 |il were mixed together in a new PCR tube with 2.5 
U of Pfu DNA polymerase, and subjected to the same PCR protocol as above for a 
further 18 cycles. Following the PCR, the reaction mixture was digested with the Dpnl 
restriction enzyme (10 U at 37 °C for 1 h) to digest the parental (nonmutated) 
supercoiled dsDNA. 5 pi of the digested PCR reaction was transformed into 50 pi of 
XLlO-Gold ultracompetent cells (Stratagene), and appropriate volumes spread onto LB 
agar plates containing ampicillin. Bacterial clones were picked and plasmid DNA 
recovered using a miniprep kit (StrataPrep, Stratagene). Clones were then sequenced 
(MWG Biotech) to confirm the success of the mutagenesis. 
Step 2: The successfully mutated clone (10 ng) was used as the template for the 
second PCR step, performed exactly as the first step, but using the following primers 
(the final mutated expression vector was verified by sequencing): 
Forward! - 5' CAT GGC ATA CGT ATC TGA AAA TAT AAA ACT GGG CAA 
TCT CTC AGC CTT AC 3' and 
Reverse! - 5' GTA AGG CTG AGA GAT TGC CCA GTT TTA TAT TTT CAG ATA 
CGT ATC CCA TG3'. 
2.3.2 Stable over-expression of neonatal Navl.5 in EBNA-293 and MCF-7 cells 
EBNA-293 or MCF-7 cells were plated at a density of 2.5 xlO^ cells/well in 6-well 
dishes the day before the transfection. Transfection was performed using Lipofectamine 
2000 (Invitrogen), according to the manufacturer's instructions. Briefly, 3 pg of DNA 
and 5 pi of Lipofectamine 2000 were used. The day after transfection, the cells were 
split (1:10) and 24 h later selected using 0.5 mg/ml HygromycinB (Invitrogen). The 
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medium was replaced every 4-5 days. Individual colonies were picked after 
approximately 2 weeks, grown and tested for VGSC expression by whole-cell patch-
clamping recording (done by Dr SP Fraser) and Western blotting. 
2.3.3 Expression of 'adult' Navl.5 protein in EBNA-293 cells 
This cells line was a kind gift from Prof Augustus Grant (Grant et al., 2002). In brief, as 
previously described, the 'adult' splice-form of Navl.5 was cloned into the pcDNAS.l 
plasmid (Chandra et al., 1998). The plasmid containing the 'adult' Navl.5 was 
transfected into EBNA-293 cells using Lipofectamine (Invetrogen). 
2,4 Cell culture 
2.4.1 Basics 
Cells were seeded into 100 mm Falcon tissue culture dishes (Beckton Dickinson Ltd., 
Plymouth, UK) and grown in an incubator (Heraeus) at 37 °C, 100 % humidity and 5 % 
CO;. All tissue culture reagents were from Invitrogen (Paisley, Scotland) unless 
otherwise stated. 
Human breast epithelial cell lines (MDA-MB-231, MCF-7, MCF-lOA) were 
grown and maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented 
with 4 mM L-glutamine and 10 % foetal bovine serum (FBS), without phenol red 
(Fraser et al., 2005). In the medium for the MCF-lOA cells, 20 ng/ml EGF (epidermal 
growth factor) was also added. EBNA-293 cells were grown and maintained in 
minimum essential medium (MEM; with Earles's salts and glutamine) supplemented 
with 10 % FBS and 1 % non-essential amino acids. Growth medium for EBNA-293 
transfectants was also supplemented with 500 |J,g/ml Hygromycin B; MCF-7 cells 
transfected with neonatal Navl.5 were supplemented with 0.5 mg/ml Hygromycin B. 
The growth medium was replaced every 2 days until the cells reached ~80 % 
confluence. 
Strongly metastatic prostate cancer (PCa) cells of human (PC-3M) and rat 
(MAT-LyLu) were also used in control experiments. PC-3M cells are a subvariant of the 
strongly metastatic PC-3 human PCa cell line (Kaighn et al., 1979; Chu et al., 2001). 
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PC-3M cells were grown in Roswell Park Memorial Institute (RPMI-164) medium, 
supplemented with 10 % foetal bovine serum (FBS), 4 mM L-glutamine, 1 g/1 sodium 
bicarbonate, 4.5 g/1 glucose and 1 mM sodium pyruvate (Mycielska et al., 2005). Mat-
Lylu cells were originally derived from a spontaneously occurring prostate tumour in an 
inbred Copenhagen rat (Isaacs et al., 1986). MAT-LyLu cells were grown in RPMI-1640 
medium supplemented with 1 % FBS, 2 mM L-glutamine, 250 /ig/ml amphotericin B 
and 250 nM dexamethasone (Isaacs et al., 1986; Grimes et al., 1995). 
2.4.2 Passaging conditions 
When the cells reached near-confluence, they were passaged. After plating, cells reached 
-80 % confluence typically after 5-7 days in the case of MCF-7 and MDA-MB-231 and 
-14 days weeks in the case of MCFIOA cells. To passage a given cell line, the medium 
was removed and 3 ml of trypsin (0.25 %) (Sigma, Dorset, UK) were added into each 
dish. The plates were placed in the incubator for about 2 minutes and then the trypsin 
was carefully removed. The dishes were placed in the incubator for a further 5 minutes 
until the cells were no longer adherent to the plastic. The cells were removed from the 
dish by pippetting with the appropriate medium and seeded into new 100 mm tissue 
culture dishes and re-incubated as normal. 
2.4.3 Cell treatments 
All treatments were started after incubating the cells in normal medium overnight after 
seeding. All pharmacological agents were dissolved in appropriate solvents and diluted 
in growth medium (Table 2.1). 
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Table 2.1 Drugs used for cell treatments. 
When necessary, a given drug was dissolved in the appropriate solvent and then diluted 
in cell culture medium. Solvents were included in control treatments. * Final 




Tetrodotoxin 1-10 Water Alomone 
(TTX) 
KT5720 500 nM DMSO* Calbiochem 
Forskolin 50 DMSO* Sigma 
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2.4.3.1 Forskolin and KT5720 
Forskolin is a stimulator of adenylate cyclase and previous studies showed that protein 
kinase A (PKA) activation can increase VGSCa expression on the cell surface (Zhou et 
al, 2000; Zhou et al., 2002; Brackenbury and Djamgoz, 2006b). KT570 (Calbiochem) is 
a potent membrane permeable inhibitor of PKA; it does not have a significant effect on 
other protein kinases, such as PKC or PKG (Kase et al., 1987; Gadbois et al., 1992; 
Cabell and Audesirk, 1993; Simpson and Morris, 1995). MCF-7 and MDA-MB-231 cell 
lines, cells were treated with 50 )j,M forskolin (dissolved in 0.025 % v/v DMSO; Sigma, 
Dorset, UK) or 500 nM KT5720 (dissolved in 0.025 % v/v DMSO) in their growth 
medium for 48 hours in the incubator. The medium was changed with fresh solution, of 
the same, after 24 hours. The cells were then used for Western blotting, 
immunocytochemistry or real-time PGR (rt-PCR), in order to determine any change in 
VGSCa protein and/or mRNA expression. 
2.4.3.2 TTX 
TTX (1-10 |iM) was diluted in dH20 and added to the normal culture medium of MCF-7 
and MDA-MB-231 cells during various in vitro functional assays (invasion, migration, 
adhesion, proliferation) for 1,8,24 or 48 hours in the incubator. Additionally, cells pre-
treated for 8, 24 or 48 hours were used for Western blotting, immunocytochemistry and 
rt-PCR in order to determine any change in VGSCa protein and/or mRNA expression. 
When cells were treated for 48 hours with TTX, the medium was changed with identical 
fresh solution after 24 hours. 
2.4.3.3 Toxicity assay 
Cells were seeded at a density of 5 x lO'^  cells/ml in 35 mm Falcon tissue culture dishes 
for assaying cell viability. After treatment with a given drug, the medium was removed 
and replaced with 800 fxl of growth medium and 200 |il 0.4 % trypan blue (Sigma, 
Dorset, UK) and incubated for 10 minutes in the incubator. The trypan blue was 
removed and the cells were washed once with 3 ml growth medium. For each treatment, 
cells from 30 random fields of view were counted under lOx magnification. The number 
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of dead cells, stained blue, was counted in each field of view. The data were expressed 
as percentages of living cells out of the total number of cells in given fields of view. The 
percentages were averaged and differences between control and treatment were 
compared from at least three independent experiments. 
2.5 Antibodies 
The following primary (Table 2.2) and secondary (Table 2.3) antibodies were used. 
2.5.1 Navl.5 polyclonal antibody 
A rabbit polyclonal Navl.S-specific antibody that recognizes residues 1122-1137 of the 
intracellular loop D2-D3 of human Navl.5 VGSCa was donated by Prof W. Catterall 
(Maier et al., 2002). This antibody was used at a concentration of 2.2 ng/100 p,l for 
immunocytochemical studies. 
2.5.2 Navl.5 polyclonal antibody (D-492 pAb) 
This rabbit D-492 antibody was raised against a 20 amino acid peptide 
(DRLPKSDSEDGPRALNQLSLC) from an intracellular segment between ID 1-2 that is 
specific to mouse and rat Navl.5 (Cohen, 1996) and was produced by Rockland Inc. 
The anti-D-492 antibody was used at 1:200 dilution for immunohistochemistry studies. 
This antibody was a kind gift from Dr E.F. Shibata. 
2.5.3 Pan-VGSC polyclonal antibody 
The rabbit polyclonal pan-VGSCa antibody, that recognizes all possible isoforms of 
VGSCa protein, was obtained from Upstate Biotechnology (Buckingham, UK). This 
antibody corresponds to a highly conserved segment in the intracellular DIII-DIV loop, 
which is identical in all known vertebrate VGSCas (Dugandzija-Novakovic et al., 1995). 
This antibody was used at 1 p,g/ml concentration for Western blotting and 1 ng/p,l for 
immunocytochemisfry. 
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Table 2.2 Primary antibodies. 
S.C.: Stock concentration; W.C.: Working concentration; WB: Western blot; MW: 
Molecular weight; kDa: kilo Daltons.* Three different antibody purifications. 
Primary Source Species s.c. W.C. for W.C. for MW References 
Antibody WB ICC/IHC 
Pan-VGSC Upstate Rabbit l|ig/ml lHg/100|il 220 kDa Dugandzija-
polyclonal Novakovic et 
al (1995) 
Anti-Navl.5 W. Rabbit 2.2 ng/|il 2.2ng/ml 2.2 ng/ 220 kDa Maier et al. 
Catterall polyclonal lOOp] (2002) 
Anti-Navl.5 E. Shibata Rabbit 3.4 mg/ml 1:200 220 kDa Cohen (1996) 
(D-492 pAb) polyclonal 
NESO-pAb - Rabbit 104 (ig/rnl 0.5-1 0.5-1 220kDa 
polyclonal 55 ug/ml |xg/ml |ig/100iil 
1 ng/ml * 
Anti-Navl.7 Chemicon Rabbit 0.6 mg/ml 1:200 - 220 kDa. Manufacturer 
polyclonal 's guidelines 
Anti-FKA Upstate Goat l|xg/ml 1.3 ng/ml 10 ng/ml 52 kDa Lester et al. 
RH polyclonal 
Anti- Epitomics Rabbit 1:2500 . 51 kDa Montminy 
phospho- monoclonal (1997) 
PKARII 
Anti-Actin Sigma Rabbit _ 1:250 1:200 42 kDa Hennan 
polyclonal (1993) 
Anti-a- Sigma Mouse . 1.2:2000 . 100 kDa Manufacturer 
actinin monoclonal 's guidelines 
Anti- Santa- Goat 200 |ig/ml 1:1000 1:300 90 kDa David et al. 
Calnexin Craz polyclonal (1993) 
(C-20) 
Anti-golgin- Molecular Mouse 100 0.5-1 l|xg/ml 97 kDa Barr(1999); 
97 Probes monoclonal |xg/500|il |xg/ml Kjer-Nielsen 
etal. (1999) 
Anti-glutl Santa- Rabbit 200 ng/ml 1:200- - 65 kDa Hajduch et al. 
Cruz polyclonal 1:1000 (1995) 
Anti-PMCA Upstate Mouse 1 |Xg/|Xl 0.5-2 0.5 |ig/ml 129-140 Hillman et al. 
(Ca+ monoclonal Hg/ml kDa (1996) 
ATPase) 
Anti-Lamin Sant-Cruz Mouse 200 |ig/ml 1:1000 1:250 67 kDa Elbashiretal. 
A/C monoclonal (2001); Paul 
et al. (2002) 
Anti- Serotec Rabbit - functional 1:100 400-220 -
Laminin polyclonal studies: kDa 
lOpl/ml 
Anti- L. Isom Rabbit - 1:500 - 36 kDa Malhotra et 
VGSCpl polyclonal al. (2000) 
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Table 2.3 Secondary antibodies. 
The table shows the secondary antibodies used and the relevant experimental details. 
Key: S.C.: Stock concentration; W.C.; Working concentration; WB: Western blot. 
Secondary 
Antibody 














Anti-rabbit FITC DAKO pig 0.8 g/L 1:50 
Anti-mouse-FITC DAKO Rabbit 
Anti-Goad-FITC DAKO Rabbit 







Anti-goad HRP DAKO Rabbit 0.5 g/L 1:2000 1:100 
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2.5.4 NESO-pAb polyclonal antibody 
Two anti-neonatal-Navl.5 polyclonal antibodies were generated in rabbits under the 
supervision of Prof M. Djamgoz and Dr G. Wilkin. The antibodies were developed 
against two synthetic peptides (Figure 2.2), a short (NESO-pAbS: CVSENIKLGNL-
NH2) and a long (NESO-pAbL: VSENIKLGNLSALRC-NH2), corresponding to the 
extracellular loop connecting the S3-S4 segments in D1 (Figure 2.2). This was a unique 
position with significant amino acid sequence differences between neonatal and adult 
Navl.5 of mouse, rat and human sources. All known antibodies against VGSC isoforms 
have previously been generated against intracellular loops. In contrast NESO-pAb's 
were generated against an extracellular epitope (Figure 2.2 and 2.3). Prior to 
immunization of the rabbits, the potential specificity of the synthetic peptide sequence 
was initially tested on the BLASTP program and its unique sequence was confirmed. 
The anti-neonatal Navl.5 (long) (NESO-pAb) antibody was used at 0.5 pg/ml for 
Western blotting and 0.6-1 |j,l /lOO pi for immunocytochemical studies. 
2.5.5 Pan-actin polyclonal antibody 
The rabbit anti-actin antibody (Sigma) recognized an epitope located on the N-terminal 
region of actin, amino acids 20-33. It was used at 1.5:1000 dilution for Western blots, to 
check the levels of protein loaded per lane on the SDS-PAGE gel for Western blots 
(Herman, 1993). 
2.5.6 a-actinin monoclonal antibody 
A monoclonal anti-a-actinin (mouse ThM isotype; Sigma) antibody was derived from a 
hybridoma produced by fusion of mouse myeloma cells with splenocytes from an 
immunized mouse. As immunogen, the cytoskeletal fraction of bovine mammary gland 
epithelium cultured cells was used, a-actinin is an actin binding protein and has a 
molecular weight of 100 kDa. This antibody was used at 1.2:2000 dilution as 'internal' 
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(amino acid position: 205-225) 
YVSENIKLGNLSALRTFRVLR 
(amino acid position: 205-225) 
VSENIKLGNLSALR(C) 
(amino acid position:204-219) 
(C)VSENIKLGNL 
(amino acid position: 204-215) 
Figure 2.2 Generation of an antibody specific for the neonatal Navl.5 isoform. 
Amino acid differences between neonatal Navl.5 (nNavl.5) and adult Navl.5 (aNavl.5) 
a-subunit splice forms are indicated. (A) Location of the adult/neonatal Navl.5 
alternative splicing is in the extracellular S3-4 linker of D1 of VGSCa, as indicated by 
the arrow and the asterisk. The NESO-pAb is against the nNavl.5 sequence (red box) 
that is located on extracellular loop between S3-4 (red). (B) The seven amino acid 
residues comprising the neonatal-specific sequence are represented in coloured letters 
whilst the regions used for creating the two immunizing peptides ('short' peptide 2 and 


















(Suppliers: Sigma, Upstate, Alomone) 
Anti-Nav1.5, Anti-Nav1.6 
(Suppliers: Prof Catterall, Alomone) 
Figure 2.3 Antigenicity map of different antibodies against various VGSCa 
isoforms. 
All pan-VGSCa antibodies recognise the conserved intracellular loop between D3-D4 
(Yellow). Anti-Navl.6 antibodies recognise intracellular loop between D2-D3 (blue). 
Anti- Navl.7, Navl.2, Navl.l, Navl.3 recognise intracellular loop between Dl-Dll 
(green). However, anti-Navl.5 antibodies have been raised from different companies 
against both D1-D2 and D2-D3 intracellular loops (green and blue). All commercial 
antibodies against various VGSCa isoforms have been raised against intracellular 
epitopes, however, because of the limited amino acid difference between neonatal and 
adult Navl.5, NESO-pAb antibody have been raised against an extracellular epitope in 
D1:S3-S4 loop (Red). 
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2.5.7 Glutl polyclonal antibody 
An anti-Glutl rabbit antibody (Santa Cruz Biotechnology) was used at 1:300 dilution, as 
a positive control for plasma membrane (PM) fractions in Western blotting. This 
antibody recognized amino acids 218-260 within an internal region of Glutl of human 
origin. Glutl, a member of a family of 7 glucose transporters, is known to be expressed 
mainly in PM and moderately in nucleus (Hajduch et al., 1995; Pantaleon et al., 2001). 
2.5.6 Calnexin polyclonal antibody 
An anti-calnexin goat antibody (Santa Cruz Biotechnology) was used at 1:1000 dilution 
for Western blotting and at 3:100 dilution for immunocytochemistry. The antibody 
recognized an epitope in the C-terminus of calnexin of human origin. This antibody was 
used as a marker for endoplasmic reticulum (ER). Calnexin protein interacts with newly 
synthesized glycoproteins in ER (David et al., 1993). 
2.5.7 Golgin-97 monoclonal antibody 
An anti-golgin-97 mouse antibody (Molecular Probes) was used at 1 jig/ml for both 
Western blotting and immunocytochemistry. It served as a marker of Golgi apparatus 
since it recognized a protein unique to the Golgi apparatus of most vertebrate species 
(Barr, 1999; Kjer-Nielsen et al., 1999). 
2.5.8 PMCA monoclonal antibody 
A mouse monoclonal anti-PMCA (Ca^^-ATPase) antibody (Upstate Biotechnology) was 
used at 1 ju.g/ml for Western blotting. Anti-PMCA recognizes PMCA of human, mouse, 
rat, bovine, porcine and rabbit origin and served as another marker of PM (Hillman et 
al., 1996). 
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2.5.9 Navl.7 polyclonal antibody 
A rabbit anti-Navl.7 antibody (Chemicon) was used at 1 [ig/ml for Western blotting to 
investigate the presence of Navl.7 protein in human BCa cell lines. This antibody 
recognized an epitope in the intracellular loop D1-D2 (Chemicon International). 
2.5.10 Phospho-PKA RII monoclonal antibody 
A rabbit monoclonal anti-Phospho-PKA RII antibody (Epitomics, California) was used 
to detect phosphorylated PKA. The antibody recognised residues surrounding Ser96 of 
human PKA regulatory subunit II (RII) (Montminy, 1997). This antibody was used at 
1:2500 dilution for Western blot studies. 
2.5.11 PKA RII polyclonal antibody 
A goat polyclonal anti-PKA RII antibody (Upstate Biotechnology; Buckingham, UK) 
recognized the regulatory subunits Rlla and P (Lester et al., 1996; Zheng et al., 2001). 
This antibody was used at 1.3 p,g/ml for Western blot studies and 10 ng/ml for 
immunocytochemistry. 
2.5.12 Lamin A/C monoclonal antibody 
A mouse monoclonal anti-lamin A/C antibody (Santa Cruz Biotechnology) recognized 
both lamin C and its splice variant lamin A that differs only at the carboxy terminus 
(manufacturer's instructions). The antibody was used at 1:1000 dilution in Western blot 
studies as a positive 'silencing' control to check efficiency of siRNA transfection 
(Elbashir et al., 2001; Paul et al., 2002). 
2.5.13 Laminin polyclonal antibody 
This rabbit anti-laminin antibody (Serotec, Oxford, UK) recognized both A and B chains 
of human laminin (Gordon-Weeks et al., 1989; Gordon-Weeks et al., 1992). This 
antibody was used as a negative control (at 10 |al/ml) in functional studies (proliferation, 
migration and invasion assays) with NESO-pAb on MDA-MB-231 cells. 
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2.5.14 VGSCpi polyclonal antibody 
A rabbit polyclonal anti-VGSCpl antibody was a kind gift from Dr L Isom. It is specific 
to the extracellular epitope of VGSCj31 subunit and recognized a 17 amino acid peptide 
(KRRSETTAETFTEWTFR). It was synthesized by the Protein and Carbohydrate 
Structure Core facility at the University of Michigan (Xiao et al., 1999; Malhotra et al, 
2000). The antibody was used at 1:500 dilution for Western blot studies. 
2.5.15 Secondary antibodies 
The following secondary antibodies at given working concentrations were used for 
Western blotting (WB), immunocytochemistry (ICC) and immunohistochemistry (IHC) 
(Table 2.3) All antibodies were from DAKO, Glostrup, Denmark unless otherwise 
stated. Their uses and working dilutions were as follows: 
1. A peroxidase-conjugated swine anti-rabbit immunoglobulin (WB; 0.3:1000). 
2. A FITC-conjugated swine anti-rabbit immunoglobulin (ICC/IHC; 1:50). 
3. An Alexafluor568-conjugated goad anti-rabbit immunoglobulin (ICC; 1:100; 
Molecular probes). 
4. A FITC-conjugated rabbit anti-mouse immunoglobulin (ICC; 1:40). 
5. A FITC-conjugated rabbit anti-goad immunoglobulin (ICC; 1:40). 
6. A peroxidase-conjugated goad anti-mouse immunoglobulin (WB; 1:1000). 
7. A peroxidase-conjugated rabbit anti-goad immunoglobulin (WB; 1:2000). 
2.5.16 IgG negative control 
As a negative control for the NESO-pAb and pan-VGSVa polyclonal antibodies, a 
rabbit immunoglobulin fraction (Solid-Phase Absorbed; DAKO, Glostrup, Dermiark) 
was used. This negative control rabbit immunoglobulin fraction was diluted each time to 
the same concentration as the primary antibodies, in order to obtain levels of background 
staining for both Western blotting and immunocytochemistry. This rabbit 
immunoglobulin fraction was also used as a negative control in functional studies 
(proliferation, migration and invasion assays) with the NESO-pAb on MDA-MB-231 
cells, at the same concentration as NESO-pAb. 
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2.6 Immunoprecipitation 
Before injecting the synthetic peptides into rabbits for the generation of the anti-neonatal 
Navl.5 antibodies (NESO-pAb), sera were taken from the animals and tested with pan-
VGSC antibody. Pre-immunised serum was immunoprecipitated and tested by Western 
blotting. 
2.6.1 Preparation of Protein A- Sepharose 
Protein A-Sepharose (Sigma, Dorset, UK) was diluted in the REPA lysis buffer (without 
proteases inhibitors; Table 2.4A) (250 mg / 10 ml) and spiimed in a microcentrifuge for 
2 minutes. The supernatant was discarded and 5 ml of RIP A lysis buffer (without 
protease inhibitors; Table 2.4A) was added again to the pellet and mixed. The mixture 
was spinned for fLirther 2 minutes and the supernatant was discarded again. Finally, the 
pellet was dissolved in 10 ml of lysis buffer. The sepharose beads were kept at 4 °C. 
2.6.2 Immunoprecipitation with pre-immune serum from rabbits 
3 jj,l of pre-immunised serum were added to 200 p,l of total protein extract from neonatal 
mouse heart, known to express Navl.5, in an Eppendorf tube and incubated for 2 hours 
at 4 °C. Then 40 |il of the beads (protein A) were added and the mixure was incubated at 
4 °C for a further 1.5 hours. After full spinning for 2 minutes in a microcentrifuge, the 
supernatant was removed and the pellet was washed three times in 400 ju,l of RIP A lysis 
buffer (without protease inhibitors; Table 2.4A). The final pellet was diluted in about 25 
[0.1 of sample buffer before loading on the SDS-PAGE. The proteins were probed for the 
presence of any VGSC protein by immunoblotting with the pan-VGSC antibody 
(Upstate Biotechnology). As a positive control, protein extracted from mouse heart was 
used after it was immunoprecipitated with pan-VGSC antibody. 
2.7 Antibody production 
These methods were described previously (Chioni et al., 2005). 
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Table 2.4 Lysis buffers. 
All chemicals were from Sigma unless otherwise stated. Phosphatase and proteases** 
inhibitors were always added minutes before the start of the experiment. 
A. RlPA Lysis Buffer 
1 % NP-40 (Nonidet P40; BDH, Poole, England) 
0.25 % Na-deoxycholated 
150 mM NaCl 
1 mM EDTA (ethlenediamine tetraacetic acid) 
1 mM NaF (BDH, Poole, England) 
1 jj-g/ml aprotinin** 
1 |u,g/ml leupeptin** 
1 p-g/ml pepstatin** 
1 mM PMSF (phenylmethylsulfonyl fluoride)** 
50 mM Tris-pH 7.4 
B. Lysis Buffer A 
250 mM sucrose 
2.5 mM MgC126H20 
2 mM dithiothreitol 
10 mM NaF 
1 mM sodium orthovanadate 
2 mM 4-nitrophenyl phosphate, disodium salt 
25 fj.M phenyl arsine oxide (dissolved in DMSO) 
lOmM benzamidine 
5 mM EGTA 
5 mM EDTA 
1 mM phenylmethylsulfonyl fluoride (PMSF)** 
25 |ag/ml leupeptin** 
25 }J.g/ml trypsin inhibitor** 
25 p-g/ml pepstatin** 
25 p-g/ml aprotinin** 
25 mM Tris-pH 7.5 
C. IP Buffer 
1 mM EDTA 
1% Triton X-100 
150 mM NaCl 
1 mM dithiothreitol 
1 jJ-g/ml apoprotinin** 
1 M-g/ml leupeptin** 
1 ng/ml pepstatin** 
50 mM Tris-pH 7.4 
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2.7.1 Peptide synthesis 
Two different synthetic peptides, termed "NESO", were designed for the neonatal 
Navl.5 (nNavl.5) protein, a 'long' and a 'short' (Figure 2.2B): NH2-
VSENIKLGNLSALRC-amide and NH2-CVSENIKLGNL-amide, respectively (Figure 
2.2). The peptides were produced at Medical Research Council Clinical Science Center 
(Imperial College London) by F-moc methods using an automated Applied Biosystems 
431A Peptide Synthesiser. The peptides were cleaved from the resin, diethylether-
precipitated and washed using standard protocols. The peptides were purified by RP-
HPLC on a high resolution CI8 column and stored at -20 °C and sequences verified by 
mass spectrometry. The purity was estimated to be around 99 %. 
The peptides differed at 6 of 14 amino acids compared to the 'adult' Navl.5 
sequence (Figure 2.2). Rabbit anti-sera were generated towards the two NESO peptides 
covalently-linked to maleimide-activated key-hole limpet heamacyanin, KLH (Perbio, 
UK), for improved immunogenicity. The C-terminal cysteine (not present in either 
sequence) allowed coupling of the peptides to maleimide-activated (i.e. thiol-reactive) 
KLH. 
2.7.2 Rabbit immunisation 
The rabbits were immunized by injection at 4 sites (two intramuscular and two sub-
cutaneous for each animal) with 0.8 mg of peptide-KLH conjugates mixed with an equal 
volume of Freund's incomplete adjuvant (vortexed vigorously for 2-4 min until a stable 
emulsion formed). Subsequent booster injections were performed on days 14, 28 and 
42. Animals were sacrificed and bled on or after day 50. 
2.7.3 Covalent-coupling of thiol-containing immunogenic peptide to idoacetyl-
activated Agarose 4B 
The immunogenic peptide (1 mg/ml) was linked to resin for use in affinity-purification 
of specific antibodies. lodoacetyl-Agarose 4B was prepared using methods described 
previously (Hermanson et al., 1992). This method rather than the maleimide activation 
procedure was employed to avoid co-isolation of Ig generated against the highly 
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immunogenic sulpho-SMCC cross-linker used for peptide carrier conjugation. 
2.7.4 Isolation of peptide antigen-specific Ig (NESO-pAb) by affinity 
chromatography 
All chemicals were obtained from Sigma-Aldrich (Dorset, UK) unless otherwise stated. 
Ig species with exclusive selectivity for NESO were removed from the crude immune 
sera (10 ml) by pre-incubation with Agarose resin (3 ml) conjugated with the NESO 
peptide. For both antibodies, serum was mixed with an equal volume of HBS buffer (20 
mM HEPES [255 mM sucrose, 20 mM N-2-hydroxyethylpiper-azine-N-2ethanesuflonic 
acid], 0.15 M NaCl; pH 7.5). The diluted serum was centrifuged at maximum speed 
(10,000 g) for 5 minutes and the pellet discarded. Serum was passed through a column 
containing the peptide for 20 minutes. After collecting the 'breakthrough', the column 
was washed five times with 4 ml aliquots of 10 mM HBS buffer (pH 7.5) containing 
additional 0.3 M NaCl, to remove proteins bonded non-specifically to the resin. After 
the column was equilibrated with 5 ml of HBS buffer, bound antibodies were eluted 
using 10 x 1 ml aliquots of citrate buffer (0.01 M citrate, 0.2 M NaCl; pH 2.6). Each 
aliquot was collected separately into an Eppendorf tube already containing 0.16 ml of a 
pH-neutralizing buffer (1 M HEPES; pH 8). The protein concentration was calculated 
from absorbancies at 280 nm (1 mg Ig/ml = 1.35 Unit/cm), and by densitometric 
comparison with known standards (BSA) on Coomassie stained SDS-PAGE gels. Into 
each recovered antibody aliquot, 1.4 mg / ml BSA, 30 % (v/v) glycerol and 0.06 % (w/v) 
sodium azide were added. An aliquot of the antibody without glycerol and sodium azide 
was kept for use in ftanctional studies (migration, invasion and proliferation). The 
antibody was stored at - 20 °C for a few months and at -80 °C for longer term. 
2.8 Coomassie staining protocol for assessing NESO-pAb purity and 
quanty 
All chemicals were from Sigma-Aldrich (Dorset, UK) unless otherwise stated. A range 
of different known BSA concenfrations (0.25 - 3 p-g) and different dilutions of purified 
NESO-pAb were loaded onto a 10 % SDS-PAGE mini-gel. Samples were treated with 
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non-reducing sample buffer (0.2 ml IM tris pH 6.8, 0.05 ml 20 % SDS, 0.4 ml glycerol 
and 10 mg of bromophenol blue) and heated for 10 minutes at 60 °C prior to loading 
onto the gel. When the dye front reached the bottom of the gel, the gel was transferred 
into a container containing 50 ml of staining solution (50 % methanol, 10 % ACCOOH, 
0.5 % Blue R 250) and incubated for 2 hours at room temperature. The staining solution 
was then removed and the gel was rinsed with water twice. The gel was then incubated 
for 1 hour at room temperature in 50 ml of destaining solution (30 % methanol and 10 % 
ACCOOH). The last step was repeated until bands were clearly visible on the gel and 
background staining was low. The gel was then scanned with a scanner (hp ScanJet 
3400C) and the density of the NESO-pAb bands were compared to the density of the 
BSA bands which correspond to known protein concentrations. Densitometric analysis 
was performed using the Image-Pro Plus software (Media Cybernetics). 
2.9 Protein extraction 
2.9.1 Total protein extraction from cells and tissues 
Protein was extracted from human breast and prostate epithelial cell lines and rat and 
mouse tissues according to the manufacturer's guidelines (Upstate Biotechnology and 
Laniado et al., 1997). All chemicals were from Sigma-Aldiich (Dorset, UK) unless 
otherwise stated. Cells at 80 % confluence (about 2x10^ cells/ml) were used for protein 
extraction. Cells were washed twice with ice cold PBS, without calcium and magnesium 
(Invitrogen, Paisley, Scotland) prior to the start of the protocol. The cells were removed 
from the plates by pippeting with 1 ml ice cold RIP A lysis buffer (Table 2.4). The cells 
were scraped with a rubber 'policeman' and the cell suspension was transferred into 
Eppendorf tubes. The cells (or tissues) were homogenised with a 2 ml syringe with a 26 
G needle, by passing about 6 times. The suspension was then gently mixed on a rocker 
in a cold room for about 15 minutes to lyse the cells. The lysate was spinned at 13,000 g 
in a pre-cooled centrifiage (Heraeus, Labofuge 400R), to prevent degradation of protein, 
for 15 minutes. Immediately afterwards, the supernatant was divided into 100 (il aliquots 
and stored at -80 °C. The supernatant contained total protein exfract from whole cells 
(plasma membrane and cytoplasm). 
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In the case of total protein extraction from animal tissues, the basic procedure 
was as described above. The tissues were homogenized first by 5 strokes with a tight 
fitting 2 ml homogenizer (Jencons, Leighton Buzzard, UK) and then with a 2 ml syringe 
with a 26 G needle (Becton Dickinson, Cowley, Oxford) for about 5 passes. About 5 g 
of each tissue was used for total protein extraction. 
2.9.2 Subcellular fractionation 
In order to determine the cellular location of the VGSCa protein, subcellular 
fractionation was performed on MCF-7 and MDA-MB-231 cell line extracts. Two 
different protocols were used, one for isolation of two subcellular fractions, and the 
other for isolation of four different fractions. Unless otherwise stated, all chemicals were 
from Sigma-Aldrich (Dorset, UK). 
2.9.2.1 Separation of two subcellular fractions 
The methodology of Buday et al. (1993) that had previously been used on cancer cell 
lines was adopted, since other protocols appeared to have been used more on tissues than 
cells(Avruch and Wallach, 1971; Matlib et al., 1978; Goldberg and Komfeld, 1983; 
Hubbard and Ma, 1983; Meier et al., 1984). After trial and error, the only change to the 
original protocol was that the homogenate was centrifuged at 215,000 g rather than the 
original 350,000 g in order to achieve a better separation of the PM from any organelles 
may be present in the particulate fraction (PF) (Buday and Downward, 1993). 
The cells were washed twice with ice cold PBS, without calcium and 
magnesium. To each dish was added 1 ml of 'Lysis buffer A' (Table 2.4B). The cells 
were scraped with a rubber 'policeman' and transferred to a tight fitting 2 ml 
homogenizer (Jencons, Leighton Buzzard, UK). The cells were disrupted by 50 sfrokes. 
The homogenate was transferred into centrifuge tubes (11 x 34 mm) (Beckman, Palo 
Alto, California) and spinned at 215,000 g in a Beckman Optima Max LJltracentrifiige 
with a TLA-100.2 rotor at 4 °C for 10 minutes. The first supernatant was the 
"cytoplasmic fraction" (CYT) (Buday and Downward, 1993) containing some 
organelles, such as nucleus, ER, golgi and mitochondria. The pellet was homogenized 
by 15 strokes with 'Lysis Buffer A' (Table 2.4B) containing 1 % Triton-x -100 and 0.5 % 
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deoxycholate and re-centrifuged at 350,000 g at 4 °C for 10 minutes. The second 
supernatant was the PF (Buday and Downward, 1993), containing mainly PM and 
possibly some vesicles involved in endocytosis and secretion (Graham and Higgins, 
1997). The PF was PM enriched and thus was termed "PM fraction". Protein extracts 
were stored in 100 jil aliquots at -60 °C. 
2.9.2.2 Separation of four subcellular fractions 
A more detailed subcellular fractionation protocol that would yield four fractions instead 
of two was also used. This enabled separation into PM, a high density microsomal 
fraction (HDM), a low-density microsomal fraction (LDM) and mitochondrial and 
nuclei (M/N) fraction (Piper et al, 1991). 
The medium was removed from the dish and the cells were washed three times in 
3 ml HES buffer (255 mM sucrose, 20 mM N-2-hydroxyethylpiper-azine-N-
2ethanesuflonic acid (HEPES), 1 mM EDTA, pH 7.4). Cells were scraped with a rubber 
policeman in HES buffer containing PMSF (50 p,g/ml) and aprotinin (10 p.g/ml) and 
homogenised by 10-15 strokes with a tight fitting 2 ml homogenizer (Jencons, Leighton 
Buzzard, UK). The homogenate was span at 19,000 g in a Beckman Optima MAX 
Ultracentriflige with a TL-100 rotor at 4 °C for 20 minutes. The resulting supernatant 
was centrifuged at 41,000 g for 20 min yielding a pellet designated as a "high-density 
microsomal fraction" (HDM). The supernatant from this spin was centrifuged at 
180,000 g for 75 min, yielding a pellet designated as "low-density microsomes" (LDM). 
The pellet from the initial spin was resuspended in HES buffer and layered onto 1.12 M 
sucrose in HES buffer and centrifuged at 100,000 g for 60 min. The white 'fluffy' band 
at the interface was the PM fraction and the viscous brown pellet was M/N fraction 
(Piper et al., 1991). 
2.9.3 Biotinylation of cell surface proteins 
The protocol followed a previously published procedure with some modifications (Hua 
and Mazzone, 2002; Zarei et al., 2004). All chemicals were from Sigma-Aldrich (Dorset, 
UK), unless otherwise stated. Cells were washed in ice cold PBS three times and 
incubated with fresly prepared Sulp-NHS-SS-Biotin/PBS solution (1 mg/ml) (Pierce 
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biotechnoligy) at 4 °C for 2 hours. Then, the solution was removed and the cells were 
washed three times with ice cold PBS containing 100 mM glycine. The cells were lysed 
as described in section 2.9.1 and the protein concentration was quantified as described in 
section 2.9.4 in order for equal amounts of protein firom each sample to be used. The 
Streptavidin beads (Pierce biotechnology) were mixed thoroughly and 500 \il were 
transferred into an Eppendorf tube. 1 ml of IP buffer (Table 2.4C)(Zarei et al., 2004) was 
added to the tube, and centrifuged for 1 minute at 7,000 g. The supernatant was removed 
and the beads were washed 3 times in PBS. 100 |ul of the slurry was added to the protein 
extract and incubated while mixing on a rotating wheel at room temperature. The 
mixture was applied to the top of a spin cup (Prierce Biotechnology) and centrifuged for 
1 minute at 10,000 g. The liquid that was washed through (supernatant) was collected 
for determination of unbiotinylated (intracellular fraction) protein (Hua and Mazzone, 
2002). The pellet was washed twice with 500 pi of IP buffer by applying it to the top of 
the cup and centrifuging at 10,000 g for 1 minute. 50 pi of SDS-PAGE sample buffer 
was boiled for 5 minutes and then applied to the pellet and incubated for 5 minutes. The 
biotinylated proteins were eluted by centrifugation for 1 minute at 10,000 g. Total, 
Streptavidin-labelled proteins were run on an SDS-PAGE gel and Western blotting was 
performed as described in section 2.10. 
2.9.4 Protein yield determination 
A dye-binding assay (Bio-Rad Protein Assay; Bio-Rad, Hemel Hemsted, UK), based on 
the differential colour change of a dye in response to various concentrations of protein, 
was used according to manufacturer's guidelines, to determine the concentration of 
proteins loaded in the SDS-PAGE (Polyacrylamide gel electrophoresis). The Bio-Rad 
protein assay is based on the observation that the absorbance maximum for an acidic 
solution of Comassie Brilliant Blue G-250 shifts from 465 imi to 595 nm when bound to 
protein. 
Bovine serum albumin (BSA) diluted in water was used as a protein standard to 
construct a standard calibration curve (Figure 2.4). The concentration range used 
produced OD^p '^s (optical densities at 595 nm) from 0.1 to 2.0. Several dilutions of the 
protein standard in the range 0.2 to 1.4 mg/ml were prepared. Aliquots of 100 pi distilled 
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Figure 2.4 Typical standard curve for Bio-Rat protein assay. 
Standard protein: bovine serum albumin. Several dilution of the protein standard from 
about 0.2 to 1.4 mg / ml was used for the construction of the standard curve. OD595 was 
corrected for blank. Protein concentration loaded to SDS-PAGE gel for Western blotting 
studies was chosen from the linear part of the curve (40-80 |j,g). 
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water were used as the reagent blank. The dye reagent was diluted (1 volume of dye 
reagent with 4 volumes of high quality distilled deionized water) and filtered with 
Watman No. 1 paper prior to use in the standard assay procedure. 
In order to obtain yields in 10 ]ul of protein samples (either total protein or 
subcellular fractionations), 10 pi of the protein sample and 90 pi of pure distilled water 
were added to 5 ml of diluted dye reagent (Coomassie Brilliant Blue G-250) and mixed 
several times by gentle inversion of the test tube. After a period of 5 minutes to 1 hour, 
the O D 5 9 5 (with the reagent 'blank' subtracted) was measured, using a 
spectrophotometer (CECIL, CE 1020) and referred to the linear part of the standard 
curve (Figure 2.4). The blank contained 10 pi lysis buffer in 90 pi pure distilled water 
and 5 ml diluted dye reagent. 
As a positive control for the amount of protein loaded on the gels, an anti-a-
actinin and a pan anti-actin antibody, which recognised all isoforms of actin ('house 
keeping' protein), were used in the Western blots (section 2.5; Table 2.1). 
2.10 Western blotting 
2.10.1 SDS-PAGE (polyacrlaznide gel electriphoresis), blotting and antibody 
labelling 
Unless otherwise stated, all chemicals were from Sigma-Aldrich (Dorset, UK). Lysates 
from cells and tissues were first treated with sample buffer (x3 sample buffer: 0.7 ml 
glycerol, 1.3 ml 10 % SDS, 0.203 g dithiothreitol (DTT), 0.004 % bromphenol blue) 
before boiling for 2 min or heating for 10 minutes at 37 or 70 °C prior loading on to the 
gel (Table 2.3). The proteins were separated by 6-12 % SDS-PAGE (Table 2.5) and run 
at 160 V for 3-4 hours in a running buffer (1 L xlO running buffer; 144 g glycine, 30 g 
Tris, 20 g SDS) and electroblotted onto nitrocellulose membrane (Protran BA83 
Cellulosenitrate, Schleicher and Schuell) at 21 V overnight in a transfer buffer (for 1 L 
xlO transfer buffer: 144 g glycine, 30 g Tris). After transfer, the blots were 'blocked' at 
room temperature for 30 minutes with gentle agitation in 5 % (w/v) solution of non-fat 
dried milk (Marvel, Sainsbury's) in PBS and for 1 hour in 2 % (w/v) BSA in PBS. Blots 
were then probed with the appropriate antibody diluted in 2 % BSA/PBS (w/v) (Table 
2.2) at 4 °C overnight after washing briefly in PBS. The blots were then washed 3 times 
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Table 2.5 Conditions for given antibody in Western blot studies. 
Temperatures at which protein extracts were treated prior loading, as well as the 
percentage of SDS-PAGE gels depending on the antibody (i.e. molecular weight of 
protein detecting) used for immunoblotting are specified. Please note that more than one 
condition might apply to a single antibody. This is because in some cases, the same blot 
was immunostained with more than one antibodies after membrane stripping (e.g. to 
check internal controls). T: temperature (°C) at which proteins were treated prior to 
loading to the gel 
Antibody T(°C) SDS-PAGE gel (%) 
Pan-VGSC 37 "C and boil 6 or 8 % 
Anti-Navl.5 boil 6 or 8 % 
NESO-pAb 70 °C and boil 6 or 8 % 
Anti-Navl.7 70 °C 6 or 8 % 
Anti-PKA RII boil 6 or 10 % 
Anti-phospIio-PKA RII boil 6 or 10 % 
Anti-Actin boil 6 or 8 or 10 or 12 
% 
Anti-a-actinin boil 6 or 8 or 10 or 12 
% 
Anti-Calnexin (C-20) boil 6 or 8 % 
Anti-golgin-97 boil 6 or 8 % 
Anti-glutl boil 6 or 8 % 
Anti-PMCA (Ca+ ATPase) boil 6 or 8 % 
Anti-Lamin AJC boil 10 % 
Anti-VGSCpl boil 12% 
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(15 minutes each) at room temperature in PBS containing 0.2 % tween-20, and then 
incubated for 1 hour at room temperature with the appropriate secondary antibody 
(Table 2.3). The blots were developed by ECL chemiluminescence (Amersham, Little 
Chalfont, Buckinghamshire, UK) after washing as described above. The protein bands 
were visualised by exposure to Super RXIOONF film (Fujifilm, London, UK). 
Densitometric analysis was performed using the hnage-Pro Plus software (Media 
Cybernetics). Signal density was normalised to anti-actinin/anti-actin antibody as a 
loading control, for at least three separate treatments. Prior to incubation with a different 
primary antibody, binding sites were stripped by incubation of the blot at 65 °C for 25 
min in a solution containing: 100 mM P-mercaptoethanol, 2 % SDS and 62.5 mM Tris-
HCl. The blot was then washed in 0.1 % tween-20/PBS three times (10 minutes each) 
and re-blocked. 
All antibodies used for densitometric analysis were tested for linearity of their 
reaction products when different amounts of proteins were loaded to the gel. A range of 
protein concentrations were loaded to the SDS-PAGE gel (20-120 jig) and then 
densitometric analyses was performed as described above (Figure 2.5). The 
concentration of a given protein loaded to the gels, was chosen from the linear part of 
the standard curve (60-80 |j.g protein). 
2.10.2 Negative controls 
The immunising peptide that was used to raise the pan-VGSC antibody (Upstate) was 
not available for pre-absorption in negative controls. Instead, incubation of the 
membrane with only PBS, without the primary antibody, at 4 °C overnight was used as a 
negative control for the secondary antibody, hi the case of NESO-pAb, the primary 
antibody could be incubated at room temperature for 30 minutes with the immunizing 
peptide (5 p,g/ml added to the primary antibody solution) and then applied to the 
membrane and left overnight at 4 °C. The rest of the procedure was as described in 
section 2.10.1. 
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Figure 2.5 Examples of various antibody standard curves used for densitometric 
analyses. 
Antibodies used for densitometric analysis were tested for their ability to recognise 
differences in protein concentration in Western blot studies. A range of protein 
concentrations (20-140 |ag) were loaded to the SDS-PAGE gel and immunolabeled with 
the appropriate antibody and then densitometric analyses were performed. 
Concentrations of proteins (60-80 p,g protein) loaded onto the gels (as used in various 
experiments) were chosen from the linear part of the corresponding standard curve. (A) 
Examples of Western blot images of neonatal mouse heart protein extracts (for pan-
VGSCa, NESO-pAb and anti-actinin antibodies), MDA-MB-231 protein extraction (for 
anti-Phospho-PKA) and MCF-7 protein extraction (for anti-VGSCpi and anti-actin 
antibodies). (B-F) Examples of standard curves from protein concentrations (20-120 jag) 
in relation to band intensity from each antibody. For most antibodies, the signal intensity 
saturated for greater than about 100 |j.g of protein. Data points are given as means ± 
SEM (n>3). 
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2.11 Immunocytochemistry, immunohistochemistry and microscopy 
2.11.1 Cell and tissue preparation 
All cell lines (MCF-7, MDA-MB-231 and EBNA-293, transfectants and non-
transfectants) were prepared as described in section 2.4.1. The cells were plated at a 
density of 5 x lO'^  into 24-well plates, containing 13 mm sterile coverslips (BDH, Poole, 
England) which were pre-coated in 0.01 mg/ml poly-L-lysine (Sigma-Aldrich) for 20 
minutes at room temperature. The cells were incubated for 24-48 hours, to achieve 
about 60 % confluency. 
Cryosections from mouse tissues were provided by Miss Lorraine Lawrence, 
Biomedical Sciences Division, Imperial College London. All sections were 5-7 p,m in 
thickness and were cut on a Bright Oft cryostat. Tissues were stored at - 80 °C until use 
for immunohistochemistry. 
2.11.2 Fixation and permeabilization 
Prior to fixation and permeabilization, the cells were examined for any contamination. 
The growth medium was removed and the cells were washed with PBS. la the case of 
fresh frozen tissues, the tissues were removed from - 80 °C and put straight into the 
fixative. Unless otherwise stated, all chemicals were from Sigma-Aldrich (Dorset, UK). 
The cells or tissues were fixed in 4 or 2 % PFA/PBS (w/v) pH 7.4 (PFA: 
paraformaldehyde) for 15 or 5 minutes at room temperature, respectively. After fixation, 
the cells/tissues were washed three times with PBS (15 minutes each). The cells were 
permeabilised for 5 minutes in 0.1 % saponin/PBS (w/v) (pH 7.4), to facilitate detection 
of intracellular antigens. After permeabilization, the cells/tissues were washed three 
times in PBS (15 minutes each). 
2.11.3 Immunofluorescence 
Unless otherwise stated, all washes were three times, ten minutes each. Non-specific 
binding sites of the cells/tissues were blocked with 5 % BSA/PBS (w/v) for 1 hour at 
room temperature on a rocking platform. The primary antibodies were diluted in 5 % 
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BSA (Sigma-Aldrich) in PBS (w/v). 5 % BSA/PBS without the primary antibody was 
used as a negative control. The primary antibodies were applied to the cells/tissues in an 
incubator chamber for 1 hour, 100 % humidity, on a rocking platform. The cells were 
washed and incubated with the appropriate secondary antibody (Table 2.2) diluted in 5 
% BSA/PBS for 1 hour, 100 % humidity, on a rocking platform. The cells/tissues were 
washed first in PBS and then once in distilled water and then mounted in Vectashield 
hard-set mounting medium (Vector laboratories). 
In the case of concanavalin A (ConA) double-staining with NESO-pAb, the cells 
were incubated with ConA (20 )ig/100 p.1) for 45 minutes at room temperature (RT; ~21 
°C) before the permeabilization step. When cells were double-stained for F-actin and 
NESO-pAb, the cells were incubated with Phalloidin -TRITC (Fluka; stock 1 |ag/10 |li1 
in distilled water) at 1:100 dilution in PBS for 40 minutes at RT, following the final 
wash after the secondary antibody incubation. The cells were then washed and mounted, 
as above. 
2.11.4 Negative controls 
Various negative controls were used for immunocytochemistry and/ or 
immunohistochemistry as follows: 
1. After double staining with two primary and corresponding secondary antibodies, 
the possibility of cross-reactivity of the secondary antibodies with the given 
primary antibodies was tested. One of the primary antibodies was applied each 
time with both secondary antibodies. Also, both primary antibodies with only 
one of the secondary antibodies were applied each time. 
2. The specificity of the primary antibodies was also tested by the use of an IgG 
control at the same concentration as each of the primary polyclonal antibodies. 
3. The specificity of the anti-Navl.5 (D-492 pAb) and NESO-pAb was tested by 
pre-incubation with five-fold (by weight) excess of the immunising peptide for 
30 minutes at RT. 
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2.11.5 Imaging 
Cells/tissues were photographed using a Zeiss fluorescence microscope under oil 
immersion (xlOO). The staining pattern was documented by direct image-capture using a 
digital camera (AxioCam; 14 bits per colour channel, resolution up to 3900x3090 pixels; 
Zeiss). The immunoreactivity was documented using Axio Visio 3.0 software (Zeiss). 
2.11.6 Confocal microscopy 
For more detailed image capture and digital analysis, confocal microscopy was used. 
Fluorescence was detected with a Leica confocal laser scarming microscope (TCS-NT 
with Ar/Kr laser; Leica Microsystems, Milton Keynes, UK). FITC and/or Alexa567 
were excited with the 488 and 568 nm laser lines, respectively. Samples were viewed in 
a Leica DM IRBE microscope with xlOO objective. The images (512 x 512 pixels) were 
obtained simultaneously from two channels using a confocal pinhole of 226.98 p,m (Airy 
1). Densitometric quantification of neonatal Navl.5 protein expression in treated and 
non-treated cells was performed with the Leica confocal software LCS Lite (version 
2.00). For the freeform "line profile" function of the LCS Lite software (Leica), cells 
were drawn around the cell surface determined by ConA staining. The "histogram 
profile" was used to obtain measurements from the whole cell. The subcellular 
distribution of VGSC protein was determined using the "straight line profile" function 
drawn across the cytoplasm avoiding the nucleus, (Okuse et al., 2002; Shah et al., 2004; 
Brackenbury and Djamgoz, 2006b). Signal intensity in plasma membrane region, set to 
cover 1.5 pm inward from the edge of ConA staining, was compared with cytoplasmic 
signal intensity within the central 30 % of the line profile. In general, minimum of 36 
cells (randomly chosen) from three independent experiments were analysed and the 
statistical significance was tested using non-parametric Mann-Witney statistical test 
from Sigmastat software (version 2.0), since the data were not normally distributed. 
135 
2.12 Functional studies 
2.12.1 Adhesion assay (SCAMA) 
This method has been previously described (Aydar et al., 2005; Pahner et al., 2006). 
Briefly, cells were trypsinized and plated into 35 mm dishes at a density of 2.5 x 10"* 
cells/ml, in order to obtain separated single cells cells 48 hours prior to using the 
SCAMA ("single cell adhesion measuring apparatus"). A glass micropipette (1.0 mm 
OD/ 0.85 mm ID; Harvard Apparatus 30-0019) was drawn to a -20 |am tip size using a 
Narishige pp-830 puller and connected to a vacuum pump via plastic tubing. An 
individual cell was observed under lOOx magnification and the glass micropipette was 
brought near the cell periphery. Increasing suction was applied to the cell and the 
moment the cell was observed to detach from the culture dish, the suction was released 
and thus the pressure returned to baseline (Figure 2.6 and 2.7). The peak ("detachment 
negative pressure" - DNP) was converted to kiloPascals (kPa) and used as a measure of 
the cell's adhesiveness. 
When adhesion was compared between different cell lines, DNP (kPa) values 
were normalised to mean cell surface area (|im^). Thus, any effect of cell size which 
could affect adhesion by general 'surface tension', rather than a molecular mechanism, 
was ruled out. Leica confocal software LCS Lite (version 2.00) was used to drawn a line 
around the cell in order to calculate the cell surface area. Around 50 each of MDA-MB-
231 and MCF-7 cells were measured and the mean value was calculated. The value of 
DNP was then normalized with respect to cell surface area of each cell line, giving DNP 
relative to the cell size (DNPR). 
The inter- and intra- SCAMA assay variations were not significant. 
Adhesiveness of given cell type did not change during the time of the assay (~ 5 % and 
~2 % variation for MDA-MB-231 and MCF-7 cells, respectively); also, there was no 
significant difference between data obtained on different days ( -0 .01 % and -0.1 % 
variation for MDA-MB-231 and MCF-7 cells, respectively; Figure 5.41). 
2.12.2 Proliferation assay 
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Figure 2.6 Schematic representation of the Single Cell Adhesion Measuring 
Apparatus (SCAMA). 
Using a micromanipulator, a glass micropipette was positioned at the periphery of a 
single cell from a 35 mm cell culture dish which was placed onto the moveable stage of 
an inverted microscope. The cells were observed with a lOOx objective. When the T-
piece was blocked with the user's finger, negative pressure generated by a vacuum pump 
connected to the micropipette via a reservoir. The pressure was measured using a digital 
manometer connected to a computer via a R2232 cable. When the cell was observed to 
be detached from the culture dish, the T-piece was unblocked and the pressure was 






I A i 
Cell detachment and immediate 





0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 
Time (sec) 
B. 35 n 
30 -
25 -






Cell detachment and immediate 








10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 
Time (sec) 
Figure 2.7 Examples of cell adhesion measurements with SCAMA in two different 
human breast cancer cell lines. 
Two examples from recordings of strongly metastatic MDA-MB-231 (green) (A) and 
weakly metastatic MCF-7 (blue) (B) cells. After the glass micropipette was positioned at 
the periphery of a single cell the negative pressure was applied (indicated by red arrow). 
When the cell just detached from the culture dish, the pressure was immediately released 
(indicated by the black arrow). DNP = detachment negative pressure measured in 
kiloPascals (kPa's). 
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to settle for 4 hours. The cells were then treated in a certain way (e.g. 
pharmacologically) for the required time of incubation (24-48 hours). If the cells were 
treated for 48 hours, the medium was changed after 24 hours with identical fresh 
medium in both control and treated dishes. At the end of the treatment, the medium was 
removed, and this was followed by the colourimetric 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay (Grimes et al., 1995) in order to determine 
change in proliferation rates between control and treated dish (section 2.14.4). 
2.12.3 Migration and invasion assays 
These assays were performed as described previously (Grimes et al., 1995; Fraser et al., 
2005) with some modifications. Briefly, cells (2 x 10^  /ml) were plated onto 12 ]u.m-pore 
Transwell migration filters in 12-well plates (Coming, NY), or at 7.5 x 10"^  cells/ml onto 
Matrigel-coated invasion chambers in 24-well plates (Becton-Dickinson) according to 
the manufacturers' instructions. Cells were incubated with or without TTX (10 nM), 
NESO-pAb (0.01-20 ^ig/ml), forskolin (50 juM) or KT5720 (500 nM) in a 1-10 % FBS 
chemotactic gradient for 8 hours or overnight (12 hours) for migration assays or 24-48 
hours for invasion assays. When cells were assayed for 48 hours, the medium in both 
control and treated wells was replaced with fresh identical solution after 24 hours. At the 
end of each assay, non-invaded/non-migrated cells were removed from the upper surface 
of the insert with two different swabs. The number of cells migrating or invading was 
determined using MTT assay (Grimes et al., 1995). Results were compiled as the mean 
of at least four repeats. For experiments with NESO-pAb, a polyclonal rabbit anti-
laminin antibody (10 |j,l/ml; Serotec, Oxford, UK) and a rabbit IgG fraction from healthy 
non-immunised rabbits (1 p,g/ml; Serotec) were used as controls. 
For immunocytochemistry on migrating vs. non-migrating MDA-MB-231 cells, 
the Transwell migration assay was performed overnight in duplicate. At the end of the 
assay, the cells on the top of one of the inserts (non-migrated cells) were removed. 
Similarly, the cells on the bottom of the insert (migrating cells) were removed from the 
second insert. The two membranes with the migrating and non-migrating cells, 
respectively, were gently removed from the insert and used for immunocytochemistry. 
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2.12.4 MTT assay 
0.15 ml MTT (5 mg/ml made up in the growth medium) and 0.6 ml growth medium was 
added in each well and the plate was incubated for 3-4 hours at 37 °C. The medium was 
then removed from the chambers and replaced with 0.89 ml dimethyl sulfoxide (DMSO) 
and 0.11 ml glycine buffer (0.1 M glycine and 0.1 M NaCl; pH 10.5). Absorbance at 570 
run was determined 15 minutes after the addition of the glycine buffer. Results were 
calculated as means of nine repeats of each of the treatment vs. control 
spectrophotometer readings from individual invasion wells. Statistical significance was 
tested using two-tailed paired t-test and also confirmed by Mann-Whitney test. 
In order to convert the absorbance values from the invasion/migration assay to 
cell number, standard calibration curves were determined for MCF-7, MDA-MB-231, 
PC-3M and Mat-LyLu cell lines. 300,000 cells/ml to 293 cell/ml were plated in wells of 
a 24-well plate and after the cells settled down (4 hours), MTT assay was performed as 
described above. The experiment was repeated 3 times and a curve with mean 
absorbance values ± SEM was plotted against the cell number for each cell line (Figure 
2.8). The 570 nm absorbance values from the invasion/migration assay were then 
converted to cell numbers using the standard curve and Origin 6.1 program. The 
standard curve was repeated every time a new MTT solution was made and used. 
2,13.1 RNA extraction 
RNA extraction from cells was performed using the Stratagene Miniprep Absolutely 
RNA Kit according to the manufacturer's instructions. Briefly, after washing the cells 
were washed once in PBS, for a 100 mm dish, 1 ml of lysis buffer and 7 |j.1 of P-ME 
were added. The cell lysate was then collected and mixed until the viscosity of the lysate 
was minimal. Up to 0.7 ml of the homogenate was transferred to a pre-filter spin cap and 
centrifuged at maximum speed for 5 minutes. An equal volume of 70 % ethanol was 
added to the filtrate. The mixture was then transferred to an RNA Binding Spin Cup and 
centrifuged in a microcentrifuge for 1 minute at maximum speed. The samples were then 
DNase treated using 50 p-l DNase digestion buffer and 5 p,l reconstituted RNase-free 
DNase I for each sample to remove any DNA contamination of the RNA. The samples 
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Figure 2.8 Examples of standard curves of MCF-7, MDA-MB-231, PC-3M and 
Mat-LyLu cell number in relation to absorbance at 570 nm as determined by MTT 
assay. 
Typical standard curves used to convert absorbance values into cell numbers for 
migration and invasion assays. Solid lines are linear regressions. 
Mat-LyLu: y=0.0773x + 0.1425; 
MCF-7: y=0.0647x+0.0761; 
MDA-MB-231: y=0.0608x + 0.0838; 
PC-3M: y=0.0576x + 0.0686. 
Values are given as means ± SEM (n=3 each). 
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the elution buffer was added twice to each sample and centrifiiged at maximum speed 
for 1 minute. The purified RNA was kept at - 20 °C for short-term and at - 80 °C for 
long-term. 
2.13 Polymerase chain reaction 
2.13.2 Assaying the quality and quantity of RNA 
The quality of the purified RNA was determined in two different ways: 
2.13.2.1 Spectrophotometry 
A small volume of extracted RNA (5 |al) was diluted in elutriation buffer (50 |al) and the 
ratio of absorbances at 260 nm and 280 nm (A260/A280) was measured. A good quality 
RNA extraction should have a ratio close to 2.0 (Sambrook et al., 1989). RNA was 
quantified by using the following equation Equation 2.1: 
Concentration^ A260 x dilution factor (55/5) x conversion factor (0.040 p.g/|J.l) 
The conversion factor for RNA was 0.040 ng/^l per OD260 (Stratagene Miniprep 
Absolutely RNA Kit according to the manufacturer's instructions). The 
spectrophotometer 'blank' was just elutriation buffer. 
2.13.2.2 Agarose gel electrophoresis 
The quality of RNA was also checked by gel electrophoresis. 5 fxg of RNA extracts of 
each sample was mixed with 1 |i.l loading buffer (6x; Promega, Madison, USA) and 
loaded onto a 0.8 % agarose gel containing 0.8 p,g/ml ethidium bromide in a 0.5x Triz-
Borate-EDTA buffer (TBE). Good quality of RNA had a more intensely illuminating 
28S than 18S rRNA band when visualised under ultraviolet radiation (UV) (Figure 2.9). 
2.13.3 Synthesis of single-stranded copy DNA (sscDNA) 
1 |ag of extracted RNA was used as a template for sscDNA synthesis (Superscript II, 
GIBCO BRL). The synthesis was primed with random hexamer mix (R6) using 




Figure 2.9 Visual determination of RNA quality by agarose electrophoresis. 
RNA quality was determined by a more intensely illuminating 28S than 18S rRNA band 
when visualised under ultraviolet radiation (UV). 5 |ig total RNA loaded from MDA-
MB-231 cells (1) and MCF-7 cells (2). 
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volume. 1 p,g RNA and 250 ng R6/pd(N)6 were mixed while placed on ice and the total 
volume was made up to 11 |j,1 with sterile distilled water. The mixture was then placed at 
70 °C for 10 minutes to separate the RNA into single strands and quickly replaced on 
ice. 8 pi of a master mix containing 2 |il 0.1 DTT, 4 p.1 Superscript II First strand buffer 
(x5), 1 pi 10 mM dNTP mix (Pharmacia Biotech) and 1 p.1 (24.5 units) porcine 
RNAguard (Amersham Pharmacia Biotech) were added. The mixture was mixed and 
placed at 25 °C for 2 minutes. 1 pi (200 units) of Superscript II RT enzyme was then 
added and the reagents were stirred and incubated for further 10 minutes at 25 °C. The 
reaction was then incubated for 1.5 hours at 42 °C. The reaction was halted by 
incubation at 70 °C for 15 minutes and then cooled on ice. The reaction products were 
stored at - 20 °C. 
2.13.4 Real-time PCR 
A real-time PCR (rt-PCR) protocol was used, as described previously (Mycielska et al., 
2005). Briefly, rt-PCR utilizing SYBR 1 Green technology was performed on cDNA 
using the DNA Engine Opticon 2 System (MJ Research) to accurately determine target 
gene expression levels. PCR reaction was performed in 20 pi final volume containing 1 
pi cDNA, 0.5 pM of both sense and antisense primers and Ix QuantiTect SYBR Green 
PCR mix (Qiagen). Amplification was performed via an initial denaturation at 95 °C for 
15 minutes to activate the HotStar Taq, with subsequent three-step cycling of 95 °C for 
30 seconds, annealing temperature depending on the primers used for 30 seconds (Table 
2.6) and 72 °C for 30 seconds. Fluorescence from incorporation of SYBR green to 
double stranded DNA was measured after each cycle (Figure 2.1 OA). A final melt curve 
was also carried out from 65 °C to 95 °C with 0.3 °C steps in order to verify product 
composition. A pure PCR product could be characterised by one sharp drop in 
fluorescence over a small temperature range (Figure 2.1 OB). Triplicate reactions on 
each sample cDNA was carried out simultaneously for both the target gene and the 
normalizing/control gene (Cytochrome b5 reductase [Cytb5R/ P-actin]). Each set of 
reactions also included a standard calibration curve for each target gene using five serial 
dilutions of a cDNA template (Figure 2.11). Blank reactions, with sterile distilled water 
instead of cDNA, were performed as a cross-contamination control. 
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Table 2.6 PCR primer sequences and related details 
AS: amplicon size; cytbSR: cytochrome 5b reductase; Ta: annealing temperature; nt: 
nucleotides; nNavl.5: neonatal Navl.5; SPL: Supplier. 










CytbSR 5'-TATACACCCATCTCCAGCGA-3' HCYTBL 60 511 Pharma 
5'-CATCTCCTCATTCACGAAGC-3' CB5B i^a 
VGSCpi 5'-AGAAGGGCACTGAGGAGTTT-3' hlbF 
5' - GCAGCGATCTTCTTGTAGCA-3' h 1 bR 
60 379 MWG 
VGSCP2 5' -GAGATGTTCCTCCAGTTCCG-3' h2bF 
5'-TGACCACCATCAGCACCAAG-3' h2bR 
62 310 MWG 
VGSCP3 5'-CTGGCTTCTCTCGTGCTTAT-3' h3bF 
5 '-TCAAACTCCCGGGACACATT-3' h3 bR 
60 353 MWG 
VGSCp4 5'-TAACCCTGTCGCTGGAGGTG-3' h4bF 64 





CTGCGGCGGGTGGATGCTGAGAAC-3' Lamin-ac 1 
5' -CCACGGCTGCGCTGCGAGGTAGG- Lamin-ac2 
3' 




5'-TATGACCATGAATAACCCGC-3' HNEl 59 
5'-TCAGGTTTCCCATGAACAGC-3' HNE2 








b-actin2F 67 167 MWG 
b-actin2R 
Total 5'-CATCCTCACCAACTGCGTGT-3' hHl 
Navl.5 5'-CACTGAGGTAAAGGTCCAGG-3' hH2 
58 509 MWG & 
380 
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Figure 2.10 Examples of real-time PCR amplifications and melting curves. 
(A) Fluorescence from SYBR green incorporation to double stranded DNA measured 
after each PCR cycle using DNA Engine Opticon 2 System (MJ Research). Dashed line, 
amplification threshold determined by Opticon Monitor 2 Software. (B) After PCR, 
product composition was verified by heating from 65 °C to 95 °C in 0.3 °C steps. Red 
line; cDNA synthesized from RNA extracted from MCF-7 cells and Blue line: cDNA 







































Figure 2.11 Examples of PGR efficiency and validation of the method. 
Two examples of the efficiency of amplification of target genes: VGSCpi (A) and 
nNavl.5 (B) with the internal control (cytochrome b5 reductase), examined using real 
time PGR. 1 |j,g of RNA was used to synthesize cDNA from MDA-MB-231 cells and 
serial dilutions (1, 0.75, 0.5, 0.25 and 0.01 for VGSCpi and 1, 0.5, 0.1, 0.01, 0.001 for 
nNavl.5) of the cDNA were amplified by real time PGR using gene specific primers. 
ACt was calculated for each cDNA dilution: (A) Cx VGSCpi - Ct cytochrome b5 
reductase and (B) Ct (nNavl.5) - C j (cytochrome b5 reductase). The data points were 
fit using semi-logarithmic regression (n=3). 
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2.13.4.1 Data analysis 
The number of threshold amplification cycles (Ct'S) was determined for each reaction 
using Opticon software (2.02). The 2-AACT method (Livak and Schmittgen, 2001) was 
used to analyse the relative gene expression of each sample by using the following 
equation (Equation 2.2): 
•\T r, -([mean AC ] - [mean AC control]) 
I — z f X 
Target gene levels were expresses as mean ± standard error (n>3). The expression of the 
target gene in each sample was normalised relative to the corresponding sample-matched 
expression level of the normalised gene cytochrome b5 reductase. Differences in 
expression between different samples were analysed statistically with two-tailed paired 
t-test or Mann-Whitney Rank sum test using SigmaStat software (version 2.0). 
2,14 RNA interference 
RNA interference was performed as it has been previously described (Brackenbury et 
al., 2006). Briefly, siRNA for VGSCpi (Genome smart pool for human SCNIB 
NM_001037; M-020909-00-0010) was synthesized by Dharmacon and resuspended and 
stored according to the manufacturer's instructions. Cells (70-80 % confluent in 6-well 
plates) were transfected for 4 h with siRNA (300 pmol/well; stock 20 pmol/pl) using 
Oligofectamine (20 |aM stock; Invitrogen, Paisley, UK), according to the manufacturer's 
instructions. Briefly, in tube A 15 |il siRNA smartpool and 250 pi Optimem 1 
(Invitrogen, Paisley, UK) were added and mixed. In tube B, 15 p,l Oligofectamine and 
60 pi Optimem 1 were also added and mixed. The tubes were stood at room temperature 
for 10 minutes and then contents of tube B were transferred to tube A and mixed with a 
pipette 3 times. The tube was stood for further 25 minutes at room temperature. A 
further 160 |xl Optimem 1 was then added to the tube to make it up to 0.5 ml. The cells 
were washed once in PBS and the solution containing the siRNA was added to the cells. 
The cells were incubated for 4 hours at 37 °C, 100 % humidity and 5 % CO2. 2 ml of 
normal medium was then added to the cells without removing the siRNA solution and 
after 2 days the cells were passaged and their medium was changed for normal medium. 
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inRNA, protein levels and functional activity were assayed after 2-12 days post-
transfection, and compared with untreated, mock (only oligofectamin without siRNA) 
and/or control siRNA-treated cells (SiControl non-targeting siRNA pool; D-001206-13-
05). Transfection efficiency was assessed independently using a positive control siRNA 
Lamin A/C (D-001050-01-05) which was compared with SiControl Non-targeting 
SiRNAl-2 (D-001210-02-20). 
2.15 Data analysis 
All quantitative data are presented as means ± standard error of the mean (SEM), unless 
otherwise stated. Real-time PCR data were analysed using the 2"'^ '^^ ^ method (Livak and 
Schmittgen, 2001). Statistical significance was determined with Student's t-tests (paired 
and un-paired), Mann-Whitney rank tests, or one way analyses of variance (ANOVA) 
followed by Student-Newman-Keuls test (when multiple treatments were performed), as 
appropriate. Results were considered significant at P < 0.05 (*). 
149 
Chapter 3: A NOVEL NEONATAL Navl.5 SPECIFIC 




In mammals, voltage gated Na"^  chamiel a-subimits (VGSCas) are members of a family 
of ten different genes which may be expected to give rise to proteins with specialized 
functional properties. In both invertebrates and vertebrates, multiple alternative spliced 
exons of VGSCa genes have been described (McClatchey et al., 1992; Plummer et al., 
1997; Souslova et al., 1997; Dib-Hajj et al., 1999; Kasai et al., 2001; Copley, 2004; Diss 
et al., 2004a). 
In mammals, a developmentally controlled alternative splicing in D1:S3 gives 
rise to two alternative transcripts differing at 19-21 nucleotides, commonly resulting in 
just 1-2 amino acid changes (Figure 1.15). Such splicing was first described for Navl.2 
and Navl.3 in rat brain (Sarao et al., 1991; Gustafson et al., 1993). Similar alternative 
splicing has been reported for three other VGSCas: Navl.l (Copley, 2004), Navl.6 
(Plummer et al., 1998) and Navl.7 (Belcher et al., 1995; Klugbauer et al., 1995; Toledo-
Aral et al., 1997). This splicing was believed to be developmentally regulated since 
neonates expressed the upstream D1:S3 (5') exon, and this was replaced after day 10, by 
transcripts having the downstream (3') exon. Hence, the first exon was designated 
'neonatal' and the second 'adult' (Sarao et al., 1991; Gustafson et al., 1993). Whether 
such D1:S3 alternative splicing is developmentally regulated in tissues other than brain 
is not yet known. 
Although the effect of this alternative splicing on channel function has not been 
fully investigated, its conservation across different VGSCa genes and species would 
suggest that it is likely to be significant. Furthermore, disruption of D1:S3 splicing may 
have a role in disease. Thus, during kainic acid induced seizures in the hippocampus and 
dentate gyrus (modelling human epilepsy), D1:S3 splicing of Navl.2 and Navl.3 is 
altered, with upregulation of 'neonatal' and concomitant downregulation of 'adult' 
isoforms (Bartolomei et al., 1997). 
Upregulation of Navl.5 expression has been found in metastatic human breast 
cancer (BCa) in vitro and in vivo (Diss, 2001; Fraser et al., 2002a; Fraser et al., 2003c; 
Fraser et al., 2005). Navl.5 expression strongly correlated with lymph node metastasis 
in BCa patients (Fraser et al., 2005) and inhibition of such VGSC activity significantly 
reduced numerous cellular behaviours integral to the metastatic process in vitro (Fraser 
151 
et al., 2002a; Fraser et al., 2003c; Fraser et al., 2005; Brackenbury et al., 2006). 
Importantly, sequencing revealed that the Navl.5 was predominantly expressed in its 
previously uncharacterized D1:S3 5' splice variant (Diss, 2001; Fraser et al., 2002a; 
Fraser et al., 2003c; Roger et al., 2003; Fraser et al., 2005). This novel isoform encodes a 
protein with a positively charged lysine residue replacing the conserved aspartate residue 
at the extreme extracellular end of D1:S3 (Figure 1.16). Since the absence of an 
aspartate residue is characteristic of all D1:S3 5' ('neonatal') exons (Copley, 2004), this 
splice form was designated "neonatal Navl.5" (nNavl.5) (Diss, 2001; Fraser et al., 
2002a; Fraser et al., 2003c; Fraser et al., 2005). However, whether expression of this 
novel nNavl.5 isoform is developmentally regulated is yet to be investigated. The 
existence of nNavl.5 has since been confirmed in human, rat and mouse (GenBank 
sequences, and Diss, 2001). In all three species, the nNavl.5 exon differs from the 
'adult' exon at 31 of its 92 nucleotides resulting in seven amino acid differences, many 
more than for other VGSCas with D1:S3 splicing. A similar D1:S3 5'-splice variant of 
Navl.5 has recently been described in the human neuroblastoma cell line, nBl (Ou et 
al., 2005). This seven amino acid difference could allow the generation of an antibody 
specific for the nNavl.5 protein. VGSCa splice variant-specific antibodies have not 
been reported before, possibly because of the minimal difference (1-2 amino acids) 
between D1;S3 alternate splice forms of all other VGSCas. 
As previously described in section 2.7.1, two immunizing peptides were 
designed and developed for the production of polyclonal antibody (NESO-pAb) specific 
for nNavl.5: short (eleven amino acids) and a long (fifteen amino acids) (Figure 2.2). 
Initial observations revealed that the short-peptide antibody had very weak affinity and it 
gave very little or no staining. Consequently, this study focused on the long-peptide 
antibody, now termed "NESO-pAb". 
3.1.1 Aims and scope 
The overall aims of this study were as follows: 
(1) To generate and validate a polyclonal antibody specific for 'neonatal' Navl.5 
(nNavl.5) protein, NESO-pAb. 
(2) To use the NESO-pAb antibody to investigate the possible developmental expression 
of this Navl.5 D1:S3 alternative splice form; and 
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(3) To use the NESO-pAb antibody as a potential blocking agent to evaluate the 
proposed role of nNavl.5 in in vitro metastatic cell behaviour (MCB) of in human BCa 
cells. 
Parts of the present study have been published (Chioni et al., 2005; Brackenbury 
et al., 2006). 
3.2 Results 
3.2.1 VGSCa protein expression in different mouse and rat tissues: Western blots 
The possible expression of VGSCa protein in various mouse and rat tissues was studied 
by Western blotting in order to choose the appropriate positive and negative controls. A 
variety of adult and neonatal tissues from rat and mouse (heart, brain, lung, liver, kidney, 
spleen, skeletal muscle, testis and bladder) were tested. Most tissues expressed VGSCa 
protein giving bands of variable intensity in the size range 200-220 kDa (Figure 3.1). 
Only protein extracts from adult rat bladder and kidney did not produce any band 
(Figure 3.1 A, lanes 5 and 9). Adult mouse and rat tissues showed similar profiles (data 
not shown). Both adult and neonatal brain (rat and mouse respectively) as well as adult 
rat skeletal muscle expressed more than one band, indicating a possible multiplicity of 
VGSCa isoform expression (Figure 3.1, lanes 1, 3 and 12). A negative control with 
rabbit IgG instead of the pan-VGSCa antibody confirmed the specificity of the pan-
VGSCa and secondary antibodies (Figure 3.IB). Expression of actin, used as a loading 
control, was tested in all the samples studied and found to be consistent (Figure 3.1C). 
3.2.2 Test of pre-immunised serum from rabbits for possible endogenous 
immunoreactivity for VGSCa 
Before immunizing rabbits with the synthetic peptides of nNavl.5 protein, pre-
immunised rabbit sera tested for possible endogeneous immunoreactivity for VGSCa. 
Neonatal mice heart and adult mice kidney were used as positive and negative controls, 
respectively. Protein extracts from neonatal mouse heart immunoprecipitated with pre-
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Figure 3.1 Expression of VGSCa in adult rat and neonatal mouse tissues by 
Western blot. 
(A) Expression of VGSCa in 12 different adult rat and neonatal mouse tissues (Lanes 1-
12). Membranes were immunostained with pan-VGSCa antibody. 
(B) Membrane was immunostained with rabbit IgG at the same concentration as the pan-
VGSCa antibody. 
(C) Actin was used as a positive loading control. 60 |j,g of total protein extraction was 
loaded in each lane. 
The lanes 1-12 are as follows: Adult rat brain; adult rat heart; neonatal mouse brain; 
neonatal mouse heart; adult rat bladder; adult rat testis; adult rat liver; adult rat lung; 
adult rat kidney; neonatal mouse kidney; adult rat spleen; adult skeletal muscle. Key: A: 
adult and N; neonatal. 
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immuni sed sera from rabbits and Western blotted with pan-VGSCa antibody showed no 
reactivity indicating that all rabbits were clear from the presence of any endogenous 
VGSCa antibody (Figure 3.2, lanes 2-5). Neonatal heart lysate incubated only with 
protein A sepharose beads and protein extract from adult mouse kidney also did not give 
any band (Figure 3.2, lanes 6 and 7). On the other hand, the positive control, protein 
extract from neonatal heart immunoprecipitated with pan-VGSCa antibody gave a clear 
single band at about 220 kDa (Figure 3.2, lane 8). 
3.2.3 Efficiency and purity of NESO-pAb purification 
After the collection of the final bleeds from the rabbits, the NESO-pAb antibody was 
recovered from the serum by affinity chromatography. The different fractions obtained, 
including the fraction with the antibody, were tested by Western blotting with protein 
extract from neonatal heart. The purified antibody revealed a band at about 220 kDa 
(Figure 3.3, lanes 2-6); increasing the concentration of the antibody (0.05-1.5 |ig/ml) 
increased the intensity of the band, although at the higher concentrations, the 
background was more intense (Figure 3.3, lanes 5 and 6). The 'wash' fraction produced 
no immunoreactivity (Figure 3.3, lane 7). The 'breakthrough' fraction lacked the band 
for the nNavl.5 but it did have a high background level (Figure 3.3, lane 8). Finally, the 
unpurified serum gave a band of the same size as the positive control but level of 
background immunoreactivity was much higher and similar to the breakthrough fraction 
(Figure 3.3, lane 9). 
The concentration and purity of the purified NESO-pAb was tested by both 
absorbance at 280 nm as described in Section 2.7.4, and by densitometric comparison 
with known BSA standards on coomasie stained SDS-PAGE gels (Figure 3.4A). 
Coomasie staining revealed a pure NESO-pAb fraction and confirmed the finding from 
absorbance at 280 nm (1 mg Ig protein/ml equivalent to an absorbance of 1.35) that the 
concentration of the purified NESO-pAb was -0.7 p-g/p-l. In Figure 3.4B, lane 5 (30 pi 
of NESO-pAb) had similar intensity as lane 4 in Figure 3.4A (2 )ig of BSA). Tlierefore, 
in 30 pi of purified NESO-pAb were around 2 pg of Ig protein. However, because prior 
loading on to the gel the NESO-pAb antibody was diluted in water (1:10), the actual 
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Figure 3.2 Rabbit pre-immune serum screening, 
In order to carry out immunizations with specific KLH-conjugated peptides, initially, 
rabbits negative for anti-sodium channel antibodies production were selected as follows; 
similar amounts of protein from neonatal mouse heart (60 |ig), known to express Navl.5 
VGSCa isoform, were immunoprecipitated with pre-immune serum or pan-VGSCa 
antibody. The complexes were recovered with protein A sepharose, washed and run on 
SDS-PAGE. Proteins were transferred to nitrocellulose and probed for the presence of 
VGSCa by immunoblotting with pan-VGSCa antibody. Lanes 2 to 5, 
immunoprecipitation with pre-immune serum from rabbits 1 to 4; lane 6, negative 
control, neonatal heart lysate incubated only with protein A sepharose beads and lane 7, 
negative control, protein extracts from adult mouse kidney. Lane 8 is positive control; 
protein extract from neonatal heart immunoprecipitated with pan-VGSCa antibody. 
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Figure 3.3 Western blots on neonatal mouse heart immunostained with different 
fractions collected after antibody purification. 
60 |ig of neonatal mouse heart protein was loaded per lane on SDS-PAGE gel. After 
transfer each lane from the Western blot was cut and immunostained separately. Lane 1 
was positive control immunostained with pan-VGSC antibody, lanes 2-6, blots were 
immunostained with purified antibody using different working concentrations. Lane 7, 
blot was immunostained with the 'wash' fraction collected after the breakthrough 
fraction and before the isolation of the antibody (2:100 dilution). Lane 8, blot was 
immunostained with the 'breakthrough' fraction (1.5:100 dilution) and lane 9, blot was 
immunostained with unpurified serum (1:100 dilution). 
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Figure 3.4 Coomasie staining of SDS-PAGE gel for assaying NESO-pAb purity and 
quantity. 
(A) A range of different BSA concentrations (0.25-3 |ig) were loaded to a 10 % SDS-
PAGE gel to obtain a standard curve (n=3). The gel was then stained with coomasie and 
scanned with a hp scanner (ScanJet 3400C). Densitometric analysis revealed the 
intensity of each band. (B) Different volumes (2.5 - 30 p,l) of the purified NESO-pAb 
(diluted 1:10 H2O) was loaded to a 10 % SDS-PAGE and then was commasie stained. 
The intensity of each band was calculated by denitometric analysis and compared to the 
density of the BSA bands which correspond to known protein concentrations. Data are 
presented as mean ± SEM (n=5). 
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3.2.4 Identification of appropriate cell line for transfection and isolation of 
transfected colonies 
In order to evaluate the specificity of the purified NESO-pAb antibody, cells transfected 
with either the 'adult' or the 'neonatal' Navl.5 (aNavl.5 and nNavl.5, respectively) 
spHce variants were used for Western blot and immunocytochemmistry (ICC) studies. 
Four different cell lines were screened by Western blot and then electrophysiology for 
basal levels of VGSCa expression. COS-7, HEK-293, TSA, and EBNA-293 cells 
expressed some VGSCa protein (Figure 3.5). The relative levels of VGSCa expression 
were as follows; EBNA-293<HEK-293<TSA<COS-7 (Figure 3.5). Thus, EBNA-293 
had the lowest level of VGSCa expression and COS-7 the highest. Transfections were 
performed by F. Pani, as previously described (Chioni et al., 2005). TSA and EBNA-293 
cells transfected with aNavl.5, as well as protein extracts from adult mouse brain were 
used as positive controls. Indeed, TSA and EBNA-293 cells transfected with aNavl.5 
had ~84 % and ~37 %, respectively, higher levels of expression compared to 
corresponding non-transfected cell lines (Figure 3.5A; lanes 3 vs. 5 and 4 vs. 6; Figure 
3.5C). 
EBNA-293 cells were chosen to be transfected with nNavl.5 protein. After 
transfection, different colonies were isolated and selected to be screened first by Western 
blot and then by electrophysiology for VGSCa expression. Colonies 2 and 8 had 
considerably higher levels of VGSCa protein (Figure 3.6) and were selected to be grown 
and used in the remainder of this study. 
3.2.5 Validation of NESO-pAb selectivity for nNavl.5 in vitro 
Three VGSCa antibodies (pan-VGSCa; anti-Navl.5 and NESO-pAb) were tested on 
native and transfectant EBNA cells by immunocytochemistry and Western blotting. The 
anti-Navl.5 antibody could only be used in ICC. Both the pan-VGSCa and the anti-
Navl.5 antibodies detected VGSCa expression in all three cell lines (EBNA-293 non-
transfected and transfected with aNavl.5 and nNavl.5), the staining in the native cells 
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Figure 3.5 Screening of cell lines for basal levels of VGSCa prior transfection with 
'neonatal' Navl.5 by Western blot. 
Total protein (60 pg each) from COS-7 (lane 1), HEK-293 (lane 2), TSA (lane 3), 
EBNA-293 (lane 4), TSA and EBNA-293 cells transfected with 'adult' Navl.5 
(aNavl.5) (lanes 5 and 6 respectively) and adult mouse brain as a positive control was 
loaded on SDS-PAGE. (A) Western blot was immunostained with pan-VGSCa antibody 
to obtain basal levels of VGSCa. (B) Actin was also obtained as an internal/loading 
control. (C) Densitormetric analysis of band intensity from pan-VGSCa normalised to 
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Figure 3.6 Western blots of total protein from various colonies of EBNA-293 cells 
transfected with 'neonatal' Navl.5. 
Total protein extracts (60 p.g of protein per lane) from colonies (1-13) of transfected 
EBNA-293 cells with 'neonatal' Navl.5 were loaded on SDS-PAGE gel. Western blots 
were immunostained with (A) pan-VGSCa, to test for colonies that were successfully 
transfected and (B) anti-actin antibodies as an internal/loading control. (C) 





























Figure 3.7 Western blots of total protein from EBNA-293 cells non-transfected, 
transfected with 'adult' Navl.5 and 'neonatal' Navl.5. 
Total protein extracts (60 |ig of protein per lane) from non-transfected EBNA-293 cells 
(lane 1), 'adult' Navl.5 EBNA transfectants (aNavl.5; lane 2) and 'neonatal' Navl.5-
transfected EBNA-293 cells (nNavl.5; lane 3) loaded on a 6 % SDS-PAGE gel. Western 
blots were immunostained with (A) pan-VGSCa, (B) NESO-pAb and (D) anti-actin 
antibodies. (C) Pre-incubation of NESO-pAb with an excess of the NESO immunizing 
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Figure 3.8 Immunocytochemistry of permeabilised EBNA-293 cells, non-
transfected and transfected with 'neonatal' and 'adult' Navl.5. 
Immunostaining of permeabilised (with 0.1 % saponin) non-transfected native EBNA-
293 cells; 'adult' Navl.5 EBNA transfectants (aNavl.5); and 'neonatal' Navl.5-
transfected EBNA-293 cells (nNavl.5). Antibodies used were pan-VGSCa (left hand 
column); anti-Navl.5 (middle column) and NESO-pAb (right hand column). Primary 
antibody binding was visualized by fluorescence microscopy using secondary antibodies 
conjugated with FITC. Scale bar (14 pm) applicable to all panes. 
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stained only the EBNA nNavl.5 transfectants (Figure 3.7 and 3.8). Furthermore, NESO-
pAb detected signal from nNavl.5 transfectants under methodological conditions where 
the plasma membrane would be non-permeabilized (Figure 3.9), consistent with it 
recognising a predicted external epitope (Figure 2.2). However, NESO-pAb did not 
detect any ICC signal from non-transfected or aNavl .5-trasfected non-permeabilised 
EBNA-293 cells (Figure 3.9). 
The specificity of NESO-pAb for nNavl.5 was further demonstrated by the 
detection of a single strong band of -220 kDa in protein extracts from nNavl.5 
transfectants in Western blots (Figure 3.7B). In contrast, the pan-VGSCa antibody 
detected bands of 200-220 kDa in all three cell lines (EBNA-293 non-transfected and 
transfected with aNavl.5 and nNavl.5; Figure 3.7A). 
Autofluorescence controls (Figure 3.10), as well as control ICC experiments 
excluding the primary antibody (Figures 3.1 IC and 3.12A-D) and replacing it with non-
specific IgG (Figures 3.1 IB and 3.12E-H) followed labeling with only the secondary 
antibody (FITC-conjugated) were performed for all three cell lines (EBNA-293 non-
transfected and transfected with aNavl.5 and nNavl.5). These control experiments 
confirmed that the cells had insignificant autofiuoresence and both the primary as well 
as the secondary antibodies bound specifically and did not cross react with any unknown 
antigen. Importantly, pre-incubation of NESO-pAb with an excess of the immunizing 
peptide abolished immunoreactivity in both Western blots (Figure 3.7C) and ICC 
(Figure 3.11 A). 
3.2.6 Expression of nNav.5 protein in vivo 
The developmental expression and tissue-specificity of nNavl.5 was determined by 
immunohistochemistry (IHC) and Western blotting using NESO-pAb (Figures 3.13, 
3.14 and 3.15). NESO-pAb immunostaining of tissues and Western blots were compared 
to those obtained using the pan-VGSCa antibody. The anti-Navl.5 antibody could not 
be used on the mouse tissues as it is specific for human Navl.5 (Maier et al., 2002). 
Instead, another anti-Navl.5 (D-492 pAb) specific for mouse and rat Navl.5 was used 
for IHC. 





Figure 3.9 Immunocytochemistry of non-permeabilised EBNA-293 cells, non-
transfected and transfected with 'neonatal' and 'adult' Navl.5. 
Immunostaining of non-permeabilised, non-transfected native EBNA-293 cells (left-
hand column); 'adult' Navl.5 EBNA transfectants (aNavl.5; middle column); and 
'neonatal' Navl.5-transfected EBNA-293 cells (nNavl.5; right hand column). Antibody 
used to obtain plasma membrane staining, was NESO-pAb. Primary antibody binding 
was visualized by fluorescence microscopy using secondary antibodies conjugated with 







Figure 3.10 Autofluorescence control for immunocytochemistry on EBNA-293 cells 
with non-transfected and transacted with 'neonatal' and 'adult' Navl.5. 
Non-transfected native EBNA-293 cells (left-hand column); 'adult' Navl.5 EBNA 
transfectants (aNavl.5; middle column); and 'neonatal' Nav 1.5-transfected EBNA-293 
cells (nNavl.5; right hand column), were tested for autofluorescence levels. Cells were 
fixed in 4 % PFA, permeabilised and mounded as normal without labelling. Cells were 
visualized by fluorescence microscopy and images for the fluorescence (FL: A-C) with a 
filter for FITC and bright field (BF: D-F) were taken. Scale bar (16 |im) applicable to all 
panels. 
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Figure 3.11 Controls for immunocytochemistry with EBNA-293 cells transfected 
with 'neonatal' Navl.5 and NESO-pAb. 
(A) 'Neonatal' Navl.5-transfected EBNA-293 cells, were stained with NESO-pAb after 
pre-absorption with the immunizing peptide; 
(B) Instead of NESO-pAb, cells were treated with a non-specific IgG at the same 
concentration as the NESO-pAb (1 pg/^il). 
(C) The primary antibody was not applied but only the secondary swine anti-rabbit-
FITC was used as normal. 
Cells visualized by fluorescence microscopy and images for the fluorescence (FL; A-C) 
with a filter for FITC and the bright field (BF; D-F) were taken. Scale bar (16 ^m) 













Figure 3.12 Controls for immunocytochemistry with non-transfected and 
transfected with 'adult' Navl.5 EBNA-293 cells. 
(A-D) The primary antibody was not applied on non-transfected and 'adult' Navl.5-
transfected EBNA-293 cells (aNavl.5), but only the secondary swine anti-rabbit-FITC 
was used as normal. (E-H) Instead of the primary antibody cells were treated with a non-
specific IgG at the same concentration as the primary antibody (2 ng/^il). Cells 
visualized by fluorescence microscopy and images for the fluorescence (FL; A, C, E, G) 
with a filter for FITC and the bright field (BF: B, D, F, H) were taken. Scale bar (16 |im) 
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Figure 3.13 Western blotting of total protein extracts from neonatal and adult 
mouse tissues. 
Western blotting of total protein extracts from heart, brain, kidney, lung, liver and 
skeletal muscle from both neonatal (lanes 1-6, left hand side, respectively) and adult 
mouse (lanes 1-6, right hand side, respectively). Antibodies: pan-VGSCa (A); NESO-
pAb (B) and anti-actin (D) to confirm that equivalent amounts of cell protein were used 
in each experiment. (C) Pre-incubation of NESOpAb with the immunizing peptide gave 
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Figure 3.14 Immunohistochemistry of neonatal mouse tissues. 
Immuno-fluorescence histological staining of cryosections (5-7 |am) fixed in 4 % PFA, 
of neonatal mouse heart, brain, lung, liver, skeletal muscle (Sk. Muscle) and kidney (1-
6) using (A) the pan-VGSCa, (B) NESO-pAb and (C) anti-Navl.5 (D-492 pAb) 
antibodies. Tissues visualized by fluorescence microscopy. Scale bar (20 pm) applicable 
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Figure 3.15 Immunohistochemistry of adult mouse tissues. 
Immuno-fluorescence histological staining of cryosections (5-7 ^m) fixed in 4 % PFA, 
of adult mouse heart, brain, lung, liver, skeletal muscle (Sk. Muscle) and kidney (1-6) 
using (A) the pan-VGSCa, (B) NESO-pAb and (C) anti-Navl.5 (D-492 pAb) 
antibodies. Tissues visualized by fluorescence microscopy. Scale bar (20 pm) applicable 
to all panels. 
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examined; heart, brain, skeletal muscle, lung, liver, kidney (Figures 3.14A and 3.15A). 
This is consistent with these tissues expressing VGSCa mRNAs, as described previously 
(Raymond et al., 2004). However, VGSCa expression levels were noticeably lower in 
adult liver and kidney (Figure 3.14A and 3.15A). Strongest staining was typically 
observed in heart, brain and lung, with no significant difference in VGSCa protein 
expression levels between neonatal and adult. Staining was also evident in adult skeletal 
muscle, whereas neonatal tissue exhibited considerable heterogeneity. Western blots 
generally were consistent with the immunohistochemical data, with the only difference 
that neonatal kidney did not express any VGSCa (Figure 3.13A). Blots also suggested 
possible expression of multiple VGSCa subtypes/forms with different molecular 
weights, which were not studied further. 
NESO-pAb revealed a markedly different staining pattern, with strong 
expression of nNavl.5 evident only in neonatal heart and brain (Figures 3.14B and 
3.15B). Corresponding Western blots yielded similar results with a single -220 kDa 
band in both neonatal heart and brain (Figure 3.13B). Additionally, blots revealed a very 
low level of nNavl.5 expression in neonatal skeletal muscle and an even lower, just 
detectable level in corresponding adult tissue. Lung, liver and kidney tissues (both 
neonatal and adult) did not stain. Importantly, nNavl.5 staining was dramatically 
reduced in the mouse heart with development. Indeed, no expression of nNavl.5 protein 
in adult cardiac tissue was detectable by IHC or western blotting. nNavl.5 protein was 
evident in adult brain, although expression was reduced compared with neonatal brain 
tissue. Although not studied in detail, NESO-pAb staining in brain and heart of four 
days old mice was reduced in comparison with one day old pups (not shown). Thus, 
expression of nNavl.5 appeared to be down-regulated very soon after birth, consistent 
with rapid post-partum changes in expression reported previously for Navl.2 and 
Navl.3 isoforms in rat brain and for Navl.5 in rat skeletal muscle (Kallen et al., 1990). 
Interestingly, the anti-Navl.5 (D-492 pAb) antibody stained all neonatal mouse 
tissues (Figure 3.14C), with strong and heterogeneous expression in heart and brain. In 
contrast kidney and liver exhibited very low levels of expression, which was not 
heterogeneous. Of the adult tissues, only heart, brain, lung and skeletal muscle showed 
immunoreactivity with the antibody. Adult skeletal muscle had lower levels of staining 
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compared to neonatal. In contrast, adult lung tissue expressed considerably higher levels 
of staining compared to the corresponding neonatal tissue. 
In control experiments, pre-incubation of NESO-pAb and anti-Navl.5 (D-492 
pAb) with an excess of the corresponding immunising peptides aboUshed 
immunoreactivity in both Western blots (Figure 3.13C) and ICH (Figures 3.16, 3.17 and 
3.18) on adult and neonatal tissues. Other control experiments on both neonatal and 
adult tissues, such as autofluoresence (Figures 3.19A and 3.20A), replacing the primary 
antibody with a non-specific IgG control (Figures 3.19B and 3.20B) and exclusion of the 
primary antibody (Figures 3.19C and 3.20C) revealed good specificity of the primary 
and secondary antibodies, as well as minimum autofluorescence. 
3.2.7 Migrating MDA-MB-231 cells expressed more nNavl.5 protein than non-
migrating cells 
Confocal immimocytochemistry with NESO-pAb was used to compare the nNavl.5 
protein expression in plasma membranes of cells that did or did not migrate through 
Transwell filters (Figure 3.21). Cells that migrated through the filter had 2.2-fold more 
plasma membrane nNavl.5 protein immunoreactivity compared with cells that did not 
migrate (P < 0.001; n > 45; Figure 3.21). 
3.2.8 NESO-pAb reduced migration and suppressed VGSC-dependent invasion 
NESO-pAb, applied during the Transwell assays, reduced MDA-MB-231 cell migration 
in a dose-dependent manner, reaching a significant reduction of 38 % at 1 fxg/ml (P < 
0.001; n = 7; Figure 3.22). NESO-pAb (1 pg/ml) also reduced Matrigel invasion of 
MDA-MB-231 cells by 49 % compared to control (P < 0.01; n = 7; Figure 3.23A). 
However, IgG control and an anti-laminin antibody had no effect on the invasiveness of 
MDA-MB-231 cells (P=0.56 and P=0.74 respectively; n=7 for both; Figure 3.23A). 
Similar control treatments had no effect on the invasiveness of rat metastatic Mat-LyLu 
and human metastatic PC-3M prostate cancer (PCa) cells, which do not highly express 
nNavl.5 (J. K. J. Diss, unpublished observations) (P= 0.48 and P=0.10, respectively, 
n=4 for both; Figure 3.23B and C) . TTX (10 )iM) reduced invasion of MDA-MB-231 
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Figure 3.16 Control immunohistochemical staining of adult mouse tissues with pre-
absorbed anti-Navl.5 (D-492 pAb) with the immunising peptide. 
Immuno-fluorescence histological staining of cryosections (5-7 jim) fixed in 4 % PFA, 
of adult mouse heart, brain, lung and skeletal muscle (Sk. Muscle) (1-4) immunostained 
with pre-absorbed anti-Navl.5 (D-494 pAb) with the immunising peptide. Tissues 
visualized by fluorescence microscopy and images for the fluorescence (FL) with a filter 
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Figure 3.17 Control immunohistochemical staining of neonatal mouse tissues with 
pre-absorbed anti-Navl.5 (D-492 pAb) with the immunising peptide. 
Immuno-fluorescence histological staining of cryosections (5-7 pm) fixed in 4 % PFA, 
of neonatal mouse heart, brain, lung, liver, skeletal muscle (Sk. Muscle) and kidney (1-
6) immunostained with anti-Navl.5 (D-494 pAb) pre-absorbed with the immunising 
peptide. Tissues visualized by fluorescence microscopy and images for the fluorescence 
(FL) with a filter for FITC and the bright field (BF) were taken. Scale bar (20 pm) 























Figure 3.18 Control immunohistoehemical staining of neonatal and adult mouse 
tissues with pre-absorbed NESO-pAb with the immunising peptide. 
Immuno-fluorescence staining of cryosections (5-7 ^m) fixed in 4 % PFA, of adult 
mouse brain (1) and neonatal mouse brain and heart (2, 3), immunostained with NESO-
pAb pre-absorbed with the immunising peptide. Tissues visualized by fluorescence 
microscopy and images for the fluorescence (FL) with a filter for FITC and the bright 
field (BF) were taken. Scale bar (20 jam) applicable to all panels. 
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ADULT TISSUES 
(A) Autofluorescence (B) IgG control (C) 2""^  antibody only 
BF FL BF FL BF FL 
(1) Heart 
(2) Brain H H 
(3) Kidney H H • • 
(4) Lung H H H H 
(5) Liver H H 
(6) Sl(. muscle 
• • 
Figure 3.19 Controls for immunohistochemistry on neonatal mouse tissues. 
Immuno-fluorescence histological staining of cryosections (5-7 [im) fixed in 4 % PFA, 
of neonatal mouse heart, brain, lung, liver, skeletal muscle (Sk. Muscle) and kidney (1-
6). The following controls were performed: (A) Autofluorescence, tissues were fixed 
and mounted without labelling. (B) Instead of the primary antibody cells were treated 
with a non-specific IgG at the same concentration as the primary antibody (l^ig/|il). (C) 
The primary antibody was not applied, but only the secondary swine anti-rabbit-FITC 
was used as normal. Tissues visualised by fluorescence microscopy and images for the 
bright field (BF) and the fluorescence (FL) with a filter for FITC were taken. Scale bar 
(20 pm) applicable to all panes. 
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NEONATAL TISSUES 
(A) Autofluorescence (B) IgG control (C) 2"'' antibody only 
BF FL BF FL BF FL 
(1) Heart l i i H l 
(2) Brain 
• H f 
(3) Kidney • • • • 
(4) Lung H H 
(5) Liver • • H H 
(6) Sk. muscle 
• • 
Figure 3.20 Controls for immunohistochemistry on adult mouse tissues. 
Immuno-fluorescence histological staining of cryosections (5-7 [im) fixed in 4 % PFA, 
of adult mouse heart, brain, lung, liver, skeletal muscle (Sk. Muscle) and kidney (1-6). 
The following controls were performed; (A) Autofluorescence; tissues were fixed and 
mounted without labelling. (B) Instead of the primary antibody cells were treated with a 
non-specific IgG at the same concentration as the primaiy antibody (l^ig/fil). (C) The 
primary antibody was not applied, but only the secondary swine anti-rabbit-FITC was 
used as normal. Tissues visualised by fluorescence microscopy and images for the bright 
field (BF) and the fluorescence (FL) with a filter for FITC were taken. Scale bar (20 ^tm) 
applicable to all panels. 
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Figure 3.21 Migrated MDA-MB-231 cells had more nNavl.5 protein at the plasma 
membrane than non-migrated cells. 
Migrated MDA-MB-231 cells expressed more neonatal Navl.5 (nNavl.5) protein in the 
plasma membrane compared to non-migrated cells in Transwell migration assays. 
Typical confocal images of (A) non-migrated and (B) migrated cells, respectively, non-
permeabilized and double-immunolabelled with NESO-pAb (red) and concanavalin A 
(ConA), a plasma membrane marker (green). Scale bar (16 |im), applicable to all panels 
m A and B. (C) Relative levels of nNavl.5 protein in non-migrated and migrated cells. 
Data presented as mean ± SEM (n > 45 cells from 3 independent experiments). Data 
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Figure 3.22 NESO-pAb reduced VGSC-dependent migration in MDA-MB-231 
cells. 
Relative numbers of MDA-MB-231 cells migrating through a Transwell chamber over 7 
h. Cells were treated with 0.01-20 |ig/ml NESO-pAb during the assays. Each condition 
was paired with a control which was treated with the same solution the antibody was 
diluted in (20 mM HEPES, 0.15 mM NaCl and 10 % BSA; without the antibody) and an 
IgG at the same concentration as the NESO-pAb. The NESO-pAb used for this 
experiment did not contain glycerol or sodium azide. Data are presented as mean + SEM 
(n=7). Treated cells were normalized with respect to the control (100 %; grey line). Data 
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Figure 3.23 NESO-pAb reduced VGSC-dependent invasion in MDA-MB-231 cells. 
Relative numbers of cells invading through Matrigel chamber over 24 h. MDA-MB-231 
(A), PC-3M (B) and Mat-LyLu (C) cells were treated with IgG (1 i^g/ml), anti-laminin 
(1:100), NESO-pAb (1 |j,g/ml) with/without TTX (10 p,M) during the invasion assay. 
Treatments were compared with the respective control which was treated with the same 
solution the antibody was diluted in (20 mM HEPES, 0.15 mM NaCl and 10 % BSA; 
without the antibody). The IgG control contained IgG at the same concentration as the 
NESO-pAb. The NESO-pAb used for this experiment did not contain glycerol or sodium 
azide. Data are presented as mean + SEM; n-7 for MDA-MB-231 cells; n=4 for PC-3M 
and Mat-LyLu cells. Data was normalized to control (100 %) and analysed by one way 
analysis of variance followed by Student-Newman-Keuls test. Significance: (**) P < 
0.01. 
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Figure 3.24 NESO-pAb treatment had no effect on cell proliferation. 
Relative numbers of cells proliferating over 24 h. MDA-MB-231, PC-3M and Mat-LyLu 
cells were treated with IgG (1 p.g/ml), anti-laminin antibody (1:100), NESO-pAb (1 
(xg/ml) during assays. Treatments were compared with the control which was treated 
with the same solution the antibody was diluted in (20 mM HEPES, 0.15 mM NaCl and 
10 % BSA; without the antibody). The IgG control contained IgG at the same 
concentration as the NESO-pAb. The NESO-pAb used for this experiment did not 
contain glycerol or sodium azide. Data are presented as mean + SEM; n=7 for MDA-
MB-231; n=5 for PC-3M and Mat-LyLu cells. Data was normalized with respect to 
control (100 %) and analysed by one-way analysis of variance. 
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TTX (10 (iM) also reduced cell invasion by 47 % (P < 0.01; n = 7), but had no further 
effect compared to either NESO-pAb or TTX alone (P = 0.231 and 0.277, respectively; n 
= 7 for each; Figure 3.23A). None of the antibody treatments had any effect on 
proliferation of MDA-MB-231, PC-3M or Mat-LyLu cells (P=0.16, P=0.30 and P-0.23; 
n= 7 for MDA-MB-231 and n=5 for PC-3M and Mat-LyLu cells; Figure 3.24). 
3.3 Discussion 
The first conclusion of this study is that it was possible to generate a novel polyclonal 
antibody termed "NESO-pAb" with high specificity for the D1:S3 5' ('neonatal') splice 
form of nNavl.5. This is the first study to successfully target a D1:S3 splice form 
protein and, indeed, the first to specifically target any VGSCa splice form. 
The specificity of NESO-pAb for nNavl.5 protein was demonstrated by Western 
blotting and immunocytochemical studies of transfectant EBNA-293 cell lines 
selectively expressing nNavl.5 and aNavl.5 splice forms. NESO-pAb exhibited strong 
immunoreactivity for cells transfected with nNavl.5, even when the cells were not 
permeabilised, consistent with plasma membrane expression of the channel protein and 
the extracellular location of the antigenic site. In contrast, native EBNA cells and those 
transfected with the aNavl.5 showed no immunoreactivity with NESO-pAb. 
Furthermore, Western blots and immunohistochemistry confirmed that nNavl.5 protein 
was indeed developmentally regulated. 
3.3.1 VGSCa protein expression in different mouse and rat tissues 
An important starting point of this study was identification and use of positive and 
negative controls for VGSCa protein expression. Controls served mainly to evaluate the 
specificity of the antibodies used as well as to compare the different human cell lines 
adopted. Both neonatal and adult tissues from mouse were used since there is an 
alternative splicing of D1;S3 in neonatal versus adult exons in five VGSCa genes: 
Navl.2, Navl.3, Navl.6 and Navl.7 (Belcher et al., 1995; Klugbauer et al, 1995; 
Bartolomei et al., 1997; Toledo-Aral et al., 1997; Plummer et al., 1998; Copley, 2004), 
and recently Navl.5 (Diss et al., 2004a; Eraser et al., 2004b; Eraser et al., 2005). One 
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amino acid substitution at exon residue seven was consistent across all the above genes. 
This substitution involved a negatively charged aspartate residue at the extreme 
extracellular end of Dl: S3 in the adult form to a non-charged amino acid in the neonatal 
form (serine in Navl.3 and asparagine in Navl.2, Navl.6 and Navl.7 (Gustafson et al., 
1993). 
The pan-VGSCa antibody revealed clear results and consistent bands at the 
expected molecular weight (about 220 kDa) for adult rat brain, heart, testis, liver, lung, 
spleen and skeletal muscle, as well as for neonatal mouse brain, heart and kidney (Figure 
3.1). These results agree with earlier demonstration of VGSC mRNA expression in these 
tissues (section 2.2) (Raymond et al., 2004; Candenas et al., 2006). Rat and mouse 
brains expressed a high level of VGSCa protein which is consistent with previous work 
showing that mammalian brain expresses a variety of different VGSCa isoforms, such as 
Navl.l, Navl.2, Navl.3, Navl.5 and Navl.7 (Beckh, 1990; Toledo-Aral et al., 1997; 
Hartmann et al., 1999; Goldin et al., 2000; Wu et al., 2002). Surprisingly, adult kidney 
did not contain any VGSCa protein although it has been reported to express Navl.l, 
Navl.3, Navl.4, Navl.6 and Navl.9 mRNAs (Diss, 2001; Raymond et al., 2004). 
However, it is possible that these isoforms are not translated in the adult tissue although 
there was low level of expression in the neonatal kidney. Somewhat surprisingly, 
bladder was also negative although it would be expected to express some VGSCa since 
it is a muscular organ. Bladder from monkey was found to express Navl.l, Navl.3, 
Navl.4, Navl.6 and Navl.9 mRNAs (Raymond et al., 2004). However, it is possible (i) 
that the level of VGSCa protein expression was very low in the bladder and thus not 
detectable by the antibody and/or (ii) that the mRNA is not translated to protein. It is 
now accepted that mRNA and protein expression dynamics can vary markedly in cells 
and not all mRNA may be translated to protein and protein synthesis can occur without 
de novo mRNA expression e.g. via local translation of pre-docked mRNA (Sola et al., 
1999; Tiedge et al., 1999; Orphanides and Reinberg, 2002; Schedel et al., 2004; St 
Johnston, 2005; Gu et al., 2006). 
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3.3.2 Production and evaluation of NESO-pAb antibody 
Pre-immunised sera from rabbits were free from any VGSCa since immunoprecipitation 
followed by Western blot did not reveal any band. Initially, two antibodies were 
developed against nNavl.5, termed as 'long' and 'short' peptides covering the spliced 
region of the protein. These two synthetic peptides had the following amino acid 
sequences (in bold) found in the extracellular S3-S4 loop segment in D1 of nNavl.5: 
Synthetic peptide 1 ('short'): CVSENIKLGNL-NH2 and 
Synthetic peptide 2 ('long'): VSENIKLGNLSALRC-NH2 
These sequences had significant amino acid differences between neonatal and adult 
forms of Navl.5, thereby maximizing the chance of generating antibodies specific for 
the nNavl .5 protein (from mouse, rat and human sources). Both antibodies were purified 
and tested for their specificity. However, the 'short' antibody lacked affinity and was not 
used for further investigation. Thus, all characterizations were performed with the 
"long" antibody termed "NESO-pAb". 
The purified antibody gave bands at the expected molecular weight of ~ 220 kDa 
for the protein extracts from neonatal mouse heart, even at the lowest tested 
concentration of 0.05 fxg/ml (Figure 3.3; lanes 2-6). The "wash fraction" did not give 
any signal (Figure 3.3; lane 7) indicating that the antibody from the serum was bound to 
the column. The "break-through fraction", which should contain all different proteins 
from the serum apart from the antibody of interest, gave a high background but not a 
specific band related to the molecular weight of interest, suggesting again that the 
antibody remained bound to the column through purification and prior to IgG collection 
from the column (Figure 3.3; lane 8). Finally, the unpurified serum fraction gave a high 
background as well as the band of interest illustrating the presence of the antibody of 
interest in the unpurified serum prior the start of the IgG isolation (Figure 3.3; lane 9). 
Comparison of coomasie stained SDS-PAGE gels with BSA standards and the 
purified NESO-pAb (Figure 3.4B) revealed that the stock concentration of NESO-pAb 
was around 0.7 |J.g/|J,l, consistent with the calculations from the absorbance at 280 nm. 
The purity of the antibody was also high since only the expected two bands appeared on 
the SDS-PAGE gel (heavy chain and light chain band) (Figure 3.4B). 
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3.3.3 Identification of appropriate cell line for transfection and isolation of colonies 
Four different cell lines (COS-7, HEK-293, TSA and EBNA-293) were tested for basal 
expression of VGSCa. All four cell lines expressed some VGSCa protein, with, EBNA-
293 expressing the least (Figure 3.5). EBNA-293 cells transacted with aNavl.5 showed 
good transfection efficiency since the VGSCa expression was ~84 % higher compared 
to the native EBNA-293 cells. In contrast, TSA cells had higher levels of basal VSGCa 
expression and moreover, TSA cells tranfected with aNavl.5 only upregulated the levels 
of VGSCa by 37 % (Figure 3.5). Therefore, EBNA-293 cells were selected for 
transfection of the nNavl.5 protein for the evaluation of NESO-pAb. A number of 
colonies were selected post trasfection and tested first by Western blot for VGSCa 
expression. Indeed, colonies number 2 and 8 were successfully transfected and selected 
for further studies with NESO-pAb (Figure 3.6). 
3.3.4 Specificity of NESO-pAb for nNavl.5 
For the first time, an antibody has been developed to target a developmentally regulated 
splice-variant of a VGSCa. From the results obtained with the EBNA-293 cell lines 
transfected with the nNavl.5 and aNavl.5, it was concluded that the NESO-pAb 
antibody was specific for the former (Figures 3.7 and 3.8). Furthermore, under non-
permeabilised conditions, the NESO-pAb still immunoreacted with EBNA-293 cells 
transfected with nNavl.5, consistent with the fact that the antibody recognizes a 
predicted external epitope (Figure 3.9). This also agreed with electrophysiological data 
EBNA-293 cells trasfected with nNav.5 displaying strong functional VGSC expression 
(Chioni et al., 2005) (Appendix 1A & B). 
3.3.5 Tissue specificity and developmental expression of nNavl.5 protein 
The D1:S3 5 splice-form of Navl.5 (Diss, 2001; Fraser et al., 2002a; Fraser et al., 2005) 
was proposed to be a "neonatal" based on the original findings of a neonatal, 
developmentally-regulated alternative spHce-form of Navl.2 (Sarao et al., 1991) and 
Navl.3 (Gustafson et al., 1993). The present study also demonstrated that the presumed 
neonatal splice form of Navl.5 was expressed mainly in neonatal but not adult tissue 
(Figures 3.13, 3.14 and 3.15). The only 'exceptions' were adult brain and skeletal 
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muscle, which were found to express low levels of nNavl.5 in both 
immunohistochemical and Western blot studies (Figures 3.17, 3.14 and 3.15; Table 3.1). 
Navl.5 was also previously found to be expressed in both neonatal and adult brain (Wu 
et al., 2002). Another study also showed the 'neonatal' splice form of another VGSCa 
subtype, Navl.7, continued to be expressed in adult dorsal root ganglion neurons, 
although at lower levels than in neonates (Raymond et al., 2004). hi adult brain, discrete 
cells were stained. At present the nature of these cells is not clear. It might be a 
(sub)population of stem cells, as reported previously (Reynolds and Weiss, 1992; Gage, 
2000). However, further research would be needed to confirm this hypothesis. 
hiterestingly, the general anti-Navl.5 (D-492pAb) antibody immunoreacted with 
all neonatal tissues studied (with lung, kidney and liver having very low expression). In 
some adult tissues (kidney, liver), the expression was completely abolished, whilst in 
skeletal muscle it was significantly reduced (Figure 3.14 and 1.15; Table 3.1). In 
contrast, Navl.5 expression was increased in lung tissue with development. Taking the 
above findings together, it is possible that during development different VGSC isoforms, 
including Navl.5, are being replaced, with other isoforms (or eliminated). Such changes 
in VGSC expression have been reported previously. For example in rat skeletal muscle, 
expression of Navl.5 was shown to be replaced by Navl.4 three days after birth (Kallen 
et al., 1990; Kallen et al., 1993). Although not studied in detail, in the present study 
expression of nNavl.5 appeared to be down-regulated rapidly soon after birth. 
Accordingly, staining patterns in brain and heart of 3 day old mice pups with NESO-
pAb antibody were much reduced in comparison with 1 day old pups. This observation 
agrees with the overall concept that VGSC expression in highly dynamic (Waxman et 
al., 2002; Diss et al., 2004a). 
These data, further support the notion that alternative splicing at D1:S3 does 
occur during development, and hence 'neonatal' and 'adult' can be used to describe 
D1:S3 5' and 3' splice forms, respectively. It should be recognized, however, that 
neonatal isoform expression strictly is not restricted to neonates (and vice-versa). 
At present, the mechanism(s) controlling developmental splicing of VGSC genes 
is not known but could include the membrane potential (Xie and Black, 2001), growth 
factors (Akopian et al., 1999), phosphorylation (Shipston, 2001), transcription factors 
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Table 3.1 Summary of VGSCa expression in adult and neonatal mice tissues. 
Key: nNav 1.5: neonatal Nav 1.5; aNav 1.5: adult Nav 1.5 
Tissue Total VGSCa nNavl.5 aNa 
ADULT 
Heart Yes No Yes 
Brain Yes Low Yes 
Lung Yes No Yes 
Liver Low No No 
Sk. Muscle Yes No Yes 
Kidney Low No No 
NEONATAL 
Heart Yes Yes Yes 
Brain Yes Yes Yes 
Lung Yes No Low 
Liver Yes No Low 
Sk. Muscle Yes No Yes 
Kidney Yes No Low 
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(Kuwahara et al., 2003), as well as particular splicing factors (Simard and Chabot, 2002; 
Li et al, 2003). NESO-pAb may be used as a novel tool to more easily investigate the 
process of developmental splicing of Navl.5. Such knowledge may also be applicable to 
analogous developmental splicing in other VGSCas. Furthermore, it is well known that 
Navl.5 protein is stored intracellularly and translocated to the plasma membrane under 
the influence of signalling mechanisms such as PKA (Herfst et al., 2004). NESO-pAb, 
therefore, may also be used to study this phenomenon and its control in a developmental 
context. 
3.3.6 Blocking efficiency of NESO-pAb 
Because the NESO-pAb antibody binds to an extracellular epitope, electrophysiological 
studies were performed (by Dr S.P Fraser) to check if the antibody would block the 
electrophysiological activity of nNavl.5 (Appendix 2A & B). The results showed (I) 
that the NESO-pAb antibody blocked the VGSC in the 293-EBNA cell line transfected 
with the nNavl.5 channel; (2) that there was a 100-1000-fold higher specificity of 
NESO-pAb for neonatal versus adult Navl.5 and (3) that the block of the channel 
appeared 400-fold greater for neonatal versus adult Navl.5 (Chioni et al., 2005). The 
above results are consistent with previous reports of antibodies blocking ion channels 
(Zhou et al., 1998; Schulte et al., 2002), including VGSCs (Weber et al., 2000). 
The finding that NESO-pAb was highly selective and efficient in blocking 
neonatal (relative to adult) Navl.5 activity in transfectant EBNA cells is consistent with 
the binding site of NESO-pAb being extracellular and located to a part of the protein 
involved in channel activation and ionic permeation. Most other VGSCa antibodies 
have been raised to internal epitopes and are thus not suitable for use on living cells 
(Dugandzija-Novakovic et al., 1995; Kolibal et al., 1998; Maier et al., 2002). 
Antipeptide antibodies made against epitopes in the pore region of two domains of the 
rat Navl.2 VGSCa were shown to effectively inhibit a-scorpion toxin binding but 
whether these antibodies could also block VGSC currents was not determined (Thomsen 
and Catterall, 1989). Other antibodies have been generated for use as blocking agents of 
voltage-gated ion channels (Morton et al., 1988; Zhou et al., 1998; Lu et al., 2002). 
Polyclonal antibodies were raised against epitopes in the pore region of Kvl.2 and 
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Kv3.1 voltage-gated channels and tested for their relative electrophysiological 
blocking efficacy (Zhou et al., 1998). These antibodies were found to have IC50S of -60 
nM, which is comparable to the value obtained for NESOpAb (<50 nM). Both the Kvl.2 
and NESO-pAb antibodies exhibited ~400-fold specificity for their specific target 
compared to the respective nearest relative (Kvl.2 vs Kvl.3; 'neonatal' vs 'adult' 
2+ 
Navl.5). The voltage-gated Ca channel monoclonal antibody produced by Morton et 
al. (1988) achieved half-maximal block at a concentration of -60 nM (c.f <1 nM for 
NESO-pAb). In all these studies, and the present, complete blockage of channel activity 
could not be achieved, although in some cases the mouth of the channel was targeted 
specifically (e.g. Zhou et al., 1998). This is probably because the deformation of the ion 
channel protein caused by the antibody binding, although substantial, may not be 
sufficient to wholly prevent channel activity. 
3.3.7 Role of nNavl.5 in potentiating metastatic cells behaviour in vitro 
Treatment with NESO-pAb, which can directly inhibit nNavl.5 functional activity 
(Chioni et al., 2005) (Figure 3.26), was found to suppress both the migration (Figure 
3.21) and invasion (Figure 3.22) of MDA-MB-231 cells, without affecting their 
proliferation (Figure 3.23), when applied during the assays. In addition, NESO-pAb had 
no effect on the invasion of PC-3M PCa cells, which express primarily Navl.7 (J. K. J. 
Diss, unpublished observations), indicating specificity of NESO-pAb for nNavl.5. 
Furthermore, an anti-laminin antibody had no effect on the migration of MDA-MB-231 
cells, consistent with the effect of NESO-pAb being through direct block of the nNavl.5 
channel. Furthermore, TTX (10 |J.M) treatment reduced MDA-MB-231 cell invasion 
(Figure 3.22A), consistent with previous studies that showed TTX to suppress a variety 
of in vitro cellular behaviours associated with the metastatic cascade, including 
galvanotaxis, endocytic membrane activity, migration and invasion (Roger et al., 2003; 
Fraser et al., 2005; Brackenbury et al., 2006). Importantly, co-application of TTX did 
not further reduce the cells' invasiveness below that of NESO-pAb alone. 
In addition, migrated MDA-MB-231 cells were found to express more plasma 
membrane nNavl.5 protein than non-migrated cells (Figure 3.21). This suggested a 
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positive correlation between surface expression of nNavl.5 and metastatic capability in 
BCa. Nevertheless, the possibility that nNavl.5 is upregulated when cells are migrating 
(rather than the assumed basal expression) needs further investigation with the use of 
other methods such as real-time PCR and Western blot. However, the number of cells 
attached to the Transwell membrane after the assay was performed would not be enough 
for isolation of protein for Western blot or even mRNA for comparative studies. One 
possibility would be to repeat the experiment on lateral migration (wound-heal assays) 
and use immunocytochemical staining of VGSC expression at various time points, from 
initiation of wound to its closure. 
Together, these data imply that nNavl.5 is alone primarily responsible for the 
VGSC-dependent potentiation of BCa metastasis, in direct agreement with recent siRNA 
data (Brackenbury et al., 2006). 
3.3.8 Clinical implications 
3.3.8.1 Cardiology 
Navl.5 is the major VGSCa subtype expressed in heart muscle (Rogart et al., 1989; 
Gellens et al., 1992). D1:S3 splicing of this VGSCa is therefore likely to be functionally 
important in cardiac physiology, especially given (1) that the change in preference for 
the expression of transcripts possessing the 'neonatal' exon to those with the 'adult' 
exon occurs very rapidly after birth; and (2) that the alternate isoforms are markedly 
different (7 amino acids compared to the 1-2 residues typically resulting from D1:S3 
splicing) in the sequence of this critical part of the protein. This potential functional 
significance may also have pathophysiological consequences. Electrophysiological 
changes associated with hyperfrophy and infarction play a key role in the 
arrhythmogenicity of failing hearts e.g (Pye and Cobbe, 1992). The major consistent 
electrophysiological abnormality is a prolongation of the action potential duration (Qin 
et al., 1996). Importantly, hypertrophied and failing hearts have elevated intracellular 
Na , potentially implicating VGSC activity in this condition (Pieske and Houser, 2003; 
Pieske et al., 2003; Pogwizd, 2003). Furthermore, hyperfrophied and infarcted failing 
hearts also exhibit a shift to a more foetal/neonatal phenotype, characterized by the re-
expression of ion channels usually restricted to foetal myocytes (e.g. HCN2, HCN4 and 
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CACNAIH; Kuwahara et al., 2003). This could also include a shift in VGSCa D1:S3 
splicing, with the re-emergence of 'neonatal' Navl.l expression (Huang et al., 2001). 
Taken together, these findings may indicate a role for VGSCs, and especially nNavl.5, 
in the initiation and progression of heart failure, which is worthy of further investigation. 
3.3.8.2 Breast cancer 
It was recently reported that nNavl.5 was expressed at high levels in metastatic human 
BCa cells in vitro and in vivo (Fraser et al., 2002a; Fraser et al., 2003a; Fraser et al., 
2005). This is a further example of embryonic/neonatal gene expression in cancer (Ariel 
et al., 1997; Monk and Holding, 2001; Lee and Herlyn, 2006; Topczewska et al., 2006). 
VGSC activity potentiated several processes important for metastasis in these cancer 
cells (Diss et al., 2001; Fraser et al., 2002a; Fraser et al., 2003a; Roger et al., 2003; 
Fraser et al., 2005). The sensitivity and selectivity of NESO-pAb were comparable or 
better than existing ion channel-blocking antibodies (Morton et al., 1988; Zhou et al., 
1998; Lu et al., 2002). Furthermore, NESO-pAb exhibited significantly greater 
efficiency for functional channel block than natural neurotoxins, such as TTX. 
Moreover, NESO-pAb found to be highly tissue specific and could inhibiting metastatic 
cell behaviours (such as cell migration and invasion) by blocking nNavl.5 in MDA-MB-
231 cells, consistent with the finding that surface expression of nNavl.5 is upregulated 
in cells capable of migrating/invading. As a consequence, NESO-pAb may have possible 
applications of diagnostic and/or therapeutic potential for BCa patients. Possible 
therapeutic potential is strengthened by the finding (1) that NESO-pAb blocked Navl.5 
functioning with great specificity when applied extracellularly (even at nanomolar 
concentrations) in vitro', (2) that NESO-pAb blocked migration and invasion in MDA-
MB-231 cells in vitro and (3) that in Navl .5-expressing adult mouse tissues there is no 
expression of 'neonatal' Navl.5 (except for very low levels in the brain and skeletal 
muscle), strongly implying that NESO antibody might be a novel, specific mechanism 
for targeting aberrant nNavl.5 expression in metastatic BCa cells in the adult cancer 
patient. A 'humanised' monoclonal antibody against nNavl.5 could therefore be used as 
antibody-based anticancer treatment, or drug-delivery mechanism, with extremely 
limited side-effects for patients (lannello and Ahmad, 2005; Ross et al., 2005; Tanner, 
2005; Willems et al., 2005; Booy et al., 2006). 
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Chapter 4: VGSCa mRNA EXPRESSION AND PROTEIN 
LOCALISATION IN HUMAN BREAST CANCER CELL 
LINES: AN EMPHASIS ON 'NEONATAL' Navl.5 
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4.1 Introduction 
Functional Voltage-gated Na"^  channel (VGSC) expression has been detected in strongly 
metastatic cell lines of human breast cancer (BCa) (Roger et al., 2003; Fraser et al., 
2005), prostate cancer (PCa) (Laniado et al., 1997), lymphoma (Fraser et al., 2004a), 
small-cell lung cancer (SCLC) (Blandino et al., 1995; Onganer and Djamgoz, 2005), 
neuroblastoma (Ou et al., 2005) and melanoma (Allen et al., 1997). Interestingly, VGSC 
upregulation has been found in human BCa, PCa and SCLC in vivo (Abdul and Hoosein, 
2002b; Onganer et al., 2004; Diss et al., 2005; Fraser et al., 2005; Onganer and 
Djamgoz, 2005). 
VGSC activity can potentiate a number of cellular behaviours involved in the 
metastatic cascade (Fraser et al., 2005) such as: (1) cellular process extension (Fraser et 
al., 1999), (2) lateral motility and galvanotaxis (Djamgoz et al., 2001; Fraser et al., 
2003c; Fraser et al., 2005), (3) invasion (Grimes et al., 1995; Laniado et al., 1997; Smith 
et al., 1998) and (4) secretory membrane activity (Mycielska et al., 2003; Krasowska et 
al., 2004). 
In fact, it has been suggested that VGSC expression alone is "necessary and 
sufficient" for cellular invasiveness (Bennett et al., 2004). The invasive sublines of 
weakly metastatic human PCa LNCaP cells exhibited a significantly greater endogenous 
VGSC protein levels, and over-expression of VGSC alone was sufficient to increase in 
vitro invasive potential (Bennett et al., 2004). 
RT-PCR determined that 'neonatal' Navl.5 (nNavl.5) VGSCa was the predominant 
isoform, differing from the known D1:S3 3'-splice form at 31 out of 92 nucleotides, 
resulting in seven amino acid difference (Diss, 2001; Chioni et al., 2005; Fraser et al., 
2005). In MDA-MB-231 cells, the predominant VGSC isoform, tetrodotoxin (TTX)-
resistant Navl.5, was expressed over 1800-fold more at mRNA level than the weakly 
metastatic human BCa cell line, MCF-7; Navl.5 constituted over 80 % of the total 
VGSC a-subunit mRNA level, the remaining ~20 % being mainly the TTX-sensitive 
Navl .7, consistent with the TTX sensitivity (Fraser et al., 2005). Furthermore, Fraser et 
al. (2005) showed that nNavl.5 protein was upregulated in clinical human BCa samples, 
and importantly, Navl.5 mRNA expression in biopsy samples correlated strongly with 
clinically assessed lymph node metastasis. 
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Proteins, including VSGCs, are mainly synthesized in endoplasmic reticulum (ER) 
and transported to Golgi for further maturation, through pre-Golgi intermediates, which 
are transport vehicles for protein delivery. Then, post-Golgi carriers transport the mature 
proteins to their final destination, the plasma membrane (PM) (Lippincott-Schwartz et 
al, 2000). As described in section 1.8.3, different types of signal peptide are 
fimdamental for determining protein destination within cells (Alberts et al., 1994). 
Recent studies on subcellular localisation of Navl.5 in cardiac myocytes and HEK293 
cells showed that Navl.5 a-subunit was localised in ER (Zimmer et al., 2002b). When 
VGSCa-, pi- and )32- subunits were co-transfected in EBNA293 cells, Navl.5 a-
subunit co-localised in ER only with VGSCpi (Zimmer et al., 2002a). Since only 
strongly metastatic PCa and BCa cells exhibit functional VGSCs (Eraser et al., 2005), it 
was of interest to investigate nNavl.5 protein expression in both weakly (MCF-7) and 
strongly (MDA-MB-231) metastatic human BCa cell lines. The subcellular localization 
and, in particular, PM expression status of nNavl.5 would be important for 
understanding how nNavl.5 could contribute to metastatic cell behaviours (MCBs). 
4.1.1 Aims and scope 
The main aim of this study was to investigate the status and localization of nNavl.5 in 
weakly (MCF-7) and strongly (MDA-MB-231) metastatic human BCa cell lines. The 
specific aims were as follows: 
1. To determine by real-time PCR (rt-PCR) the mRNA expression levels of the two 
main VGSC isoforms (nNavl.5 and Navl.7) found previously in MDA-MB-231 
cells relative to MCF-7 cells (Diss, 2001); 
2. To determine the protein levels of nNavl.5, the predominant VGSCa expressed in 
MDA-MB-231 compared with MCF-7 cells; and 
3. To study the intracellular localization of nNavl .5 protein in MCF-7 and MDA-MB-
231 cells. 
Parts of the results of the present study have been published (Eraser et al., 2005). 
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4.2 Results 
4.2.1 VGSCa expression in MDA-MB-231 and MCF-7 cells 
4.2.1.1 mRNA levels of expression 
Real-time PGR revealed that mRNAs for total Navl.5, 'adult' Navl.5 (aNavl.5), 
'neonatal' Navl.5 (nNavl.5) and Navl.7 were expressed at much higher levels in the 
strongly metastatic, MDA-MB-231, compared with the weakly metastatic, MCF-7 cells 
(Figure 4.1): Total Navl.5 mRNA was expressed > 7500-fold; aNavl.5 ~200-fold and 
nNavl.5 > 4200-fold (P<0.05 each; n = 4 independent RNA extractions). Navl.7 mRNA 
was expressed ~37-fold more in MDA-MB-231 than in MCF-7 cells (P<0.05; n = 4 
independent RNA extractions). 
Typical gel images of PCR products for total Navl.5, aNavl.5, nNavl.5, Navl.7 
and the normalising gene, cytochrome-b5 reductase (Cytb5R) confirmed the high quality 
of the PCR products with the predicted band sizes; there was no amplification with 
template control (NTC) (Figure 4.1 A). 
4.2.1.2 Protein levels of expression 
Total protein extracts from (1) normal human breast epithelial cells (MCF-lOA), (2) 
weakly metastatic human BCa cells (MCF-7), (3) MCF-7 cells transfected with nNavl.5 
(MCF-7-T1) and (4) strongly metastatic human BCa cell line (MDA-MB-231) were 
tested by Western blotting for VGSCa expression. All four cell lines expressed VGSCa 
protein (~ 220 kDa) as detected by the pan-VGSCa antibody (Figure 4.2A). However, 
only the MDA-MB-231 cell line expressed a strong double band at about 220 kDa; 
MCF-7 cell line expressed a single weak band (Figure 4.2A). 
The MCF-7-T1 transfectant cell line expressed VGSCa giving a band of the 
same size as the normal MCF-7 but of much stronger intensity. Interestingly, even the 
MCF-lOA normal breast epithelial cells expressed a single band of VGSCa but this was 
much weaker than the others (Figure 4.2A). 
When blots were immunostained with the NESO-pAb antibody, a single band 
just below 220 kDa was present in all cell lines except MCF-lOA; expression in the 
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Figure 4.1 Total Navl.5, adult Navl.5, neonatal Navl.5 and Navl.7 mRNA 
expression in MCF-7 and MDA-MB-231 cells human breast cancer cell lines. 
(A) Typical gel images of PCR products for total Navl.5, aNavl.5 (adult Navl.5), 
nNavl.5 (neonatal Navl.5), Navl.7, and cytochrome-b5 reductase (Cytb5R). Lanes: 1, 
MCF-7; 2, MDA-MB-231; 3, no template control (NTC) (B) Relative mRNA expression 
in MCF-7 and MDA-MB-231 cells. Data were expressed relative to MDA-MB-231 
cells. VGSC mRNA level was normalised to Cytb5R by the method. Errors are 
propagated through the 2"^^ analysis. Significance; (*) P < 0.05 with Mann-Whitney 
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Figure 4.2 Pan-VGSCa and neonatal Navl.5 protein expression in human breast 
cancer cell lines. 
(A) Western blot of 60 ]xg of total protein per lane from normal human breast epithelial 
cells; MCF-lOA (lane 1), MCF-7 (lane 2), MDA-MB-231 (lane 4) and MCF-7-T1, 
transfected with nNavl.5 protein (lane 3). Blots were immuno stained with pan-VGSCa 
and NESO-pAb antibody, and an actinin antibody as an internal control for loading. (B) 
Relative levels of nNavl.5 and total VGSCa protein in MDA-MB-231 (black bars) and 
MCF-7 cells (white bars). The signal from NESO-pAb or pan-VGSC antibodies was 
normalised to the respective actinin control. Data presented as mean and SEM (n = 6). 
Significance: (**) P < 0.01 with Mann-Whitney Rank Sum test. 
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Band intensities compared by densitometric analysis suggested that there was 
-4-fold more VGSCa protein in MDA-MB-231 compared to MCF-7 cells and most of 
this was nNavl.5 (P< 0.01; n= 6 for both; Figure 4.2B). 
Western blot analysis of total protein extracts of MCF-7 and MDA-MB-231 cell 
lines for Navl.7 protein expression revealed a band at about 220 kDa (Figure 4.3).The 
band in MCF-7 cells appeared slightly weaker compared to MDA-MB-231 cells; there 
was no signal from MCF-lOA cells (Figure 4.3). Positive controls, human strongly 
metastatic PCa cell lines (PC-3 and PC-3M) (Laniado et al., 1997) and mouse brain 
(both neonatal and adult) (Toledo-Aral et al., 1997) expressed a single band at the same 
molecular weight as for the human BCa cell lines (Figure 4.3). Interestingly, weakly 
metastatic human PCa cell (LNCaP) also expressed Navl.7. However, 'normal' prostate 
epithelial cells (PNT2) and mouse heart (both adult and neonatal) did not give any signal 
(Figure 4.3). 
Immunocytochemistry by conventional fluorescence microscope with NESO-
pAb and pan-VGSCa antibodies showed immunoreactivity in both MCF-7 and MDA-
MB-231 cell lines (Figures 4.4, 4.5, 4.6 and 4.7). However, the staining was generally 
stronger in the MDA-MB-231 cells (Figure 4.4 and 4.5), compared with the MCF-7 cells 
(Figures 4.6 and 4.7). Furthermore, MCF-7 cells appeared to express VGSCa mainly in 
perinuclear areas rather than the PM (Figure 4.6). In MDA-MB-231 cells, 'hot spots' 
were common, indicating possible staining of PM or spatial VGSCa protein 
organization; staining in the perinuclear area and cells processes was also observed 
(white arrows in Figure 4.4). The level of staining within both cell lines was very 
heterogeneous. Interestingly, in the MCF-7 cells, some paired round cells, possibly 
dividing cells, appeared to express noticeably higher levels of immunoreactivity, 
relatively to the rest of the cell population (Figure 4.6H and Figure 4.71). MDA-MB-231 
cells expressed signal with NESO-pAb antibody under both permeabilised and non-
permeabilised conditions (Figure 4.5). In contrast, MCF-7 cells stained with NESO-pAb 
antibody only when permeabilised (Figure 4.7). Negative controls for both cell lines and 
both antibodies did not give any signal (Figure 4.4J, Figure4.5E&F and K&L, 
Figure4.6J, 4.7E&F and K&L). 
More detailed images of MCF-7 and MDA-MB-231 cells were obtained by 
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Figure 4.3 Navl.7 protein expression in human breast and prostate cell lines and 
mouse tissues. 
Western blot of 60 p,g of total protein per lane from strongly metastatic (MDA-MB-231, 
lane 1) and weakly metastatic (MCF-7; lane 2) human breast cancer cells, normal human 
breast epithelial cells (MCF-lOA, lane 3), strongly metastatic human prostate cancer 
cells (PC-3 and PC-3M; lanes 4 and 5), strongly and weakly rat prostate cancer cells 
(LNCaP and PNT2 respectively; lanes 6 and 7), mouse adult heart and brain (lanes 8 and 
9) and mouse neonatal heart and brain (lanes 10 and 11). Blots were immunostained 
with anti-Navl.7 antibody (A), and an anti-actin antibody as an internal control for 
loading (B). Key: A: adult; N: neonatal. 
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Figure 4.4 Immunocytochemistry of MDA-MB-231 cells with pan-VGSCa. 
Representative images of MDA-MB-231 cells fixed in 4 % PFA and permeabilised in 
0.1 % saponin/PBS showing the quality and quantity of immunoreactivity. Cells were 
immunostained with pan-VGSCa antibody (A-H). (J) Negative control, i.e. only the 
secondary antibody applied. Arrows indicate staining in cell processes. Scale bar (16 
l^ m) applicable to all panels. 
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IWDA-MB-231 cells 
(i) Non-permeabilised (ii) Permeabilised 
Figure 4.5 Immunocytochemistry of MDA-MB-231 cells with NESO-pAb. 
Representative images of MDA-MB-231 cells fixed in 4 % PFA and were either 
permeabilised in 0.1 % saponin/PBS (A-F) or non-prermeabilised (G-L) showing the 
quality and quantity of immunoreactivity. Cells were immunostained with NESO-pAb 
antibody. (F) and (L) negative controls, pre-incubation with the immunising peptide 
(panel F for non-permeabilised cells and panel L for permeabilised cells). Panels (E) and 
(K) are bright field images for F and L, respectively. Scale bar (16 jxm) applicable to all 
panels. 
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Figure 4.6 Immunocytochemistry of MCF-7 cells with pan-VGSCa. 
Representative images of MCF-7 cells fixed in 4 % PFA and permeabilised in 0.1 % 
saponin/PBS showing the quality and quantity of immunoreactivity. Cells were 
immunostained with pan-VGSCa antibody (A-H). (J) negative control, i.e. only the 
secondary antibody applied. Scale bar (16 p,m) applicable to all panels. 
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MCF-7 cells 
(i) Non-permeabilised (ii) Permeabilised 
% 
Figure 4.7 Immunocytochemistry of MCF-7 cells with NESO-pAb. 
Representative images of MCF-7 cells fixed in 4 % PFA and were either permeabilised 
in 0.1 % saponin/PBS (A-F) or non-prermeabilised (G-L) showing the quality and 
quantity of immunoreactivity. Cells were immunostained with NESO-pAb antibody. (B) 
and (D), bright field images for panel A and C, respectively. (F) and (L) negative 
controls, pre-incubation with the immunising peptide (panel F for non-permeabilised 
cells and panel L for permeabilised cells). Panels (E) and (K) are bright field images for 
(F) and (L), respectively. Arrows indicate example areas of staining. Scale bar (16 jxm) 
applicable to all panels. 
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concanavalin A (ConA). Confocal images from MDA-MB-231 and MCF-7 cells with 
pan-VGSCa (Figure 4.8), anti-Navl.5 (Figure 4.9 and 4.10), and NESO-pAb (Figure 
4.11) antibodies, confirmed the findings from conventional fluorescence microscope: (1) 
a higher level of total VGSCa and nNavl.5 was present in MDA-MB-231 cells with 
clear PM staining, and (2) the corresponding VGSCa signal from MCF-7 cells was 
much weaker and mainly perinuclear (Figures 4.8, 4.9 and 4.10) . 
4.2.2 Subcellular localisation of nNavl.5 protein in MDA-MB-231 and MCF-7 cells 
4.2.2.1 Immunocytochemical imaging 
Confocal images from XZY scans showed that MDA-MB-231 cells had nNavl.5 
immunostaining in whole PM (Figure 4.1 IL & P) In confrast, MCF-7 cells had 
exclusively apical membrane staining (Figure 4.11 J & N). nNavl.5 PM 
inununoreactivity measured from XZY images was ~3.2-fold stronger for MDA-MB-
231 cells compared with MCF-7 cells (P<0.05; n=4 independent experiments, minimum 
32 cells measured in each; Figure 4.12). 
Analysis of confocal series of images revealed that MDA-MB-231 cells 
expressed nNavl.5 protein in both PM (apical and basal) and cytoplasm (especially 
perinuclear area) (Figure 4.13). Sections from the basal membrane (Figure 4.13B & 
C[a,b,c,d for both]) showed nNavl.5 immunoreactivity overlapping with ConA staining 
(Figure 4.13A[a,b,c,d]). On the other hand, MCF-7 cells expressed some nNavl.5 in 
apical membrane (Figure 4.14B, C[a,b,c,d,e,f]) consistent with ConA staining (Figure 
4.14A[a,b,c,d,e,f]); there was no basal nNavl.5 staining (Figure 4.14B,C[r]). However, 
both cells lines expressed intracellular nNavl.5 (Figures 4.13B and 4.14B[i,j,k,l,m for 
both]). 
Analysis of the nNavl.5 immunoreactivity signal intensity across a section 
through the MDA-MB-231 and MCF-7 cells gave information on the relative 
distribution of protein in PM vs. intracellular (Okuse et al., 2002). A cross section of an 
XYZ image of MDA-MB-231 cells confirmed that nNavl.5 was located on the PM and 
a considerable amount of nNavl.5 protein was situated intracellularly (Figure 4.15). 
Cross section of an XZY image of MDA-MB-231 cell also established the existence of 
nNavl.5 protein on both the apical and basal PM (Figure 4.16). In contrast, overlap of 
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Figure 4.8 Confocal images from immunocytochemistry of MCF-7 and MDA-MB-
231 cells with pan-VGSCa. 
Typical images of MDA-MB-231 cells (A-F) and MCF-7 cells (G-L), co-stained with 
concanavalin A (ConA) plasma membrane marker (green) and pan-VGSCa antibody 
(red). Merged images (C, F, I and L) are also shown. Scale bar (16 ^m) applicable to all 
panels. 
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ConA Anti-Nav1.5 Merged image 
Figure 4.9 Confocal images from MDA-MB-231 cells with anti-Navl.5 antibody. 
Typical images of MDA-MB-231 cells, stained with concanavalin A (ConA) plasma 
membrane marker (green) and anti-Navl.5 antibody (red). Merged images (C, F, I and 
L) are also shown. Scale bar (16 j^m) applicable to all panels. 
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ConA Anti-Nav1.5 Merged image 
16 pm 
Figure 4.10 Confocal images from immunocytochemistry of MCF-7 cells with anti-
Navl.5 antibody. 
Typical images of MCF-7 cells, co-stained with concanavalin A (ConA) plasma 
membrane marker (green) and anti-Navl.5 antibody (red). Merged images (C, F and I) 







Figure 4.11 Confocal images from immunocytochemistry of MCF-7 and MDA-MB-
231 cells with NESO-pAb. 
Typical XYZ scan images of MCF-7 cells (A, B, E, F) and MDA-MB-231 cells (C, D, 
G, H). Typical XZY scan images of MCF-7 cells (I, J, M, K) and MDA-MB-231 cells 
(K, L, O, P). Cells were co-stained with concanavalin A (ConA) plasma membrane 






Figure 4.12 MDA-MB-231 cells expressed higher levels of neonatal Navl.5 plasma 
membrane protein than MCF-7 cells. 
nNavl.5 protein level (immimoreactivity) was measured around the edge of MDA-MB-
231 (black bar) and MCF-7 (white bar) cells using Concanavalin A (ConA) as a marker 
for plasma membrane. XZY images were used for the analysis since MCF-7 cells 
expressing nNavl.5 protein only in apical membrane, and can only visualised in XZY 
images. Data are presented as mean and SEM (n=4 independent experiments; minimum 
32 cells were measured from each experiment), relative to MDA-MB-231 cells (100 %). 
Y-axis represents fluorescence intensity (arbitrary units; %). Significance: (*) P < 0.05 




C. Merged image 
Figure 4.13 Confocal image series from immunocytochemistry of MDA-MB-231 
cells with NESO-pAb. 
Typical sections from image series of MDA-MB-231 cells. Cells were co-stained with 
concanavalin A (ConA) plasma membrane marker (green; A) and NESO-pAb antibody 
(red; B). Corresponding merged images are shown in (C). Scale bar (16 |j.m) applicable 




C. Meraed imaae 
Figure 4.14 Confocal image series from immunocytochemistry of MCF-7 cells with 
NESO-pAb. 
Typical sections from image series of MCF-7 cells. Cells were stained with 
concanavalin A (ConA) plasma membrane marker (green; A) and NESO-pAb antibody 
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Figure 4.15 Subcellular distribution of nNavl.5 protein in MDA-MB-231 cells. 
(A) Typical confocal XYZ images of MDA-MB-231 cells stained with Concanavalin A 
(ConA) plasma membrane marker (green), NESO-pAb antibody (red) and the merged 
image is also shown. Yellow lines show cross-sections that were used for digital 
analysis. Scale bar (16 jim) applicable to all panels. (B) Signal intensity of NESO-pAb 
immunofluorescence along cross-section compared with signal intensity of ConA (used 























Figure 4.16 Sub-cellular distribution of nNavl.5 protein relative to plasma 
membrane in MDA-MB-231 cells. 
(A) Typical confocal XZY images of MDA-MB-231 cells stained with Concanavalin A 
(ConA), plasma membrane marker (green) and NESO-pAb antibody (red). The merged 
image is also shown. Yellow lines show cross-sections that were used for digital 
analysis. Scale bar (16 pm) applicable to all panels. (B) Signal intensity of NESO-pAb 
immunofluorescence along cross-section compared with signal intensity of ConA. 
Apical and basal membranes are indicated in confocal images (A) and the cross-
sectional profile (B). Key; AU: arbitrary unit of fluorescence. 
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nNavl.5 protein with ConA (the PM marker) did not occur in MCF-7 cells when a cross 
section of an XYZ scan was taken, but a most of the nNavl.5 occurred intracellularly 
(Figure 4.17). However, cross-sectioning of a MCF-7 cells from an XZY scan showed 
an overlap with ConA only at the apical membrane but not at basal (Figure 4.18). In 
addition, staining of live cells with NESO-pAb showed PM staining in MDA-MB-231 
cells, confirmed by the correlation with ConA staining (Figure 4.19A, B). However, 
there was no staining in MCF-7 cells (Figure 4.19C, D). 
A number of controls were carried out for the immunocytochemical staining of 
MCF-7 and MDA-MB-231 cells (Figures 4.20, 4.21 and 4.22). Staining with an IgG 
control at the same concentration as the primary antibodies, NESO-pAb pre-absorbed 
with the immunising peptide, and application of only the secondary antibody all verified 
the good specificity of the antibodies at the concentrations used (Figure 4.20). 
Furthermore, controls to ensure that the signal from each confocal channel [i.e. for FITC 
(green) or Alexafluor568 (red)] did not 'leak' through each other, verified that the origin 
of signal was due to specific cell staining (Figures 4.21 and 4.22). For both MDA-MB-
23 1 and MCF-7 cell lines, when both channels 1 and 2 were open, staining from both 
ConA and NESO-pAb were observed. However, when one of the laser channels was 
closed, staining for only the other open channel was visualised (either ConA or NESO-
pAb). There was no cross reaction between the two laser chaimels. 
4.2.2.2 Cellular compartmentalisation 
Proteins in two main subcellular fractions - plasma membrane enriched (PM) and 
cytoplasm enriched (CYT) - from MCF-7 and MDA-MB-231 cells were tested for 
VGSCa expression by Western blotting with the pan-VGSCa antibody. Of PM fractions, 
only MDA-MB-231 cells expressed a strong VGSCa band (Figure 4.23, lane 5 vs. 2). 
On the other hand, the cytoplasmic fractions from both MCF-7 and MDA-MB-231 cells 
contained VGSCa protein (Figure 4.13, lanes 3 and 6). These findings agreed with the 
data from confocal microscopy (Figures 4.11, 4.13 and 4.14). 
hi order to confirm the purity of the fractions, Glutl was used as a positive 
control for PM (Hajduch et al., 1995; Pantaleon et al., 2001) (Figure 4.24). A Glutl 
protein band of about 65 kDa (expected size) appeared only in the total protein extract 
219 








7.5 10 12.5 15 
Cross-section (jim) 
Figure 4.17 Sub-cellular distribution of nNavl.5 protein in MCF-7 cells. 
(A) Typical confocal XYZ images of MCF-7 cells stained with Concanavalin A (ConA), 
plasma membrane marker (green) and NESO-pAb antibody (red). The merged image is 
also shown. Yellow lines show cross-sections that were used for digital analysis. Scale 
bar (16 pm) applicable to all panels. (B) Signal intensity of NESO-pAb 
immunofluorescence along cross-section compared with signal intensity of ConA. Key; 
AU; arbitrary unit of fluorescence; PM: plasma membrane. 
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Figure 4.18 Sub-cellular distribution of nNavl.5 protein relative to plasma 
membrane in MCF-7 cells. 
(A) Typical confocal XZY images of MDA-MB-231 cells stained with Concanavalin A 
(ConA), plasma membrane marker (green) and NESO-pAb antibody (red). The merged 
image is also shown. Yellow lines show cross-sections that were used for digital 
analysis. Scale bar (16 fim) applicable to all panels. (B) Signal intensity of NESO-pAb 
immunofluorescence along cross-section compared with signal intensity of ConA. 
Apical and basal membranes are indicated in confocal images (A) and the cross-
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Figure 4.19 Sub-cellular distribution of nJNavl.5 protein relative to plasma 
membrane in MCF-7 cells. 
Typical confocal XYZ images of MDA-MB-231 (A) and MCF-7 (C) cells co-stained 
with Concanavalin A (ConA) plasma membrane marker (green) and NESO-pAb 
antibody (red). The merged and bright field images are also shown. Cells were stained 
alive and fixed in 2 % PFA. Yellow lines show cross-sections that were used for digital 
analysis. Scale bar (16 |im) applicable to all panels. (B) & (D)Signal intensity of NESO-
pAb immunofluorescence along cross-section was compared with signal intensity of 
ConA. Key; AU; arbitrary unit of fluorescence; PM; plasma membrane. 
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Bright field 
Figure 4.20 Controls for immunocytochemistry with VGSCa antibodies (NESO-
pAb, pan-VGSCa and anti-Navl.5). 
MCF-7 (i) and MDA-MB-231 (ii) cells were treated as follows. (A) IgG, at the same 
concentration as the primary antibodies (highest concentration was 2.2 ng / 100 ^1 for 
anti-Navl.5, thus it was used for IgG control). (B) Pre-absorption of NESO-pAb with 
the immunizing peptide prior to use. (C) Only secondary antibody (anti-rabbit 
Alexafluor568) was used for all three antibodies. Images from the signal of 
Concanavalin A (ConA; green), antibody (red) and the bright field were taken each time. 
Scale bar (16 pm) applicable to all panels. 
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Figure 4.21 Controls for possible cross-excitation of the two confocal laser channels 
(FITC and Alexafluor568) in MDA-MB-231 cells. 
Typical XZY image from MDA-MB-231 cells stained with Concanavalin A (ConA) 
plasma membrane marker (green), and NESO-pAb (red). Merged image is also shown. 
(A-C) Images taken when both charmels 1 and 2 (for FITC and Alexafluor568) were 
open. (D-F) Images taken when only channel 1 (for FITC) was open. (F-I) Images taken 
when only channel 2 (for Alexafluor568) was open. Scale bar (16 |am) applicable to all 
panels. 
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Figure 4.22 Controls for possible cross-excitation of the two confocal laser channels 
(FITC and Alexafluor568) in MCF-7 cells. 
Typical XZY image from MCF-7 cells stained with Concanavalin A (ConA) plasma 
membrane marker (green), and NESO-pAb (red). Merged image is also shown. (A-C) 
Images taken when both channels 1 and 2 (for FITC and Alexafluor568) were open. (D-
F) Images taken when only channel 1 (for FITC) was open. (F-I) Images taken when 
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Figure 4.23 Western blot of two subcellular fractions showing plasma membrane 
VGSCa protein expression in MDA-MB-231 and not in MCF-7 cells. 
Western blot of protein extracts from subcellular fractions of weakly (MCF-7) and 
strongly (MDA-MB-231) human breast cancer cell lines. Membrane was immunostained 
with pan-VGSCa antibody. In lanes 1 and 4, 60 |ig of protein was loaded. In lanes 2, 3, 5 
and 6, only 40 |ig of protein was loaded due to limited amount of protein recovered from 
the fractionation. Lanes are as follows: 
1, total protein extract from MCF-7 cells [MCF-7 (T)]; 
2, protein extract from the plasma membrane fraction of MCF-7 cells [MCF-7 (PM)]; 
3, protein extract from the cytoplasmic fraction of MCF-7 cells [MCF-7(CYT)]; 
4, total protein extract from MDA-MB-231 cells [MDA-MB-231 (T)]; 
5, protein extract from the plasma membrane fraction of MDA-MB-231 cells [MDA-
MB-231 (PM)]; 
6, protein extract from the cytoplasmic fraction of MDA-MB-231 cells [MDA-MB-
231(CYT)]. 
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Figure 4.24 Western blot control experiment for sub-cellular fractionation. 
Western blot of protein extracts from subcellular fractions of weakly (MCF-7) and 
strongly (MDA-MB-231) human breast cancer cell lines. Membrane was immunostained 
with anti-glut 1 antibody as a positive control for plasma membrane. 40 p,g of protein 
was loaded in each lane. Lanes are as follows: 
1-2, total protein extracts from MCF-7 [MCF-7 (T)] and MDA-MB-231 [MDA-MB-231 
(T)], respectively; 
3, protein extract from the cytoplasmic fraction of MCF-7 cells [MCF-7(CYT)]; 
4, protein extract from the plasma membrane fraction of MCF-7 cells [MCF-7 (PM)]; 
5, protein extract from the cytoplasmic fraction of MDA-MB-231 cells [MDA-MB-
231(CYT)]; 
6, protein extract from the plasma membrane fraction of MDA-MB-231 cells [MDA-
MB-231 (PM)]; 
Key: T: total, PM: plasma membrane enriched, CYT: cytoplasm enriched. 
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and in PM fraction, but not in the CYT fraction, confirming that the latter did not 
contain any significant amount of PM but the PM fraction did (Figure 4.24). 
The Western blot analyses were extended to four different subcellular fractions 
from both MCF-7 and MDA-MB-231 cell lines (Figure 4.25). These revealed the 
presence of VGSCa and nNavl .5 in PM, low-density microsomal fraction (LDM), high-
density microsomal fraction (HDM) and for a lesser extent, in nuclei and mitochondria 
fraction (N/M) in both cell lines (Figure 4.25). For MCF-7 cells, VGSCa and nNavl.5 
expression was sfrong in LDM, moderate in PM fraction, low in HDM and very low in 
N/M fraction (Figure 4.25A, B). For MDA-MB-231 cells, VGSCa and nNavl.5 
expression was stronger in PM and LDM and weaker in HDM and N/M fractions 
(Figure 4.25A & B). 
The possible nature of the various sub-cellular fractions was studied using a 
variety of antibody markers. Anti-Golgin antibody gave a strong band in the LDM 
fractions of both cell lines, suggesting substantial presence of Golgi apparatus in the 
LDM fraction (Figure 4.25E). Anti-Glut 1 antibody gave two strong bands in PM and 
N/M only, indicating the sfrong presence of plasma membrane in the PM fraction 
(Figure 4.25C). The presence of Glutl in nuclei was expected since Glutl has also been 
found to be expressed in nucleus (Pantaleon et al., 2001). For both cell lines, anti-
calnexin antibody gave a strong band in HDM, suggesting the presence of ER (Figure 
4.25D). 
The Western blot sub-cellular studies were extended to confocal microscopy 
(Figures 4.26 & 4.27). Double staining with NESO-pAb and anti-calnexin or anti-golgin 
confirmed that a part of the infracellular nNavl.5 protein was localized in ER and Golgi 
in both MCF-7 and MDA-MB-231 cells (Figures 4.26 & 4.27). Confrols for double 
staining with NESO-pAb and anti-calnexin/anti-golgin confirmed that the secondary 
antibodies were not cross-reacting with given antibody (Figure 4.28). 
4.2.3 Sporadic apparent strong immunoreactvity in MCF-7 cells 
As noted earlier by conventional fluorescence microscopy (Figures 4.6H & 4.71), paired 
rounded MCF-7 cells expressed sporadic apparent sfrong immunoreactivity (SASIR) 
around PM (Figure 4.19A). However, these cells still did not show basal membrane 
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Figure 4.25 Western blots of four subcellular fractions showing subcellular 
distribution of VGSCa protein expression in MDA-MB-231 and MCF-7 cells. 
Western blots of protein extraction from four subcellular fractions: (Plasma membrane 
(PM), high density microsomal (HDM), low density microsomal (LDM) and 
mitochondria and nuclei (M/N) of MDA-MB-231 cells (lanes 1-4) and MCF-7 cells 
(lanes 5-8). Western blots were immunostained with (A) pan-VGSCa, (B) NESO-pAb, 
(C) anti-glut 1, (D) anti-calnexin or (E) anti-golgin antibodies. 60 jug of protein was 
loaded in each lane. (F) Qualitative assessment of band intensities in different sub-
cellular fraction as seen in the Western blots: (-): insignifican/no immunoreactivity; (+): 
very low; (++): moderate; (+++): strong. 
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Figure 4.26 Confocal images from immunocytochemistry of strongly metastatic 
human breast cancer cell line (MDA-MB-231) showing that nNavl.5 is localized in 
plasma membrane, Golgi and endoplasmic reticulum. 
Typical images of MDA-MB-231 cells, doubled stained with the following: 
(1) Concanavalin A (ConA) plasma membrane marker (green; A) and NESO-pAb 
antibody (red; B). 
(2) Anti-golgin Golgi marker (green; D) and NESO-pAb antibody (red; E). 
(3) Anti-calnexin Endoplasmic reticulum marker (green; G) and NESO-pAb 
antibody (red; H). 
Merged images (C, F and I) are also shown. Scale bar (16 jim) applicable to all panels. 
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Figure 4.27 Confocal images from immunocytochemistry of weakly metastatic 
human breast cancer cell line (MCF-7) showing that nNavl.5 is localized in Golgi 
and endoplasmic reticulum. 
Typical images of MCF-7 cells, doubled stained with the following: 
(1) Concanavalin A (ConA) plasma membrane marker (green; A) and NESO-pAb 
antibody (red; B). 
(2) Anti-golgin Golgi marker (green; D) and NESO-pAb antibody (red; E). 
(3) Anti-calnexin Endoplasmic reticulum marker (green; G and J) and NESO-pAb 
antibody (red; H and K). 
Merged images (C, F, I and L) are also shown. Scale bar (16 pm) applicable to all 
panels. 
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A. NESO-pAb +anti-rabbit + anti-mouse B. NESO-pAb +anti-rabbit + anti-goat 
Anti-golgin NESO-pAb BF Anti-calnexin NESO-pAb BF 
C. Anti-golain + anti-rabbit + anti-mouse D. Anti-calnexin + anti-rabbit + anti-goat 
Anti-golgin NESO-pAb BF Anti-calnexin NESO-pAb BF 
Figure 4.28 Immunocytochemistry controls for double staining with NESO-pAb 
and anti-calnexin or anti-golgin antibody. 
(A) Staining with NESO-pAb and both secondary antibodies (anti-rabbit and anti-
mouse) for NESO-pAb and anti-golgin. Signal from anti-golgin (green), NESO-pAb 
(red) and bright field images are shown. (B) Staining with NESO-pAb and both 
secondary antibodies (anti-rabbit and anti-goat) for NESO-pAb and anti-calnexin. Signal 
from anti-calexin (green), NESO-pAb (red) and bright field images are shown. (C) 
Staining with anti-golgin and both secondary antibodies (anti-rabbit and anti-mouse) for 
NESO-pAb and anti-golgin. Signal from anti-golgin (green), NESO-pAb (red) and 
bright field images are shown. (D) Staining with anti-calnexin and both secondary 
antibodies (anti-rabbit and anti-goat) for NESO-pAb and anti-calnexin. Signal from anti-
calnexin (green), NESO-pAb (red) and bright field images are shown. Scale bar (16 ^im) 
applicable to all panels. 
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Figure 4.29 Confocal images from immunocytochemistry of weakly metastatic 
MCF-7ceils showing sporadic apparent strong immunoreactivity expression in 
paired ceils. 
(A) Apparent sporadic strong immimoreactivity of the plasma membrane nNavl.5 
protein expression in MCF-7 cells. MCF-7 cells were stained with concanavalin A 
(ConA) plasma membrane marker (green) and NESO-pAb antibody (red). Merged 
image is shown as well. (B) Sections from image series. Scale bars (16 pm) applicable 
to all panels. 
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staining (Figure 4.15Ba). Interestingly, even in middle sections, these cells did not have 
any intracellular nNavl.5 (e.g. around the perinuclear area); instead, nNavl.5 protein 
was concentrated around the PM (Figure 4.15Bb, c). In sections of the basal membrane 
(e.g Figure 4.15Ba), nNavl.5 protein appeared around the edges of the cell but not in the 
middle area. Such observations were made on a small population (< 5 %) of MCF-7 
cells. The vast majority of the MCF-7 cells with SASIR were paired round cells, smaller 
compared to the rest of the MCF-7 cell population and not as flat (Figure 4.29). 
Although this result was based on observation only, it was consistent in many different 
and independent immunocytochamical experiments. Such a phenomenon was not seen in 
MDA-MB-231 cells. 
4.3 Discussion 
The overall conclusion of this study was that at both mRNA and protein levels, 
VGSCa/nNavl.5 expression was higher in the strongly metastatic human BCa cell line, 
MDA-MB-231, compared with the weakly metastatic, MCF-7, consistent with previous 
functional and in vivo studies (Fraser et al., 2005). The specific conclusions at protein 
level were as follows: (1) MDA-MB-231 cells expressed higher levels of nNavl5 
protein in PM than MCF-7 cells and (2) unlike MDA-MB-231 cells, MCF-7 retained 
their polarity and expressed nNavl.5 only on their apical membrane. Both cell lines had 
high levels of intracellular nNavl.5 protein, mainly in ER and Golgi. 
4.3.1 VGSCa mRNA expression in human BCa cell lines 
Real-time PCR showed that the strongly metastatic human BCa cell line, MDA-MB-
231, expressed significantly higher levels of total Navl.5, nNavl.7 aNavl.5, and Navl.7 
compared with the weakly metastatic MCF-7 cell line (Figure 4.1). Previous work 
showed that the main isoform expressed in human metastatic BCa cells was indeed 
Navl.5, consistent with the pharmacological data suggesting mainly TTX-R VGSCa 
expression (Fraser et al., 2005). Importantly, DNA sequencing revealed that the Navl.5 
expressed was in its neonatal form (Diss, 2001; Fraser et al., 2005). Total Navl.5 mRNA 
was -7500-fold higher in MDA-MB-231 than in MCF-7. Specific primers for nNavl.5 
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revealed ~4200-fold difference in mRNA expression between MDA-MB-231 and MCF-
7. In addition, specific primers for aNavl.5 showed mRNA upregulation of ~200-fold. 
Finally, Navl.7, which constitutes only -18 % of the overall VGSCa mRNA (Fraser et 
al., 2005), was expressed only ~37-fold more in MDA-MB-231 than MCF-7 cells. 
Interestingly, the main isoform expressed in these cell lines, nNavl.5, was also the 
isoform that proved to have the biggest difference between the two cell lines. 
4.3.2 VGSCa protein expression in human BCa cell lines 
Western blots and immunofluorecence using the pan-VGSCa antibody demonstrated 
that VGSCa protein expression occurred in both human BCa cell lines tested (MCF-7, 
MDA-MB-231) as well as in normal breast epithelial MCF-lOA cells (Figure 4.2). 
These experiments also demonstrated that overall expression of VGSCa was 
significantly higher in MDA-MB-23 cells. Western blot experiments gave a stronger, 
double band for MDA-MB-231 compared to the weaker single band in the MCF-7 and 
MCF-lOA cell lines (Figure 4.2). Densitometric analysis confirmed that MDA-MB-231 
cells expressed about 4-fold more total VGSCa and nNavl.5 protein than MCF-7 cells 
(Figure 4.2B). Furthermore, the level of nNavl.5 protein expression in MCF-7 was 
weaker compared to MCF-7-T1 cells transfected with the nNavl.5. This confirmed (1) 
that the transfection was successful and therefore could be used as a positive control for 
the antibody and (2) that the antibody recognised the correct molecular weight size band 
(just below 220 kDa). 
Although both mRNA and protein VGSCa/nNavl.5 levels were upregulated in 
MDA-MB-231 cells, compared to MCF-7 cells, the fold difference was much higher at 
mRNA levels compared to protein (For example, for nNavl.5, the difference was 
~4200-fold at mRNA level and only -4-fold at protein level). There is increasing 
evidence suggesting that regulation of mRNA and protein levels can be independent, in 
particular in cancer cells (Sola et al., 1999; Orphanides and Reinberg, 2002; Schedel et 
al., 2004; Gu et al., 2006). This might also be the case in MCF-7 and MDA-MB-231 
cells. Another possible explanation for this 'discrepancy' is that docked mRNA that does 
not translated into protein (Bassell and Twiss, 2006) until the metastasizing cell requires 
a rapid and dynamic regulation of functional VGSC expression. 
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The double band expressed in the MDA-MB-231 cells might be due to a variety 
of reasons, such as the presence of more than one isoform and/or phosphorylation, 
glycosylation or proteolysis of the same VGSCa. Western blots with the NESO-pAb 
antibody also revealed that only MCF-7 and MDA-MB-231 cell lines expressed 
nNavl.5 protein and not the human normal epithelial breast cell line (MCF-lOA) (Figure 
4.2A). This may indicate that further processing of VGSC protein expression occurs in 
BCa cells compared with normal. 
Western blots analyses with the anti-Navl.7 antibody showed protein expression 
in both MCF-7 and MDA-MB-231 cell lines (Figure 4.3). However, this was slightly 
weaker in MCF-7 compared with the MDA-MB-231 cells. Normal human epithelial 
MCF-lOA cells did not express Navl.7. The positive controls (neonatal and adult mouse 
brain) expressed a strong single band at about 220 kDa; adult mouse brain expressed a 
second, much weaker lower molecular weight band, possibly a result of protein 
degredation or protein phosphorylation. It is known that Navl.7 can be phosphorylated 
e.g. by PKA (Marban et al., 1998). Human strongly metastatic PCa PC-3 cell line was 
also used as a positive control since Navl.7 was shown to be predominant in these cells 
(Diss, 2001). Interestingly, normal human prostate epithelium cells (PNT2) did not 
express any Navl.7, similar to MCF-lOA not expressing the corresponding predominant 
VGSCa isoform (nNavl.5 in BCa). Moreover, the weakly metastatic human PCa cells 
(LNCaP) also expressed protein Navl.7 although these cells would not express 
functional VGSC (Laniado et al., 1997), again similar with MCF-7 cells. 
Interestingly, both the normal human breast epithelial cells (MCF-lOA) as well 
as the weakly metastatic BCa cell line (MCF-7) contained VGSCa, nNavl.5, 
additionally being present in the latter, whilst electrophysiology suggested that 
functional VGSCa expression was absent in these cells (Fraser et al., 2005). This 
situation is analogus to prostate/PCa cell lines. This difference may be due to a number 
of reasons as follows: 
1. The VGSCa protein(s) in MCF-7 and MCF-lOA is not functionally active, for 
some reason(s). 
2. The level of functional expression in PM is very low, below the threshold level 
detectable by electrophysiology. 
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3. The protein expressed in MCF-lOA and MCF-7 is mainly intracellular. A 
comparable phenomenon has been documented previously in developing 
neurons where there is considerable intemalisation of VGSCa protein, and 
action potentials are produced only after a high enough channel density is 
reached (Dargent et al, 1994). 
A previous study suggested that the low density of VGSCs expressed in glial cells 
could produce graded potentials and influence intracellular Ca^ "^  signalling (Black and 
Waxman, 1996), which may well also be the case for the weakly metastatic BCa cells. 
Further work is required in order also to determine whether the basal VGSCa expression 
is a normal feature of epithelial cells in normal breast. If that proved to be the case, 
VGSCa could play a role in cellular homeostasis. It is also possible that VGSC protein is 
ready-synthesized and stored at an early stage in metastasis and externalized later during 
cancer progression. Such a notion would be consistent with VGSCa expression being an 
early event in BCa metastasis. 
Immunocytochemistry with pan-VGSCa and NESO-pAb antibodies also 
revealed that MDA-MB-231 cells stained more intensely than MCF-7 cells. These 
observations agreed broadly with previous finding that strongly metastatic cells 
specifically express functional VGSCa (Grimes et al., 1995; Laniado et al., 1997; Roger 
et al., 2003; Fraser et al., 2005). 
Although, at first (e.g. under non-permeabilised conditions), it appeared that 
MCF-7 cells did not have any nNavl.5 PM expression, confocal microscopy revealed 
that some PM expression was present but (1) at very low levels (~ 3.2-fold less) 
compared to MDA-MB-231 cells and (2) retained its polarised nature and expressed 
nNavl.5 only on the apical membrane. Unlike MDA-MB-231 cells, the fact that non-
permeabilised or live MCF-7 cells did not express any nNavl.5 protein in PM might be 
because the levels of protein on PM are low to be detected under these conditions. 
Although MCF-7 cells did not exhibit overall high levels of VGSCa, in 
immunocytochemical experiments, a small population of cells exhibited a sporadic 
apparent strong immunoreactivity (SASIR). MCF-7 cells exhibiting SASIR were mostly 
paired and occasionally single. These profiles may represent cells that are preparing to 
divide or just divided (single round cells) or they are in the process of division (paired 
round cells). If so, VGSCa protein may be upregulated in these cells transiently during 
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mitosis and this may also explain the VGSCa protein expression in MCF-7 cell, in both 
Western blot and immnnocytochemical experiments. Ion channels, especially 
channels have been shown to be mvolved in the proliferation of the weakly metastatic 
rat PCa cell line (AT-2), but interestingly not in the strongly metastatic rat MAT-LyLu 
cell line (Fraser et al., 2000). Furthermore, it has being shown that ATP-sensitive 
channels and Ca^^-activated K"^  channels controlled proliferation of MCF-7 cells (Strobl 
et al., 1995). Possible caused of the SASIR seen in MCF-7 cells are as follows: 
1. There is a direct involvement of VGSC activity in MCF-7 cell proliferation. 
Although there is not much evidence so far to indicated that VGSC play a 
significant role in cell cycle progression, investigation of the role of VGSCa 
in proliferation of MCF-7 would be interesting. 
2. Proliferating cells may be reduced in their adhesiveness to substrate and this 
way upregulated VGSC expression (as in VGSCpi silencing; Chapter 6). 
3. Basal activity of modulatory proteins that are upregulated in proliferating 
cells (e.g. extracellular signal-regulated kinases [ERKs]) might increase 
nNavl.5 expression. Although there is no evidence that ERKs are involved in 
VGSC regulation, a closely related enzyme, MAPK, has recently been shown 
to associate with VGSC activity (Wittmack et al., 2005). hiterestingly, ERK 
has also been linkled to growth factor signalling (Huang et al., 2006; Krejci 
et al., 2006) which can affect both proliferative activity (Schmitz et al., 2006) 
and VGSC expression (Brackenbury and Djamgoz, 2006a), although it is not 
known if these are associated in breast cancer cells. 
4. VGSC activity may be involved in functions other than proliferation, such as 
suppressing any tendency for apoptosis. 
4.3.2.1 Predominance of specific VGSCa isoform expression 
A major issue relevant to the present study was identification of the VGSCa isoform(s) 
responsible for enhancing the metastatic potential of cancer cells. Thus, it was shown 
that both nNavl.5 and, to a lesser extent Navl.7, isoforms were expressed in both MCF-
7 and MDA-MB-231 cell lines. Accordingly, if there is more than one VGSCa isoform 
expressed in the metastatic phenotype, would each affect different cellular processes as 
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parts of the metastatic process? So far the main isoform suggested to be involved in BCa 
metastasis is the nNavl.5 (Eraser et al., 2005; Brackenbury et al., 2006). Certain 
characteristic features of the Navl.5 that may facilitate its involvement in metastasis 
include the followmg (as reviewed by Diss et al., 2004): 
(1) PDZ domain. The C-terminal PDZ domain may mediate interactions with the 
cytoskeleton and other proteins, e.g. syndrophin (review: Diss et al., 2004). 
(2) Glvcosvlation. Navl.5 is the only VGSC with a low level of glycosylation. In 
the first instance, this characteristic may relate to the cancer process generally, 
since many proteins in cancer cells are normally glycosylated (Dall'Olio, 1996; 
Kobata and Amano, 2005; Jia et al., 2006). There is some evidence that 
glycosylation can affect electrophysiological properties of VGSCs. 
Deglycosylation of Navl.4 resulted in a depolarizing shift in activation voltage 
(Bennett, 2002), which might affect (reduce) the amount of Na"^  entering cells. 
Activation voltage of Navl.5 (in adult cardiac mycocytes) shifted to depolarized 
potentials after deglycosylation (Stocker and Bermett, 2006). Interestingly 
deglycosylating agents had no effect on Navl.5 in neonatal cardiac mycocytes, 
which could imply that the glycosylation status of nNavl.5 is even less than the 
adult. If so, Na^-dependent enzyme and transporter (e.g. Ca^ "*") activities could 
be higher and this could have significant consequences for cancer progression 
(e.g. effecting major signalling pathways). Further work is required to determine 
the glycosylation status of nNavl.5 and how this could affect MCB. 
(3) Kinetics. The slow activation and inactivation kinetics would allow more Na"^  in 
to the cells and thus activate major signalling pathways possibly important for 
cancer progression (Mattis et al., 2006). Indeed, the present study (Chapter 5), 
as well as Brackenbury and Djamgoz (2006) have shown that increase of 
intracellular Na"^  activates PKA pathway via cAMP. 
4.3.2.2 Polarization of VGSC expression 
Confocal XZY scan images revealed that MCF-7 cells expressed low levels of nNavl.5 
in the PM but only in the apical and not the basal membrane, a characteristic of 
epithelial cells (Muth and Caplan, 2003; Brone and Eggermont, 2005). In contrast. 
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MDA-MB-231 cells showed stainmg in both the apical and basal PM, consistent with 
that highly metastatic cells losing their membrane polarity (Fok et al., 2006; Gardiol et 
al., 2006). Normal epithelial cells are highly polarised and this property regulates 
cellular morphology, intracellular signalling, trans-cellular junctioning, transport, 
asymmetric cell division, cell migration and organ morphogenesis (Belting et al., 1998; 
Belting et al., 2001; Muschler et al., 2002). It was not surprising therefore, that cells that 
are aggressive and have the ability to metastasize, such as MDA-MB-231 cells, would 
lose their polarisation properties. This might be necessary in order for the MDA-MB-
231 cells to be able to invade other tissues. Loss of polarisation in epithelial cells has 
previously been described in proximal tubular epithelial cells (PTECs) as a response to 
acute tubular necrosis (Fujigaki et al., 2003). Also, it has been well documented that 
dismption of epithelial polarity leads to hyperproliferation and mimic the cancerous state 
(De Lorenzo et al., 1999; Bilder et al., 2000; Vasioukhin et al., 2001; Muschler et al., 
2002). Furthermore, restoration of polarity to a carcinoma cell line can re-establish 
growth control (Weaver et al., 1997; Wang et al., 1998b; Muschler et al., 2002). 
The mechanism of how cellular polarity controls MCB is not known but would 
be wide ranging. It would be expected that loss of polarity would disrupt coordinated 
signalling in cells which may result in loss of regulated cell behaviour. Recent studies 
have demonstrated a molecular link between loss of cell polarity and tumour malignancy 
(Igaki et al., 2006; Klezovitch et al., 2006). For example, mutation of a number of 
polarity genes activated c-Jun N-terminal kinase (JNK) signalling (Igaki et al., 2006). 
Furthermore, such mutations downregulated E-cadherin/(3-catenin adhesion complex 
(Igaki et al., 2006). Both activation of JNK signalling and downregulation of E-
cadherin/p-catenin were 'necessary and sufficient' for Ras-induced benign tumours in 
the developing eye (Igak et al., 2006). 
4.3.2.3 Cell processes and cell-cell contacts 
The staining observed in cell processes of MDA-MB-231 may support the idea these 
cells have the ability to metastasize. Neuromuscular junction and myelinated nerves are 
known to express VGSC in the axonal region devoid of myelin and glia cell processes 
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that contribute to highly efficient saltatory conduction of myelinated fibers (Novakovic 
et al., 2001). 
Staining at cell-cell contacts was observed in both MCF-7 and MDA-MB-231 
cells. The p-subunits of VGSC (VGSC|3s) have their extracellular domains containing 
immunoglobulin-like motifs, similar to those found in adhesion molecules and variable 
regions of antibodies (Isom et al., 1994). Thus, it has been suggested that VGSC(3 may 
play a role in cell-cell attachment (Novakovic et al., 2001). It has also demonstrated by 
modulation of VGSCa activation/inactivation kinetics that VGSCPs interact directly 
with a variety of VGSCa sub-types (Patton et al., 1994; Qu et al., 1995; Dietrich et al., 
1998; Smith and Goldin, 1998; Morgan et al., 2000). Furthermore, VGSCa can be 
modulated by more than one VGSCP (Morgan et al., 2000). Thus, it is possible that the 
VGSCa staining at cell-cell contact may be the indirect result of VGSCa modulation by 
VGSCp. 
4.3.2.4 Possible splicing variants 
The presence of the double protein band in MDA-MB-231 cells in Western blots with 
pan-VGSC antibody might also be because of alternative splicing of one or more 
isoforms. As reviewed previously, alternative splicing forms such as D1:S3 adult and 
neonatal, which differ by only one amino acid in Navl.7, Navl.6, Navl.2 and Navl.3 
(Gustafson et al., 1993; Plummer et al., 1997) have been monitored by cloning. Also, 
Eraser et al. (2005) found neonatal forms of Navl.5 and Navl.7 to be expressed in 
MDA-MB-231 cells. The present study also confirmed the expression of at least three 
different isoforms (aNavl.5, nNavl.5, Navl.7), by real-time PCR and Western blots, in 
MDA-MB-231 and also in MCF-7 cells. However, the difference in amino acids 
between different isoforms is often very small and thus would not always detectable as a 
different molecular weight band. 
4.3.2.5 Possible phosphorylation of VGSCa 
The multiple bands observed in Western blot analysis of MDA-MB-23 cell protein 
extract with the pan-VGSCa antibody and rarely even with the NESO-pAb, might be 
due to VGSCa phosphorylation. Modulation of VGSC function by phosphorylation in 
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tissues such as brain and heart has been documented (Fozzard and Hanck, 1996; Murphy 
et al., 1996; Cantrell et al., 1997). Phosphorylation of VGSCas by PKA and PKC occurs 
mainly at Dl/2 and D3/4 intracellular loops. Although VGSCas have a number of 
possible PKA phosphorylation sites, in vitro studies suggested that only some of them 
could be phosphorylated (Murphy et al., 1996). PKA phosphorylation of Dl/2 linker of 
Navl.5 can increased whole-cell conductance (Marban et al., 1998). In another study 
they found that PKC phosphorylation of a conserved serine residue in D3/4 linker 
altered the function of all VGSCas (Murray et al., 1997). Although in all lysis buffers 
phosphates inhibitors were present (e.g. NaF and Na3V04), it may be possible that the 
lower molecular weight bands were products of phosphorylation. The molecular weight 
difference between phosphorylated and non-phosphorylated VGSCa protein would 
expected to be very small even if detectable by Western blot, since the addition of 
phosphate group into about a 300 kDa protein (-2730 amino acids), such as the VGSCa, 
would not made a significant difference in the molecular weight size of the protein band. 
However, the change in the protein charge (making the protein more negatively charged 
after the addition of phosphate groups) is possible to have an effect on the protein 
migration on the gel. Thus, a more negatively charged protein would migrate faster in a 
SDS-PAGE gel giving a lower molecular weight band than the non-phosphorylated 
protein. 
4.3.2.6 Possible glycosylation of VGSCa 
VGSCas have a number of potential glycosylation sites in the putative pore-lining 
regions of D1 and D3 and are known to be heavily glycosylated (Marban et al., 1998). 
Brain and muscle VGSCa are glycosylated with up to 40 % of the mass being 
carbohydrate, whilst Navl.5 is only 5 % sugar by weight although it has 14 putative sites 
of glycosylation (Marban et al., 1998). Navl.7 has about 6 putative sites of glycosylation 
(Marban et al., 1998). Thus, the higher molecular weight band observed with the pan-
VGSCa on BCa cells and rarely with the NESO-pAb may also be a result of 
glycosylation. It has been suggested that addition of sialic acid (which, is a characteristic 
component of the N-linked carbohydrate of VGSCs) affects the voltage dependence of 
gating through alteration of the surface charge of the VGSC protein, due to the addition 
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of such highly charged carbohydrate (Bennett et al., 1997). Biochemical characterisation 
of purified VGSC suggested that glycosylation may provide a significant source of 
protein-associated negative surface charges (Bennett et al., 1997). Hence, a general 
feature of many VGSCs is that they are heavily glycosylated with a large firaction of 
carbohydrate in the form of sialic acid residues that have a negative charge at 
physiological pH (Miller et al., 1983; Bennett et al., 1997). Bennet et al. (1997) also 
showed that neuraminidase treatment, to remove sialic, produced a depolarizing shift in 
steady-state inactivation of Navl.4. 
It is likely that the higher molecular weight bands observed in Western blots are 
due to glycosylation, rather than phosphorylation or splicing. However, further 
experiments are needed to test if the protein is indeed glycosylated must be carried out 
by protein glycosylation and deglycosylation techniques. 
4.3.2.7 Possible proteolysis of VGSCa 
The lower molecular weight band observed in Western blots might be a result of protein 
break-down. However, lysis buffers used for protein extraction contained a number of 
protease inhibitors (e.g. PMSF, EDTA, leupeptin, aprotinin and pepstatin) in order to 
reduce this effect. In fact, in the early days of this study, when the experimental 
conditions were still under investigation, the concentration of the protease inhibitors 
used were lower than the optimised, and high levels of proteolysis were observed 
especially with heart muscle, suggesting that the a-subunit of VGSC is sensitive to 
cleavage by endogenous proteases. Storage of the protein extracts also was very 
important for avoiding protein-break down; samples stored at -20 °C showed higher 
degree of proteolysis than when those stored at -70 '^ C. The sensitivity of VGSCa 
protein to cleavage by endogenous proteases have previously demonstrated (Kraner et 
al,1989^ 
4.3.3 Intracellular location of VGSCa protein 
From the immunocytochemical studies using conventional fluorescence microscopy, it 
was difficult to determine the precise sub-cellular localization of VGSCa protein in 
MCF-7 and MDA-MB-231. However, Western blot analysis of subcellular fractions and 
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confocal microscopy gave more conclusive results and proper observational analysis of 
the location of the VGSC protein, in particular nNavl.5. 
Fluoresence microscopy initially suggested staining in the perinuclear region of 
both MDA-MB-231 and MCF-7 cells, possibly in ER and Golgi. Western blotting on 
PM and CYT fractions showed that VGSCa protein was intracellular in both MCF-7 and 
MDA-MB-231 cells and that only the latter expressed high levels of PM VGSCa (Figure 
4.23). More detailed subcellular fractionation and confocal microscopy of double 
staining with markers for PM, ER and Golgi and the NESO-pAb antibody supported 
these findings and gave further information on the location of VGSC inside the cell 
(Figures 4.15-4.19, 4.25-4.27). Part of the intracellular nNavl.5 protein was located 
indeed in ER and Golgi in both MCF-7 and MDA-MB-231 cells, proposing the 
formation of VGSCa protein, which been transported through ER and Golgi for 
expression in PM. The high density of staining in these areas may also suggest high up-
regulation and renewal levels of VGSC protein in the cells. 
The observation that considerable high levels of VGSCa protein were present 
intracellularly in both MDA-MB-231 and MCF-7 cell lines, would raise the possibility 
of intracellular frafficking of VGSCa. 
The presence of a large infracellular pool of VGSCa has being reported in 
developing neurons of rat brain (Schmidt and Catterall, 1986). Cohen (1996) 
demonstrated a cytoplasmic location of VGSCs in rat myocytes, favouring the idea of 
intracellular trafficking. Another study showed that Navl.5 is localised in ER, Golgi 
apparatus and perinuclear region of HEK293 cells and dog cardiac myocytes (Zimmer et 
al., 2002b). It was also proposed that intracellular frafficking of Navl.5 occurred from 
the perinuclear region through the ER and Golgi to the PM, in agreement with the 
Western blot data and confocal observations of the present study. 
4.3.3.1 Technical problems with confocal analysis 
hi Figure 4.15, the signal for fluorescence intensity was 'off scale' in some areas, 
because of the high levels of intracellular nNavl.5 in relation to PM nNavl.5. Reducing 
the singal intensity in order to avoid saturation levels would made PM nNavl.5 staining 
very weak to be studied. However, this particular figure has been used here for 
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qualitative purposes only. The graph (Figure 4.15) clearly shows the markedly different 
staining patems of nNavl.5 vs. ConA. In particular, the strong intracellular presence of 
nNavl.5 as well as the co-localisation of nNavl.5 with ConA at the PM, were apparent 
(irrespective of the saturated signal level). However, later in the studies (Chapter 5) 
when the problem persists and the analysis is quantitative, the problem is discussed 
further. The basic consequence is that, in some experiments/treatment, the extent of the 
intemalisation would be underestimated but the conclusion is not affected. 
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Chapter 5: REGULATION OF VGSC EXPRESSION IN 
MCF-7 AND MDA-MB-231 CELLS 
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5.1 Introduction 
Regulation of voltage-gated Na"^  channel (VGSC) can be transcriptional and/or post-
transcriptional (Diss et al., 2004a). Transcriptional regulation of VGSC includes a 
variety of stimuli such as nerve growth factor (NGF) or fibroblast growth factors (FGF) 
that have been shown to modulate VGSC activity in PC12 cells and CNS respectively 
(Rudy et al., 1987; Toledo-Aral et al., 1995a; Lou et al., 2005). Nerve injury can also 
alter VGSC expression/activity (Waxman et al., 1994; Dib-Hajj et al., 1996; Black et al., 
1999; Waxman, 2001). In adult rat dorsal root ganglion (DRG) neurons, Navl.l and 
Navl.2 mRNA were the main isoforms expressed, whilst in embryonic DRG, Navl.3 
mRNA expression was dominant (Waxman et al., 1994). The latter was upregulated, 
possibly because of the reversion to an embryonic mode of VGSC expression (Waxman 
et al., 1994; Dib-Hajj et al., 1996). Denervation of adult rat skeletal muscle (soleus) 
caused upregulation of Navl.5 mRNA expression after a week (Awad et al., 2001). The 
transcription factor REST has been found to inhibit the expression of at least one 
VGSCa isoform (Chong et al., 1995; Toledo-Aral et al., 1997). REST is present in most 
tissues/cells, apart from neurons, and its absence permits expression of the Navl.2 
isoform in brain (Marban et al., 1998). 
Evidence of activity-dependent regulation of VGSC has been well documented. 
Increase of intracellular Na^ concentration in fetal rat brain neurons in vitro, mediated by 
VGSC activators (scorpion a-toxin [a-ScTX], batrachotoxin, or veratridine) or a Na"^  
ionophore (Amphotericin B), decreased VGSC expression (Dargent and Couraud, 1990). 
Other studies indicated that Na^ influx into cultured rat brain neurons can cause VGSC 
internalization, thus adjusting functional VGSC density in plasma membrane (PM) by an 
activity-dependent endocytic process (Dargent et al., 1994; Paillart et al., 1996). Other 
studies on fetal rat brain neurons demonstrated that persistent activation of VGSC by a-
ScTX treatment also down-regulated VGSC mRNA expression (Lara et al., 1996). 
Activity-dependent down-regulation of Navl.8 and Navl.9 mRNA and protein levels 
were observed in cultured embryonic mouse sensory neurons after NGF treatment (Klein 
et al., 2003). In bovine adrenal chromaffin cells, long-term (24 h) treatment with 
pharmacological agents that blocked VGSC activity (e.g. the local anaesthetic, 
bupivacaine) upregulated PM expression of VGSC protein via translation and 
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extemalization (Shiraishi et al., 2003). Blocking VGSC activity in primary cultures of 
rat myotubes using bupivacaine or tetrodotoxin (TTX) increased PM VGSCs as 
measured by binding of [^HJsaxitoxin (STX) (Sherman and Catterall, 1984). Another 
study showed in developing rat muscle cells a correlation between changes in VGSC 
mRNA levels and channel density in PM. These results suggested that regulation of 
VGSC mRNA level could be an important mechanism of feedback regulation of VGSC 
density by electrical activity (Offord and Catterall, 1989). A recent study has provided 
first evidence that VGSC activity in Mat-LyLu rat prostate cancer cells was upregulated 
via a positive feedback mechanism involving PKA (Brackenbury and Djamgoz, 2006b). 
Post-transcriptional mechanisms of VGSC regulation include: phosphorylation, 
glycosylation, intracellular trafficking, association with VGSC P-subunits, cytoskeletal 
proteins and G-proteins (see section 1.8). It is well documented that VGSCs can be 
regulated by protein kinase A (PKA) and protein kinase C (PKC) phosphorylation (see 
section 1.8.1) (Marban et al., 1998; Diss et al., 2004a; Chahine et al., 2005). 
Phosphorylation by PKA can have different effects on different VGSC isoforms. For 
example, phosphorylation by PKA reduced current amplitude of Navl.l but Navl.5 
whole-cell conductance increased (Murphy et al., 1993; Cantrell et al., 1997). After 
treatment of bovine adrenal chromaffin cells with membrane permeant dibutyryl-cAMP 
(dbcAMP) or an activator of adenylate cyclase (AC), forskolin, an increase in the 
number of VGSCs was detected by [^H] STX binding; the effect was reversed by the 
addition of either a PKA inhibitor (H-89) or an inhibitor of protein synthesis 
(cyclohexamide) (Yuhi et al., 1996). The PKA-mediated increase in Navl.8 current 
amplitude was prevented by the Golgi blocker, chloroquine, suggesting that intracellular 
trafficking could contribute to the changes in Navl.8 current amplitudes (Vijayaragavan 
et al., 2004). 
Interestingly, modulation of VGSCa by PKA and PKC can involve both 
electrophysiological effects (e.g. Murphy et al. 1993; Cantrell et al. 1997; Chahine et al. 
2005) and protein trafficking (Figure 1.15) (Chahine et al., 2005). Although the 
mechanism involved in trafficking is not yet known, evidence from Xenopus oocyte 
expression studies indicated that activation of PKA can modulate the trafficking of both 
Navl.5 and Navl.8 firom endoplasmic reticulum (ER) to PM (Zhou et al., 2000; 
Vijayaragavan et al., 2004). Furthermore, increase of cAMP levels could stimulate 
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transcription of Navl.4 gene. Thus, increase in functional Navl.4 channels would 
require synthesis of VGSC protein via cAMP/PKA -dependent mechanism(s) (Yuhi et 
al., 1996). Another study demonstrated that PKA could upregulate Navl.7 expression by 
modulating its intemalisation from PM and/or extemalisation from Golgi (Wada et al., 
2004). Thus, phosphorylation/dephosphorylation could up- or down-regulate functional 
VGSCa expression by regulating mRNA stability and intracellular trafficking of 
VGSCa protein (Wada et al., 2004). 
Although there are reports of VGSC expression in cancer cells (Grimes et al., 
1995; Allen et al., 1997; Laniado et al., 1997; Fraser et al., 2004b; Eraser et al., 2005; 
Onganer and Djamgoz, 2005), it is not well documented which mechanism(s) are 
involved in VGSC regulation in these cells. Interestingly, a recent study showed that 
VGSC activity in Mat-LyLu rat prostate cancer cells was upregulated via a positive 
feedback mechanism involving PKA, and this enhanced metastatic cell behaviour 
(MCB), migration (Brackenbury and Djamgoz, 2006b). 
5.1.1 Aims and scope 
The main aim of this study was to investigate VGSCa regulation by PKA as well as 
autoregulation in human breast cancer (BCa) weakly metastatic, MCF-7 and strongly 
metastatic, MDA-MB-231 cell lines, with emphasis on the latter. The emphasis was on 
'neonatal' Navl.5 (nNavl.5) protein, since this is the predominant isoform expressed in 
MDA-MB-231 and MCF-7 cell lines (Fraser et al., 2005). The specific aims were as 
follows: 
1. To test if PKA was involved in VGSC regulation by at mRNA and protein levels. 
2. To determine if VGSC expression was controlled by auto-self-regulation, again 
at mRNA and protein levels; and 
3. To determine any consequence of the above on MCBs (proliferation, migration, 
adhesion and invasion). 
Previous studies have highlighted the possible role of PKA in VGSC regulation 
by proposing the hypothesis that Na"^  influx through VGSC can activate AC/PKA 
(Cooper et al., 1998; Murakami et al., 1998) and thus increase functional VGSC 
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expression (Yiohi et al., 1996; Zhou et al., 2000; Wada et al., 2004; Brackenbury and 
Djamgoz, 2006b). 
Parts of this study have being published (Chioni and Djamgoz, 2005b; Chioni 
and Djamgoz, 2005a) 
5.2 Results 
5.2.1 Effects of forskolin on VGSCa expression 
Forskolin is an adenylate cyclase (AC) / PKA activator that was used to test the 
hypothesis that PKA was involved in VGSC regulation. The focus was on the effects of 
PKA activation on nNavl.5 mRNA and protein expression and trafficking in MDA-MB-
231 and MCF-7 with an emphasis on the latter. 
Incubation of MDA-MB-231 and MCF-7 cells with forskolin (50 jiM) for 48 
hours did not alter their viability (Table 5.1). Similar treatment with the solvent DMSO 
(0.025 % v/v) also had no effect on cell viability (P = 0.69 for MDA-MB-231 cells and P 
= 0.89 for MCF-7 cells; with one way analysis of variance-ANOVA; n = 4 for both). 
The light microscopic morphology of the cells incubated with forskolin appeared to 
change after 48 hours, becoming flatter and elongated with long processes compared to 
control cells (not shown). Although this was just an observation and was not 
investigated further, change in cell morphology would imply altered cytoskeleton and 
hence possible role in MCB. 
5.2.1.1 Effects of forskolin on nNavl.5 mRNA level 
MDA-MB-231 and MCF-7 cells were incubated with forskolin (50 )j,M) for 48 hours, 
after which the nNavl.5 mRNA levels were assessed by real-time polymerase chain 
reaction (rt-PCR). Typical agarose gel images with rt-PCR products (Figure 5.1 A) 
confirmed a specific single band at the expected size for both nNavl.5 and cytochrome 
b5 reductase (Cytb5R) (219 nt and 511 nt respectively). The no-template control (NTC) 
did not give any signal (Figure 5.1 A). Pre-treatment with forskolin significantly 
increased the nNavl.5 mRNA levels by 238 % in MDA-MB-231 cells, and by 174 % in 
MCF-7 cells (P < 0.05; n= 4 for both; Figure 5. IB & C). 
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Table 5.1 Cell viability after treatment 
Data presented as percent (%) mean ± SEM (n = 4: 30 field of views per experiment). 
Cell viability (%) 
Treatments MDA-MB-231 MCF-7 
24 hours 
Control 99.7 ±0.04 99.7 ±0.03 
TTX 99.6 ±0.05 99.6 ± 0.04 
48 hours 
Control 99.7 ±0.08 99.8 ± 0.04 
DMSOl 99.8 ± 0.04 99.7 ± 0.20 
KT5720 99.7 ± 0.04 99.5 ± 0.30 
Forskolin 99.8 ±0.05 99.7 ± 0.07 
































Figure 5.1 Forskolin increased nNavl.5 mRNA level in both MCF-7 and MDA-MB-
231 cells. 
(A) Typical PCR products for nNavl.5 and cytochrome b5 reductase (Cyt5bR). Lanes: 1, 
MCF-7 control cells; 2, MCF-7 cells pre-treated for 48 h with 50 pM forskolin; 3, 
MDA-MB-231 control cells; 4, MDA-MB-231 cells pre-treated for 48 h with 50 |a,M 
forskolin; 5, no-template control (NTC). (B) Relative levels of nNavl.5 mRNA in 
control MDA-MB-231 cells and following forskolin treatment (48 h; 50 jiM). (C) 
Relative levels of nNavl.5 mRNA in control MCF-7 cells and following forskolin 
treatment (48 h; 50 p.M). nNavl.5 mRNA level was normalized to Cytb5R by the 2 '^^ ' 
method (with propagated errors; n = 4). Data were analysed by paired t-test. 
Significance: (*) P< 0.05. 
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5.2.1.2 Effects of forskolin on total VGSCa and nNavl.5 protein expression 
Western blots with pan-VGSCa and NESO-pAb antibodies were used to assess the 
effect of similar forskolin treatment (50 p,M; 48 h) on the total VGSCa and nNavl.5 
protein levels in MDA-MB-231 and MCF-7 cells (Figure 5.2). Forskolin treatment did 
not alter the whole cell total VGSCa protein level in either MDA-MB-231 (P = 0.68; n = 
7) or MCF-7 cells (P = 0.10; n - 7) (Figure 5.2A & B). Similarly, forskolin treatment 
did not affect whole cell nNavl.5 Protein expression in either MDA-MB-231 cells (P = 
0.66; n = 7) or MCF-7 (P = 0.15; n = 7) cells (Figure 5.2A & C). 
5.2.1.3 Effects of forskolin on subcellular distribution of nNavl.5 protein 
Confocal immunocytochemistry with the NESO-pAb antibody was used to determine 
whether the forskolin treatment (50 pM; 48 h) had an effect on the subcellular 
distribution of nNavl.5 protein in MDA-MB-231 and MCF-7 cells. In addition, Western 
blot experiments with subcellular fractions and biotinylated cell surface proteins were 
used to study subcellular distribution of total VGSCa and nNavl.5 protein in MDA-MB-
231 cells. Control labelling experiments confirmed that there was no autofluorescence 
and that the binding of NESO-pAb was specific (Figure 4.20). 
Confocal images (from both XYZ and XZY scans) revealed upregulation of 
rLNavl.5 in PM in both MDA-MB-231 cells (Figures 5.3 and 5.4) and MCF-7 cells 
(Figure 5.5) after the forskolin treatment, hiterestingly, although in MDA-MB-231 cells 
the nNavl.5 upregulation appeared evenly distributed in PM, in MCF-7 cells the 
upregulation occurred only to the apical membrane, thereby maintaining their polarised 
nature (Figure 5.5). 
Initially, PM expression in MDA-MB-231 cells was quantified by drawing a freeform 
line profile around the edges of the cells using concanavaling A (ConA) labelling as a 
marker for PM in XYZ (Figure 5.3) and XZY scans (Figure 5.4). In MCF-7 cells, PM 
expression was quantified by only using XZY images because of their polarised nature 
that did not allow full visualisation of the PM staining with XYZ scan (Figure 5.5). 
Forskolin treatment increased nNavl.5 immunoreactivity in PM of MDA-MB-231 cells 
in both XYZ and XZY images by 57 % and 48 %, respectively (P < 0.05; n = 3: cells > 
30 per experiment, for both; Figure 5.6A). In MCF-7 cells, PM expression 
253 















Figure 5.2 Forskolin did not affect the total VGSCa and nNavl.5 protein levels. 
(A) Western blots of whole cell total protein (60 |.ig) from MDA-MB-231 and MCF-7 
cells, using Pan-VGSCa and NESO-pAb antibodies. Lanes: 1, Control cells; 2, cells 
treated with forskolin (50 (iM; 48 h). (B) Relative total VGSCa protein levels in MDA-
MB-231 and MCF-7 control cells and cells treated with forskolin (50 p.M; 48 h). (C) 
Relative total nNavl.5 protein levels in both MDA-MB-231 and MCF-7 control cells 
and cells treated with forskolin (50 |uM; 48 h). Data are presented as means and SEMs 
(n=4) and were analysed by paired t-test. 
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Figure 5.3 Forskolin altered subcellular distribution of nNavl.5 protein in MDA-
MB-231 cells. 
Typical XYZ confocal images of control cells (A & B) and cells treated with forskolin 
(50 ^M; 48 h) (C & D). Signal from concanavalin A (ConA) plasma membrane marker 
(green), NESO-pAb antibody (red) and overlays of both (merged image) are shown. 
White arrows in nNavl.5 images indicate plasma membrane staining. White lines in the 
merged images indicate typical cross-sections used for digital analysis (data shown in 
Figure 5.9). Scale bar (16 jim), applicable to all panels. 
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Figure 5.4 Forskolin altered plasma membrane expression of nNavl.5 protein in 
MDA-MB-231 cells. 
Typical XZY confocal images of control cells (A & B) and cells treated with forskolin 
(50 |iM; 48 h) (C & D). Signal from concanavalin A (ConA) plasma membrane marker 
(green), NESO-pAb antibody (red) and overlays of both (merged image) are shown. 
Scale bar (16 [im), applicable to all panels. 
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Figure 5.5 Forskolin altered subcellular distribution of nNavl.5 protein in MCF-7 
cells. 
Typical XYZ (A & B) and XZY (C & F) confocal images of control cells (A, C & D) 
and cells treated with forskolin (50 |iM; 48 h) (B, E & F). Signal from concanavalin A 
(ConA), plasma membrane marker (green), NESO-pAb antibody (red) and overlays of 




























q! Control Forskolin 
Figure 5.6 Forskolin increased nNavl.5 protein level in plasma membranes of both 
MDA-MB-231 and MCF-7 cells. 
nNavl.5 protein level (immimoreactivity) measured around the edge of MDA-MB-231 
cells (A) and MCF-7 cells (B) under control conditions and following treatment with 
forskolin (50 p,M; 48 h). Data were obtained from both XYZ and XZY images for 
MDA-MB-231 cells, and from XZY images for MCF-7 cells. Data are presented as 
means and SEMs (n=3 experiments: cells > 30 for each) and were analysed by paired t-
test. Significance: (X) P > 0.05, (*) P < 0.05. 
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was also increased after forskolin treatment by 55 % (P < 0.05; n=3: cells > 30 per 
experiment) (Figure 5.6B). 
Immunostaining of live control and forskolin-treated MDA-MB-231 cells with 
NESO-pAb antibody and cross-sectional analysis of immunoreactivity confirmed that 
PM nNavl .5 expression was indeed higher following forskolin treatment (Figure 5.7). 
In a farther method for quantifying relative PM and intracellular 
immunoreactivity in MDA-MB-231 cells, sections were taken across immunofluorescent 
labelled cells from XYZ images (white lines in 'Merged image' of Figure 5.3), through 
the PM, avoiding the nucleus, as described previously (Okuse et al., 2002; Shah et al., 
2004; Brackenbury and Djamgoz, 2006b). Staining with ConA, a PM marker, was used 
as a tool for determining the cell edges in cross-sections. In MDA-MB-231 cells treated 
with forskolin, this analysis showed peaks of high immunofluorescence at the edges, 
around the PM, compared with controls where the peaks were less pronounced (Figure 
5.8A vs. B). Furthermore, the level of intracellular nNavl.5 expression appeared lower 
in the forskolin-treated MDA-MB-231 cells, compared with controls (Figure 5.8A vs B). 
The nNavl.5 cross-sectional immunoreactivity was compared in the two regions: 
(1) 'plasma membrane', a 1.5 |xm section inward from the periphery of the cell (typically 
at the edge of ConA staining), and (2) 'internal', the middle 30 % of the cross-section 
(Brackenbury and Djamgoz, 2006b). Forskolin treatment increased nNavl.5 expression 
in PM from 2.6 ± 0.3 % to 5.7 ± 0.8 % of total immunofluorescence in the cross-section 
(P < 0.01; n = 20 cells for each; Figure 5.9 left hand bars). Importantly, forskolin 
treatment had an opposite effect on the internal region, decreasing immunofluorescence 
from 50 ± 1.9 % to 40.3 ± 2.7 % (P < 0.05; n = 20 cells for each; Figure 5.9 right hand 
bars). 
Further studies involved Western blots with subcellular fractions for 'PM' and 
'cytosol' (Figure 5.10), as well as cell surface biotinylated/non-biotinylated proteins 
(Figure 5.11). Western blots with 'PM' fractions from MDA-MB-231 (Figure 5.1 OA; 
lane 1 vs. 2) and MCF-7 (Figure 5.1 OB; lane 1 vs. 2) cells, using the pan-VGSCa 
antibody, showed an increase in the band intensity after forskolin treatment. In the 
cytosolic fraction (CYT) the difference was not as obvious (Figure 5.10A & B; lane 3 & 
4). However, although these experiment could not be repeated many times (n = 2) to 
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Figure 5.7 Forskolin increased nNavl.5 protein level of in plasma membrane of live 
MDA-MB-231 cells. 
(A) Plasma membrane nNavl.5 protein expression in control cells. (B) Signal intensity 
of ConA (green) plasma membrane marker and nNavl.5 (red) immunofluorescence 
along cross-section from a typical control cell. (C) Plasma membrane nNavl.5 protein 
expression in cells treated with forskolin (50 pM; 48 h). (D) Signal intensity of ConA 
(green) plasma membrane marker and nNavl.5 immunoreactivity along cross-section 
from a typical forskolin (50 pM) treated cell for 48 hours. Orange line indicates typical 
cross-sections. In B and D, the horizontal dashed line indicates the approximate level of 
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Figure 5.8 Foskolin shifted nNavl.5 immunoreactivity in plasma membrane whilst 
reducing it intracellularly in MDA-MB-231. 
Traces show signal intensity of concanavalin A (ConA) plasma membrane marker 
(green line) and NESO-pAb (red line) immunofluorescence along cross-sections from a 
typical control cell (A) and a cell treated with forskolin (50 |iM; 48 h). Dotted grey lines 
and arrows indicate approximate levels of cytosolic and plasma membrane nNavl.5 





















Figure 5.9 Forskolin increased the relative proportion of nNavl.5 protein in plasma 
membrane and decreased it intracellularly in MDA-MB-231 cells. 
The figure shows distribution of nNavl.5 protein (immunoreactivity) along subcellular 
cross-sections as a percentage of total (%). Left hand bars, 1.5 p.m sections measured 
inward from the edge of ConA staining. Right-hand bars, middle 30 % of cross section. 
Black bars, control cells; white bars, cells treated with forskolin (50 |j.M; 48 h). Data are 
presented as means and SEMs (n=20) and were analysed by Mann-Whitney Rank Sum 





















Figure 5.10 Plasma membrane expression was increased after forskolin treatment 
in MDA-MB-231 and MCF-7 cells. 
The figure shows Western blots of plasma membrane (PM) and cytosolic (CYT) 
fractions (60 ^g) from MDA-MB-231 and MCF-7 cells, using pan-VGSCa antibody. 
Lanes are as follows: 
(1) PM fraction of control cells; 
(2) PM fraction from cells treated with forskolin (50 ]u.M; 48 h); 
(3) CYT fraction from control cells; 
(4) CYT fraction from cells treated with forskolin (50 p-M; 48 h). 
Molecular size is indicated on the right. 
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intensity of both MDA-MB-231 and MCF-7 cells treated with forskolin was evident in 
both experiments (Figure 5.1 OA & B; lanes 3 vs. 4). 
Supplementary experiments from Western blots with biotinylated cell surface proteins 
from MDA-MB-231 cells, using both pan-VGSCa and NESO-pAb antibodies, also 
suggested an increase in PM expression after forskolin treatment compared to control 
(Figure 5.1 lA; lanes 2 vs. 3). Western blots with non-biotinylated (intracellular) proteins 
showed that NESO-pAb expression decreased (Figure 5.1 IB; lanes 2 vs. 3). However, 
immunostaining with pan-VGSCa antibody did not show a clear difference in the 
expression of intracellular VGSCa proteins after forskolin treatment (Figure 5.1 IB; 
lanes 2 vs. 3). 
These results were consistent with forskolin increasing nNavl.5 protein 
trafficking to PM in MDA-MB-231 and MCF-7, without affecting the level of total 
protein in the cells, i.e. mainly the balance between PM and intracellular nNavl.5 
protein expression was changed. 
5.2.2 Effects of KT5720 on VGSC expression 
The involvement of PKA in VGSC/nNavl.5 regulation in MDA-M-231 and MCF-7 
cells was studied further by treating the cells with KT5720 (500 nM) for 48 hours. 
KT5720 is a potent and specific inhibitor of PKA (Cabell and Audesirk, 1993). 
Treatment with KT5720, did not affect MDA-MB-231 or MCF-7 cell viability (P = 
0.886 for MCF-7 cells and P = 0.689 for MDA-MB-231 cells; with ANOVA; n = 4 for 
both; Table 5.1). Also, KT5720 had no noticeable effect on the cells' morphology 
compared to controls. 
5.2.2.1 Effects of KT5720 on nNavl.5 mRNA 
Pre-treatment with KT5720 significantly decreased the nNavl.5 mRNA level by 69 % 
(P < 0.05; n = 4) in MDA-MB-231 cells, and by 74 % (P < 0.001; n= 4) in MCF-7 cells 
(Figure 5.12). Typical agarose gels with rt-PCR products (Figure 5.12A) confirmed 
specific single bands at the expected sizes for both nNavl .5 and Cytb5R (219 nt and 511 
nt, respectively). The no-template control (NTC) did not give any signal (Figure 5.12A). 
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Figure 5.11 Plasma membrane biotinylated total VGSCa and nNavl.5 protein 
expressions were altered after TTX and forskolin treatment of MDA-MB-231 cells. 
The figure shows Western blots of (A) biotinylated cell surface (plasma membrane) 
proteins and (B) non-biotynilated (intracellular) proteins from MDA-MB-231 cells, 
using pan-VGSCa and NESO-pAb antibodies. Lanes are as follws: 
(1) cells treated with TTX (10 fj-M; 48 h); 
(2) control cells; and 
(3) cells treated with forskolin (50 |iM; 48 h). 
Equal amounts of protein extracts (1 mg) were used in all cases. Molecular size is 
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Figure 5.12 KT5720 decreased nNavl.5 mRNA level in both MCF-7 and MDA-MB-
231 cells. 
(A) Typical PCR products for nNavl.5 and cytochrome b5 reductase (Cyt5bR) mRNAs. 
Lanes: 1, MCF-7 control cells; 2, MCF-7 cells pre-treated for 48 h with 500 nM 
KT5720; 3, MDA-MB-231 control cells; 4, MDA-MB-231 cells pre-treated for 48 h 
with 500 nM KT5720; 5, no-template control (NTC). (B) Relative levels of nNavl.5 
mRNA in control MCF-7 cells and treated for 48 h with 500 nM KT5720. (C) Relative 
nNavl.5 mRNA level in control MDA-MB-231 cells and treated for 48 h with 500 nM 
KT5720. nNavl.5 mRNA level was normalized to Cytb5R by the method (with 
propagated errors; n = 4). Data were analysed by paired t-test. Significance: (*) P< 0.05, 
(***)?< 0.001. 
266 
5.2.2.2 Effects of KT5720 on total VGSCa and nNavl.5 protein expression levels 
Western blots with pan-VGSCa and NESO-pAb antibodies were used to assess the 
effect of the KT5720 treatment on the total VGSCa and nNavl.5 protein levels in MDA-
MB-231 and MCF-7 cells (Figure 5.13). In a similar manner to forskolin (section 
5.2.1.2), KT5720 had no effect on the total VGSCa protein expression in either MDA-
MB-231 (P = 0.84; n = 4) or MCF-7 cells (P = 0.84; n = 4) (Figure 5.13A & B). 
KT5720 treatment did not affect the nNavl.5 protein levels in either MDA-MB-231 
cells (P = 0.82; n = 4) or MCF-7 cells (P = 0.65; n = 4; Figure 5.13A & C). 
5.2.2.3 Effects of KT5720 on subcellular nNavl.5 protein distribution 
Confocal immunocytochemistry with NESO-pAb antibody was used to determine 
whether the KT5720 treatment would have an effect on the subcellular distribution of 
nNavl.5 protein in MCF-7 and MDA-MB-231 cells (Figures 5.14-5.20). 
Confocal imaging revealed a decrease of nNavl.5 PM expression in both MDA-
MB-231 cells (Figures 5.14 and 5.15) and MCF-7 cells (Figure 5.16) after the KT5720 
treatment. The KT5720 treatment, like the forskolin treatment, did not alter the polarised 
nature of nNavl.5 protein expression in MCF-7 cells (Figure 5.16). Freeform line profile 
analysis of XYZ scans of MDA-MB-231 cells (Figure 5.14) and XZY scans of MCF-7 
cells (Figure 5.16) revealed a decrease in PM nNavl.5 immunoreactivity after the 
KT5720 treatment, opposite to the effect of forskolin. The KT5720 treatment decreased 
nNavl.5 immunoreactivity in the PM of MDA-MB-231 cells by 39 % (P < 0.05; n = 3: 
cells > 30 per experiment) and of MCF-7 cells by 34 % (P < 0.01; n = 3 / cells > 30 per 
experiment) (Figure 5.17). 
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Figure 5.13 KT5720 did not affect total VGSCa and nNavl.5 protein levels. 
(A) Western blots of total protein (60 fig) extracts from MDA-MB-231 and MCF-7 
cells, using pan-VGSCa and NESO-pAb antibodies. Lanes: 1, Control cells; 2, cells 
treated cells with KT5720 (500 nM) for 48 hours. (B) Relative total VGSCa protein 
levels in MCF-7 and MDA-MB-231 control cells and cells treated with Kr5720 (500 
nM; 48 h). (C) Relative total nNavl.5 protein levels in MCF-7 and MDA-MB-231 
control cells and cells treated with KT5720 (500 nM; 48 h). Data are presented as means 
and SEMs (n=4) and were analysed by paired t-test. 
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Figure 5.14 KT5720 altered subcellular distribution of nNavl.5 protein in MDA-
MB-231 cells. 
Typical XYZ confocal images of control cells (A & B) and cells treated with KT5720 
(500 nM; 48 h) (C & D). Signal from concanavalin A (ConA) plasma membrane marker 
(green), NESO-pAb antibody (red) and overlays of both (merged image) are shown. 
White arrows in nNavl.5 images indicating plasma membrane staining. White lines in 
the merged images are indicating typical cross-sections used for digital analysis (data 
shown in figure 5.20). Scale bar (16 ^im), applicable to all panels. 
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Figure 5.15 KT5720 altered plasma membrane expression of nNavl.5 protein in 
MDA-MB-231 cells. 
Typical XZY confocal images of control cells (A & B) and cells treated with KT5720 
(500 nM; 48 h) (C &D). Signal from concanavalin A (ConA) plasma membrane marker 
(green), NESO-pAb antibody (red) and overlays of both (merged image) are shown. 
Scale bar (16 jam), applicable to all panels. 
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Figure 5.16 KT5720 altered plasma membrane expression of nNavl.5 protein in 
MCF-7 cells. 
Typical XZY confocal images of control cells (A & B) and cells treated with KT5720 
(500 nM; 48 h) (C & D). Signal from concanavalin A (ConA) plasma membrane marker 
(green), NESO-pAb antibody (red) and overlays of both (merged image) are shown. 








Figure 5.17 KT5720 decreased nNavl.5 protein levels in plasma membranes of both 
MDA-MB-231 and MCF-7 cells. 
nNavl.5 protein level (immunoreactivity) measured around the edge of MDA-MB-231 
cells (A) and MCF-7 cells (B) under control conditions and following treatment with 
KT5720 (500 nM; 48 h). Data obtained from XYZ images for MDA-MB-231 cells and 
from XZY images for MCF-7 cells. Data are presented as means and SEMs (n=3 
experiments: cells > 25 for each) and were analysed by paired t-test. Significance: (*) P 
<0.05, (**)P<0.01. 
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Immunostaining of live control and KT5720-treated MDA-MB-231 cells with 
NESO-pAb antibody confirmed that PM nNavl.5 expression was indeed reduced by the 
KT5720 treatment (Figure 5.18). 
Cross-sectional analysis of MDA-MB-231 cells revealed that cells treated with KT5720 
typically had lower peaks of immunofluorescence at the edges (i.e. in PM) compared 
with controls (Figure 5.19A vs. B). On the other hand, the intracellular nNavl.5 protein 
expression was higher in KT5720-treated MDA-MB-231 cells, compared with control 
untreated cells (Figure 5.19A vs. B). The nNavl.5 immunoreactivity along the 'plasma 
membrane' region of the cross-section decreased after the KT5720 treatment from 3.3 ± 
0.2 % to 1.2 ± 0.1 % of total (P < 0.001; n=20 cells for each; Figure 5.20 left-hand 
bars). However, nNavl.5 immunoreactivity of the 'internal' region of the cross-section 
increased after the KT5720 treatment from 45.1 ± 1.4 % to 57.1 ± 1 % (P < 0.01; n = 20 
cells for each; Figure 5.20 right-hand bars). Thus, KT5720 treatment decreased PM and 
increased intracellular nNavl.5 protein expression, opposite to the effects of forskolin. 
The effects of KT5720 and the forskolin treatments were consistent with the 
hypothesis that VGSC can be regulated by PKA. 
5.2.3 Effects of TTX pre-treatment on VGSC expression 
MDA-MB-231 and MCF-7 cells were incubated with TTX (10 jiiM) for 24-48 hours, in 
order to chronically block all VGSC activity (Fraser et al., 2005). The TTX pre-
treatment did not effect cell viability compared to confrols after 24 hours (P = 0.31 for 
MCF-7 and P = 0.17 for MDA-MB-231 cells; n = 3 experiments: 30 field of views for 
each), or 48 hours (P = 0.57 for MCF-7 and P = 0.42 for MDA-MB-231 cells; n = 4 
experiments: 30 field of views for each; Table 5.1). Cells incubated with TTX (10 |J,M) 
did not show any noticeable change in cell morphology up to 48 hours of treatment 
compared with controls. 
5.2.3.1 Effects of TTX on nNavl.5 and Navl.7 mRNAs 
Pre-treatment with TTX for 24 and 48 hours significantly increased nNavl.5 mRNA 
levels in MDA-MB-231 cells by 147 % (P < 0.01; n = 3) and 122 % (P < 0.05; n - 5) 
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Figure 5.18 KT5720 decreased nNavl.5 protein level in plasma membrane of live 
MDA-MB-231 cells. 
(A) Plasma membrane nNavl.5 protein expression in control cells. (B) Signal intensity 
of ConA (green) plasma membrane marker and nNavl.5 (red) immunofluorescence 
along cross-section from a typical control cell. (C) Plasma membrane nNavl.5 protein 
expression in cells treated with KT5720 (500 nM; 48 h). (D) Signal intensity of ConA 
(green) plasma membrane marker and nNavl.5 immunoreactivity along cross-section 
from a typical KT5720 (500 nM) treated cell for 48 hours. Orange line indicates typical 
cross-sections. In B and D, the horizontal dashed line indicates the approximate level of 
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Figure 5.19 KT5720 shifted nNavl.5 immunoreactivity inward along typical 
cellular cross-sections in MDA-MB-231 cells. 
Traces show signal intensity of concanavalin A (ConA) plasma membrane marker 
(green line) and NESO-pAb (red line) immunofluorescence along cross-sections from a 
typical control cell (A) and a cell treated with KT5720 (500 nM; 48 h). Dotted grey lines 
and arrows indicate approximate levels of cytosolic and plasma membrane nNavl.5 
immunoreactivity, respectively. AU, arbitrary unit of flluorescence. 
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Figure 5.20 KT5720 decreased the relative proportion of nNavl.5 protein in plasma 
membrane and increased it intracellularly in MDA-MB-231 cells. 
The figure shows distribution of nNavl.5 protein (immunoreactivity) along subcellular 
cross-sections as a percentage of total (%). Left hand bars, 1.5 sections measured 
inward from the edge of ConA staining. Right-hand bars, middle 30 % of cross section. 
Black bars, control cells; white bars, cells treated with KT5720 (500 nM; 48 h). Data are 
presented as means and SEMs (n=20) and were analysed by Mann-Whitney Rank Sum 
test. Significance: (***) P < 0.001. INT: internal, PM: plasma membrane. 
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Figure 5.21 TTX decreased nNavl.5 mRNA level in MCF-7 cells but increased it in 
MDA-MB-231 cells. 
(A) Typical PGR products for nNavl.5 and cytochrome b5 reductase (CytSbR). Lanes 
are as follows: 
(1) MCF-7 control cells; 
(2) M C F - 7 cells pre-treated with TTX (10 |liM; 24 h); 
(3) MDA-MB-231 control cells; 
(4) MDA-MB-231 cells pre-treated with TTX (10 ^M; 24 h); 
(5) & (10) no-template control (NTC); 
(6) MCF-7 control cells; 
(7) MCF-7 cells pre-treated with TTX (10 p.M; 48 h); 
(8) MDA-MB-231 control cells; 
(9) MDA-MB-231 cells pre-treated with TTX (10 p,M; 24 h). 
(B) Relative nNavl.5 mRNA level in control MDA-MB-231 cells and cells treated with 
TTX (10 ^M; 24h & 48 h). 
(C) Relative nNavl.5 mRNA level in control MCF-7 cells and cells treated with TTX 
(10 |j,M; 24 h & 48 h). nNavl.5 mRNA level was normalized to Cytb5R by the 2-AACt 
method (with propagated errors; n > 5). Data were analysed by paired t-test. 
Significance; (*) P< 0.05, (**) P<0.01. 
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MCF-7 cells by 71 % (P < 0.05; n= 3) and 59 % (P < 0.01; n=4), respectively (Figure 
5.21 A & C). 
Similar treatment with TTX for 24 and 48 hours significantly decreased Navl.7 
mRNA level in MDA-MB-231 cells by 55 % (P < 0.05; n=3) and 27 % (P < 0.01; n=3), 
and in MCF-7 cells by 40 % (P < 0.01; n = 3) and 44 % (P < 0.05; n = 3), respectively 
(Figure 5.22). 
Typical agarose gels of rt-PCR products (Figure 5.21A and 5.22A) confirmed 
specific single bands at the expected size for nNavl.5, Navl.7 and CytbSR (219 nt, 389 
nt and 511 nt, respectively). The no-template control (NTC) did not amplify any signal 
(Figures 5.21A and 5.22A; lanes 5 and 10). Thus long-term suppression of VGSC 
activity had different effects on nNavl.5 and Navl.7 at mRNA level and these effects 
were dependent on cell type. 
5.2.3.2 Effects of TTX pre-treatment on VGSCa protein expression 
Western blots with pan-VGSCa and NESO-pAb antibodies were used to assess the 
effect of the TTX pre-treatment on whole cell total VGSCa and nNavl.5 protein levels 
MDA-MB-231 and MCF-7 cells. The TTX treatment did not alter the total VGSCa 
protein expression in either MDA-MB-231 cells (P = 0.39; n = 5) or MCF-7 cells (P = 
0.28; n = 5) (Figure 5.23C). The TTX treatment also did not affect the nNavl.5 protein 
levels in MDA-MB-231 cells (P = 0.76; n = 5) and MCF-7 cells (P = 0.26; n = 5) 
(Figure 5.23D). These effects of TTX were similar to those of KT5720 (section 5.2.2.2) 
and forskolin (section 5.2.1.2) 
5.2.3.3 Effects of TTX on subcellular nNavl.5 protein distribution 
Confocal immunocytochemistry with NESO-pAb antibody was used to determine if the 
TTX treatment would have any effect on the subcellular distribution of nNavl.5 protein 
in MCF-7 and MDA-MB-231 cells. 
Confocal images revealed a decrease of nNavl .5 expression in PMs of both 
MDA-MB-231 (Figures 5.24 and 5.25) and MCF-7 (Figure 5.26) cells after TTX pre-
treatment for 48 hours. However, the TTX treatment did not alter the polarised nature of 
nNavl.5 expression in MCF-7 cells (Figure 5.26). 
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Figure 5.22 TTX decreased Navl.7 mRNA level in both MCF-7 and MDA-MB-231 
cells. 
(A) Typical PGR products for Navl.7 and cytochrome b5 reductase (Cyt5bR). Lanes are 
as follows: 
(1) MCF-7 control cells; 
(2) MCF-7 cells pre-treated with TTX (10 p.M; 24 h); 
(3) MDA-MB-231 control cells; 
(4) MDA-MB-231 cells pre-treated with TTX (10 ^M; 24 h); 
(5) & (10) no-template control (NTC); 
(6) MCF-7 control cells; 
(7) MCF-7 cells pre-treated with TTX (10 pM; 48 h); 
(8) MDA-MB-231 control cells; 
(9) MDA-MB-231 cells pre-treated with TTX (10 p.M; 24 h). 
(B) Relative Navl.7 mRNA level in control MDA-MB-231 cells and cells treated with 
TTX (10 |iM; 24 h and 48 h). 
(C) Relative Navl.7 mRNA level in control MCF-7 cells and cells treated with TTX (10 
|iM; 24 h and 48 h). Navl.7 mRNA level was normalized to CytbSR by the 2-AACt 
method (with propagated errors; n = 3). Data were analysed by paired t-test Test. 





























Figure 5.23 TTX did not affect total VGSCa or nNavl.5 protein levels. 
(A) Western blots of total protein (60 p.g) extracts from MDA-MB-231 and MCF-7 
cells, using pan-VGSCa and NESO-pAb antibodies. Lanes: 1, Control cells; 2, treated 
cells with TTX (10 p,M) for 48 hours. (B) Relative total VGSCa protein level in both 
MDA-MB-231 and MCF-7 control cells and cells treated with TTX (10 pM; 48 h). (C) 
Relative total nNavl.5 protein level in both MDA-MB-231 and MCF-7 control cells and 
cells treated with TTX (10 (iM; 48 h). Data are presented as mean and SEM (n=5) and 
were analysed by paired t-test. 
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Figure 5.24 TTX altered subcellular distribution of nNavl.5 protein in MDA-MB-
231 cells. 
Typical XYZ confocal images of control cells (A & B) and cells treated with TTX (10 
|iM; 48 h) (C & D). Signal from concanavalin A (ConA) plasma membrane marker 
(green), NESO-pAb antibody (red) and overlays of both (merged image) are shown. 
White arrows in nNavl.5 images indicating plasma membrane staining. White lines in 
the merged images are indicating typical cross-sections used in digital analysis (data 
shown in figure 5.30). Scale bar (16 pm), applicable to all panels. 
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Figure 5.25 TTX altered plasma membrane expression of nNavl.5 protein in MDA-
MB-231 cells. 
Typical XZY confocal images of control cells (A & B) and cells treated with TTX (10 
HM; 48 h) (C & D). Signal from concanavalin A (ConA) plasma membrane marker 
(green), NESO-pAb antibody (red) and overlays of both (merged image) are shown. 
Scale bar (16 pm), applicable to all panels. 
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Figure 5.26 TTX altered plasma membrane expression of nNavl.5 protein in MCF-
7 cells. 
Typical XZY confocal images of control cells (A & B) and cells treated with TTX (10 
HM; 48 h) (C & D). Signal from concanavalin A (ConA) plasma membrane marker 
(green), NESO-pAb antibody (red) and overlays of both (merged image) are shown. 
Scale bar (16 jim), applicable to all panels. 
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Quantification by jfreeform line profile analysis of XYZ scans of MDA-MB-231 
cells (Figure 5.24) and XZY scans of MCF-7 cells (Figure 5.26) revealed a decrease in 
PM nNavl.5 immunoreactivity by TTX after 48 hours. The TTX treatment decreased 
nNavl.5 immunoreactivity in PM of MDA-MB-231 cells by 46 % and in PM of MCF-7 
cells by 30 % (P < 0.01 for both; n = 3: cells > 30 per experiment for both; Figure 5.27). 
These effects were similar to the effect of KT5720, but opposite to the effect of 
forskolin. 
Similar results were obtained when live control and TTX-treated MDA-MB-231 
cells were immunostained with NESO-pAb antibody. These results confirmed that PM 
nNavl .5 expression was indeed reduced by the TTX treatment (Figure 5.28). 
The second 'cross-section' method of quantifying relative PM and intracellular VGSCa 
immunoreactivity in MDA-MB-231 cells revealed that cells treated with TTX typically 
showed peaks of lower immunofluorescence at the edges (i.e. around the PM) compared 
to controls (Figure 5.29A vs. B). Furthermore, the levels of intracellular nNavl.5 protein 
expression were higher in the TTX-treated MDA-MB-231 cells, compared with controls 
(Figure 5.29A vs. B). The nNavl.5 immunoreactivity along the 'plasma membrane' 
region of the cross-sections decreased after the TTX pre-treatment, from 2.9 ± 0.4 % to 
0.65 ±0.1 % (P < 0.001; n=20 cells for each; Figure 5.30 left-hand bars). The 'internal' 
nNavl.5 immunoreactivity increased after the TTX treatment, from 44.4 ±1.9 % to 56.1 
± 1.3 % (P < 0.01; n = 20 cells for each; Figure 5.30 right-hand bars). 
Thus, pre-treatment with TTX, like KT5720, changed the balance of nNavl.5 
protein distribution in favour of PM, without affecting the total protein levels. Thus was 
similar to the effects of forskolin and KT5720 treatments. 
5.2.4 Effect of TTX pre-treatment on PKA phosphorylation 
Western blots on total protein extracts from control and TTX (10 fxM; 48 h) treated 
MDA-MB-231 cells was used to test the possible effect of TTX on the phosphorylation 
status of PKA using a phospho-PKA specific antibody. A control experiment confirmed 
that treatment with forskolin (50 p,M; 48 h) increased PKA phosphorylation (Figure 
5.31 A; lane 2). Importantly, treatment with KT5720 (500 nM; 48 h), had the opposite 































Figure 5.27 TTX decreased nNavl.5 protein levels in plasma membranes of MDA-
MB-231 and MCF-7 cells. 
nNavl.5 protein level (immunoreactivity) was measured around the edges of MDA-MB-
231 cells (A) and MCF-7 cells (B) under control conditions and following treatment 
with TTX (10 |j,M; 48 h). Data were obtained from XYZ images for MDA-MB-231 cells 
and from XZY images for MCF-7 cells. Data are presented as means and SEMs (n=3 
experiments: cells>30 for each) and were analysed by paired t-tests. Significance: (*) P 
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Figure 5.28 TTX decreased nNavl.5 protein level in plasma membrane of live 
MDA-MB-231 cells. 
(A) Plasma membrane nNavl.5 protein expression in control cells. (B) Signal intensity 
of ConA (green) plasma membrane marker and nNavl.5 (red) immunofluorescence 
along cross-section from a typical control cell. (C) Plasma membrane nNavl.5 protein 
expression in cells treated with TTX (10 |iM; 48 h). (D) Signal intensity of ConA 
(green) plasma membrane marker and nNavl.5 immunoreactivity along cross-section 
from atypical TTX (10 [xM; 48 h). Orange line indicates typical cross-sections. In B and 
D, the horizontal dashed line indicates the approximate level of nNavl.5 protein 
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Figure 5.29 TTX shifted nNavl.5 immunoreactivity inward along typical cellular 
cross-sections in MDA-MB-231 cells. 
Traces show signal intensity of concanavalin A (ConA) plasma membrane marker 
(green line) and NESO-pAb (red line) immunofluorescence along cross-sections from a 
typical control cell (A) and a cell treated with TTX (10 |iM; 48 h). Dotted grey lines and 
arrows indicate approximate levels of cytosolic and plasma membrane nNavl.5 
immunoreactivity, respectively. AU, arbitrary unit of fluorescence. 
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Figure 5.30 TTX decreased the relative proportion of nNavl.5 protein in plasma 
membrane and increased it intacellularly in MDA-MB-231 cells. 
The figure shows distribution of nNavl.5 protein (immunoreactivity) along subcellular 
cross-sections as a percentage of total (%). Left hand bars, 1.5 [im sections measured 
inward from the edge of ConA staining. Right-hand bars, middle 30 % of cross section. 
Black bars, control cells; white bars, cells treated with TTX (10 jiM; 48 h). Data 
presented as means and SEMs (n=20) and were analysed by Mann-Whitney Rank Sum 
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Figure 5.31 Forskolin and KT5720 treatment altered the level of phosphorylated 
PKA in MDA-MB-231 cells. 
The figure shows Western blots with (60 jag) of total protein extract per lane, using 
antibodies for phospho-PKA (A), PKA (B) and actinin (C) antibody as a loading control. 
Lanes are as follows: 
(1) control cells; 
(2) cells treated with forskolin (50 p.M; 48 h); 
(3) cells treated with KT5720 (500 nM; 48 h); 
(4) 3T3/A31 cell lysate (Upstate) as a positive control for PKA antibody (Lehman et al., 
2003). 
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Treatment with forskolin or KT5720 did not alter the basal levels of non-phosphorylated 
PKA protein (Figure 5.3 IB; lanes 1, 2 & 3). In 3T3/A31 cell lysates (Upstate), used as a 
positive control (Lehman et al., 2003), the PKA antibody indeed recognised a single 
band of the expected molecular size, -52 kDa (Figure 5.3 IB, lane 4). 
Treatment with TTX (10 |iM; 48 h) reduced the level of phosphorylated PKA in 
MDA-MB-231 cells by 31 % (P < 0.01; n=7; Figure 5.32). However, the TTX treatment 
did not change the basal level of PKA in the cells (P = 0.835; n = 8; Figure 5.33). 
These data were consistent with the hypothesis that activation of PKA by Na^ 
influx through VGSC could result in upregulation of VGSC expression (Brackenbury 
and Djamgoz, 2006b). 
5.2.5 Co-localisation of nNavl.5 and PKA in MCF-7 and MDA-MB-231 cells 
Confocal immunocytochemistry and double labelling with NESO-pAb and anti-PKA 
antibodies were used to investigate the possible co-localisation between nNavl.5 and 
PKA in MCF-7 and MDA-MB-231 cells (Figures 5.34-5.36). Control labelling 
experiments with one of the primary antibodies and both secondary confirmed that both 
antibodies were specific (Figure 5.34A & B). In both MDA-MB-231 cells (Figure 5.35) 
and MCF-7 cells (Figure 5.36), there was indeed some co-locaUsation of nNavl.5 
protein and PKA in cytosol. 
5.2.6 Functional studies 
Migration through a 12 pim-pore Transwell filter, invasion through Matrigel-coated 
chambers, cell proliferation and single cell adhesion were used as in vitro measures of 
metastatic potential (Grimes et al., 1995; Laniado et al., 1997; Fraser et al., 2005). TTX 
has being applied in three different ways as follows: (1) short-term (only during the 
assay ~8 h), (2) pre-treatment (48 h) and (3) pre-treatment and during the assay. 
Forskolin and KT5720 treatment was performed over 48 hour prior the assay as well as 












Figure 5.32 TTX reduced the level of phosphorylated PKA protein in MDA-MB-31 
cells. 
(A) Western blot with (60 ^g) of total protein extract per lane, using a phospho-PKA 
antibody and an actinin antibody as a loading control. Lanes are as follows: 
(1) control cells; 
(2) cells treated with TTX (10 jj.M; 48 h). 
(B) Relative levels of phosphorylated PKA in control cells and cells treated with TTX 

















Figure 5.33 TTX did not alter the basal levels of PKA protein in MDA-MB-231 
cells. 
(A) Western blot with (60 |ig) of total protein extract per lane, using a PKA antibody 
and an actinin antibody as a loading control. Lanes are as follows: 
(1) control cells; 
(2) cells treated with TTX (10 jiM; 48 h). 
(B) Relative levels of PKA in control cells and cells treated with TTX (10 [iM; 48 h). 
Data were presented as means and SEMs (n=8) and were analysed by paired t-test. 
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A. NESO-pAb + anti-rabbit + anti-goat 
Anti-PKA NESO-pAb BT 
B. Anti-PKA + anti-rabbit + anti-goat 
Anti-PKA NESO-pAb BT 
Figure 5.34 Immunocytochemistry controls for double staining with NESO-pAb 
and anti-PKA (MCF-7 cells). 
(A) Staining with NESO-pAb and both secondary antibodies (anti-rabbit and anti-goat) 
for NESO-pAb and anti-PKA. Signal from anti-PKA (green), NESO-pAb (red) and 
bright field images are shown. 
(B) Staining with anti-PKA and both secondary antibodies (anti-rabbit and anti-goat) for 
NESO-pAb and anti-PKA. Images from anti-PKA (green), NESO-pAb (red) and bright 
fields (BT) are shown. Scale bar (16 pm), applicable to all panels. 
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PKA nNav1.5 Merged image 
B. 
8 urn . 
Figure 5.35 PKA and nNavl.5 were co-localised in MDA-MB-231 cells. 
Typical confocal images of MDA-MB-231 cells immunostained with an anti-PKA and 
NESO-pAb antibody. Images of PKA protein (green), nNavl.5 protein (red) and overlay 
of the two (merged image) are shown (four examples of field of view, A-D). Panels A-
C, scale bar is 16 pm; panel D, scale bar is 8 |im. 
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PKA nNav1.6 Merged image 
B. 
D. 
Figure 5.36 PKA and nNavl.5 were co-localised in MCF-7 cells. 
Typical confocal images of MCF-7 cells immunostained with an anti-PKA and NESO-
pAb antibody. Images of PKA protein (green), nNavl.5 protein (red) and overlay of the 
two (merged image) are shown (four examples of field of view, A-D). Scale bar (16 
urn), applicable to all panels. 
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5.2.6.1 Effects on proliferation 
There was no significant effect on cell proliferation after 48 hours treatment with TTX 
(10 fiM; 48 h) in both MDA-MB-231 cells (P = 0.69; n = 8; Figure 5.37A) and MCF-7 
cells (P = 0.47; Figure 5.37B). KT5720 (500 nM; 48 h) also had no effect on 
proliferation of MDA-MB-231 cells (P = 0.17; n = 8) and MCF-7 cells (P = 0.13; n = 8) 
(Figure 5.37). Treatment with forskolin (50 p,M), or forskolin + TTX (10 p,M) or 
forskolin + KT5720 (500 nM) for 48 hours did not affect MCF-7 cell proliferation (P = 
0.46, P = 0.33 and P = 0.13, respectively; n = 8 each; Figure 5.37B). However, forskolin 
(50 pM) treatment reduced MDA-MB-231 cell proliferation by 16 % (P < 0.001; n = 8; 
Figure 5.37A). Similarly, co-treatment with forskolin + TTX (10 |liM) or forskolin + 
KT5720 (500 nM), also reduced MDA-MB-231 cell proliferation by 12 % (P < 0.001 
and P < 0.05, respectively; n = 8 each; Figure 5.37A). 
5.2.6.2 Short- and long-term effects of TTX on migration 
Short-term treatment with TTX (applied only during the assay) reduced the migration of 
MDA-MB-231 cells in a dose-dependent way (Figure 4.38). Thus, 1 |j.M TTX had no 
effect (P = 1.99; n = 7), 5 |iM TTX reduced migration by 25 % (P < 0.05; n = 7) whilst 
10 nM TTX reduced cell migration by 40 % (P < 0.01; n - 6; Figure 5.38A). In contrast, 
similar short-term TTX treatment had no effect on the migration of MCF-7 cells (Figure 
5.38B). 
Long-term pre-treatment with TTX (10 |xM; 48 h) significantly reduced the 
number of MDA-MB-231 cells that could subsequently migrate through the Transwell 
filter by 55 % (P < 0.01; n = 6; Figure 5.39A, bars 1 vs. 3). Interestingly, when TTX was 
applied additionally during the assays there was no further effect on migration, final 
migration being reduced by 63 % which was significant when compared to control 
(untreated) cells (P < 0.01; n = 6; Figure 5.39A, bars 1 vs. 4), but not significant when 
compared with TTX pre-treated cells (P = 0.51, n = 6; Figure 5.39A, bars 4 vs. 3) or 
non-pre- treated with TTX only during assay (P = 0.09, n = 6; Figure 5.39A, bars 4 vs. 
2). Thus, the VGSC-dependent component of migration was suppressed completely by 
the long-term treatment with TTX, consistent with the previous results that TTX reduced 
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Figure 5.37 Only forskolin treatment decreased cell proliferation in MDA-MB-231 
but not MCF-7 cells. 
Data are shown for MDA-MB-231 (A) and MCF-7 (B) control cells and cells treated 
with TTX (10 nM), forskolin (50 |xM), KT5720 (500 nM), forskolin + TTX (50 pM and 
10 jiM, respectively) and forskolin + KT5720 (50 |iM and 500 nM, respectively) were 
plated at the same density prior the assay and treated for 48 hours. Data were normalized 
to control (100 %) and presented as mean and SEM (n = 7). Data were analysed by 
paired t-test since each treatment was performed with a separate control. Significance: 
(*) P < 0.05, ( * * * ) P < 0.001, (X) P > 0.05. 
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Control 1 ijM 5 mM 10 mM 
Compar ison P<0.05 
Control vs 10 pM TTX Yes 
Control vs 5 [jM TTX Yes Control v s l p M TTX No 
1 mM TTX vs 10 ijM TTX Yes 
1 (jM TTX vs 5 |jM TTX Yes 
5 ijM TTX vs 10 ijM TTX Yes 
B. 
Control 10 |jM 
Figure 5.38 Short-term treatment with TTX reduced MDA-MB-231 cell migration 
in a dose response manner but it had no effect on MCF-7 cells. 
(A) The number of MDA-MB-231 cells migrating through a Transwell chamber over 8 
hours, expressed as % relative to the control. Cells were treated with different 
concentrations of TTX (1-10 (iM), as indicated, during the assay. Inset: Table of 
multiple comparisons between treatments for statistical significance. Data are presented 
as mean and SEM (n=7). Data were analysed by one way analysis of variance followed 
by Newman-Keuls test. (B) The number of MCF-7 cells migrating through a Transwell 
chamber over 8 hours, expressed as % relative to the control. Cells were treated with 10 
jiM TTX during assay. Data are presented as mean and SEM (n=7). Data was analysed 
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Figure 5.39 Long-term pre-treatment with TTX eliminated the VGSC-dependent 
potentiation of MDA-MB-231 cell migration. 
The number of cells migrating through a Transwell chamber over 8 hours, expressed as 
% relative to control. (A) MDA-MB-231 cells. Histobars: 1, control; 2, cells treated with 
TTX (10 )j,M) during the assay; 3, cells pre-treated with 10 |aM TTX for 48 hours (no 
TTX during the assay); 4, cells pre-treated with TTX (10 p.M; 48 h) and continued 
during the assay. (B) Black histobars: Control MDA-MB-231 and MCF-7 cells. White 
histobars: MDA-MB-231 and MCF-7 cells pre-treated with TTX (10 p.M; 48 continued 
during the assays). Data are presented as means and SEMs (n=6) and were analysed with 
two different statistical methods. Each treatment was done with a separate control, thus, 
comparison between each treatment with the control was analysed by paired t-test. 
Comparison between different treatments was analysed by ANOVA followed by 
Newman-Keuls test. Significance: (X) P > 0.05, (*) P < 0.05, (**) P < 0.01. 
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Interestingly, following the 48 hours TTX pre-treatment (also 10 p,M TTX added during 
the assays), the level of MDA-MB-231 cell migration was the same as that of MCF-7 
cells (P > 0.05; n = 6; Figure 5.39B & 5.40, bars 3[i] vs. l[ii]). TTX pre-treatment (10 
^M; 48 h, continued during assays) also reduced MCF-7 cell migration by 41 % (P < 
0.05; n = 6; Figure 5.39B & 5.40, bar 1 vs. 3). 
5.2.6.3 Effects of forskolin and KT5720 on migration 
Forskolin pre-treatment (50 jiM; 48 h, continued during assays) increased migration by 
82 % (P < 0.05; n = 6; Figure 5.40, bar 1 vs. 2) in MDA-MB-231 cells and by 57 % (P = 
0.01; n = 6; Figure 5.40, bar 1 vs. 2) in MCF-7 cells. KT5720 (500 nM) pre-treatment 
(48 hours continued during assays) decreased cell migration by 57 % (P < 0.05; n = 6; 
Figure 5.40, bars 1 vs. 4) in MDA-MB-231 cells, and by 67 % (P < 0.05; n = 6; Figure 
5.39, bar 1 vs. 4) in MCF-7 cells. Co-application of TTX (10 pM) + forskolin (50 jaM) 
for 48 hours (continued during assays) decreased migration by 62 % (P < 0.05; n = 6; 
Figure 5.40 bar 2 vs. 5), compared with forskolin-treated in MDA-MB-231 cells. 
MCF-7 cell migration was also reduced after co-application with TTX + 
forskolin by 68 % (P < 0.001; n = 6; Figure 5.40, bar 2 vs. 5) compared with forskolin 
treatment alone. Importantly, co-application with TTX + forskolin also reduced cell 
migration compared with controls in both MDA-MB-231 and MCF-7 cells by 32 % and 
52 %, respectively (P< 0.05; n = 6; Figure 5.40, bar 1 vs. 5, for both). However, there 
was no significant difference between co-application of TTX + forskolin and TTX 
treatment alone in both MDA-MB-231 and MCF-7 cells (P > 0.05; n = 6; Figure 5.40, 
bar 3 vs. 5, for both). Co-application of forskolin + KT5720 reduced migration 
compared to forskolin treatment alone in both MDA-MB-231 and MCF-7 cells by 76 % 
(P < 0.05; n = 6) and 74 % (P < 0.001; n = 6), respectively (Figure 5.40, bar 2 vs. 6, for 
both). Furthermore, co-application with KT5720 + forskolin reduced cell migration 
compared to control in both MDA-MB-231 and MCF-7 cells by 57 % and 40 %, 
respectively (P < 0.05; n = 6; Figure 5.40, bars 1 vs. 6, for both). However, there was no 
significant difference between KT5720 treatment and co-application with KT5702 + 
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Forskolin vs. TTX Yes Yes <0.001 
Forskolin vs. KT5720 Yes Yes <0.001 
Forskolin vs. (Forskolin + KT5720) Yes Yes <0.001 
Forskolin vs. (Forskoli + TTX) Yes Yes <0.001 
Forskolin vs. Control Yes Yes 0.012 
Control vs. TTX Yes Yes 0.029 
Control vs. KT5720 Yes Yes 0.043 
Control vs. (Forskolin + KT5720) Yes Yes 0.028 
Control vs. (Forskoli + TTX) Yes Yes 0.025 
(Forskolin + TTX) vs. TTX No No 0.862 
(Forskolin + TTX) vs. KT5720 No No 0.905 
(Forskolin + TTX) vs. (Forskolin + KT5720) No No 0.715 
(Forskolin + KT5720) vs. TTX No No 0.911 
(Forskolin + KT5720) vs. KT5720 No No 0.955 
KT5720 vs. TTX No No 0.725 
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Figure 5.40 TTX, forskolin and KT5720 treatments and their specific combination 
altered MDA-MB-231 and MCF-7 cell migration. 
The numbers of cells migrating through Transwell filter over 8 hours were expressed as 
% relative to MDA-MB-231 control. Histobars: 
(1) control cells; 
(2) cells treated with forskolin (50 p.M); 
(3) cells treated with TTX (10 p.M); 
(4) cells treated with KT572G (500 nM); 
(5) cells co-treated with Forskolin + TTX; 
(6) cells co-treated with forskolin and KT5720. 
All treatments were for 48 hours including during the assay. Inset: Tables of multiple 
comparisons between treatments for statistical significance in MCF-7 and MDA-MB-
231 cells. Data are presented as mean and SEM (n=6). Data were analysed by one way 
analysis of variance followed by Newman-Keuls test. 
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5.2.6.4 Effects of TTX on cell adhesion 
The "single-cell adhesion measuring apparatus" (SCAMA) was used to measure the 
adhesiveness of MDA-MB-231 and MCF-7 cells under control conditions and following 
short- and long-term treatment with TTX (10 |aM; 1-48 hours) (Figure 5.42-5.44). 
i. Control experiments 
A control experiment confirmed that adhesiveness of MDA-MB-231 and MCF-7 cells 
did not alter during the time (usually 15-20 min) of assaying (Figure 5.41 A). The mean 
values of "detachment negative pressure" (DNP; kPa) were calculated every 2 minutes 
from the start of the assay to the end and these were consistent throughout the 
experimental period (Figure 5.41A). Importantly, SCAMA identified a significant 
difference in the adhesiveness of MDA-MB-231 and MCF-7 cells, MCF-7 cells being ~ 
80 % more adhesive than the MDA-MB-231 cells (P < 0.001; n = 3; Figure 5.41B). In 
addition, MDA-MB-231 and MCF-7 cell adhesiveness did not change after 1 day or 2 
days post-plating the cells (P = 2.9; n = 3; Figure 5.41B) 
11. Lack of short-term effect 
TTX (10 fj.M) treatment for 1 hour did not alter cell adhesion in either MDA-MB-231 (P 
= 0.261; n = 3; Figure 5.42) or MCF-7 cells (P = 0.848; n = 3; Figure 5.42). 
iii. Long-term effects of TTX 
TTX treatment for 24 hours increased adhesiveness in MDA-MB-231 by 70 % (P < 
0.001; n = 3; Figure 5.43) and in MCF-7 cells just 8 % (P < 0.05; n = 3; Figure 5.43). 
TTX (10 (iM) treatment for 48 hours also increased cell adhesion in MDA-MB-231 cells 
by 93 % (P < 0.001; n = 3; Figure 5.44) and in MCF-7 cells by 21 % (P < 0.001; n = 3; 
Figure 5.44). Interestingly, TTX treatment for both 24 and 48 hours increased MDA-
MB-23 1 cell adhesiveness to the same levels as MCF-7 cells (control). There was no 
difference in adhesion between MDA-MB-231 cells treated with TTX (for 24 and 48 
hours) and untreated MCF-7 (P = 0.144 [24 h] & P = 0.402 [48 h]; n = 3 for both; 
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Figure 5.41 Cell adhesiveness did not change during the time the assay was 
performed (A) and MDA-MB-231 cells were less adhesive than MCF-7 cells (B). 
(A) Single cell adhesion (DNP [kPa]; detachment negative pressure) of MCF-7 (black 
line) and MDA-MB-231 (dashed line) was measured with SCAMA (single- cell 
adhesion measuring apparatus). The mean of DNP values every 2 minutes until the end 
of the assay was calculated .Date are presented as mean ± SEM (n = 20-40 cells). (B) 
MDA-MB-231 and MCF-7 cell adhesion did not change 1 or 2 days after plating the 
cells. Data were presented as means and SEMs (n = 3 experiments: 85 > cells from each 
experiment) and were analysed by unpaired t-test (when compared between the two 
















• TTX(1 h) 
MDA-MB-231 MCF-7 
Comparison P P<0.050 
MCF-7 control \^. MDA-MB-231 control 0.001 Yes 
MCF-7 control vs. MDA-MB-231 TTX 0.002 Yes 
MCF-7 control vs. MCF-7 TTX 0.848 No 
MCF-7 TTX vs. MDA-MB-231 control <0.001 Yes 
MCF-7 TTX vs. MDA-MB-231 TTX 0.001 Yes 
MDA-MB-231 TTX\^. MDA-MB-231 control 0.261 No 
Figure 5.42 Short-time (1 h) TTX treatment did not alter adhesiveness of MCF-7 or 
MDA-MB-231 cells. 
Single cell adhesion of control cells (black bars) and cells treated with TTX (10 ^M) for 
1 hour prior to assaying (white bars) was measured with the SCAMA (single- cell 
adhesion measuring apparatus). DNP (detachment negative pressure; kPa) values were 
normalised to the average cell surface area of MDA-MB-231 and MCF-7 cells, giving 
DNPR values (kPa/(im^) were plotted. Inset: Table of multiple comparisons between 
treatments for statistical significance. Data are presented as mean and SEM (n=3 
experiments; 85 > cells for each experiment) and were analysed by one way analysis of 
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• TTX (24 hs) 
MDA-MB-231 MCF-7 
Comparison P P<0.050 
MCF-7 TTX vs. MDA-MB-231 control <0.001 Yes 
MCF-7 TTX vs. I\/DAI\/B-231 TTX 0.007 Yes 
MCF-7 TTX vs. MCF-7 control 0.032 Yes 
MCF-7 control vs. MDA-MB-231 control <0.001 Yes 
MCF-7 control vs. MDAMB-231 TTX 0.144 No 
IVDAMB-231 TTX vs. MDAMB-231 control <0.001 Yes 
Figure 5.43 Long-term (24 h) pre-treatment with TTX increased adhesiveness of 
MDA-MB-231 and MCF-7 cells. 
Single cell adhesion of control cells (black bar) and cells treated with TTX (10 jiM) for 
24 hours prior to assaying (white bars) was measured with SCAMA (single-cell 
adhesion measuring apparatus). DNP (detachment negative pressure; kPa) values were 
normalised to the average cell surface area for MDA-MB-231 and MCF-7 cells and 
resulted DNPR values (kPa/^m^) of were plotted. Inset; Table of multiple comparisons 
between treatments for statistical significance. Data are presented as mean and SEM 
(n=3 experiments: 100 > cells for each experiment) and were analysed by one way 







Comparison P P<0.050 
MCF-7 TTX vs. MDA-MB-231 control <0.001 Yes 
MCF-7 TTX vs. MDA-MB-231 TTX <0.001 Yes 
MCF-7 TTX vs. MCF-7 control <0.001 Yes 
MCF-7 control vs. MDA-MB-231 control <0.001 Yes 
MCF-7 control vs. MDA-MB-231 TTX 0.402 No 
MDA-MB-231 TTX vs. MDA-MB-231 control <0.001 Yes 
Figure 5.44 Long term (48 h) pre-treatment with TTX increased adhesiveness of 
MDA-MB-231 and MCF-7 cells. 
Single cell adhesion of control cells (black bar) and cells treated with TTX (10 p,M) for 
48 hours prior to assaying (white bars) was measured with SCAMA (single-cell 
adhesion measuring apparatus). DNP (detachment negative pressure; kPa) values were 
normalised to the average cell surface area for MDA-MB-231 and MCF-7 cells and 
resulted DNPR values (kPa/|am^) of were plotted. Inset: Table of multiple comparisons 
between treatments for statistical significance. Data are presented as mean and SEM 
(n=3 experiments: 120 > cells for each experiment) and were analysed by one way 
analysis of variance followed by Newman-Keuls test. 
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In MDA-MB-231 cells, the population of cells that had distinctive low DNP 
values (i.e. that were less adhesive) was shifted towards higher DNP values after TTX 
treatment (Figure 5.45A). The frequency (%) of cells with the peak DNP value of 5 kPa 
was significantly reduced from 50 % to 19 % (P < 0.01; n = 3). However, there was no 
distinct population shift in MCF-7 cells after TTX treatment (Figure 5.45B). 
Furthermore, no distinct sub-populations were apparent in the DNP values of either cell 
line, before or after long-term (48 h) TTX treatment (Figure 5.45). 
5.2.6.5 Effects of TTX and forskolin on invasion 
Pre-treatment with TTX (10 p.M) for 48 hours (continued during the assays) inhibited 
Matrigel invasion by 51 % and 18 % in MDA-MB-231 and MCF-7 cells, respectively (P 
< 0.05; n = 9; Figure 5.46, bar 1 vs. 3, for both). Invasiveness of MDA-MB-231 cells 
following the TTX treatment became the same as control MCF-7 cells (P = 1.5; n - 6; 
Figure 5.46, bars l[i] vs. 3[ii]). 
Forskolin treatment (50 |j,M; 48 h continued during assays), increased 
invasiveness by 152 % and 90 % in MDA-MB-231 and MCF-7 cells, respectively (P < 
0.05; n = 9; Figure 5.46, bar 1 vs. 2, for both). Co-application of TTX + forskolin (both 
long-term) reduced invasiveness of MDA-MB-231 and MCF-7 cells by 50 % and 54 %, 
respectively compared to forskolin-treated cells (P < 0.05; n = 9; Figure 5.46, bar 2 vs. 
4). Invasiveness measured following co-application of TTX + forskolin was the same as 
the control level in both MDA-MB-231 and MCF-7 cells (P > 0.05; n - 9; Figure 5.46, 
bar 1 vs. 4). There was a significant difference between the effect of treatment with TTX 
and TTX + forskolin in both MDA-MB-231 and MCF-7 cells (P < 0.05; n = 9; Figure 
5.46, bar 3 vs. 4). MDA-MB-231 and MCF-7 cells co-treated with forskolin + TTX were 
more invasive by 152 % and 70 %, respectively compared to TTX treated cells ( P < 

















15 20 25 30 
DNP (kPa) 
40 45 
Figure 5.45 Long-term TTX pre-treatment (48 h) reduced the number of MDA-
MB-231 cells that exhibited low DNP values 
Single cell adhesion (DNP [kPa]; detachment negative pressure) of control cells (black 
line) and cells treated with TTX (10 |iM) for 48 hours prior the assay (dashed line) was 
measured with SCAMA (single- cell adhesion measuring apparatus) for MDA-MB-231 
(A) and MCF-7 (B) cells. Data plotted as a percentage distribution showing peaks. Data 
are presented as mean ± SEM (n = 3 experiments: 100 cells for each experiment). 


















4. Forskolin + TTX 
J L 
1 2 3 
(ii) MCF-7 
Comparison P<0.05 
Forskolin vs. TTX Yes 
Forskolin vs. CNTRL Yes 
Forskolin vs. (forskolin + TTX) Yes 
(Forskolin + TTX) vs. TTX Yes 
(Forskolin + TTX) vs. Control No 
Control vs. TTX Yes 
Figure 5.46 TTX and forskolin treatments altered MCF-7 and MDA-MB-231 cell 
invasiveness. 
The number of cells invaded through a Matrigel chamber over 48 hours expressed as % 
relative to MDA-MB-231 control. Histobars: 1, control cells; 2, cells treated with 
forskolin (50 |J.M); 3, cells treated with TTX (10 |J.M); 4, cells co-treated with forskolin 
and TTX. All treatments were for 48 hours during the assay. Inset: Tables of multiple 
comparisons between treatments for statistical significance in both MCF-7 and MDA-
MB-231 cells. Data are presented as mean and SEM (n=9) and were analysed by one 
way analysis of variance followed by Newman-Keuls test. 
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5.3 Discussion 
The main findings of this study are as follows: 
(1) PKA activation by forskolin increased nNavl.5 mRNA and PM protein expression 
without affecting the total protein levels in MCF-7 and MDA-MB-231 cells. 
(2) Inhibition of PKA by KT5720 decreased nNavl.5 mRNA and PM protein expression 
without any effect on the total protein level in MCF-7 and MDA-MB-231 cells. 
(3) There was some co-localisation of PKA and nNavl.5 proteins in both MCF-7 and 
MDA-MB-231 cells, mainly intracellularly. 
(4) Long-term (48 h) VGSC blockage with TTX reduced nNavl.5 mRNA in MCF-7 
cells but increased it in MDA-MB-231 cells. 
(5) Long-term (48 h) VGSC blockage with TTX did not affect total protein levels in 
either MCF-7 or MDA-MB-231 cells but decreased PM nNavl.5 expression in both. 
(6) Long-term (48 h) VGSC blockage with TTX reduced PKA activity in MDA-MB-231 
cells. 
(7) Long-term (48 h) VGSC blockage by TTX completely suppressed the VGSC-
dependent component of in vitro migration in MDA-MB-231 cells. 
(8) Activation of PKA by forskolin increased MDA-MB-231 and MCF-7 cell migration 
and invasion in vitro but the effect was abolished when cells were co-treated with 
forskolin and TTX 
(9) Long term (24-48 h) VGSC blockage with TTX increased MDA-MB-231 and MCF-
7 cell adhesion; short term (1 h) treatment had no effect. 
The effects of long-term (48 h) treatment with forskolin, KT5720 and TTX on 
VGSCa (total and nNavl.5) mRNA and protein expression are summarized in Table 5.2. 
5.3.1 VGSC regulation at mRNA and protein levels 
5.3.1.1 Effects of TTX: auto-regulation 
In MDA-MB-231 cells, long-term (24-48 h) treatment with TTX increased nNavl.5 
mRNA levels. Surprisingly, in MCF-7 cells similar treatment with TTX had the opposite 
effect, reducing nNavl.5 mRNA levels. Navl.7 mRNA expression was reduced in both 
MDA-MB-231 and MCF-7 cell lines. The phenomenon, of TTX having opposite effects 
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Table 5.2 Effects of long term (48 h) treatment with forskolin, KT5720 and TTX on 
VGSCa expression in human BCa cell lines. 
The working concentrations used for the treatments were as follows: Forskolin: (50 
;M); KT5720: (500 nM); TTX: (10 pM). 
nNavl .5 Nav1.7 Total VGSCa 
mRNA Protein mRNA Protein 
Treatment Total PM INT Total PM INT 
Forskolin + 0 + - n/t 0 + -
KT5720 - 0 - + n/t 0 n/t n/t 
TTX + (MDA) / - (MCF) 0 - + - 0 n/t n/t 
Key: 
nNav 1.5: neonatal Nav 1.5; 




0: no change; 
n/t: not tested; 
MDA: MDA-MB-231 cells; 
MCF: MCF-7 cells. 
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on mRNA levels in different cancer cell lines has been documented before (Mycielska et 
al., 2005; Brackenbury and Djamgoz, 2006b). Long term TTX treatment (24-48 h) 
increased Navl.7 mRNA level by about 2.5 fold in strongly metastatic human prostate 
cancer (PC-3M) cells (Mycielska et al., 2005), but decreased Navl.7 mRNA by 52 % in 
strongly metastatic rat prostate cancer (Mat-LyLu) cells (Brackenbury and Djamgoz, 
2006b). It is also possible, however, that VGSC activity-dependent regulation is species 
dependant. It is interesting that TTX had opposite effects on the two human BCa cell 
lines (MCF-7 and MDA-MB-231), possibly indicating the existence of multiple auto-
regulatory mechanisms for VGSC transcription, depending on the metastatic potential of 
the cell. 
The mechanism(s) by which long term (24-48 hs) TTX treatment could affect 
VGSC transcription it is not well understood. However, taking the previously published 
evidence together, it is possible that intracellular Na"^  concentration could activate 
intracellular enzymes that might regulate gene transcription (Page and Di Cera, 2006). 
The present study indeed showed that Na^ could directly increase PKA activity (Cooper 
et al., 1998; Murakami et al., 1998; Brackenbury, 2006). Furthermore, Brackenbury and 
Djamgoz (2006) as well as the present study have shown that PKA activity could 
upregulate VGSC transcription in rat PCa and human BCa cell lines, respectively. PKA 
activation can lead to translocation of its catalytic subunit to the nucleus where 
regulation of gene transcription can occur (Asyyed et al., 2006). There are a number of 
other studies that showed regulation of gene transcription (e.g. VGSC, vitamin D 
hydroxylases, type I interferons) by cAMP-dependant PKA signalling (Offord and 
Catterall, 1989; Avila et al., 2006; Benjanirut et al., 2006; Collado-Hidalgo et al., 2006). 
Therefore, a possible mechanism of action might be that blokadge of VGSC by TTX, 
would lead to a decrease in Na"^  influx, reduced PKA activity and alter VGSC gene 
expression. Another possibility is that the reduction of intracellular Na"^  concentration 
would lead to an increase of intracellular Ca^^ and thus control transcriptional events 
(Berridge et al., 2003; Berridge, 2006). 
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5.3.1.2 Involvement of PKA 
Forskolin is a drug used for PKA activation via stimulation of the secondary messenger 
CAMP synthesizing enzyme AC and has been used previously in studies on VGSC 
expression (Zhou et al., 2000; Zhou et al., 2002; Brackenbury, 2006). KT5720 is a 
potent membrane-permeable inhibitor of PKA, that directly inhibits PKA and it does 
not have a significant effect on other protein kinases, such as PKC and PKG (Kase et al., 
1987; Gadbois et al., 1992; Cabell and Audesirk, 1993; Simpson and Morris, 1995). 
Long term treatment with KT5720 caused almost complete loss of phosphorylated PKA, 
suggesting that it is indeed a very potent drug whivh may inhibit a variety of PKA 
subtypes. The effectiveness of KT5720 has been shown previously on a variety of cells 
(Ungefroren et al., 1997; Yang et al., 2003; Yoshida et al., 2005; Brackenbury, 2006). In 
this study, it was assumed that KT5720 inhibited all PKA phosphorylation sites on 
nNavl.5 protein. 
Long-term (48 h) treatment with forskolin increased nNavl.5 mRNA expression 
in both MDA-MB-231 and MCF-7 cells. Similar treatment with KT5720 had the 
opposite effect in both cell lines, reducing the nNavl.5 mRNA level. A similar result 
was obtained from Mat-Lylu rat PCa cells, where KT5720 treatment reduced the 
predominant Navl.7 mRNA level (Brackenbury and Djamgoz, 2006b). However, co-
treatment with KT5720 + TTX did not produce a cumulative effect suggesting that both 
VGSC blockage and inhibition of PKA affected the same component(s) of the cellular 
signalling, as concluded also for rat PCa cells by Brackenbury and Djamgoz (2006). 
The finding that PKA protein was co-localised with nNavl.5 in both MCF-7 and 
MDA-MB-231 cells would suggest that the two proteins are in a macromolecular 
complex and that nNal.5 might be regulated by PKA even under control conditions. 
This co-localisation may also relate to (1) efficiency of nNavl.5 phosphorylation 
(Marban et al., 1998); (2) spatial specificity and directionality of this micromolecular 
complex (PKA-nNavl.5); (3) nNavl.5 protein recycling via ubiquitinylation (Hoang et 
al., 2004; Hino et al., 2005; Tempe et al., 2006); and (4) regulation of nNavl.5 traffic to 
PM along the exocytic route (Muniz et al., 1996; Muniz et al., 1997). 
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5.3.1.3 mRNA vs. protein level regulation 
Interestingly, the effect of forskolin, KT5720 and TTX treatments on nNavl.5 mRNA 
expression in both MDA-MB-231 and MCF-7 cells were not reflected on the nNavl.5 
protein level in either cell line. The reason(s) for this is not clear at present. However, 
there is evidence suggesting that mRNA regulation and protein levels can be controlled 
by separate pathways (Orphanides and Reinberg, 2002). Post-transcriptional/pre-
transcriptional regulatory mechanisms include protein trafficking and mRNA docking 
and/or localisation (Tiedge et al., 1999; Ben Fredj et al., 2004; St Johnston, 2005). For 
example, intracellular localisation/transport of mRNA by motor proteins is a common 
mechanism for targeting proteins to specific regions of the cell whilst preventing its 
expression elsewhere (St Johnston, 2005). Furthermore, protein translation can be a 
result of not only newly synthesized mRNA but can occur from pre-docked mRNA 
stored intracellularly (Bassell and Twiss, 2006). Such a theory might especially be 
important in cancer cells that may require fast processing/regulation of proteins. mRNA-
protein mismatches also occur pathophysiologically. A variety of studies in a range of 
disease conditions (e.g. rheumatoid arthritis, psoriasis, B-chronic lymphoproliferative 
disorders, prostate cancer), have reported a discrepancy between mRNA and protein 
expression (Sola et al., 1999; Schedel et al., 2004; Sano et al., 2005; Brackenbury and 
Djamgoz, 2006b; Gu et al., 2006). Studies on rheumatoid arthritis and tumour cells from 
patients with B-chronic lymphoproliferative disorders have speculated that the contrast 
between mRNA and protein expression may indicate a post-transcriptional dysregulation 
or conformational protein alterations due to unknown mutations (Sola et al., 1999; 
Schedel et al., 2004). 
5.3.2 Trafficking of VGSC protein 
TTX, KT5720 and forskolin treatments did not affect total VGSCa protein levels but did 
alter subcellular distribution of nNavl.5 protein in MCF-7 and MDA-MB-231 cells, 
promoting expression in PM. MDA-MB-231 cells were mainly used for these 
experiments, the reason being that these cells express functional VGSCs, at high levels 
both nNavl.5 mRNA and protein (Fraser et al., 2005). In contrast, MCF-7 cells express 
only a low level nNavl.5 protein in PM and only in the apical membrane. Thus, analysis 
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of subcellular distribution of nNavl.5 protein in MCF-7 cells with confocal microscopy 
was difficult and, in fact, PM staining was almost undetectable in XYZ images. 
TTX and KT5720 pre-treatments for 48 hours reduced nNavl.5 expression in 
PM, with an associated increase of intracellular protein in MDA-MB-231 cells. The 
levels of intracellular nNavl.5 protein expression often reached the saturation level of 
confocal imaging, which would result in an underestimation of the real percentage 
increase (Figures 5.19B and 5.29B). However, in order to visualise low levels of PM 
staining in the TTX- or KT5720-treated cells, the laser settings could not be reduced 
further (e.g. Figure 5.29B). Thus, blockage of VGSC/nNavl.5 activity (as well as 
inhibition of PKA) in MDA-MB-231 cells resulted in inhibition of nNavl.5 protein 
trafficking to PM, and nNavl.5 protein was retained in internal membranes without 
changing the net protein expression. These data are consistent with the hypothesis that 
these treatments altered nNavl.5 protein recycling. The same conclusion was reached in 
another study, in which the effects of long-term TTX treatment was investigated on Mat-
Lylu cells (Brackenbury and Djamgoz, 2006b). The latter study also found that TTX 
treatment reduced VGSC current density after 24 hours pre-treatment, as well as 
inhibiting VGSC protein trafficking to PM, by altering the recycling balance of VGSC 
protein in favour of 'intemalisation'. 
Forskolin treatment for 48 hours had the opposite effect, upregulating nNavl.5 
protein expression in PM and decreasing the intracellular level of nNavl.5 protein. This 
result would further suggest that activation of PKA would trigger nNavl.5 protein 
trafficking from intracellular stores to PM. Interestingly, a previous study has shown that 
activation of PKA altered Navl.5 by both a direct effect on channel function and an 
indirect effect on protein recycling in Xenopus oocytes (Zhou et al., 2000). Thus, PKA 
stimulation appeared to modulate trafficking of Navl.5 and to increase VGSC 
expression in PM. These findings suggested a novel mechanism by which cardiac cells 
may regulate endogenous Navl.5 currents that may also apply to human BCa cells. 
Another study also showed that PKA activation caused increase of VGSC current in PM 
of Xenopus oocytes (Frohnwieser et al., 1997). Furthermore, PKA activation has been 
found to increase functional VGSC expression in the PM of rat cardiomyocytes (Lu et 
al., 1999). It would be of interest to explore if the nNavl.5 PM protein upregulation after 
forskolin treatment is also functional, especially in the weakly metastatic MCF-7 cells. 
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The present study examined this issue in functional studies by co-application of 
forskolin + TTX. However, electrophysiological studies on MCF-7 and MDA-MB-231 
cells treated with forskolin could give further insights to this issue. 
The presence of signal peptides in the VGSC protein sequence might also be 
involved in VGSC protein trafficking. It has being demonstrated that both 
phosphorylation of Navl.5 and the presence of an ER retention signal were required for 
PKA-mediated increase in functional Navl.5 expression (Zhou et al., 2002). 
Interestingly, PKA mediated an increase in functional expression of Navl.5 in PM, but 
the effect was eliminated when the ER retention motif was altered (Zhou et al., 2002). 
Thus, PKA activity could mask the ER retention motif (Herfst et al., 2004). 
5.3.2.1 VGSC interaction with other proteins 
Interaction of VGSC with other proteins might also facilitate its trafficking. Syntrophins, 
which mediate interactions so as to adapt different proteins (e.g. protein kinases or ion 
channels), have PDZ domains and can interact with Navl.4 and Navl.5 that also have 
PDZ-binding domains in their C-terminals (C-Ts) (Gee et al., 1998; Abriel and Kass, 
2005). Interactions between Navl.5 C-T and syntrophin PDZ domain in HEK-293 cells 
reduced membrane currents (Ou et al., 2003; Chahine et al., 2005). In a recent review, 
Abriel et al. (2005) speculated that the association of VGSCa with syntrophin might be 
important for targeting or stabilization of Navl.5 in PM. Mutation studies determined 
that ankyrin-G facilitated normal trafficking of Navl.5 (Mohler et al., 2004a). It has also 
been suggested that ankyrin-G could anchor VGSCas to PM (Garrido et al., 2003). 
Ubiquitin is a protein that plays a key role in trafficking, internalization, 
lysosomal or proteasomal degradation of membrane proteins, including VGSCa (Abriel 
et al., 2000; Hicke and Dunn, 2003; Abriel and Kass, 2005). Any change in the balance 
between synthesis and degradation of VGSC protein can control the expression levels of 
functional VGSCs in PM (Herfst et al., 2004). Ubiquitin-dependent internalization and 
degradation of VGSCs have been shown to control PM expression of Navl.5 (Abriel et 
al., 2000; Herfst et al., 2004). Interaction of Navl.5 with ubiquitin protein ligase Nedd4 
reduced the expression of Navl.5 in PM possibly by ubiquitinylation of the protein and 
subsequent endocytosis (Abriel et al., 2000; van Bemmelen et al., 2004). Nedd4-2 also 
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increased the internalization rate of Navl.5 in HEK293 cells (Rougier et al., 2005). 
Interestingly, there is evidence that PKA could regulate ubiquitinylation (Hoang et al., 
2004; Hino et al., 2005; Tempe et al., 2006). A recent study showed that 
phosphorylation of Gli3 (a zinc finger protein) by PKA led to ubiquitinylation (Tempe et 
al., 2006). Furthermore, ubiquitinylation of GRIPl (glucocorticoid receptor-interacting 
protein) was increased by activation of PKA in COS-1 cells (Hoang et al. 2004). 
Another study demonstrated that phosphorylation of P-catenin by PKA could inhibit the 
ubiquitinylation of P-catenin (Hino et al., 2005). Furthermore, it has previously been 
demonstrated that phosphorylation of the C-T could alter the affinity of ENaC for 
ubiquitin protein ligase (Nedd4) binding, which could affect the rate of intemalisation 
(Dinudom et al., 2004; Anantharam et al., 2006; Rauh et al., 2006). It is possible, 
therefore, that PKA activation in MDA-MB-231 and MCF-7 cells might also regulate 
ubiqutinylation of nNavl .5. 
5.3.3 Involvement of PKA in VGSC autoregulation 
Treatment of MDA-MB-231 cells with TTX for 48 hours reduced the levels of 
phosphorylated PKA in the cells. These results are consistent with previous studies that 
showed Na"^  (permeated by VGSC activity) could directly elevate cAMP levels and 
hence increase PKA activity (Cooper et al., 1998; Murakami et al., 1998). Indeed, 
Brackenbury and Djamgoz (2006) showed that chronic (48 h) TTX treatment decreased 
PKA activity in Mat-LyLu rat prostate cancer cells. The latter study also demonstrated 
that short- and long-term effects of PKA affected fimctional VGSC expression/activity 
through direct phosphorylation of VGSCs (short-term) or increased PM VGSC 
availability (long-term) (Brackenbury and Djamgoz, 2006b). The exact mechanism(s) 
involved in the observed affect of TTX treatment on PKA phosphorylation is not clear. 
However, it has been demonstrated that Na^ can activate a range of intracellular 
enzymes, consistent with the finding that VGSC blockage would downregulate 
phosphorylated PKA (Page and Di Cera, 2006). 
The long-term effects that activation or inactivation of PKA had on the 
availability of nNavl.5 protein in PMs of MCF-7 and MDA-MB-231 cells are 
comparable to previous evidence that PKA can modulate trafficking of proteins (Muniz 
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et al., 1996; Muniz et al., 1997). Earlier studies showed that PKA activity could regulate 
budding of vesicles from the trans-Go Igi network along the exocytic route to PM (Muniz 
et al., 1996; Muniz et al., 1997). Furthermore, chronic (>12 h) treatment with forskolin 
and agents (e.g. 8-bromo-cyclic AMP) that mimic cyclic AMP (cAMP) action or 
increase intracellular cAMP levels increased VGSC density in rat muscle cells 
(Sherman et al., 1985). Similarly, treatment of cultured bovine adrenal chromaffin cells 
with forskolin increased [^HjSTX binding to PM, and the effect was abolished by H-89, 
an inhibitor of PKA (Yuhi et al., 1996). There is evidence suggesting that PKA can also 
be involved in transcriptional processes. For example, long-term (8 days) treatment with 
8-br-cycIic AMP, increased VGSCa mRNA expression in developing rat muscle cells 
(Offord and Catterall, 1989). 
5.3.4 VGSC regulation and control of metastatic cell behaviour 
Long-term (48 h) treatment with TTX or KT5720 had no effect on MDA-MB-231 and 
MCF-7 cell proliferation. Similarly, long-term (48 h) treatment with forskolin did not 
effect cellular proliferation in MCF-7 cells. However, similar treatment with forskolin 
inhibited MDA-MB-231 cell proliferation by 16 %, thus, underestimating the positive 
effect of forskolin on cell invasion assays, which run for 48 hours. There is evidence that 
activation of PKA could suppress the proliferation of many cell types, and increase cell 
growth of endocrine cells (Hino et al., 2005). A recent study showed that PKA activation 
decreased cell proliferation in human thyroid cancer cells (Calebiro et al., 2006). 
Surprisingly, long-term (48 h) co-treatment with forskolin + TTX, and forskolin + 
KT5720 did not reverse the effect of forskolin on MDA-MB-231 proliferation, 
indicating the complexity of control of cell proliferation and also suggesting some 
VGSC-independent effects of PKA. However, proliferation was not a main concern of 
the present study, and it is generally assumed that proliferation in not strictly a 
"metastatic cell behaviour". In fact, proliferation was studied mainly as a control for the 
invasion assays. Since the latter iim over 48 hours, it was important to verify that any 
observed effect in invasiveness, after treatment, was not due to a change in proliferative 
activity. 
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Cell migration and invasion in vitro were decreased after TTX treatment in both 
MDA-MB-231 and MCF-7 cells, consistent with the involvement of VGSC 
activity/expression in enhancing metastatic cell behaviour (MCB). Previous studies have 
also demonstrated the involvement of VGSC in carcinomas, both in vitro (Laniado et al., 
1997; Grimes and Djamgoz, 1998; Bennett et al., 2004; Eraser et al., 2004b; Fraser et al., 
2005; Brackenbury and Djamgoz, 2006b) and in vivo (Diss et al., 2005; Fraser et al., 
2005). The present study also showed that TTX treatment reduced MDA-MB-231 cell 
migration and invasion to the same levels as MCF-7. Another potentially significant 
finding of this study is that the VGSC-dependent component of migration was 
suppressed completely by long-term treatment with TTX, consistent with autoregulation 
by positive feedback of nNavl.5 protein expression in PM. 
Further evidence for involvement of PKA in VGSC regulation comes from the 
results on in vitro cell migration and invasion assays. Thus, migration and invasion of 
both MDA-MB-231 and MCF-7 cells were significantly increased after long-term (48 h) 
pre-treatment with forskolin but the effect was abolished when cells were co-treated 
with forskolin + TTX, suggesting that cell migration and invasion were indeed VGSC 
dependent and the effect of forskolin occurred through VGSC activity. Importantly, after 
long-term co-treatment with forskolin + TTX, migration of both MDA-MB-231 and 
MCF-7 cells were reduced to a level even lower than the respective controls, similar to 
the levels of TTX pre-treated cells. This result would further support the view that the 
effect of forskolin on MDA-MB-231 and MCF-7 cell migration was primarily through 
VGSC. However, the fact that the levels of MDA-MB-231 and MCF-7 cell invasion 
after TTX + forskolin co-application were not lower than the respective controls would 
suggest that the effect of forskolin on invasion involved additional cellular signalling 
pathways. Interestingly, forskolin treatment slightly decreased MDA-MB-231 cell 
proliferation over the 48 hours of analysis, thereby suggesting that its effect on invasion 
was probably underestimated. 
For the first time, the present study also demonstrated the involvement of VGSC 
expression/activity in single cell adhesion. Long term pre-treatment (24-48 h; also 
continued during the assay) with TTX increased cell adhesion in both MDA-MB-231 
and MCF-7 cells. Importantly, long-term TTX pre-treatment of MDA-MB-231 cells 
increased the level of cellular adhesiveness to that of the weakly metastatic MCF-7 cells. 
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Taken together, these data suggest that long-term (24-48 h) blockage of VGSC activity 
by TTX can significantly reduced the metastatic potential of BCa cells. 
5.3.5 A model of regulation of VGSC expression in PM 
The main conclusions of this study are as follows: 
(1) Activation of PKA increased nNavl.5 protein expression in PM, and thus 
enhanced MCBs, including invasiveness. 
(2) Functional VGSC expression was involved auto-regulation by positive feedback, 
via PKA. 
Taking the available evidence together, the following possible mechanism of VGSC 
regulation involving PKA can be proposed (Figure 5.47). Essentially, forskolin activates 
PKA by stimulating AC, which in turn generates cAMP. The downstream effects of 
PKA can be as follows: 
(1) Direct. PKA can phosphorylate intracellular stored and/or PM VGSCa protein. 
Direct phosphorylation of intracellular VGSCa could lead to translocation of the 
protein to PM thereby giving rise to the observed increased PM expression. Direct 
phosphorylation of VGSCa already expressed on PM would lead to reduction of 
channel activity (Cantrell and Catterall, 2001; Brackenbury and Djamgoz, 2006b). 
(2) Indirect. By interacting with other protein(s) and/or signalling mechanisms 
(indicated as 'X'; Figure 5.47), PKA can induce trafficking of the intracellular 
VGSCa. The nature of 'X' is not known at present but could involve some 
cytoskeletal components. PKA can also interact with P-subunit(s) which are known 
to control expression/stability of VGSCa in PM (Kazarinova-Noyes et al, 2001; 
Chen et al., 2002). 
This model also has intrinsic positive feedback capacity. Na"^  entering via VGSC activity 
could itself stimulate AC (Cooper et al., 1998; Murakami et al., 1998). Thus, under a 
given set of conditions, VGSC would be expressed in the steady-state, in balance with 
the various controlling mechanisms. The steady-state level of VGSC expression/activity 
could change if the functional states of one of the components is altered. For example, 
enhancing PKA activity with forskolin could give rise to increased expression of VGSC 
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Minor/additional pathways 
Feed-back pathways 
Figure 5.47 Possible mechanism of VGSC expression/activity through PKA (cAMP-
dependant) pathway. 
Activation of protein kinase A (PKA) (by Na^ influx) would stimulate intracellular 
VGSC protein to traffic to the plasma membrane (PM) and thus increase metastatic cell 
behaviour (MCB). PKA can interact directly with intracellular and/or PM VGSCs by 
phosphorylation or indirectly through other mechanism(s) (X). The latter can be 
transcriptional or represent interaction with other proteins, thus initiating a separate 
signalling cascade. The net effect is control of VGSC expression in PM and MCBs. The 
effect of Na"^  influx via VGSC activity could result in a positive feedback effect. 
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5.3.6 Clinical implications 
Previous studies on human BCa cells with different metastatic potential proposed that 
VGSC upregulation occurs as an integral part of the metastatic process (Eraser et al., 
2005), similar to the situation shown earlier for prostate cancer (Grimes et al., 1995; 
Laniado et al., 1997; Bennett et al., 2004). Eraser et al. (2005) also showed the 
correlation between expression of the neonatal splice variant of Navl.5 in vivo with BCa 
biopsy tissues and lymph node metastasis. Thus, apart from being a potential metastatic 
marker in BCa, nNavl.5 may also have therapeutic potential. It has already been 
reported that Navl.5 is linked to some forms of heart disease and arrhythmia, and thus, 
is a therapeutic target of anti-arrhythmic and anti-convulsant drugs (Jongsma, 1998; 
Glaaser and Clancy, 2006). 
Various studies have demonstrated that VGSC activity contributes to cellular 
behaviors that would be involved in metastasis generally, such as migration (Eraser et 
al., 2003c; Eraser et al., 2004b; Eraser et al., 2005; Brackenbury and Djamgoz, 2006b; 
Eulgenzi et al., 2006), cellular process extension (Eraser et al., 1999), secretory 
membrane activity (Mycielska et al., 2003) and invasion (Grimes et al., 1995; Laniado et 
al., 1997; Smith et al., 1998). In this study, for the first time, VGSC activity was also 
linked with cell adhesion. 
VGSCs may contribute to the excitability of the membrane of metastatic cells, 
and this may explain the hyperactivity of these cells in terms of metastatic behaviour. 
This study demonstrated that suppression of VGSC activity by long term (48 hours) 
TTX treatment completely abolished the VGSC-dependent component of the MDA-MB-
231 cells migration. Therefore, it may be possible with the use of VGSC blockers to 
suppress or even to reverse metastasis. Whilst it is promising that VGSCa may play a 
role in BCa metastasis, this needs to be studied further, including in in vivo. Since this 
field is new and promising, further investigation could generate interesting results and 
possible clinical applications. 
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Chapter 6; BETA SUBUNITS OF VGSC-EXPRESSION, 
ROLE IN ADHESION, MIGRATION AND INTERACTION 




Voltage gated Na"^  channel a-subunits (VGSCots) are usually associated with one or 
more modulatory VGSCp-subunits (Catterall, 1992). Up to now, five VGSCp subunits 
have been identified: VGSCpl/SCNlB and VGSCpiA a splice variant of the SCNIB 
gene (Qin et al, 2003), VGSCp2/SCN2B (Catterall, 1992), VGSCp3/SCN3B (Morgan 
et al, 2000) and VGSCp4/SCN4B (Yu et al, 2003). VGSCp 1 and VGSCp3 have the 
highest homology between them and are both associated noncovalently with the a-
subunit (Isom et al., 1992; Morgan et al, 2000). Similarly, VGSCp2 and VGSCP4 also 
have sequence similarities and they are disulfide-linked with the a-subunit (Isom et al, 
1995; Yu et al, 2003). 
VGSCP-subunits (32-42 kDa) are glycoproteins with one transmembrane 
segment. They have a large extracellular N-terminal and a smaller intracellular C-
terminal domain (Hanlon and Wallace, 2002). The extracellular N-terminal domain, 
which includes an immunoglobulin-like loop (Isom et al, 1995), is important for 
interactions with the VGSCa-subunit as well as cell adhesion molecules (CAMs) (Isom, 
2001). The intracellular domain interacts with ankyrin and receptor tyrosine phosphatase 
P (RPTPP) (Isom, 2001) and possibly also is involved in a-subunit regulation (An et al, 
1998^ 
VGSCP-subunits are multifunctional molecules. Apart from their role in 
modulating VGSC kinetics (Isom, 2001; Hanlon and Wallace, 2002), they can also 
regulate the level of functional VGSCa expression in the plasma membrane (PM) 
(Kazarinova-Noyes et al, 2001; Chen et al., 2002) and frmction as CAMs (Isom and 
Catterall, 1996; Isom, 2002). The latter can involve: (1) extracellular matrix (ECM) 
proteins, thus influencing cell migration (Undrovinas et al, 1995; Faissner, 1997; 
Srinivasan et al, 1998; Xiao et al, 1999), (2) cytoskeleton (Peles et al, 1995; Malhotra 
et al, 2000; Ratcliffe et al, 2000) and (3) other CAMs (Isom, 2001; McEwen and Isom, 
2004). 
Both VGSCpi and VGSCP2 associate with Navl.5 in cardiac muscle (Malhotra 
et al, 2001) but the nature of this interaction is not yet clear. In human heart, a Navl.5-
VGSCpl (but not p2) complex exists in the endoplasmic reticulum (ER) and possibly 
assists trafficking of VGSC to the PM (Zimmer et al., 2002a). An interaction of Navl.5 
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with VGSCP2 can occur in PM following passage through the Golgi (Zimmer et al., 
2002a). Accordingly, it has been suggested that |32 can modulate the conduction 
properties of the channel (Cruz et al., 1999). 
Both VGSCpi and VGSCp2 are CAMs of the immunoglobulin superfamily and 
can interact with ankyrin in areas of cell-cell contact (Malhotra et al., 2000), as well as 
with the ECM molecules tenascin-C and tenascin-R (Srinivasan et al., 1998; Xiao et al., 
1999). In neurons, VGSCpi subunit can mediate cell adhesive interactions in neurons 
(Davis et al., 2004). Interactions of VGSCpi, but not VGSCp2, with contactin and 
neurofascin-186 CAMs have been reported to result in increased VGSC density in PM 
(Kazarinova-Noyes et al., 2001; Ratcliffe et al., 2001; McEwen et al., 2004). Association 
of non-phosphorylated VGSCpi with TTX-sensitive VGSCs and ankyrinB in cardiac 
myocytes can mediate excitation contraction coupling (Malhotra et al., 2004). The 
VGSCp2 subunit has been shown to play a crucial role in generating normal action 
potential activity and to control excitability, as well as regulating VGSC density in 
neurons (Isom et al., 1995; Chen et al., 2002). In addition, VGSCP2 can regulate both 
translocation and immobilization of VGSCs in PM, and thus change their kinetics in 
injured and non-injured sensory neurons and, as a result, can contribute to neuropathic 
pain (Pertin et al., 2005). Recently, in vivo studies in DRG neurons showed that 
VGSCP2 could modulate TTX-sensitive VGSC mRNA and protein expression that 
resulted in increased VGSC currents and kinetics changes (Lopez-Santiago et al., 2006). 
The first detailed structural and functional analysis of the VGSCpS subunit was 
published recently (Yu et al., 2005). It was found that transport of VGSCa to PM did not 
depend on VGSCpS, but functional association between them could occur either in PM 
or ER. Similar to VGSCpi (McCormick et al., 1998), VGSCPS was essential for VGSC 
gating (Yu et al., 2005). 
Less is known about VGSCp4. In rat brain and skeletal muscle, VGSCp4 subunit 
co-expression caused negative shifts in the voltage-dependence of Navl.2 and Navl.4 
activation, but Navl.5 was unaffected (Yu et al., 2003). It has been predicted that, like 
the other VGSCp-subunits, VGSCp4 would also have an extracellular Ig-like fold that 
could associate with ECM and/or CAMs (Yu et al., 2003). 
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6.1.1 Aims and scope 
The general aim of the study was to investigate which VGSC P-subunits were expressed 
in weakly (MCF-7) and strongly (MDA-MB-231) metastatic human breast cancer (BCa) 
cell lines and to explore VGSCP-subunit involvement in the adhesion to substrate and 
migration, as indicators of metastatic cell behaviour (MCB). 
The specific aims were as follows: 
1. To identify which VGSCP-subunit was predominant in MDA-MB-231 and MCF-7 
cells and then choose the appropriate VGSCP-subunit for further investigation; 
2. To identify which human BCa cell line (MCF-7 vs. MDA-MB-231) expresses 
higher levels of VGSCps and then choose the more suitable cell line for further 
investigation; 
3. To silence the chosen VGSCP-subunit by an RNA interference (RNAi) approach 
using small-interfering RNA (siRNA); 
4. To determine the effects of siRNA on mRNA and protein levels. 
5. To determine the effects of siRNA on nNavl .5 mRNA and protein expression; and 
6. To determine the effects of siRNA on cell migration and adhesion in vitro. 
Parts of this study have being published (Chioni and Djamgoz, 2006). 
6.2 Results 
6.2.1 Expression of VGSCp in human BCa cell lines 
Real-time PCR revealed that in both weakly (MCF-7) and strongly (MDA-MB-231) 
metastatic human BCa cell lines, VGSCpi had the highest level of expression. The 
relative levels of expression in both cell lines were as follows; p i » P4> p2 (Table 6.1; 
Figure 6.IB). Furthermore, MCF-7 cells had higher levels of all VGSCp-subunits 
compared to MDA-MB-231 cells (Table 6.2; Figure 6.1C). The VGSCp3 subunit was 
not expressed in either cell line. However, when strongly metastatic human prostate 
cancer cells (PC-3M) were used, a band about 353 nt was amplified (Figure 6.1). 
Interestingly, VGSCP4 was present in both BCa cell lines in two splice forms, consistent 
with expression of an exon skipped form (310 nt) and the full-length (459 nt) product 
(Figure 6.1A). Western blot with anti-VGSCpi antibody revealed that VGSCpi protein 
was highly expressed in MCF-7 and almost absent in MDA-MB-231 cells (Figure 6.2). 
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Table 6.1 Fold differences in VGSC p-subunit expression in MCF-7 and MDA-MB-
231 cell lines. 
VGSCpi subunit was expressed higher than VGSCp2 and VGSCp4 subunits in both 
MCF-7 and MDA-MB-231 cell lines. VGSCp4 was expressed at a higher level 
compared to VGSCp2 in both cell lines. VGSCpS was not expressed in either cell line. 
Cell l ine P1 » p2 p4 > p2 p1 » p4 
MCF-7 
MDA-MB-231 
1500-fold 4-fold 450-fold 
800-fold 2-fold 500-fold 
Table 6.2 Fold differences in VGSC P-subunit expression between MCF-7 and 
MDA-MB-231 cell lines. 
MCF-7 cells expressed higher levels of all P-subunits compared to MDA-MB-231 cells. 
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p1 p2 |34 
Figure 6.1 Patterns of VGSCp isoform mRNA expression in MCF-7 and MDA-MB-
231 cells. 
(A) Typical gel images of PCR products for VGSC-pi, -P2, -^3, -|34 and cytochrome-b5 
reductase (cytbSR) from MCF-7, MDA-MB-231 and PC-3M cells. (B & C) Real-time 
PCR results indicated the patterns of relative VGSCpi, -^2, -(33 and -(34 mRNA 
expression in MCF-7 (black bars) and MDA-MB-231 (white bars) cells. (B) Data shows 
that VGSCpi is the highest P-subunit expressed in both MCF-7 and MDA-MB-231 cells 
(C) Data shows the difference of VGSCPs mRNA expression between MCF-7 and 
MDA-MB-231 cells. VGSCP subunits mRNA levels were normalised to CytbSR by the 
2-AAct (with propagated errors). Data was analysed by paired t-test. Significance: 
(**) P < 0.01, (***) P < 0.001 (n = 3). 










Figure 6.2 VGSCpi protein expression in MCF-7 and MDA-MB-231 ceils. 
Western blot with 70 jig of total protein per lane from MCF-7 (lane 1) and MDA-MB-
231 (lane 2) cells, using anti-VGSCpi and an actinin antibody as a control for loading. 
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6.2.2 Effects of VGSCpi siRNA onMCF-7 cells: itiRNA studies 
6.2.2.1 Control experiments 
MCF-7 cells were transfected with a positive control siRNA targeting lamin AJC to 
confirm the transfection efficiency. Lamin A/C mRNA levels were reduced by 55 % 
after 2 days (P < 0.05; n = 3), increasing to 86 % after 4 days (P < 0.01; n = 3) compared 
to siControl/non-targeting siRNA transfected cells (Figures 6.3 & 6.4). After 5 days the 
reduction was less marked, reaching 71 % (P < 0.05; n = 3). The three different control 
conditions used for siRNA experiments (control untreated cells, siControl/non-targeting 
siRNA treated and mock-treated only with oligofectamin) did not effect lamin A/C 
mRNA levels (P = 0.89; n = 3; Figure 6.5). 
In order to confirm siRNA specificity for VGSCpi, the respective mRNA levels 
of two other closely related VGSCp-subunits expressed in MCF-7 cells (VGSCp2 and 
VGSCp4) were monitored 4 days post transfection. siRNA targeting VGSCpi had no 
effect on mRNA levels of VGSCp2 (P = 0.77; n = 3) or VGSC|34 (P = 0.97; n = 3) 
(Figure 6.6). 
6.2.2.2 VGSCpi mRNA expression 
Cells were transfected with SMARTpool siRNAs targeting the VGSCpi subunit. The 
siRNA treatment did not notably alter cell morphology 5, 8 or 12 days post-transfection 
(Figure 6.7). Importantly, the three different control conditions used for siRNA 
experiments (control untreated cells, siControl/non-targeting siRNA-treated, and mock-
treated only with oligofectamin) did not affect the VGSCpi mRNA levels (P = 0.72; n = 
3; Figure 6.8). In siRNA-transfected cells, 2 days after transfection there was no 
noticeable reduction in VGSCpi mRNA level (P = 0.61; n = 3; Figure 6.3). However, 
VGSCpi mRNA level was reduced by 76 %, 4 days post-transfection (P < 0.01; n = 3; 
Figures 6.6 & 6.3). After 5 and 6 days, the reductions in VGSCpi mRNA levels were 
less evident, only 63 % (P < 0.01; n = 3) and 46 % (P < 0.05; n = 3) (Figure 6.3). 
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Figure 6,3 siRNAs respectively reduced VGSCpi and lamin A/C in a time 
dependent manner in MCF-7 cells. 
(A) Typical gel images of PCR products for VGSCpi, Lamin A/C and CytbSR. lanes are 
as follows: 
(1) siRNA transfected cells; 
(2) siControl (non-targeting siRNA) transfected cells; and 
(3) no cDNA template included in PCR (NTC) 
(B) Time course (2-6 days) of relative VGSCpi (squares; black line) and lamin A/C 
(circles; black dashed line) mRNA level after transfection with respective siRNA. 
mRNA levels compared with siControl (non-targeting siRNA). mRNA level was 
normalised to CytbSR by the 2 ' ^ ^ method (with propagated errors). Data were analysed 





























SiControl Lamin A/C 
Figure 6.4 siControl lamin A/C RNAi reduced lamin A/C mRNA level in MCF-7 
cells. 
(A) Typical gel images of PCR products for lamin A/C and CytbSR. Lanes are as 
follows: 
1) siControl (non-targeting siRNA) transfected cells; 
2) lamin A/C siRNA-transfected cells; and 
3) no cDNA template included in PCR (NTC). 
(B) Relative lamin A/C mRNA level 4 days after transfection with siControl (non-
targeting siRNA) transfected cells and siRNA targeting lamin A/C. Lamin A/C mRNA 
level was normalised to CytbSR by the 2'^°^ method (with propagated errors). Data 


















Control siControl Mock 
Figure 6.5 siControl (non-targeting siRNA) and mock (no siRNA) transfection did 
not alter lamin A/C mRNA levels in MCF-7 cells. 
(A) Typical gel images of PCR products for lamin A/C and CytbSR. Lanes are as 
follows: 
1) control (untreated); 
2) siControl (non-targeting siRNA) transfected cells; 
3) mock control (no siRNA); and 
4) no cDNA template included in PCR (NTC). 
(B) Relative lamin A/C mRNA levels 4 days after transfection with siControl (non-
targeting siRNA) transfected cells and mock treatment. Lamin A/C mRNA level was 
normalised to CytbSR by the 2 ' ^ ^ method (with propagated errors). Data were analysed 
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si Control VGSC(31 VGSC(32 VGSC(34 
siRNA-treated 
nNavl .5 
Figure 6.6 VGSCpi siRNA reduced specifically VGSCpi mRNA levels but 
increased nNavl.5 mRNA in MCF-7 cells. 
(A) Typical gel images of PCR products for VGSCpi, VGSCp2, VGSC(34, nNavl .5 and 
cytbSR. Lanes are as follows: 
1) siControl (non-targeting siRNA) transfected cells; 
2) siRNA transfected cells; and 
3) no cDNA template included in PCR (NTC). 
(B) Relative levels of VGSCpi, VGSC|32, VGSCp4, nNavl.5 mRNA 4 days after 
transfection with siControl non-targeting siRNA, or siRNA. mRNA levels were 
normalised to CytbSR by the 2'^ ^"^ method (with propagated errors). Data were analysed 
by paired t-test since each treatment had a separate control. Significance: (X) P >0.05; 
(*) P < 0.05; (**) P < 0.01; (n = 3). 
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Figure 6.7 VGSCpl siRNA did not change the morphology of MCF-7 cells. 
Control cells (untreated), mock transfected (no siRNA, oligofectamin only), siControl 
(non-targeting siRNA) and VGSCpi siRNA-treated were photographed after (A) 5 days; 















Control siControl Mock 
Figure 6.8 siControl (non-targeting siRNA) and mock (no siRNA) transfection did 
not alter VGSCpi mRNA levels in MCF-7 cells. 
(A) Typical gel images of PCR products for VGSCpi and CytbSR. Lanes are as follows: 
1) control (untreated); 
2) siControl (non-targeting siRNA) transacted cells; 
3) mock control (no siRNA); and 
4) no cDNA template included in PCR (NTC). 
(B) Relative VGSCpi mRNA level 4 days after transfection with siControl non-
targeting siRNA transfected cells and mock treatment. VGSCpi mRNA levels were 
normalised to CytbSR by the method (with propagated errors). Data were analysed 
by one way analysis of variance. Significance: (X) P >0.05 (n = 3). 
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6.2.3 Interaction of VGSC a- and P-subunits: mRNA studies 
6.2.3.1 nNavl.5 mRNA expression 
Interestingly, 4 days after siRNA, the level of nNavl.5 mRNA was increased by about 
280 % (P<0.05; n=3) compared to siControl/non-targeting siRNA treated cells (Figure 
6.6). Similar to lamin A/C and VGSCpi mRNA levels, the three control conditions used 
in the siRNA experiments (control untreated cells, siControl/non-targeting siRNA-
treated and mock-treated only with oligofectamin) did not effect the nNavl.5 mRNA 
level (P = 0.72; n = 3; Figure 6.9). 
6.2.3.2 Effects of long-tern TTX treatment on VGSCp mRNA levels 
Long term TTX treatment (48 hours; 10 jiM) had no significant effect on VGSCpi 
mRNA expression in both MCF-7 and MDA-MB-231 cells (P = 0.85 and P = 0.16, 
respectively; n = 3 for both; Figure 6.10). Similarly, VGSCP4 mRNA levels in both cell 
lines were not affected (P=0.7 and P=0.98, respectively; n=3 for both; Figure 6.11). 
Interestingly, the TTX treatment significantly decreased VGSCP2 mRNA levels by 55 
% in MCF-7 cells (P < 0.05; n = 3; Figure 6.12) and by 90 % in MDA-MB-231 cells (P 
< 0.01; n = 3; Figure 6.12). 
6.2.4 Effect of VGSCpi siRNA on MCF-7 cells: protein studies 
6.2.4.1 Control experiments 
Western blots with anti-lamin A/C antibody revealed that MCF-7 cells transfected with a 
positive control siRNA targeting lamin A/C significantly reduced protein levels by 70 
%, after 5 days, compared to siControl/non-targeting siRNA-transfected cells (P<0.001; 
n=9; Figure 6.13). However, 7 days post-transfection, the lamin A/C protein level was 
only 36 % less than the siControl non-targeting siRNA transfected cells (P < 0.05; n = 6; 
Figure 6.13). 
6.2.4.2 VGSCpi protein expression 
Western blots revealed that siRNA targeting VGSCpi reduced the VGSCpi protein 
levels by 18 % after 5 days (P < 0.05; n = 6) and 40 % after 8 days (P < 0.05; n = 8; 




















Control siControl Mock 
Figure 6,9 siControl non-targeting siRNA and mock (no siRNA) transfection did 
not alter nNavl.5 mRNA levels in MCF-7 cells. 
(A) Typical gel images of PGR products for nNavl.5 and CytbSR. Lanes are as follows: 
1) control (untreated); 
2) siControl (non-targeting siRNA) transfected cells; 
3) mock control (no siRNA); and 
4) no cDNA template included in PGR (NTC). 
(B) Relative nNavl.5 mRNA level 4 days after transfection with siControl non-targeting 
siRNA transfected cells and mock treatment. nNavl.5 mRNA level was normalised to 
Cytb5R by the method (with propagated errors). Data were analysed by one way 
analysis of variance. Significance: (X) P >0.05 (n = 3). 
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Figure 6.10 Long-term TTX treatment did not affect VGSCpi mRNA levels in 
MCF-7 and MDA-MB-231 cells. 
(A) Typical gel images of PCR products for VGSC(31 in MCF-7 (lanes 1-2) and MDA-
MB-231 (lanes 3-4) cells after 48 hours pre-treatment with 10 p-M TTX. Lanes: 1 & 3, 
control; 2 & 4, TTX-treated for 48 hours; 5, no cDNA template included in the PCR 
(NTC^ 
(B) Relative VGSCpi mRNA level after TTX treatment (10 [iM) for 48 hours (h) in 
MCF-7 and MDA-MB-231 cells. mRNA levels were normalised to CytbSR by the 2" 
method (with propagated errors). Data were analysed by paired t-test (n = 3). 
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Figure 6.11 Long-term TTX treatment did not affect VGSCp4 mRNA levels in 
MCF-7 and MDA-MB-231 cells. 
(A) Typical gel images of PCR products for VGSC|34 in MCF-7 (lanes 1 -2) and MDA-
MB-231 (lanes 3-4) cells after 48 hours pre-treatment with 10 |iM TTX. Lanes: 1 & 3, 
control; 2 & 4, TTX-treated for 48 hours; 5, no cDNA template included in the PCR 
CNTCy 
(B) Relative VGSC(34 mRNA level after TTX treatment (10 p.M) for 48 hours (h) in 
MCF-7 and MDA-MB-231 cells. mRNA levels were normalised to CytbSR by the 2" 
method (with propagated errors). Data were analysed by paired t-test (n = 3). 
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Figure 6.12 Long-term TTX treatment reduced VGSCp2 mRNA levels in MCF-7 
and MDA-MB-231 cells. 
(A) Typical gel images of PCR products for VGSCP2 in MCF-7 (lanes 1-2) and MDA-
MB-231 (lanes 3-4) cells after 48 hours pre-treatment with 10 |j.M TTX. Lanes: 1 & 3, 
control; 2 & 4, TTX-treated for 48 hours; 5, no cDNA template included in the PCR 
(NTCy 
(B) Relative VGSCp2 mRNA level after TTX treatment (10 |iM) for 48 hours (h) in 
MCF-7 and MDA-MB-231 cells. mRNA levels were normalised to CytbSR by the 2" 
method (with propagated errors). Data were analysed by paired t-test (n = 3). 
Significance: (*) P < 0.05; (**) P < 0.01. 
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Figure 6.13 siControl: lamin A/C siRNA reduced lamin A/C protein level in MCF-7 
cells. 
(A) Western blots with 70 |ig of total protein per lane, extracted 5 (lanes 1 & 2) and 7 
(lanes 3 & 4) days post-transfection, using an anti-lamin A/C and anti-actinin antibody. 
Lanes: 1 & 3, siControl treated cells; 2 & 4, lamin A/C siRNA-transfected cells. 
(B) Relative lamin A/C protein levels (normalised to actinin) 5 and 7 days after 
transfection with lamin A/C siRNA, compared with siControl non-targeting siRNA. 
Data are presented as mean and SEM (n > 6). Data were analysed by paired t-test since 
each condition had a separate control. Significance: (*) P < 0.05; (***) P < 0.001. 
345 
A. 5 Days 8 Days 12 Days 
















5 Days 8 Days 12 Days 
Figure 6.14 VGSCpi siRNA reduced VGSCpi protein levels in MCF-7 cells. 
(A) Western blots with 60 |j.g of total protein per lane, extracted 5-12 days post-
transfection, using an anti-VGSCpi and an anti-actin antibody as a control for loading. 
Lanes are as follows: 
1) siRNA-transfected cells; 
2) siControl (non-targeting siRNA) transfected cells; and 
3) control (untreated) cells. 
(B)VGSCpi protein expression levels (normalised to actin control) in cells 5, 8 and 12 
days after transaction with siRNA and control cells (untreated), relative to siControl 
(non-targeting siRNA). Data are presented as mean and SEM (n > 4). Data were 
analysed by one way analysis of variance followed by Newman-Keuls test. Significance: 
(X)P>0.05; ( * )P<0.05. 
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no change in the VGSCpi protein level 12 days post-transfection (P = 0.45; n = 4; 
Figure 6.14). 
6.2.4.3 VGSCa protein expression 
Western blots demonstrated that after 8 and 12 days post-siRNA, total VGSCa protein 
expression was increased by 147 % and 99 %, respectively compared to siControl cells 
(P <0.05, n = 4, for both; Figure 6.15A & B). Similarly, nNavl.5 protein was also 
increased after 8 and 12 days post-siRNA, by 256 % and 117 % respectively, when 
compared with siControl cells (P < 0.05; n=4 for both; Figure 6.15A & C). However, 
there was no change in total VGSCa or nNavl.5 protein levels after 5 days post-siRNA 
(P= 0.99; n=4 for both; Figure 6.15A-C). 
In addition to the upregulation of the total nNavl.5 protein expression in MCF-7 
cells, PM expression was also increased after 8 days post-siRNA (Figure 6.16). Confocal 
microscopy revealed a 39 % increase in PM nNavl.5 protein expression after 8 days 
post-siRNA compared to siControl (P < 0.05; n = 3 experiments: cells > 50 from each 
experiment; Figure 6.17). 
6.2.4.4 Association of nNavl.5 protein with F-actin 
Double staining with NESO-pAb and phalloidin was used to assess if there was any 
obvious change in actin cytoskeleton and/or in its association with nNavl.5 protein. 
Control labelling experiments without phalloidin or without NESO-pAb confirmed the 
specificity of the NESO-pAb antibody and phalloidin labelling (Figure 6.ISA & B). 
Furthermore, controls to ensure that the signal from each channel, i.e. for FITC (green) 
or TRITC (red) did not 'leak' through each other, verified that the origin of each signal 
was due to specific labelling (Figure 6.19). Confocal images firom double staining with 
NESO-pAb and phalloidin under control conditions did not show any noticeable 
association between nNavl.5 and F-actin (Figure 6.20). Furthermore, double staining 
with NESO-pAb and phalloidin did not show any noticeable cytoskeletal change 8 days 
post-siRNA (Figure 6.20). 
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Figure 6.15 VGSCpi siRNA increased nNavl.5 protein levels in MCF-7 cells. 
(A) Western blots with 80 |ig of total protein per lane, extracted 5-12 days post-
transfection, using NESO-pAb and an anti-actinin antibody as a control for loading. 
Lanes are as follows: 
1) siRNA-transfected cells; 
2) siControl (non-targeting siRNA) transfected cells; and 
3) control (untreated) cells. 
(B) Pan-VGSCa and (C) nNavl.5 protein levels (normalised to actinin control) 5, 8 and 
12 days after transfection with siRNA, compared to siControl (non-targeting siRNA) 
and control cells (untreated). 
(D) Comparison of time courses of VGSCpi, pan-VGSC, NESO-pAb and Lamin A/C 
protein expression post-siRNA transfection with appropriate siRNAs (targeting 
VGSCpi for the first three and targeting Lamin A/C for the latter). Protein levels 
compared with siControl (non-targeting siRNA; grey dashed line). 
Data are presented as mean and SEM (n > 4). Data were analysed by one way analysis 
of variance followed by Newman-Keuls test. Significance: (X) P > 0.05; (*) P < 0.05. 
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Figure 6.16 siRNA increased nNavl.5 protein expression in MCF-7 cell apical 
plasma membrane. 
Typical confocal XZY images of MCF-7 cells double-stained with NESO-pAb (red) and 
concanavalin A (ConA) plasma membrane marker (green) 8 days after transfection with 
siControl (non-targeting siRNA) (images on the left) or siRNA targeting VGSCpl 


























Figure 6.17 siRNA significantly increased peripheral nNavl.5 immunoreactivity in 
MCF-7 cells 
Densitometric analysis of peripheral (PM) nNavl.5 immunoreactivity from confocal 
XZY images in MCF-7 cells 8 days after transfection relative to siControl (non-targeting 
siRNA) or siRNA targeting VGSCpi. Data shown as mean + SEM, were analysed by 
paired t-test (n=3). Significance: (*) P < 0.05. 
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nNav1.5 Phalloidin Bright field 
Figure 6.18 Controls for immunocytochemistry with NESO-pAb and phalloidin. 
(A-C) MCF-7 cells stained only with NESO-pAb (green; without phalloidin). (D-F) 
MCF-7 cells stained only with phalloidin (red; without NESO-pAb) and anti-rabbit-
FITC secondary antibody (for NESO-pAb). Corresponding bright field images are also 




Channel 2: Merged image 
Phalloi din 
Channel 1 & 2 
Channel 1 
Channel 2 
Figure 6.19 Controls for possible cross-excitation of the two confocal laser channels 
(FITC and TRITC) in MCF-7 cells. 
Typical confocal images from MCF-7 cells stained with NESO-pAb (green), and 
phalloidin (red). Corresponding merged images are also shown. (A-C) Images when 
both channels 1 and 2 (for FITC and TRITC) were open. (D-F) Images when only 
channel 1 (for FITC) was open. (F-I) Images when only channel 2 (for TRITC) was 
open. Scale bar (16 |im) applicable to all panels. 
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A. siControl 
nNav1.5 Phalloidin Merged 
B. siRNA 
nNav1.5 Phalloidin IVIerged 
Figure 6.20 siRNA did not have any obvious effect on F-actin cytoskeleton in MCF-
7 cells. 
Typical confocal images of MCF-7 cells, double-immunolabelled with NESO-pAb 
(green) and phalloidin, a cytoskeleton marker for F-actin (red) 8 days after transfection 
with siControl (non-targeting siRNA) (A) or siRNA targeting VGSCpl (B). White 
boxes indicate the areas that were magnified for further examination. Scale bars (a-f & 
m-r & y-dd; 16 [im; g-1 & s-x: 4 jim) applicable to all panels. 
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6.2.5 Functional studies 
6.2.5.1 Adhesion 
"Single-cell adhesion measurement apparatus" (SCAMA) was used on MCF-7 cells to 
measure their single-cell adhesion as a measure of metastatic potential. The 
measurements on siRNA- and SiControl-treated cells showed a significant reduction by 
25 % (P< 0.05; n=3) and 35 % (P< 0.001; n=6) after 5 and 8 days post-siRNA, 
respectively (Figure 6.21 A). However, after 12 days of siRNA treatment there was no 
significant difference in cell adhesion (P= 0.13; n=3; Figure 6.21). 
After 48 hours pre-treatment (included during the assay) with TTX (10 piM) 
siControl treated cells increased their adhesiveness by 16 %, compared to untreated 
siControl (P<0.01; n=4; Figure 6.21B, bar 1 vs. 2). Similarly, 48 h pre-treatment with 
TTX (10 jiM) caused an increase of siRNA-treated cells' adhesiveness by 28 % 
compared to untreated siRNA cells (P<0.05; n=4; Figure 6.21B, bar 3 vs. 4). These data 
were consistent with VGSCpi being not the only adhesive element involved in the effect 
of TTX on adhesion. 
6.2.5.2 Migration 
Migration through 12 pm Transwell pore filters was used as another measure of 
metastatic potential. After 8 days of transfection with siRNA targeting VGSCpi, the 
number of migrating cells increased significantly by 121 % compared to siControl (non-
targeting siRNA) transfected cells (P < 0.05; n = 8; Figure 6.22, bars 1 vs. 3). 
Pre-treatment with TTX (10 pM) for 48 hours (included during the assay) 
reduced the migration of siControl-treated cells by 27 % compared to untreated 
siControl cells (P < 0.05; n - 8; Figure 6.22, bar 1 vs. 2). Similarly, TTX pre-treatment 
also reduced the migration of siRNA-treated cells by 43 % compared to untreated 
siRNA cells (P < 0.05; n = 8; Figure 6.22, bar 3 vs. 4). Importantly, there was no 
difference in the migration of TTX-pretreated cells with VGSCpi either 'silenced' or 
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siControl vs. (siRNA + TTX) 0.011 
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Figure 6.21 VGSCpi siRNA decreased cell adhesion of MCF-7 cells. 
(A) Time course of reduction in MCF-7 cell adhesion after transfection with siRNA 
targeting VGSCpi. Adhesion was quantified as "detachment negative pressure" (DNP) 
measured in kiloPascals (kPa's). Data are plotted as reduction of DNP (ADNP, %) 
relative to the control value at time = 0. Squares (siRNA-treated cells), triangles 
(control, untreated cells) and circles (mock-transfected controls without siRNA), 
compared with siControl (non-targeting siRNA). 
(B) Results from measurements of MCF-7 cell adhesion using the single cell adhesion 
measurement apparatus (SCAMA), 8 days after transfection with siControl (non-
targeting siRNA), or siRNA targeting VGSCpi. Cells were pre-treated with or without 
TTX (10 jiM) for 48 hours. Inset: Table of multiple comparisons between treatments for 
statistical significance. Data are presented as mean + SEM (n > 3). Data were analysed 
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siRNA vs. siControl Yes 
siControl vs. (siControl + TTX) Yes 
siControl vs. (siRNA + TTX) No 
(siRNA + TTX) vs. (siControl + TTX) No 
Figure 6.22 SiRNA increased cell migration in MCF-7 cells. 
Bars represent relative number of cells migrating through a 12 (j.m Transwell pore filter 
over 12 h, 8 days after transfection with siControl (non-targeting siRNA), or siRNA 
targeting VGSCpi. Cell number is given as a percentage relative to the control 
(siControl) value as 100 %. Cells were pre-treated with or without TTX (10 |j,M) for 48 
hours (included during the assays). Inset: Table of multiple comparisons between 
treatments for statistical significance. Data are presented as mean + SEM (n=8). Data 
were analysed by one way analysis of variance followed by Newman-Keuls test. 
358 
6.3 Discussion 
The main findings of this study are as follows: (1) MCF-7 cells expressed considerably 
higher levels of VGSC-pi, -P2 and -P4 subunits than MDA-MB-231 cells, with 
VGSCpi having the highest expression level; P3 was not expressed in either cell line. 
(2) siRNA targeting VGSCpi specifically reduced VGSCpi at both mRNA and protein 
levels. (3) VGSCpi siRNA increased nNavl.5 mRNA and protein levels in MCF-7 
cells. (4) Partially silencing VGSCpi with siRNA in MCF-7 cells enhanced their 
metastatic behaviour (i.e. increased cell migration and decreased adhesion). (5) Long-
term TTX incubation decreased VGSCp2 mRNA expression, but had no effect on 
VGSCpi and VGSCp4 mRNAs, in both MCF-7 and MDA-MB-231 cells. 
6.3.1 Profiles of VGSCp subunit expression in MCF-7 and MDA-MB-231 cells 
This is the first study of VGSCP expression in human BCa cells. In both weakly (MCF-
7) and strongly (MDA-MB-231) cell lines, VGSCpi was the highest expressed, with 
VGSCp4 and VGSCp2 following. MCF-7 cells had higher levels of all p-subunits 
compared to MDA-MB-231 cells. Interestingly, VGSCp3 subunit was not expressed in 
either MCF-7 or MDA-MB-231 cells, but was present in the strongly metastatic human 
prostate cancer (PC-3M) cells, also shown previously to express the VGSCp3 gene (Diss 
et al., 2006). VGSCp4 was present in both MCF-7 and MDA-MB-231 cell lines in two 
sphce forms, possibly an exon skipped form (310 nt) that was expressed at lower levels 
than the fall length product (459 nt). A similar situation has been found in human 
prostate cancer cell line (LNCaP) (Diss et al., 2006). 
VGSCpi and -P4 mRNAs were highly expressed in most normal human tissues 
assayed (i.e. bone marrow, adrenal gland, brain, liver, heart, kidney, lung, skeletal 
muscle, prostate, spleen, thyroid gland, placenta) (Candenas et al., 2006). Furthermore, 
VGSCP2 was only expressed in brain and skeletal muscle, whilst the VGSCp3 was 
expressed only in brain (Candenas et al., 2006). 
Since MCF-7 cells expressed much higher levels of VGSCP-subunits, in 
particular VGSCpi, these cells were used for further characterisation. It is well 
established that VGSCpi functions as a CAM (Isom and Catterall, 1996; Isom, 2002) by 
interacting with ECM proteins and influencing cell migration (Undrovinas et al., 1995; 
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Faissner, 1997; Srinivasan et al., 1998; Xiao et al., 1999). VGSCpi can also interact 
with the cytoskeleton (Peles et al., 1995; Malhotra et al., 2000; Ratcliffe et al., 2000) and 
other CAMs (Isom, 2001; McEwen and Isom, 2004). Indeed, the weakly metastatic 
MCF-7 cells were more adhesive than strongly metastatic MDA-MB-231 cells, 
providing additional grounds for choosing MCF-7 cells and VGSC(31. Furthermore, only 
MCF-7 not MDA-MB-231 cells expressed VGSCpi protein. 
6.3.2 Effects of VGSCpi siRNA on VGSCpi mRNA and protein expression 
In this study, the VGSCpi gene was 'silenced' with siRNA. Although siRNA has 
previously been used to target VGSC a-subunits (Xu and Shrager, 2005; Brackenbury et 
al., 2006), this is the first report where siRNA has been used to specifically target a P-
subunit of VGSC. The siRNA caused a 76 % reduction of VGSCpi mRNA after 4 days. 
Although the RNAi technique can have some limitations associated with poor mRNA 
and protein downregulation as well as possible off-target effects (Jackson et al., 2003; 
Couzin, 2004), the specificity of the siRNA used in this study was good and none of the 
nearest possible off-target mRNAs (VGSCp2 and VGSCp4) were affected. Interestingly, 
on many occasions, RNAi does not completely eliminate the target gene (Jackson et al., 
2003; Couzin, 2004). Furthermore, the subsequent reduction in protein translation may 
result in significant phenotypical changes (Marusina, 2006). For example, 40-60 % 
silencing was enough to disrupt critical angiogenesis (Kremmidiotis, G. as reviewed in 
Marusina, 2006). VGSCpi protein level was also reduced, but less dramatically, by 40 
%. Thus, the reduction of VGSCpi protein was smaller than mRNA level reduction and 
became significant after 8 days post-siRNA, whilst mRNA levels reduced most after just 
4 days. The apparent discrepancy between the time course and extent of target mRNA 
and protein-level reduction could be due to many reasons. Although, at present, the 
dynamics of VGSC p- and a-subunit mRNA/protein expression in cancer cells are not 
known, it is possible that large stores of intracellular protein and/or slow turnover rates 
can give rise to the observed discrepancy (Zhang et al., 1996; Brackenbury et al., 2006). 
It has previously been shown that siRNA targeting vitamin K epoxide reductase gene 
reduced mRNA level after 3 days, but protein was not reduced until after 11 days (Li et 
al., 2004). Another recent study, targeting nNavl.5 by siRNA in MDA-MB-231 cells, 
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also showed that siRNA caused -90 % reduction of nNavl.5 mRNA after 5 days but 
only ~ 26 % reduction of nNavl.5 protein level, even after 13 days (Brackenbury et al., 
2006). 
6.3.3 Effects of VGSCpi siRNA on nNavl.5 mRNA and protein expression 
Importantly, VGSCpi siRNA upregulated nNavl.5 mRNA and protein levels in MCF-7 
cells. Confocal immunocytochemistry with NESO-pAb (Chioni et al., 2005) showed that 
nNavl.5 protein was present intracellularly and at low levels in the apical membrane, 
which was increased after the siRNA treatment. Whilst the siRNA increased total and 
PM nNavl.5 protein in MCF-7 cells, they retained their polarized nature. Interestingly, 
significant PM nNavl.5 expression was found in strongly metastatic MDA-MB-231 
cells (Eraser et al., 2005). 
The reason(s) why nNavl.5 gene and protein expression were upregulated after 
silencing VGSCpi is not clear. VGSCp-subunits can regulate the level of functional 
VGSCa expression by assisting trafficking to PM (Kazarinova-Noyes et al., 2001; Chen 
et al., 2002; Zimmer et al., 2002a). However, the observation that downregulation of 
VGSCpi expression in MCF-7 cells had the opposite effect, upregulating nNavl.5 
gene/protein expression would suggest another role of VGSCpi in these cells, possibly 
because of the pathophysiological nature of the cells under study. Thus the following 
possibilities can be considered: 
(1) VGSCpi may bind to intracellular nNavl .5 protein at a site close to a signal peptide 
responsible for nNavl.5 export to the PM and hence masking it. Upon silencing of 
VGSCpi, this signal peptide might be unmasked whereupon the protein would be 
free to traffic to PM. Although there is no evidence for such a relationship between 
nNavl.5 and VGSCpi, there are other studies reporting intramolecular 
masking/regulation of localisation signal peptides (Hawkins et al., 2006; Wagstaff 
and Jans, 2006). 
(2) Upregulation of nNavl.5 gene/protein was due to the fact that VGSCpi could act 
independently like a CAM (Isom and Catterall, 1996; Isom, 2002). In that case, by 
downregulating VGSCpi (i.e. reducing adhesion), the MCBs of the MCF-7 cells 
would be enhanced whereupon more functional VGSC/nNavl.5 would be required. 
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It is not clear yet whether nNavl.5 expression is needed for the initiation of MCB 
or whether nNavl.5 expression is acquired later in cancer progression when the 
cancer cells have become metastatic and they need nNavl .5 expression as a driving 
force for MCBs. This issue is further discussed in Section 6.3.4. 
(3) Another VGSC(3 subunit could be compesating for the downregulation of VGSCpi 
after the siRNA treatment and thus mediate nNavl.5 trafficking to PM. However, 
the present study demonstrated that after VGSCpi siRNA treatment none of the 
remaining VGSCps (P2 and p4) expressed in MCF-7 cells were upregulated at 
mRNA level. Nevertheless, this could happen at protein level. The lack of 
antibodies did not allow us to investigate this further but it is an interesting question 
to be answered in the future. 
6.3.3,1 Possible effects of VGSCpi siRNA on nNavl.5 function 
The central question of the present study was the involvement of VGSCpi in adhesion 
and migration, since VGSCpi is known to act as a CAM (Isom and Catterall, 1996; 
Isom, 2002), as well as its involvement in VGSC functioning. The finding that VGSCpi 
siRNA upregulated nNavl.5 gene/protein in MCF-7 cells raised the question of its 
possible effects on nNavl.5 functioning. Although the study did not focus on this 
subject, it would be of interest to investigate if nNavl.5 upregulation also led to 
upregulation of functional nNavl.5 VGSC activity in MCF-7 cells, especially since 
these cells do not express fimctional VGSCs under normal conditions (Fraser et al., 
2005X 
It is well known that VGSCps can interact with VGSCa and can modify VGSC 
electrophysiological properties. For example, VGSCpi can modulate Navl.4 current by 
increasing PM density (Ferrera and Moran, 2006). In the absence of VGSCpi and -p2 
subunits in Xenopus oocytes, currents from brain and skeletal muscle VGSCs were 
activated and inactivated more slowly. However, co-expression with VGSCpi and -P2 
subunits could accelerate channel gating and bring it to normal rates (Isom et al., 1992; 
Schreibmayer et al., 1994). Furthermore, VGSCpi could produce an increase in Na"^  
current amplitude consistant with an increase in the level of VGSC expression (Patton et 
al., 1994; Qu et al., 1995). Thus, the downregulation of VGSCpi might have a dual 
362 
effect. It could affect MCB via its action as a CAM (Section 6.3.4) and it could also 
affect functional nNavl.5 expression. Further investigation on this area would be very 
interesting since it would be the first study on the effect of VGSCpi on nNavl.5 
function in human BCa. 
6.3.4 Involvement of VGSCpi in metastatic activity of MCF-7 cells 
6.3.4.1 Adhesion 
In MDA-MB-231 cells, TTX (10 (iM) treatment was shown previously to suppress a 
variety of in vitro behaviours associated with the metastatic cascade, including 
galvanotaxis, endocytic membrane activity, migration and invasion, consistent with the 
involvement of TTX-resistant VGSC activity (Roger et al., 2003; Fraser et al., 2005; 
Brackenbury and Djamgoz, 2006b) The VGSCpi siRNA treatment reduced cell 
adhesion by 34 %, comparable to the sizes of the previously reported effects of TTX. 
However, in siRNA-treated cells, TTX did not increase adhesion to the level of 
siControl or siControl + TTX cells (Figure 6.21; bars 1 & 2, respectively). This 
suggested the involvement of VGSCpi in the effect of TTX on cell adhesion. Since PM 
nNavl.5 protein level was elevated after siRNA treatment in MCF-7 cells, siRNA-
treated cells could be expected to be more sensitive to TTX. However, TTX treatment 
had almost the same effect on cell adhesion of siRNA- and siControl-treated cells 
(Figure 6.21, bar 1 vs. 2 & bar 3 vs. 4). Thus, reduction of cell adhesion after siRNA 
was primarily due to VGSCpi mRNA and protein downregulation, rather than 
upregulation of nNavl.5. 
6.3.4.2 Migration 
VGSCpi siRNA treatment increased MCF-7 cells' migration by 121 % and this was 
reduced back to the control level by the addition of TTX. Unlike the adhesion assay, 
therefore, TTX treatment of siRNA-treated cells decreased cell migration more radically 
compared to the level of siControl cells (Figure 6.22; bar 3 vs. 4 & bar 1 vs. 2). Thus, 
the increase of cell migration after siRNA was VGSC activity dependent. Interestingly, 
siRNA treatment increased nNavl.5 levels considerably by 280 % at mRNA level and 
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256 % at protein level. It is now well established that high levels of nNavl.5 is a 
property that strongly metastatic MDA-MB-231 human BCa cells possess (Fraser et al., 
2005; Brackenbury and Djamgoz, 2006b). 
It is possible that the decreased adhesion due to VGSCpi gene/protein 
downregulation made the weakly metastatic MCF-7 cells more metastatic and this led to 
the increased levels of nNavl.5. This is consistent with findings suggesting that the 
cellular environment can influence functional VGSC expression (Ding and Djamgoz, 
2004). For example, rat prostate cancer (Mat-LyLu) cells growing on more strongly 
adhesive poly-l-lysine coated plates expressed less functional VGSC compared to cells 
growing on glass (Mycielska et al., 2004). 
It was thus concluded (1) that VGSC(31 was involved in MCF-7 cells' adhesion 
and this influenced cell migration; and (2) that increased metastatic cell behaviour 
required increased levels of nNavl.5 expression. 
Staining with phalloidin did not show any obvious change in F-actin after 
VGSCpi siRNA treatment. This was surprising since several studies have shown an 
association between cytoskeletal elements (especially actin) and adhesion (i.e. 
interaction with (31 and |33 integrins and ECM) (Filla et al., 2006; Kimata et al., 2006; 
Takizawa et al., 2006). Furthermore, there is evidence suggesting that Navl.5 can 
interact with actin cytoskeleton via syntrophin (Ou et al., 2003). A more extended study 
should be performed in order to investigate if the reduction of VGSCpi could affect 
other components of the cytoskeleton and if this is one of the reasons why we observed 
reduced cell adhesion and increased cell migration. The cytoskeleton is composed of 
three kind of protein filaments: (1) actin, (2) intermediate filaments and (3) 
microtubules, and VGSCpi might interact with any of these to reduce cell adhesiveness 
and promote cell migration or even regulate nNavl.5 protein trafficking to PM. 
6.3.5 Effects of TTX on VGSCp mRNA expression 
Long-term TTX incubation had no significant effect on VGSCpi or -P4 mRNA levels in 
both MCF-7 and MDA-MB-231 cells. However, similar treatment decreased VGSCp2 
mRNA by 55 % in MCF-7 and by 90 % in MDA-MB-231 cells. Thus, VGSC activity 
can control VGSCP2 subunit expression and possibly adhesion. It has been shown 
previously that specific patterns of action potentials could affect expression of LI CAM 
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in mouse sensory neurons (Itoh et al., 1995). Blocking the nNavl.5 a-subunit, the 
predominant VGSC in both MCF-7 and MDA-MB-231 cells, might stop/inhibit 
trafficking of either newly synthesized nNavl.5 protein or intracellularly stored nNavl.5 
protein to PM through VGSCP2 expression. This assumption is consistent with the 
finding that expression of VGSCp2 subunit is fundamental for translocation of newly 
synthesized VGSCs from intracellular stores to PM (Schmidt et al., 1985; Schmidt and 
Catterall, 1986; Isom, 2001). It is well documented that VGSCp2 subunit is responsible 
for regulating VGSC density and function in PM (Chen et al., 2002; Pertin et al., 2005), 
that might be assisted by its association with contactin (Kazarinova-Noyes et al., 2001). 
The possible role of the VGSC(32 subunit protein could not be studied due to 
nonavailability of an antibody. 
6.3.6 A model for VGSCp involvement in metastatic cell behaviour 
The results presented in this Chapter, taken together with other available evidence, are 
consistent with a model incorporating several pathways, illustrated in Figure 6.23. 
Basically, there are two (direct and indirect) possible ways in which VGSCp could be 
involved in MCBs (adopting data from MCF-7 cells), as follows (Figure 6.23): 
I. Direct: 
1) Down regulation of VGSCpi, which functions as a CAM (Isom and Catterall, 1996; 
Malhotra et al., 2000; Isom, 2002), could enhance MCBs (i.e. decrease adhesion 
and increase migration). 
II. Indirect: 
2) Down regulation of VGSCpi could increase VGSCa (nNavl.5, predominant 
VGSCa) expression/activity and protein trafficking to PM via unknown 
mechanisms (Xi). A possible mechanism might be through the VGSCp2-subunit, 
which is known to facilitate trafficking of VGSCa to PM (Pertin et al., 2005). It is 
also possible that the VGSCpi-subunit binds to a signal peptide on the a-subunit 
that might be necessary for VGSC protein export to PM (Stockklausner and 
Klocker, 2003). Thus, upon down-regulation of VGSCpi the signal peptide might 
be unmasked and the retention effect abolished and hence the protein is permitted 















Figure 6.23 A hypothetical model of possible ways in which VGSCps could be 
involved in metastatic cell behaviour 
There are two possible ways (direct and indirect) in which VGSCp could be involved in 
metastatic cell behaviour (MCB); adopting data from MCF-7 cells; 
Direct: 
1) Down regulation of VGSCpi, enhancing MCB by decreasing adhesion and increasing 
migration. 
Indirect: 
2) Down-regulation of VGSCpi increasing VGSCa (nNavl.5) expression/activity and 
protein trafficking to PM (via unknown mechanism(s) Xi). 
3) Increased VGSCpi expression by VGSC activity and its possible reciprocity. 
4) VGSC activity induces regulation of other mechanisms (Xz) that could further affect 
adhesion. 
5) Possible influence of VGSC activity on (31-subunit protein expression. 
6) Autoregulation of VGSCa expression/activity by VGSC activity (positive feedback). 
7) Feedback effect of MCB on VGSCa expression/activity (via unknown mechanism 
X3) and regulation by 'knock-on' factors. 
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3) The present study showed that blocking VGSC activity resulted in decreased 
VGSCp2 mRNA. Hence, VGSCa activity could normally increase VGSCp2 
expression. This relationship between VGSCa activity and VGSCp2 expression 
might also be reciprocal, with VGSCP2 facilitating the transport of newly 
synthesized VGSCa protein to PM (Pertin et al., 2005). Although this scheme 
would imply that VGSCp2 is not involved in cell adhesion (since VGSCa 
blockage, which resulted in increased cell adhesion, decreased VGSCp2 mRNA), 
an effect on MCBs such as migration (and adhesion) might still occur at a different 
level. There is evidence that VGSCp2, like VGSCpi, is a CAM that can interact 
with ankyrin in areas of cell-cell contact (Malhotra et al., 2000), as well as with 
components of ECM, such as tenascin-C and tenascin-R (Srinivasan et al., 1998; 
Xiao et al., 1999). 
4) VGSCa activity can also alter other mechanisms (X2), such as CAMs, which in turn 
might influence adhesion (Itoh et al., 1995). 
5) Although, blockage of VGSCa did not alter VGSCpi mRNA levels, it is possible 
that an interaction at the protein level might exist, hideed, there is sustained 
evidence that mRNA and protein expressions in cells can be dynamic and 
independent (Sola et al., 1999; Orphanides and Reinberg, 2002; Schedel et al., 
2004; Gu et al., 2006). 
6) Autoregulation of VGSCa expression/activity occurs by positive feedback and this 
may include post-transcriptional/translational regulation/modification (e.g. 
phosphorylation). A possible mechanism might be protein kinase A (PKA). 
Evidence from the present study (Chapter 5), as well as previous studies, suggested 
that Na"^  in f lux via VGSCs could directly elevate cAMP levels and hence increase 
PKA activity (Cooper et al., 1998; Murakami et al., 1998). In addition, studies on 
Mat-LyLu cells also demonstrated that short- and long-term effects of PKA 
affected functional VGSC expression through direct phosphorylation of VGSC or 
over a longer period PKA activity increased PM VGSC availability (Brackenbury 
and Djamgoz, 2006b). Any change in VGSC activity could have knock-on effect 
upon the P-subunit. 
7) Change in MCBs (i.e. reduction in adhesion when VGSCpi was down regulated) 
through VGSCpi could have a positive feedback by increasing PM VGSCa 
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expression. For example, an unknown mechanism (X3) such as VGSCP subunit(s) 
as well as ubiqutination mechanism (e.g. Nedd-4 like) might be involved in protein 
trafficking to PM, thus modulating MCBs. Indeed, blockage of VGSCa by TTX 
reduced VGSC|32 mRNA in both MCF-7 and MDA-MB-231 cells. This is 
consistent with the finding that VGSCp2 facilitates VGSCa trafficking to PM 
(Schmidt et al., 1985; Schmidt and Catterall, 1986; Isom, 2001). 
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Chapter 7: GENERAL DISCUSSION 
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Breast cancer (BCa) is the third most common cancer in the world; its impact is 
significant since it can affect one in eight women in Europe and USA (Wingo et al., 
1998; Parkin et al., 1999; Schwirzke et al., 1999; Edwards et al., 2005; Veronesi et al., 
2005). Oncogenes (e.g. ras, c-myc), cell cycle associated markers (e.g. Ki67), motility 
factors (e.g. HGF/SF), growth factors (e.g. EGF, FGF) and their receptors, adhesion 
molecules (e.g. E-cadherins), and steroid hormones (e.g. estrogen, progesterone) are all 
associated with BCa metastasis (Schwirzke et al., 1999; Heimann and Hellman, 2000; 
van' t Veer et al., 2002a; Duffy, 2005; Weigelt et al., 2005). Established prognostic 
markers for development of metastatic disease include: size of primary carcinoma, loss 
of histopathological differentiation, presence of lymph node metastasis, vessel invasion, 
and status of hormone receptors, e.g. progesterone receptor, estrogen receptor (ER) and 
HER2 (Veronesi et al., 2005; Weigelt et al., 2005; Chom, 2006; Kurebayashi, 2006; 
Nicolini et al., 2006; Reis-Filho et al., 2006). However, these markers do not always 
enable definitive diagnosis. For example, one-third of women with BCa that did not 
have lymph node metastasis develop distant metastasis and one-third of patients with 
lymph node metastasis remain free of distant metastasis for over 10 years (Mansi et al., 
1999; Heimann and Hellman, 2000; Weigelt et al., 2005). It is crucial therefore for 
clinicians to have new prognostic markers to help identify more accurately which 
patients are likely to develop metastatic disease. 
Apart from the need for new, effective prognostic markers for metastatic disease, 
it is also necessary to develop new therapeutic approaches. Breast cancer is commonly 
treated by a combination of surgery, radiation therapy, hormone therapy and 
chemotherapy (Veronesi et al., 2005). New therapies that work on proliferating, 
invading and dormant tumour cells (e.g. immunotherapy) are in the pipeline (Pantel and 
Brakenhoff, 2004). New small-molecule anti-cancer drugs for proteins acting upon 
kinases (e.g. MEKl and MEK2 inhibitors) and the molecular chaperone heat shock 
protein 90 (HSP90) are also new approaches to molecular cancer therapeutics (Collins 
and Workman, 2006). However, the facts that patients become resistant to endocrine 
therapies (Howell et al., 1996; Ali and Coombes, 2002), that chemotherapy some times 
fails to reduce the size of the primary tumour (Veronesi et al., 2005), and therapies 
targeting angiogenesis have not been very successful so far (Sledge and Miller, 2003; 
Veronesi et al., 2005), indicate the need also for new therapies. 
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7.1 Summary of key findings 
The present study is a part of an on-going effort to develop novel diagnostic/prognostic 
and therapeutic approaches to clinical management of metastatic BCa. At the centre of 
these approaches are ion channels, in particular voltage-gated Na"^  channels (VGSCs). 
The present findings/achievements are as follows: 
1. A novel polyclonal antibody highly specific for the D1:S3 5' ('neonatal') splice 
form of Navl.5 (nNavl.5), termed NESO-pAb, was developed. This is also the 
first study to successfully target a developmentally regulated D1:S3 splice 
variant or any VGSCa splice form. nNavl.5 was suggested earlier to be the 
predominant VGSC functionally expressed in metastatic BCa cells and tissues 
(Eraser et al, 2005) 
2. Strongly metastatic human BCa MDA-MB-231 cells expressed considerably 
higher levels of nNavl.5 mRNA and protein compared with weakly metastatic 
human BCa (MCF-7) cells. In fact, nNavl.5 mRNA was 4200-fold and total 
protein expression 70 % higher than in MCF-7 cells. Furthermore, the levels of 
plasma membrane (PM) nNavl.5 protein expression was 67 % higher in MDA-
MB-231 cells. 
3. A positive feedback mechanism was involved in steady-state VGSC regulation in 
MDA-MB-231 and MCF-7 cells, with stimulation of protein kinase A (PKA) by 
Na"^  influx through VGSC. This mechanism caused elevation of nNavl.5 mRNA 
and protein levels in PM without a subsequent alteration in total nNavl.5 protein. 
4. This positive feedback mechanism enhanced metastatic cell behaviour (MCB), 
i.e. migration, invasion. Thus, activation of PKA increased MCBs in MCF-7 and 
MDA-MB-231 cells, and this was reversed by co-treatment with tetrodotoxin 
(TTX), i.e. it was VGSC-mediated. 
5. Blockage of VGSC activity by long-term (48 h) application of TTX reduced PM 
nNavl.5 protein levels in MDA-MB-231 and MCF-7 cells. Importantly, long-
term (48 h) blockage of the channel completely suppressed the VGSC-dependent 
component of MDA-MB-231 cell migration in vitro. 
6. Long-term VGSC blockage by TTX significantly increased single-cell adhesion 
in both MDA-MB-231 and MCF-7 cells. In fact, MDA-MB-231 cell adhesion 
was elevated to the level of MCF-7 cells. 
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7. MCF-7 cells expressed considerably higher levels of VGSC-pl, -P2 and -P4 
subunits than MDA-MB-231 cells with VGSCpi having the highest expression 
level. However, neither MCF-7 nor MDA-MB-231 cells expressed any VGSCpS. 
8. hi MCF-7 cells, an RNAi approach revealed that VGSCpi controlled cell 
adhesion and also influenced cell migration. Reduction of VGSCpi gene and 
protein expression in these cells also upregulated nNavl.5 expression and 
enhanced their MCBs (i.e migration and adhesion). 
9. Long-term TTX incubation had no effect on VGSCpi and VGSCP4 mRNA 
levels but decreased VGSCp2 mRNA expression in both MCF-7 and MDA-MB-
231 cells. This finding highlighted the possibility that VGSCp2 might play a 
significant role in VGSCa protein trafficking to PM. 
7.2 Specificity and usage of NESO-pAb 
An antibody specific for nNavl.5, termed "NESO-pAb", was developed and tested for 
its specificity. Western blots and immunocytochemical studies on EBNA-239 cells 
transfected with the 'adult' and 'neonatal' splice forms of Navl.5 verified the high 
specificity of this antibody. In addition, immunohistochemical and Western blot studies 
on a variety of adult and neonatal mouse tissues demonstrated that nNavl.5 protein 
expression was indeed developmentally expressed in these tissues. The mechanism(s) 
controlling the developmental splicing of VGSC genes is not known yet, but could 
involve membrane potential (Xie and Black, 2001), growth factors (Akopian et al., 
1999), phosphorylation (Shipston, 2001), transcription factors (Kurokawa and Arteaga, 
2003) or splicing factors (Simard and Chabot, 2002; Li et al., 2003). 
NESO-pAb also blocked the electrophysiological activity of nNavl.5 expressed 
in EBNA cells (Chioni et al., 2005). Consequently, treatment with NESO-pAb inhibited 
MCBs (i.e migration and invasion) of MDA-MB-231 cells, consistent with surface 
expression of nNavl.5 and its enhancement of migration/invasion (Chapter 3). These 
results raise the possibility of using a 'humanised' monoclonal antibody against nNavl.5 
as a specific mechanism for targeting aberrant nNavl.5 expression in metastatic BCa 
cells in the adult cancer patient (lannello and Ahmad, 2005; Ross et al., 2005; Tanner, 
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2005; Willems et al., 2005; Booy et al., 2006), or drug-delivery systems, with limited 
side-effects for patients. 
7.3 iiNavl.5 expression in human BCa cell lines 
Real-time PCR (rt-PCR) showed that MDA-MB-231 cells expressed higher levels of 
total Navl .5, adult (a) Navl .5, nNavl .5 and Navl .7 than MCF-7 cells (Chapter 4). From 
previous work, it was known that the main isoform expressed is Navl.5, consistent with 
electrophysiological data that suggested a mainly TTX -resistant nature of VGSCa . 
Importantly, DNA sequencing revealed that the Navl.5 was in its neonatal form and 
hence its upregulation in metastatic BCa may be part of an oncofetal expression pattern 
(Monk and Holding, 2001; Diss et al., 2004b; Eraser et al., 2005). Importantly, the main 
isoform expressed, nNavl.5, was also the isoform that proved to have the biggest 
difference between the two cell lines. Cancer has been known to arise from cells that 
possess common properties with undifferentiated, embryonic cells (Dean, 2006). Recent 
studies on cells resembling stem cells (termed "cancer stem cells") from solid tumours 
support the notion that cancer is intimately associated with developmental phenomena 
(Bao et al., 2006; Costea et al., 2006; Dean, 2006; Lynch et al., 2006; Ponti et al., 2006; 
Tang et al., 2006). Furthermore, tumour cells generally express a number of cell 
adhesion molecules (CAMs), important for cancer progression (Steeg, 2006). 
Interestingly, a neuronal CAM (NCAM), which is a potential tumour marker for small-
cell carcinoma (Ledermaim et al., 1994; Onganer et al., 2005), was also expressed early 
in embryonic cells, as well as in P19 cells, a mouse embryonal carcinoma cell line 
(Mauro et al., 1994). Thus, the stem cell model of cancer, as well as the embryonic 
status of NCAMs in cancer, are consistent with the neonatal nature of Navl.5 expression 
in human BCa. 
In agreement with rt-PCR, Western blots and immunocytochemical studies using 
the NESO-pAb and pan-VGSCa antibody demonstrated that overall expression of 
VGSCa was significantly higher in MDA-MB-23 cells compared with MCF-7. Indeed, 
densitometric analysis confirmed that MDA-MB-231 cells expressed about 4-foId more 
VGSCa and nNavl.5 protein (Chapter 4). Interestingly, both the normal human breast 
epithelial cells (MCF-lOA) as well as the weakly metastatic BCa cell line (MCF-7) 
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expressed VGSCa protein but only MCF-7 cells expressed nNavl.5. Furthermore, 
Western blot studies with subcellular fractions and confocal microscopy revealed that 
both MDA-MB-231 and MCF-7 cells expressed PM nNavl.5 but (1) MCF-7 cells had 
lower levels compared to MDA-MB-231 cells (70 % less) and (2) MCF-7 cells retained 
their polarized nature and expressed nNavl.5 only on the apical membrane, unlike 
MDA-MB-231 which expressed nNavl.5 around the whole PM (Chapter 4). However, 
electrophysiology suggested that functional VGSCa was absent in the MCF-lOA and 
MCF-7 cells and only MDA-MB-231 cells expressed functional VGSC (Fraser et al., 
2005). This apparent discrepancy between PM nNavl.5 protein levels and functional 
VGSC may be due to a number of reasons, such as the following: (1) The PM VGSCa 
protein in both MCF-7 and MCF-lOA was not functionally active; and (2) the level of 
expression was very low in both cell lines and therefore not detectable by 
electophysiology. 
Both MCF-7 and MDA-MB-231 cells also expressed large amounts of 
intracellular nNavl.5. This finding might be evidence that VGSC protein is ready-
synthesized and stored at an early stage in metastasis, to be used later when the cancer 
may achieve an aggressive status. If so, the expression of VGSCa in weakly metastatic 
cell line may also suggest that up-regulation of VGSC expression is an early event in 
breast metastasis. Intracellular VGSC has previously been reported in developing 
neurones where action potentials are produced after a high enough channel density is 
reached (Dargent et al., 1994). 
Only high concentration of TTX (10 |J.M used to block TTX-R VGSCs, like 
Navl.5), as well as silencing nNavl.5 (Brackenbury et al., 2006) completely abolished 
the VGSC-dependent component of MCBs. Smaller concentrations of TTX (1-5 |j,M 
used to block TTX-S VGSCs) did not have any effect on MCB, consistent with the 
predominant nNavl.5 being responsible for enhancing MCB. Therefore, non-
predominant TTX-S Navl.7 and Navl.6 expressed in MDA-MB-231 and MCF-7 cells 
(Fraser et al., 2005) might have another role in cancer. The reason why nNavl.5 
specifically underlined the MCB in MDA-MB-231 and MCF-7 cells is still unclear. 
However, the fact that Navl.5 is the one of two VGSCas that has PDZ domain and thus 
could enable interactions with the cytoskeleton (Gellens et al., 1992), as well as the low 
level of glycosylation and the slow activation and inactivation kinetics might also be 
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further characteristics that make Navl.5 isoform good candidate for facilitating MCB in 
breast cancer (as reviewed by Diss et al., 2004). 
7.4 Regulation of VGSC expression in human BCa cells 
Taking the available evidence together, including published data, VGSCs and, in 
particular, the predominant isoform nNavl.5 is known to be expressed functionally in 
metastatic BCa both in vitro and in vivo (Roger et al., 2003; Eraser et al., 2005; 
Brackenbury et al., 2006). The present study showed that VGSC expression could 
potentiate MCB in vitro by enhancing migration and invasion, but reducing adhesion in 
human BCa cells (Chapter 5). Furthermore, blockage of the nNavl.5 isoform with 
NESO-pAb indicated that in vitro MDA-MB-231 cell migration and invasion were 
entirely dependent on nNavl.5 (Chapter 3). Importantly, supporting evidence from RNA 
interference (RNAi) studies targeting nNavl.5 in MDA-MB-231 cells also showed that 
the VGSC-dependent component of migration was exclusively dependent on nNavl.5 
(Brackenbury et al., 2006). 
A recent study showed that in rat metastatic prostate cancer (PCa) cells (Mat-
LyLu), VGSC activity was upregulated via a positive feedback mechanism involving 
PKA (Brackenbury and Djamgoz, 2006b). Similarly, the present study showed that in 
BCa positive feedback VGSC activity-dependent regulation also operates in human BCa 
(Chioni and Djamgoz, 2005b; Chioni and Djamgoz, 2005a). 
However, activity-dependent regulation of VGSCs by negative feedback appears 
to be much more common. Another study showed that Na"^  current was down-regulated 
when ENaC-expressing cells were exposed to high extracellular Na"^  (Anantharam et al., 
2006). This study suggested that intracellular Na"^  has a role in negative feedback 
modulation of ENaCs. Other studies showed that pharmacological blockade of VGSC 
with local anesthetic bupivacaine or TTX, upregulated VGSC translation and 
exteranalisation (Sherman and Catterall, 1984; Offord and Catterall, 1989; Shiraishi et 
al., 2003). Furthermore, a range of in vitro studies showed that VGSC 'activator' drugs 
(i.e. scorpion a toxin (a-ScTx), batrachotoxin, and veratridine) and Na"^  ionophores (i.e. 
monensin and amphotericin B), could down-regulate VGSCa mRNA expression, 
functional VGSCa in PM, and increase protein intemalisation and degradation (Dargent 
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and Couraud, 1990; Dargent et al., 1994; Lara et al., 1996; Paillart et al., 1996; Klein et 
al., 2003). 
Thus, Brackenbury and Djamgoz (2006), and the present study are the first 
studies to suggest a positive feedback regulation of VGSC via Na"^  influx in PCa and 
BCa, respectively. 
7.4.1 A model of VGSC regulation in BCa cell lines 
A model of VGSC regulation in BCa has been developed by putting together the results 
of this study with published evidence (Figure 7.1). Briefly, the resuhs of this study 
demonstrated that Na"^  influx through VGSC could result in activation of PKA through 
adenylate cyclase (AC)/cAMP (Figure 7.1 [1]). Activation of PKA by increased Na"^  
influx has previously been demonstrated in perfiised rat anterior pituitary cells 
(Murakami et al., 1998), cerebellar granule cells (Cooper et al., 1998) and in rat Mat-
LyLy PCa cells (Brackenbury and Djamgoz, 2006b). 
Activation of PKA resulted in an increase of PM nNavl.5 in MDA-MB-231 cells 
by trafficking/extemalisation of intracellular nNavl.5 protein (Chapter 5; Figure 7.1 [2]). 
PKA activation induced by Na"^  influx can also decrease functional activity by direct 
phosphorylation of VGSCa (Figure 7.1 [3]) (Yuhi et al., 1996; Zhou et al., 2000; 
Vijayaragavan et al., 2004; Wada et al., 2004; Brackenbury and Djamgoz, 2006b). There 
is no evidence, at present, for any such direct phosphorylation of VGSCP, although 
phosphorylation by tyrosine kinases is known to occur (Isom, 2001). PKA activity can 
also control transcription of VGSCa and hence increase PM VGSC (Figure 7.1 [4a]). 
Transcriped VGSCa gene might not always be translated into protein, but instead stored 
as 'docked mRNA' (Figure 7.1 [4b]) and translated later by a stimulus (e.g. activation of 
PKA; Figure 7.1 [5]) (Tiedge et al., 1999; Ben Fredj et al., 2004; St Johnston, 2005; 
Bassell and Twiss, 2006) (Figure 7.1 [5b]). This might also explain the discrepany 
between mRNA and protein expression observed in the present study (Section 5.3.1.3). 
Blockage of VGSC activity in BCa cells by long- term (48 h) TTX treatment reduced 
PM nNavl.5 protein expression via intemalisation of the protein. In addition, VGSC 
blockage reduced the levels of phosphorylated PKA protein, in support of the model of 
Na"^  influx-mediated PKA activation and suggesting the existence of a positive feedback 
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Figure 7.1 An integrated model of VGSC regulation in BCa cell lines. 
This model is based on results from both MCF-7 and MDA-MB-231 cell lines, with 
emphasis on MDA-MB-231 cells, taken together with other available evidence. The 
VGSCa isoform studied for this model was neonatal Navl.5 (nNavl.5). The pathways 
(numbered) represent the following: 
(1) Influx of Na"^  through VGSC activates adenylate cyclase (AC) which in turn 
activates cyclic adenosine monophosphate (cAMP)-dependant protein kinase A (PKA) 
pathway. 
(2) Activation of PKA leads to post-transcriptional effects such as phosphorylation of 
intracellular VGSCa and/or other cytoskeletal components to initiate trafficking of 
intracellular VGSC to plasma membrane (PM). 
(3) Activation of PKA can also lead to direct phosphorylation of VGSCo/p in PM. 
However, there is no evidence, at present, for PKA-induced phosphorylation of 
VGSCps. 
(4a & b) Activated PKA can affect VGSC transcription machinery by a positive 
feedback. Transcriptional regulation of VGSC can also affect PM VGSC 
expression/activity. Transcriptional regulation of VGSC might also involve VGSC 
mRNA docking or translation of pre-docked VGSC mRNA. 
(5) Activation of PKA can promote translation of pre-docked VGSC mRNA and hence 
increase PM VGSC expression/activity. 
(6 & 7) Interaction of intracellular VGSCP subunits with intracellular VGSCa subunit 
and/or PM VGSCa subunit might also modulate VGSC trafficking to PM. 
(8) Interaction between VGSCa and P-subunits can also occur in PM. 
(9) Intracellular VGSCp subunits might be regulated/interact with a variety of 
mechanisms and cytoskeletal components (denoted as X). Increase of PM VGSC 
expression/activity can then enhance metastatic cell behaviours (MCBs), e.g. increased 
cell migration and invasion. 
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Regulation by interaction between VGSCa- and |3-subunits could occur 
intracellularly (Figure 7.1 [6]) or in PM (Figure 7.1 [7 & 8]). VGSCp subunits might 
modulate VGSC PM expression (Kazen-Gillespie et al., 2000; Vijayaragavan et al., 
2001; Chahine et al., 2005) directly or by interacting with a variety of mechanism(s), 
e.g. cytoskeletal components (Figure 7.1[9]; denoted as X) (Peles et al., 1995; Malhotra 
et al., 2000; Ratcliffe et al., 2000). Further details of the model are discussed in section 
7.4.6. 
7.4.2 Other possible mechanisms involved in VGSC regulation 
Apart from the PKA-mediated VGSC auto-regulation mechanism, other kinases such as 
(1) Src kinase (Hilbom et al., 1998); (2) Ca^Vcalmodulin (Herzog et al., 2003; Kim et 
al., 2004); (3) mitogen-activated protein kinase (Jin and Gereau, 2006); (4) protein 
kinase C (PKC) (Schreibmayer et al., 1991; Bendahhou et al., 1995; Murray et al., 1997; 
Gold et al., 1998; Tateyama et al., 2003; Vijayaragavan et al., 2004; Wada et al., 2004; 
Baker, 2005; Chahine et al., 2005) and (5) growth factors (i.e. EGF) (Ding et al., 2006a) 
might also be involved. 
Another mechanism that might be involved in VGSC regulation is trk receptor 
activation by nerve growth factor (NGF). It has been demonstrated in PCa (Montano and 
Djamgoz, 2004), as well as in sensory hair cells of the rat utricle (Chabbert et al., 2003) 
and PC-12 cells (Kalman et al., 1990; Hilbom et al., 1997) that NGF can stimulate PKA 
via activation of trk receptor and thus alter VGSC expression/activity. A recent study on 
PCa showed that NGF/trk-dependent PKA activation increased total VGSC protein level 
in Mat-LyLu cells (Brackenbury and Djamgoz, 2006b). However, although the role of 
NGF in BCa progression (e.g. increase Matrigel BCa cell invasion) is documented 
(Dolle et al., 2005), there is no evidence to link its effect with VGSC expression/activity 
in BCa. 
An additional possible mechanism of VGSC regulation in metastatic BCa that 
has been demonstrated recently is through epidermal growth factor (EGF) receptor 
tyrosine kinase pathway (Pan and Djamgoz, 2005). Treatment of MDA-MB-231 cells 
with EGF (50 ng/ml) increased in vitro cell migration and the effect was blocked when 
379 
TTX (10 |4.M) was co-applied, suggesting that VGSC activity might be a key 
intermediary in the EGF-induced potentiation of MCB (Pan and Djamgoz, 2005). 
7.4.3 Differential VGSC subtype expression in BCa vs. PCa 
It is interesting that regulation of VGSC expression can be through similar mechanisms 
(i.e. PKA) in both PCa and BCa, even though the predominant isoforms expressed are 
different, Navl.7 in PCa and nNavl.5 in BCa (Diss, 2001; Diss et al., 2001; Fraser et al., 
2005). Moreover, the different predominant isoforms in PCa and BCa have the same 
effect on in vitro migration and invasion by potentiating MCB (Laniado et al., 1997; 
Chioni and Djamgoz, 2005a; Chioni and Djamgoz, 2005b; Fraser et al., 2005; 
Brackenbury et al., 2006; Brackenbury and Djamgoz, 2006b). This observation suggests 
that the contribution of VGSCs to MCB may not strictly be a specific isoform but quite 
possibly due to tissue specificity instead. Indeed, recently it has been shown that 
transfection of the non-predominant Navl.4 isoform (instead of Navl.7) into weakly 
metastatic LNCaP human PCa cells enhanced the cells' invasiveness (Bennett et al., 
2004). 
7.4.4 Strongly vs. weakly metastatic cell line: differences in VGSC regulation 
Long-term (48 h) treatment with TTX, reduced mRNA levels of non-predominant 
Navl.7 isoform in both MCF-7 and MDA-MB-231 cells (Chapter 5). However, the same 
treatment had opposite effects on the predominant nNavl.5 isoform in MCF-7 and 
MDA-MB-231 cells, by reducing mRNA levels in the former and increasing in the latter 
(Chapter 5). These finding suggests the possibility that activity-dependent regulation of 
nNavl.5 mRNA level functions differently in diverse cell lines. A similar inconsistency 
has been observed between rat Mat-LyLu (Brackenbury and Djamgoz, 2006b) and 
human PC-3M (Mycielska et al., 2005) PCa cells. Long-term TTX treatment reduced 
Navl.7 mRNA level in Mat-LyLu cells (Brackenbury and Djamgoz, 2006b), whilst in 
PC-3M cells it had the opposite effect (Mycielska et al., 2005). 
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7.4.5 mRNA vs. protein level regulation 
Although, long-term TTX treatment altered VGSC mRNA levels in MDA-MB-231 and 
MCF-7, these changes were not reflected at the level of total protein expression. Instead, 
PM expression was reduced in both MCF-7 and MDA-MB-231 as a result of 
intracellular nNavl.5 protein translocation to intracellular membranes (Chapter 5). A 
similar discrepancy between mRNA- and protein-level expression was also observed 
after forskolin and KT5720 treatment. Long-term (48 hours) forskolin treatment 
increased nNavl.5 mRNA in MDA-MB-231 and MCF-7 cells; KT5720 treatment had 
the opposite effect. However, neither treatment had any effect on total VGSC and 
nNavl.5 protein, although nNavl.5 PM expression was increased in the case of forskolin 
and decreased in the case of KT5720 treatment. The change in PM nNavl.5 expression 
was accompanied by the opposite effect on intracellular nNavl.5 protein after each 
treatment, suggesting that the change in PM nNavl.5 protein was due to protein 
trafficking rather than transcriptional regulation of VGSC (Chapter 5). 
Indeed, there is increasing evidence suggesting that mRNA regulation and 
protein levels can be part of separate pathways both in cancer and normal conditions 
(Sola et al., 1999; Orphanides and Reinberg, 2002; Schedel et al., 2004; Gu et al., 2006). 
Post-transcriptional mechanisms can include not only protein trafficking but also mRNA 
docking and/or localization (Tiedge et al., 1999; Ben Fredj et al., 2004; St Johnston, 
2005). Furthermore, protein translation can be a result of not only newly synthesized 
mRNA but from pre-docked mRNA already stored intracellularly (Bassell and Twiss, 
2006). Such stimulation might be particularly well developed in cancer cells that might 
require fast and coordinated regulation of proteins. 
7.4.6 VGSCa regulation by VGSCp-subunits 
VGSCa association with VGSCP-subunits might also play a role in regulation of VGSC 
expression/activity (Figure 7.1), e.g. by mediating interaction of VGSCas with 
modulatory molecules such as protein tyrosine phosphatase (3 (Ratcliffe et al., 2000). 
Interaction of VGSCa with VGSCP-subunits is important for VGSC expression in PM 
(Kazen-Gillespie et al., 2000; Vijayaragavan et al., 2001; Chahine et al., 2005). 
Interestingly, when VGSCpl was co-expressed with Navl.5 in HEK-293 cells, the 
protein complex was retained in ER (Zimmer et al., 2002a). On the other hand, in 
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Xenopus oocytes, co-expression of either VGSCpi or VGSCp3 with Navl.5 caused 
increase in current amplitude possibly because VGSCpi and VGSCPS facilitied VGSC 
export from ER to PM (Fahmi et al., 2001). Another study revealed that co-expression of 
VGSCP2 with VGSCa in Xenopus oocytes increased functional expression possibly by 
transporting newly synthesized VGSC protein to the PM via vesicle (Isom et al., 1995). 
It is possible that a given VGSCP-subunit could effect trafficking of a specific VGSCa 
subtype, since VGSCps can interact with specific VGSCa isoforms (Table 1.2). For 
example, Navl.5 has being reported to interact with VGSCpi, -P2 and -P3 but not with 
VGSCp4 (Qu et al., 1995; Xiao et al., 2000; Yu et al., 2003; Yu et al., 2005). 
Interestingly, long-term TTX treatment increased MDA-MB-231 and MCF-7 
cells' adhesion (Chapter 5). This effect might be due to VGSC regulation of VGSCP-
subunit expression/activity, since VGSCP-subunits can function as cell adhesion 
molecules (CAMs) (Isom and Catterall, 1996; Isom, 2002). In fact, both VGSCpi and 
VGSCP2 are CAMs of the immunoglobulin superfamily and they can interact with the 
following: 
(1) ankyrin to areas of cell-cell contact (Malhotra et al., 2000); 
(2) the cytoskeleton (Peles et al., 1995; Malhotra et al., 2000; Ratcliffe et al., 2000); 
(3) other CAMs (i.e. contactin and neurofascin-186) (Isom, 2001; Kazarinova-
Noyes et al., 2001; Ratcliffe et al., 2001; McEwen and Isom, 2004; McEwen et al., 
2004); and 
(4) the extracellular matrix (ECM) elements tenascin-C and tenascin-R (Srinivasan 
et al., 1998; Xiao et al., 1999), important for neuronal migration and regeneration 
(Faissner, 1997; Schachner, 1997; Davis et al., 2004). 
RNAi studies targeting VGSCpi demonstrated that VGSCpi-subunit was responsible 
for MCF-7 cells' adhesion (Chapter 6). In addition, silencing VGSCpi increased MCF-7 
cells' migration. VGSCP subunits can interact with ECM proteins and can thus also 
influence cell migration (Undrovinas et al., 1995; Faissner, 1997; Srinivasan et al., 1998; 
Xiao et al., 1999). 
Importantly, RNAi treatment increased total nNavl.5 protein level in MCF-7 
cells. It is possible that decreased cellular adhesion (and subsequent increase in cell 
migration) due to decrease of VGSCpi gene/protein put the weakly metastatic MCF-7 
cells into a more metastatic 'mode' and this led to nNavl.5 upregulation. This agrees 
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generally with findings suggesting that the cellular environment, including the state of 
adhesion, can influence functional VGSC expression (Mycielska et al., 2004). Thus, a 
change in MCB (e.g. by reduction of cell adhesion when VGSCpi was down regulated) 
could have a feedback by increasing expression of VGSCa in PM, and possibly other 
proteins involved in the cells metastatic machinery. 
7.4.7 VGSC protein trafficking 
7.4.7.1 Interaction with other proteins 
hi principle, intracellular VGSCa in MDA-MB-231 and MCF-7 cells should require an 
intracellular link to facilitate its transport to PM and eventually to become functional. 
Two cell adhesion molecules (CAMs), Nr-CAM and neurifascin, through interaction 
between them, mediate the localisation of VGSCas to the nodes of Ranvier (Lusting et 
al., 2001). Both Nr-CAM and neurifascin, associate with ankyrin-G, which interacts 
with VGSC and cytoskeleton (Lusting et al., 2001). Okuse et al. (2002), identified 
annexin II light chain (pll) as a regulatory factor that facilitates the expression of 
Navl.8, by binding directly to its amino terminus and promoting the translocation of 
Navl.8 protein to PM, thereby producing functional VGSCs. It was also suggested that 
the cytoskeleton may play an important role in modulation of VGSCa activity (Tabarean 
et al., 1999). VGSC can interact with the cytoskeleton via VGSC^s or with proteins that 
are either linked directly to the cytoskeleton, such as dystrophin or indirectly, such as 
receptor kinases. Furthermore, VGSCa Navl.5 and Navl.4 possess PDZ domains which 
could enable interaction with the cytoskeleton (Gellens et al., 1992). Seven intracellular 
proteins have been reported to interact with and contribute to regulation of VGSCa: (1) 
ankyrin, (2) fibroblast growth factor homologous factor IB (FHFIB), (3) calmodulin, 
(4) Nedd4-like ubiquitin-protein ligases, (5) syntrophin proteins and (6) annexin II 
(Abriel and Kass, 2005; Chahine et al., 2005), and (7) VGSCp subunits (Kazen-Gillespie 
et al., 2000; Vijayaragavan et al., 2001; Chahine et al., 2005). Similar 
mechanism/protein-protein interactions may occur in MDA-MB-231 and MCF-7 cells 
and facilitate the trafficking of VGSCa protein from cytoplasm to PM. 
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7.4.7.2 Ubiquitinylation 
It has recently become clear that protein ubiquitinylation also plays a role in a variety of 
biological processes, such as DNA repair, transcripition, translation and protein 
trafficking (Pickart, 2000b, 2000a; Fisher et al., 2003). Any change in the balance 
between synthesis and degradation of VGSC protein, therefore, can control the 
expression levels of functional VGSCs in PM (Herfst et al., 2004). Ubiquiting-protein 
ligases, Nedd4 and Nedd4-2, interact with the PY motif-containing Navl.l, Navl.2, 
Navl.3, Navl.5 Navl.7 and Navl.8 channels (Rotin et al., 2000; Fotia et al., 2004). 
Furthermore, these VGSCs have conserved protein-protein interaction WW domain 
binding specificity (Staub et al., 1996). InXenopus oocytes, Navl.2, Navl.7 and Navl.8 
activities were strongly inhibited by Nedd4-2 (Fotia et al., 2004). Ubiquitin-dependent 
internalization and degradation of VGSCs has been shown to control PM expression of 
Navl.5 (Abriel et al., 2000; Herfst et al., 2004). Interaction of Navl.5 with ubiquitin 
protein ligase Nedd4 reduced the expression of Navl.5 in PM possibly by 
ubiquitinylation of the protein and subsequent endocytosis (Abriel et al., 2000; van 
Bemmelen et al., 2004). In addition, Nedd4-2 increased the internalization rate of 
Navl.5 in HEK293 cells (Rougier et al., 2005). Interestingly, there is evidence that PKA 
can regulate ubiquitinylation (Hoang et al., 2004; Hino et al., 2005; Tempe et al., 2006). 
Furthermore, phosphorylation of the C-terminal was found to alter the affinity of ENaC 
for ubiquitin protein ligase (Nedd4) binding, which could affect the rate of its 
internalization (Dinudom et al., 2004; Anantharam et al., 2006; Rauh et al., 2006). 
Therefore, it is possible that ubiqutinylation might be involved in the PKA-induced 
trafficking of nNavl.5 in MDA-MB-231 and MCF-7 cells. 
7.4.7.3 Signal peptides 
Signal peptides (e.g. ER retention motifs) that might affect protein translocation and 
trafficking have been identified in ion channels, including VGSCs (Zerangue et al., 
1999; Scott et al., 2001; Zhou et al., 2002; Stockklausner and Klocker, 2003; Herfst et 
al., 2004; Jones et al., 2004; Zarei et al., 2004). For Navl.5, it has been demonstrated 
that both phosphorylation and the presence of a putative ER retention signal are required 
for PKA-mediated increase in functional Navl.5 expression (Zhou et al., 2002). ER may 
also have particular chaperones that bind to the ER retention signals of proteins (Kim 
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and Arvan, 1998). In the case of the ER retention signal of Navl.5, PKA mediated an 
increase in functional expression of Navl.5 in PM, but the effect was eliminated when 
the ER retention motif was altered (Zhou et al., 2002). This result indicated that masking 
of the ER retention motif depended on PKA activity (Herfst et al., 2004). 
Full sequencing of the nNavl.5 gene/protein and use of a data base, such as 
PrediSi (Prediction of Signal Peptides) to predict signal peptides and their cleavage 
positions would give more information about the control of protein trafficking (Killer et 
al., 2004). Bioinformatics can predict the subcellular localisation of a protein from its 
amino acid sequence, which has implications both for the function of the protein and its 
possible interaction with other proteins (Emanuelsson, 2002). Different signal peptides 
can give information on the destination of proteins, e.g. to mitochondria, Golgi, ER or 
PM (Emanuelsson, 2002). Sequencing and comparing the neonatal Navl.5 protein from 
both MCF-7 and MDA-MB-231 cells might also give information about the 
intemalisation machinery of VGSC protein and why it does not traffic to PM in MCF-7 
cells. One possibility is that the internalised protein does not have a signal peptide for 
the protein to travel to the PM but instead is destined to be retained in an internal 
membrane. 
7.5 Role of VGSC in cancer 
There is a increasing evidence that ion channels are important in cancer progression 
(Schonherr, 2005). Many types of ion channels have been found to be expressed in 
various cell lines derived from several cancers, such as prostate, lung, melanoma, breast, 
bladder, liver, brain, colon and cervix (Eraser et al., 2002b). Importantly, VGSC 
expression/activity has been linked with metastatic PCa (Laniado et al., 1997), BCa 
(Roger et al., 2003; Fraser et al., 2005), small-cell lung cancer (SCLC) (Blandino et al., 
1995; Onganer and Djamgoz, 2005), neuroblastoma (Ou et al., 2005), lymphoma (Fraser 
et al., 2004a), neoplastic mesothelia (Fulgenzi et al., 2006), and melanoma (Allen et al., 
1997). Furthermore, Bennett et al. (2004) made a very important statement that VGSC 
expression was "necessary and sufficient" for in vitro cellular invasiveness in PCa. 
However, it is not clear whether VGSC expression/activity triggers or facilitates 
metastasis. Unfortunately, to date, the mechanism(s) behind the involvement of VGSC 
expression/activity in cancer progression and MCBs is not known and need further 
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investigation. Nevertheless, the fact that TTX is effective on cells in tissue culture would 
suggest that VGSCs are tonically active in 'resting' cells. The mechanisms triggering 
activation of VGSCs could include mechanical stimulation and growth factor signalling. 
7.5.1 Metastatic cell behaviours 
Studies on VGSC expression in PCa and BCa showed that VGSC activity can enhance a 
variety of m vitro cellular functions involved in cancer progression, such as: (1) changes 
in morphology and process extension (Fraser et al., 1999); (2) motility (Eraser et al., 
2003, 2005; Fulgenzi et al., 2006); (3) invasion (Grimes et al., 1995; Smith et al., 1998; 
Laniado et al., 1997, Fraser et al., 2005; Bennett et al., 2004); (4) proliferation (Abdul 
and Hoosein, 2002); (5) adhesion (Palmer et al., 2006); (6) gene expression (Mycielska 
et al., 2005); (7) secretory membrane activity (Mycielska et al., 2003; Krasowska et al., 
2004; Fraser et al., 2005) and (8) galvanotaxis (Djamgoz et al., 2001; Fraser et al., 
2005^ 
In the present study, single cell adhesion measurements with SCAMA, Transwell 
migration, Matrigel invasion and proliferation assays have been used as measurements 
of MCB in MDA-MB-231 and MCF-7 cells (Chapter 5). Although cell proliferation was 
not VGSC dependent, migration, invasion and adhesion was VGSC-dependent in both 
MDA-MB-231 and MCF-7 cells, even though the latter do not express any detectable 
functional VGSCs (Fraser et al., 2005). However, MDA-MB-231 cells, which express 
functional VGSC, are more metastatic compared to MCF-7 cells that do not express 
VGSCs. Similarly, previous findings on PCa indicated that blockage of VGSC activity 
inhibited several MCBs (Laniado et al., 1997; Mycielska et al., 2003; Brackenbury and 
Djamgoz, 2006b; Palmer et al., 2006). 
A possible mechanism by which VGSCs might induce MCB is through 
membrane depolarization and hence PKA activation via Na"^  influx. Increased 
intracellular Na^ could also trigger Ca^ "^  release and therefore activate other signalling 
cascades through Ras, calmodulin-dependent protein kinase and protein kinase C (PKC) 
(Cullen and Lockyer, 2002; Berridge et al., 2003; Kahl and Means, 2003) that might 
result in phosphorylation of cytoskeletal components (Trifaro et al., 2000). 
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Growth factors such as EGF, NGF and fibroblast growth factor (Montano and 
Djamgoz, 2004), peptide hormones such as insulin (Boehmer et al., 2003) and steroid 
hormones like estrogen and pituitary hormone melanocortin (Dunlap et al., 1997; 
Stoddard et al., 2006) are also mechanisms involved in cancer progression that have 
been also associated with VGSCs. 
Interaction of VGSCs with tumour suppressor genes might also be another 
mechanism of MCB potentiation. A recent study reported that expression of endogenous 
VGSCpS (localized in endoplasmic reticulum) was upregulated in mouse embryonic 
fibroblasts by DNA damage in a p53-dependent manner (Adachi et al., 2004). 
Furthermore, VGSCpS mediated a p53-dependent apoptotic pathway (Adachi et al., 
2004). Interestingly, in MDA-MB-231 and MCF-7 cells the VGSCP3 was the only 
subunit not present (Chapter 6). It is not known if similar interaction with other (3-
subunits might also occur in these cell lines. 
Furthermore, one transcription factor has been identified to inhibit the expression 
of at least one specific VGSCa (Chong et al., 1995; Toledo-Aral et al., 1997). Repressor 
element 1 (REl) binding silencer protein (REST) is a transcription silencer that binds to 
a specific RE-1 in the promoter of the Navl.2. Moreover, electrophysiological studies 
have shown that over-expression of REST in cultured neurones resulted in reduction of 
VGSC currents, similar to long-term TTX treatment (Nadeau and Lester, 2002). 
Interestingly, REST has also been implicated as a human tumour suppressor that might 
present a novel approach to identify candidate genes that suppress cancer development 
(Westbrook et al., 2005). Interaction with REST and p53 could suggest that VGSC 
might arbitrate effects of tumor suppressor genes in cancer. 
7.6 Clinical implications 
The correlation between VGSC expression and cancer progression has being well 
documented in BCa, PCa and SCLC both in vitro and in vivo (Grimes et al., 1995; 
Laniado et al., 1997; Abdul and Hoosein, 2002b; Roger et al., 2003; Diss et al., 2005; 
Eraser et al., 2005; Onganer and Djamgoz, 2005; Brackenbury and Djamgoz, 2006b). 
The 'neonatal' splice variant of Navl.5 (nNavl.5) has being shown to be expressed at 
high levels in breast cancer cells in vitro and in vivo (Eraser et al., 2002a; Eraser et al., 
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2003a; Roger et al., 2003; Fraser et al., 2005). Interestingly, the 'neonatal' nature of 
Navl.5 is a further example of embryonic/neonatal gene expression in cancer (Ariel et 
al., 1997; Monk and Holding, 2001; Lee and Herlyn, 2006; Topczewska et al., 2006). 
This study showed that in BCa, VGSC expression/activity could potentiate a number of 
in vitro metastatic cell behaviours (i.e. migration, invasion, and adhesion). In addition, 
Fraser et al. (2005) have shown that nNavl .5 expression was correlated with lymph node 
BCa metastasis in cancer patients. Similar results showing that VGSC expression can 
serve as a potential prognostic marker were obtained from PCa patients (Diss et al., 
2005). Therefore, VGSC expression might be a promising target to restrain or even stop 
metastasis with the use of VGSC blockers. In fact, VGSC blockers are already in clinical 
use for treatment of VGSC-related neuropathological conditions, such as cardiac 
arrhythmias and epilepsy (e.g. the anti-convulsants phenytoin, carbamazepine, 
hydroxyamides and hydantoin) (Abdul and Hoosein, 2001; Anderson et al., 2003). Thus, 
it may be possible to also use similar treatment for cancer patients. Also, in support of 
the use of VGSC blockers in cancer treatment, it has been shovm that in PCa the VGSC-
blocking anticonvulsants phenytoin and carbamazepine inhibit secretion of prostate-
specific antigen (PSA) and interleukin-6 (Abdul and Hoosein, 2001). 
The activity-dependent regulation of nNavl.5 expression via a PKA mechanism 
in BCa that was investigated in this study as well as in PCa (Brackenbury and Djamgoz, 
2006b) might be an additional characteristic that could be exploited for down-regulating 
VGSC activity in cancer. Therefore, VGSC expression/activity not only can be used as a 
novel prognostic marker for metastatic cancer, but can also provide a target for therapy 
by inhibiting or even preventing metastatic cancer. 
The NESO-pAb antibody that was developed and tested in this study (Chapter 3) 
might form the basis for an antibody-based anticancer treatment, or drug-delivery 
mechanism, with limited side-effects for patients (lannello and Ahmad, 2005; Ross et 
al., 2005; Tanner, 2005; Willems et al., 2005; Booy et al., 2006). Possible therapeutic 
potential is strengthened by the finding that (1) NESO-pAb blocked Navl.5 functioning 
with great specificity when applied extracellularly (even at nanomolar concentrations) in 
vitro-, (2) NESO-pAb blocked migration and invasion in MDA-MB-231 cells in vitro 
and (3) in Navl.5-expressing adult mouse tissues there was no expression of nNavl.5 
(except for very low levels in the brain and skeletal muscle), strongly implying that 
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NESO-pAb might be a novel, specific mechanism for targeting aberrant nNavl.5 
expression in metastatic BCa cells in the adult cancer patient. NESO-pAb may also have 
applications as diagnostic marker for metastasis in BCa patients. Furthermore, NESO-
pAb might form the bases of a novel, blood-based early test for metastatic BCa 
(Srivastava, 2006). Breast cancer patients with metastatic disease might express NESO-
like auto-antibodies in their blood. An example of auto-antibodies in cancer is the anti-
thyroglobulin auto-antibodies (ATG) in differentiated thyroid cancer (DTC) that were 
present in the sera of one-third of patients (Adil et al., 2003). Other example is the auto-
antibodies against p53 protein in patients with bladder cancer and lymphoma (Sanchez-
Carbayo et al., 1999; Jezersek et al., 2001). Also, around 40 % of human PCa patient 
blood samples contained auto-antibodies against FLJ23438 and VAMP3, transcripts of 
which were highly expressed in low-Gleason score (i.e. non-metastatic) cases (Pontes et 
al., 2006). 
The present study also demonstrated correlation between VGSC protein 
trafficking to PM and MCB, which might be an additional area to target for a potential 
cancer treatment. Indeed, proteosome inhibitors have being increasingly considered for 
clinical applications. For example, bortezomib (Velcade), which targets the ubiquitin-
proteosome system in many hematologic and solid tumours, has been approved for 
treatment of multiple myeloma (Joazeiro et al., 2006; Montagut et al., 2006). On going 
clinical trials with bortezomib alone or with combination (i.e. the blc-2 antisense 
molecule oblimersen) have given encouraging results in lung cancer and lymphoma 
(Shirley et al., 2005; Leonard et al., 2006; Montagut et al., 2006; O'Connor et al., 2006; 
Tan et al., 2006). However, although bortezomid has being shown to block the 
proteolytic degradation of short-lived proteins that are involved in cell maintenance, 
growth division and cell death, such cancer drug might have some limitations due to its 
possible lack of specificity (Bailly et al., 2004; Shirley et al., 2005). 
Recently, it has been shown that an RNAi approach targeting nNavl.5 in MDA-
MB-231 cells successfully inhibited the VGSC-dependent component of in vitro 
migration (Brackenbury et al., 2006). Thus, nNavl.5 may also be a good target for 
RNAi-based therapy (Rye and Stigbrand, 2004; Karagiannis and El-Osta, 2005; 
Uprichard, 2005). 
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Results from Chapter 6 on VGSCp might also have some clinical implications, 
whereby targeted over-expression of VGSCpi could result in suppression of metastatic 
BCa. Also, VGSCp2 expression may be targeted for controlling nNavl.5 PM 
expression. For example, reduction of VGSCP2 expression with RNAi-based therapy 
might reduce fimctional expression of nNavl.5 in PM and hence suppress MCBs in 
BCa. 
7.8 Future perspectives 
There are still many aspects of VGSC expression/activity in cancer that need to be 
investigated. The present work can be extended further in many ways, as follows: 
It would be of a great interest to elucidate the role/reason behind nNavl .5 protein 
expression in the PM of MCF-7 cells even though they do not express functional VGSC 
(Eraser et al., 2005). Transfecting nNavl.5 into MCF-7 cells and studying nNavl.5 
protein localization and MCB would not only give insights about the status/role of 
nNavl.5 in this cell line but also will give additional evidence about the role of VGSC in 
cancer progression. It might be that regulation of VGSC expression/activity in MCF-7 
cells involves partially different mechanism(s), even though upregulation of nNavl.5 via 
PKA activity indeed increased their MCB (i.e. migration and invasion; Chapter 5). 
Identification of more mechanisms involved in VGSC regulation would also give 
a better understanding of the role of VGSC in cancer. Therefore, it will provide us with 
more tools to abolish/inhibit VGSC action in cancer. The involvement of steroid 
hormones (e.g. estrogen), growth factors (e.g. EGF, NGF), and protein kinases (e.g 
PKC) in VGSC-dependent cancer progression would be interesting mechanisms to 
investigate further. Investigation of VGSC interaction with the cytoskeleton or 
molecules like small G-proteins (e.g. Rho) might also give information about the 
mechanism by which VGSC activity potentiates MCB (Vasiliev, 2004; Vasiliev et al., 
2004). Also, investigation into the discrepancy between VGSC mRNA and protein 
regulation that was shown in this study would be interesting. Candidate mechanism for 
such a phenomenon could be mRNA docking. 
Electrophysiological studies to test the proposed model of activity-dependent 
VGSC regulation via PKA action in MDA-MB-231 cells would be very important. It 
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would be significant to verify that indeed the upregulation of PM nNavl.5 in MCF-7 and 
MDA-MB-231 cells after activation of PKA would also result in VGSC functional 
activity. 
Further investigation of the role of VGSC P-subunits in cancer is also necessary. 
This study showed that VGSCpi was responsible for cell adhesion in MCF-7 BCa cell 
line and silencing of VGSCpi subunit not only disturbed cell adhesion but also 
increased nNavl.5 expression and MCE. Also the interaction of VGSCp3 with the 
tumour suppressor p53 suggest that VGSC P-subunits might be a very promising 
mechanism worth of investigating. Interaction of VGSC P-subunits with the 
cytoskeleton and their action as cell adhesion molecules might aid MCB (e.g. adhesion 
and migration). Also their involvement in VGSC expression/activity in cancer as well as 
the nature of interaction is also important. Studies on MDA-MB-231 over-expressing 
VGSCP-subunits (e.g. VGSCpi) might give more information about their involvement 
in cancer. 
Last but not least, in vivo studies on BCa and PCa models would be important to 
verify and test further the involvement of VGSC in cancer progression with view to 
clinical applications and management of metastatic disease. 
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Electrophysiology of 'neonatal' Navl.5 (nNavl.5) VGSCs. (A) Voltage-gated 
membrane currents recorded in EBNA-293 cells transfected with nNavl.5. The currents 
were generated by pulsing the membrane potential from a holding voltage of-100 mV, 
in 5 mV steps, from -60 mV to +60 mV for 20 ms. Voltage pulses were applied with a 
repeat interval of 10 s. Only every second current trace generated is displayed. (B) A 
typical current-voltage (I-V) relationship generated in nNal.5 EBNA transfectants by 
pulsing the membrane potential from a holding voltage of -100 mV to test potentials 
between -70 to +70 mV in 5 mV increments. Voltage pulses were applied with a repeat 
interval of 10 s. For both parts of the figure, the patch pipette contained Cs^ to block 
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Blocking nNavl.5 activity with NESO-pAb. (A) Effect of NESO-pAb (at 5 ng/ml) on 
voltage-gated Na"^  currents recorded in EBNA-293 cells transfected with (i) aNavl.5 or (ii) 
nNavl.5. The currents were generated by pulsing the membrane potential from a holding 
voltage o f -100 mV to 0 mV for 20 ms. Voltage pulses were applied with a repeat interval of 
10 s. The effect of the antibody shown was recorded on the fifth pulse following application. 
Scale bar applies to both traces. The patch pipettes contained Cs^ to block outward 
currents. The effect of the antibody was, at least, partially reversible (not shown). (B) 
Current-voltage (I-V) relationship for the VGSC currents recorded in EBNA-293 cells 
transfected with nNavl.5 before (control) and during application of NESO-pAb (50 ng/ml). 
(C) Dose-response curve over the concentration range 0.025 to 500 ng/ml for the effect of 
NESO-pAb on the voltage-gated Na"^  channel in the EBNA-293 cell line transfected with 
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